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“…the immunology of transplantation is important not merely for its 
bearing upon surgery and cancer research or the repair of radiation 
damage, but above all because it offers one of the few negotiable pathways 
into the central regions of biology, where immunology, genetics, 
embryology and the rest of them lose their identities in problems that bear 
upon biology as a whole”. 
 
        Peter B. Medawar, 1957
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ABSTRACT 
 
Allogeneic T cell stimulation requires not only antigen-specific signals but also 
costimulatory signals, most importantly between CD80/86 on the antigen presenting cell 
and CD28 or CTLA4 on the T cell. Engagement of the T cell receptor without 
costimulation can lead to anergy and the subsequent induction of regulatory T cells 
(Tregs). T cell activation is also controlled by dendritic cell (DC) expression of the 
tryptophan-catabolising, immunomodulatory enzyme indoleamine 2,3-dioxygenase 
(IDO). Depletion of this essential amino acid, and/or the production of tryptophan 
metabolites (kynurenines) inhibits T cell proliferation. 
 
With the aim of generating tolerogenic DCs for the induction of donor-specific 
transplantation tolerance, lentiviral vectors were used in this study for gene transfer into 
murine DCs. Firstly, an intracellular approach that prevents costimulation was 
developed: A fusion protein- CTLA4-KDEL- consisting of the extracellular domain of 
CTLA4 and the KDEL peptide [an endoplasmic reticulum (ER) retention signal] was 
expressed in DCs and prevented surface CD80/86 expression due to ER retention. A 
second approach used in the study involved the lentiviral gene transfer of IDO into DCs. 
 
The induction of donor-specific tolerance (mediated by Tregs with direct and indirect 
pathway allospecificity) was demonstrated, both in vitro and in vivo, using 
CTLA4-KDEL-expressing DCs. Linked suppression was observed and mediated by 
donor-specific Tregs. Although IDO-expressing DCs did not induce and/or sustain 
allogeneic T cell proliferation, this anergy lacked donor specificity. It was demonstrated 
that IDO+CD80/86+ DCs fail to induce and/or expand FoxP3+CTLA4+ Treg 
populations. Furthermore, IDO+CD80/86- DCs failed to sustain pre-induced populations 
of FoxP3+CTLA4+ Tregs (associated with a high rate of cell death). The capacity of 
CTLA4-KDEL- and IDO-expressing DCs to induce tolerance to allografts was 
investigated using a murine corneal allograft model, and administration of 
CTLA4-KDEL-expressing DCs prevented allograft rejection. The study demonstrates 
the clinical potential of CTLA4-KDEL-expressing DCs to induce Treg-mediated, 
donor-specific transplantation tolerance. 
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Chapter 1: INTRODUCTION 
 
1.1. The Quest for Donor-Specific Tolerance in Transplantation 
Immunology 
 
The concept of transferring tissues from one individual to another has been the great 
ambition of those who have contemplated treatment for end-stage failure of several 
organs. Evidence of this idea is provided in the writings of several civilisations- ranging 
from ‘accounts’ of the Chinese physician Bian Que (circa 500 B.C.) who performed a 
‘dual-heart transplant’ on the warriors Gong Hu and Qi Ying (‘in order to exchange 
hearts between the man of strong spirit but weak will with the one of a weak spirit but 
strong will in an attempt to achieve balance in each man’), to more reasonable accounts 
provided of the Indian surgeon Sushurata in the 2nd century B.C., who used skin 
autografts in nose reconstruction rhinoplasty (Lock et al., 2001). Tissue and organ 
transplantation has also been an inspiration to the minds of artists depicting the Saints 
Cosmos and Damian [Figure 1]. In Catholic accounts, legend held that the 3rd-century 
saints, who were twin brothers, miraculously transplanted the limb of a recently-
deceased Ethiopian onto the body of the Roman deacon Justinian after the latter’s own 
gangrenous leg was amputated (Farmer, 1992). Until the mid-20th century, prolonged 
survival of transplants had been largely impossible [with isolated exceptions such as 
corneal transplantation demonstrated by Eduard Zirm in 1905 (Armitage et al., 2006)- 
see section 1.5], until seminal discoveries were made in the field of transplantation 
immunology (in addition to developments in surgical practice). 
 
The immunology of transplantation has its origin in the nineteenth century (Starzl and 
Zinkernagel, 1998) [Figure 2]. After the cellular, humoral and complement 
constitutents of the immune response were discovered, evidence emerged early in the 
twentieth century that an immune reaction was responsible for the failure of 
transplanted tissue and most tumour allografts to survive indefinitely (Brent, 1997; 
Starzl and Zinkernagel, 2001). However, these early accomplishments faded with the 
decline of transplantation research during and after World War I. Similarly, the 
significance of the neonatal tolerance shown in tumour and viral-infection models was  
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Figure 1. Limb Transplantation Miracle by the Saints Cosmos and Damian- Ditzingen, 16th Century. 
Swabian wood panel painting (Württembergische Landesmuseum, Stuttgart, Germany). Legend held that 
the third-century saints miraculously transplanted the (black) limb of a recently-deceased Ethiopian onto 
the (white) body of the Roman deacon Justinian after the latter’s own gangrenous leg was amputated. In 
this depiction, an angel assists by drawing back the covers. Some accounts have the saints only 
instructing living surgeons who performed the procedure. 
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Milestones in Transplantation Immunology
1884-1895 Metchnikoff, von Behring and Kitasato, and Bordet discover immune system components
1901 Landsteiner discovers ABO blood groups, the f irst histocompatibility antigens
1943 Gibson and Medawar demonstrate that rejection is an immune reaction
1945 Owen discovers natural blood-cell chimerism in f reemartin cattle
1948 Gorer and Snell discover mouse MHC (earlier incomplete description published by Gorer in 1937)
1953 Billingham, Brent and Medawar demonstrate neonatal tolerance in mice
1954 Mitchison shows that rejection is cell mediated
1955 Main and Prehn demonstrates acquired adult tolerance in mice, presaging bone marrow transplantation
1957 Simonsen, Billingham and Brent recognise graf t-versus-host disease in chickens and mice
1958 Dausset and van Rood discover f irst human MHC antigens- human leukocyte antigen (HLA)
1959 Schwartz and Dameshek discover drug immunosuppression and postulate drug-assisted deletional tolerance
1962 Murray carries out the f irst successful kidney transplantation (17 months) under drug immunosuppression only
1967 First clinical use of  anti-lymphoid antibodies in transplantation, originally conceived by Woodruff in 1950
1968 Def initive demonstration of  immunological ignorance of  allografts by Barker and Billingham
1969 Nishizuka and Sakakura demonstrate induction of  autoimmunity by day-3 thymectomy
1970 Gershon and Kondo demonstrate T cell-mediated suppression
1976 Borel and colleagues discover cyclosporine immunosuppression; clinical introduction (Calne) 3 years later
1985 Hall and colleagues demonstrate transfer of  allograf t tolerance by CD4+CD25+ T cells
1986 Goto discovers tacrolimus; clinical introduction 3 years later
Mosmann and Coffman demonstrate the T helper 1 (TH1)/TH2 paradigm
1991 Weiner and colleagues provide f irst evidence of  bystander suppression
1993 Demonstration of  infectious tolerance by Waldmann and colleagues
1994 Roncarolo et al. demonstrate association of  interleukin-10 production and tolerance in vivo (IL-10 dependent TR1 cells)
1995 Sakaguchi and colleagues demonstrate prevention of  day-3 thymectomy-induced autoimmunity by CD4+CD25+ T cells
1998 Shevach, Sakaguchi and colleagues demonstrate requirement of  cell-cell contact for in vitro suppression by CD25+ T Cells
 
 
 
Figure 2. Milestones in Transplantation Immunology. 
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not fully appreciated until Burnet’s formulation of the tolerance and clonal selection 
hypothesis (Burnet and Fenner, 1949). Similarly, the phenomenon of immunological 
ignorance was first demonstrated in 1934 (Stone et al., 1934), but discounted until its 
discovery several years later (Barker and Billingham, 1968; Lafferty et al., 1983). 
Modern transplantation immunology is often dated to experiments by Sir Peter 
Medawar in 1944, which showed that skin allograft rejection is a host-versus-graft 
response (Medawar, 1944), the cell-mediated features of which were later defined by 
Mitchison (Mitchison, 1954). The term major histocompatibility complex (MHC) was 
introduced by Gorer, Snell and Lyman (Gorer et al., 1948; Snell, 1986) for the genetic 
locus that encodes antigens associated with allograft rejection, tumour surveillance and 
other expressions of cell-mediated immunity. The MHC-restricted mechanisms of T cell 
recognition of, and response to, antigens, viruses and other intracellular organisms were 
elucidated in the 1970s (Zinkernagel and Doherty, 1997). 
 
Non-cytopathic microorganisms are controlled primarily by cytotoxic T lymphocytes 
that recognise as ‘non-self’ host cells which display complexes composed of self-MHC 
molecules and peptides derived from the infecting microorganism. Allograft rejection 
was the apparent transplantation equivalent of the host-versus-pathogen adaptive 
immune response. In London, Billingham, Brent and Medawar were inspired by Ray 
Owen’s discovery that dizygotic cattle twins are born with and long retain blood cells of 
the other twin (his description of “blood-cell chimerism in Freemartin cattle”) and that 
most cattle twins are fully tolerant of skin grafts from each other at birth and for a long 
time afterwards (Owen, 1945). This observation, along with Burnet and Fenner’s 
recognition of its significance (Burnet and Fenner, 1949), led the London trio to 
formulate the idea of immunological tolerance (Billingham et al., 1953). They showed 
between 1953 and 1956 that allogeneic spleen and bone marrow (BM) cells induce 
tolerance when they are not rejected by the incompletely-developed immune system of 
neonatal mouse recipients, and that the tolerance extends to donor strain skin allografts. 
This model is analogous to successful BM cell transplantation in humans whose 
immune-deficiency diseases makes host cytoablation unnecessary (Gatti et al., 1968).  
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The landmark Nature paper by Billingham, Brent and Medawar- ‘actively acquired 
tolerance of foreign cells’- was published in 1953, the same year as a paper by Milan 
Hašek in Prague, in which the Hungarian scientist observed the effects of parabiosis of 
chick embryos (Hasek, 1953). Hašek’s paper (written in Russian with a German 
summary) was not primarily an immunologic paper, and Hašek was interested in 
whether the exchange of blood elements between chick embryos of different breeds or 
embryos of different species, would lead to ‘vegetative hybridisation’, a state in which 
the parabionts were expected to display some of the characteristics of their partners (the 
use of embryos seemed to him to be particularly favourable because of their inability to 
make antibodies). Hašek established clearly that the technique of in ovo parabiosis led 
to the exchange of blood elements and that antibodies against serum proteins were not 
formed by the parabiont partners; and that even active immunisation after hatching 
failed to induce the formation of antibodies. Hašek responded with enthusiasm to the 
suggestion by Medawar and Brent (at an international conference) that his published 
work on vegetative hybridistion could very well be interpreted in terms of acquired 
immunologic tolerance (Brent, 1997).  
 
The immunological tolerance model proposed by Billingham, Brent and Medawar is 
analogous to successful BM cell transplantation in humans whose immune-deficiency 
diseases makes host cytoablation unnecessary (Gatti et al., 1968). During 1955-1956, 
similar tolerance was also induced in adult mice whose mature immune system was 
cytoablated with supralethal total body irradiation (Main and Prehn, 1955). The mouse 
model subsequently evolved into clinical BM transplantation for a wide range of 
indications (Thomas et al., 1975). The avoidance of lethal graft-versus-host (GVH) 
disease in the experimental tolerance models and in humans requires a close tissue 
match. Until Human Leukocyte Antigen (HLA) matching became available in 1968, a 
decade after the discovery by Dausset and van Rood of the first HLA antigens (Brent, 
1997), prolonged survival after clinical BM transplantation was limited to a single case 
(Mathe et al., 1963). GVHD seemed to be a mirror-image version of tissue and organ 
rejection, host-versus-graft (HVG), in that the host, rather than the graft, was the 
immune target. 
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Leslie Brent notes in A History of Transplantation Immunology that Medawar gave a 
lecture in New York in 1961 in which he discussed the antigens important in graft 
rejection and the mechanisms thought to be involved (Brent, 1997). The now prominent 
transplantation scientist Fritz Bach was in the audience and likes to recall how after the 
lecture he had asked Medawar whether he really believed that one could analyse it all in 
vivo; should one not try to do it in vitro? Apparently the reply from Medawar was: “I 
think you should do just that, young man!” In 1964, Bach and his colleages had 
developed the Mixed Lymphocyte Response (MLR) assay, which provided an in vitro 
analogue of allograft reactivity and the basis for the cell-mediated lympholysis assay. 
Both became indispensable tools in the analysis of allograft effector mechanisms (the 
MLR was the most common assay used for experiments making up this thesis), and 
Bach and his colleagues used them to great effect in the study of histocompatibility 
antigens, first putting forward the notion that there are two kinds of histocompatibility 
antigens- the serologically identifiable (later class I) and those defined by mixed 
lymphocyte cultures (later class II) (Brent, 1997). 
 
MLR assays reinforced the idea that one-way immune reactions- GVH or HVG- were 
induced after BM and organ transplantation, respectively. In view of this idea, 
successful BM transplantation was generally viewed as total replacement of the 
recipient immune apparatus, even after the discovery in 1989 that recipient leukocytes 
could be found in the blood of essentially all human ‘complete donor BM chimeras’ 
(Przepiorka et al., 1991). The early hypothesis that donor and recipient immune-
competent cells might coexist, become mutually non-reactive and even function 
collaboratively (e.g. in a joint response to a new infection) (Simonsen, 1960; Michie et 
al., 1961) lacked experimental support and was abandoned. 
 
The strategy of cotransplanting BM and skin allografts to supralethally irradiated mice 
was extended in the late 1950s by Mannick and Hume to kidney/BM transplantation in 
irradiated beagle and outbred dogs, but yielded only a single survival exceeding 1 
month (73 days). Although the survival of dog kidney transplants was even worse when 
the adjunct BM was omitted, six humans conditioned with sublethal doses of total body 
irradiation achieved renal allograft function for at least 1 year (Murray et al., 1960; 
Chapter 1: Introduction 
Adnan Khan, Department of Immunology, Division of Medicine, Imperial College London 21 
Hamburger et al., 1962; Kuss et al., 1962). Subsequent demonstrations that organ 
transplantation was feasible without adjunct BM cells, together with the major 
differences between organ and BM transplantation, led to agreement by the early 1960s 
that organ engraftment did not involve donor leukocyte chimerism. This conclusion 
presumably was compatible with the identification of the ‘sessile’ and/or recirculating 
passenger leukocytes of BM origin contained in all organs, as the immunogenic 
component of allografts (Steinmuller, 1967; Elkins and Guttmann, 1968; Lechler and 
Batchelor, 1982b). When it was subsequently learned that most passenger leukocytes 
are replaced in the engrafted organ by comparable recipient cells, it was assumed that 
the donor leukocytes had undergone immune destruction either within the graft or after 
their migration to host lymphoid organs, with selective preservation of the graft 
parenchyma. An explanation of organ engraftment by means other than the chimerism-
associated mechanisms of BM transplantation was not challenged until small numbers 
of multilineage donor haematopoietic cells (microchimerism) were shown in the tissues 
or blood of long-survival human liver or kidney allograft recipients (Starzl et al., 1992). 
Organ engraftment and BM-cell engraftment seemed to be mirror images with reversed 
proportions of donor-recipient haematolymphopoieitc cells, placing both in a continuum 
of leukocyte chimerism-associated tolerance models that could be related to the 
neonatal mouse experiments of Billingham, Brent and Medawar, and to Owen’s original 
observation of blood-cell chimerism in freemartin cattle (Starzl and Zinkernagel, 2001). 
 
Transplantation of cells and organs today is regarded as the only therapeutic choice for 
end-stage failure of several organs and has been made possible by the development of 
powerful immunosuppressive treatments that prevent transplant rejection. However, 
most of these drugs non-specifically target the immune response, leading to unwanted 
side effects, and have limited ability to prevent chronic rejection (Halloran, 2004; 
Sayegh and Carpenter, 2004). The era of drug immunosuppression began after Schwartz 
and Dameshek demonstrated that the anti-leukaemic drug 6-mercaptopurine was 
immunosuppressive in rabbits (Schwartz and Dameshek, 1959). When approximately 
5% of dog kidney recipients treated by Calne and Zukoski with 6-mercaptopurine, or its 
analogue azathioprine, survived for ≥100 days, human trials were undertaken by Murray 
and colleagues (Murray et al., 1963). In the sixth case of kidney transplantation, a renal 
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allograft from a non-related donor functioned for 17 months after its transplantation 
under azathioprine-based therapy (Murray et al., 1963). When large doses of prednisone 
were added to azathioprine in response to clinically diagnosed rejection, there were ten 
cases of “reversal of rejection in human renal homografts with subsequent development 
of homograft tolerance” (Starzl et al., 1963). The partial tolerance referred to the time-
related diminution of dependence on immunosuppression (Starzl et al., 1996), which 
eventually was stopped in two patients whose grafts still functioned 39 years after 
transplantation. In 1966, heterologous anti-lymphoid globulin (ALG) was added in a 
triple-agent protocol (Starzl et al., 1967) that was used for the first successful 
transplantation of the human liver in July 1967 and heart in January 1968. Subsequent 
developments in the field of transplantation and immunosuppression [including the 
discovery and subsequent clinical use of more potent immunosuppressants such as 
cyclosporine by Borel and Calne respectively, and the discovery of tacrolimus by Goto 
and its clinical introduction 3 years later (Starzl and Zinkernagel, 2001)] have greatly 
improved the clinical outcome of organ transplantation. Yet the immunosuppression is 
still non-specific, and prolonged treatment using these regimens can cause side-effects 
that include post-transplantation malignancy and infections. 
 
Elucidation of the mechanisms of allograft rejection and acceptance has allowed for the 
potential of reaching the goal of a sustained state of specific tolerance to donor 
alloantigens with minimisation or complete withdrawal of immunosuppression (Lechler 
et al., 2003). Recent reports have described several organ transplant recipients in whom 
allografts have maintained good function for upto five years without 
immunosuppressive treatment (Alexander et al., 2008; Kawai et al., 2008; Scandling et 
al., 2008). In two reports concerning combined kidney and haematopoietic stem cell 
transplantation, the authors attributed the successful outcome in their patients to the 
cotransplantation of donor stem cells (Kawai et al., 2008; Scandling et al., 2008). The 
third report, by Alexander et al., concerns a female recipient who received a completely 
HLA-mismatched liver from a deceased male donor but did not receive a donor stem 
cell infusion (Alexander et al., 2008). 
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The research conducted for this thesis investigates the potential of modified dendritic 
cells to induce donor-specific transplantation tolerance without the requirement for non-
specific immunosuppression. 
 
1.2. Dendritic Cells as Initiators and Regulators of Immune Outcomes 
 
Ralph Steinman discovered and subsequently characterised dendritic cells (DCs) in a 
series of landmark publications throughout the 1970s (Steinman and Cohn, 1973; 
Steinman and Cohn, 1974; Steinman et al., 1974; Steinman et al., 1975; Steinman et al., 
1979). DCs were first noted for their probing, tree-like or dendritic shapes (from the 
Greek ‘dendron’, meaning tree). Although DCs stained strongly for MHC class II, the 
cells lacked markers expressed by B cells or macrophages. Furthermore, Steinman 
observed that these cells did not have lymphocytic or phagocytic properties, and were 
abundant in peripheral lymphoid organs. DCs constitute a heterogenous population of 
professional, BM-derived antigen presenting cells (APC). Matzinger coined the term 
‘professional APC’ in recognition of the prominent antigen-presenting role of certain 
cells. DCs are the most efficient of all APCs (Lassila et al., 1988). 
 
DCs are specialised to capture and process antigens in vivo (Trombetta and Mellman, 
2005), converting proteins to peptides that are presented on MHC molecules and 
recognised by T cells. DCs also migrate to T cell areas of lymphoid organs, where the 
two cell types interact to bring about clonal selection (Cyster, 1999; Itano and Jenkins, 
2003; Randolph et al., 2005). The DC system is designed to harness the recognition 
repertoire of T cells, each with a randomly arranged antigen receptor. Following clonal 
selection, DCs control many T cell responses. Antigen-selected T cells undergo 
extensive expansion, a thousand-fold or more, as a result of division at a rate as a high 
as 2-3 cell cycles a day (Hawiger et al., 2001). A T cell clone subsequently undergoes 
differentiation to bring about an array of potential helper, killer and suppressive 
activities. For example, under the control of DCs, CD4+ helper T cells acquire the 
capacity to produce powerful cytokines like interferon-γ (IFNγ) to activate macrophages 
to resist infection by facultative and obligate intracellular microbes [T helper 1 (TH1) 
cells] (Maldonado-Lopez et al., 1999; Pulendran et al., 1999; Napolitani et al., 2005), or 
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interleukin (IL)-4, -5 and –13 to mobilise white cells that resist helminths (TH2 cells) 
(Seder et al., 1992) or IL-17 to mobilise phagocytes at body surfaces to resist 
extracellular bacilli (TH17 cells) (Leibundgut-Landmann et al., 2007). 
 
DCs differentiate or mature in distinct ways in response to a spectrum of environmental 
and endogenous stimuli. The maturation pathway then helps to designate which 
lymphocyte functions will be induced, and which products will be made by both DCs 
and lymphocytes. DCs are key regulators of immune outcomes, and depending on 
circumstance, are capable of promoting or suppressing T cell responses (Moser, 2003). 
There is accumulating evidence that DCs can induce tolerance, rather than immune 
activation, to the antigens they present, and it has become clear that unactivated or 
immature DCs might be important in maintaining tolerance toward antigens in the 
periphery (Steinman et al., 2003). At an immature stage of development, DCs act as 
sentinels in peripheral tissues, continuously sampling the antigenic environment. It has 
been shown that DCs may also have a role transporting antigens from the periphery for 
the purpose of inducing and/or maintaining peripheral tolerance in the draining lymph 
node (Kurts et al., 1997; Huang et al., 2000). 
 
On maturation, DCs will redeploy, although the mechanism of the rapid and extensive 
DC differentiation is still unclear. One mechanism may be the high levels of required 
transcription factor nuclear factor-κB (NF-κB) family proteins, with each family 
member(s) able to control different DC responses (Steinman and Banchereau, 2007). 
Similarly, precursor DCs have been recognised to rapidly adapt their morphology and 
function in response to stimuli from the extracellular environment (Shortman and Naik, 
2007). However, despite such intensive study of DCs, the mechanisms involved in the 
formation and regulation of dendrites, key to their discovery and manifest both in 
immature and mature forms, remain poorly defined (Chain, 2003). A coordinated 
process orchestrated by the Rho GTPases and mediated by interactions between β1 
integrins and the extracellular matrix, however, has been reported (Swetman et al., 
2002). Any encounter with microbial products or tissue damage initiates the migration 
of the DC to lymph nodes and alteration in the expression of hundreds of genes 
(Granucci et al., 2001), leading to the synthesis of cytokines, for example IL-12 and 
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type I interferons, which enhance innate and adaptive resistance (Reis e Sousa et al., 
1997; Dalod et al., 2002). Although cytokines in turn can induce some components of 
DC maturation, the DCs that directly interact with microbial ligands are the 
immunologically more-active ones (Sporri and Reis e Sousa, 2005). The types of 
cytokines are influenced by the DC subset and the mode of DC activation. Several 
chemokines are also secreted in groups at a time (Sallusto et al., 1998), attracting 
different cells in succession to the site of DC maturation: phagocytes, memory 
lymphocytes and naïve T cells (Piqueras et al., 2006).  
 
Maturation regulates antigen processing by lowering the pH of endocytic vacuoles, 
activating proteolysis and transporting MHC-peptide complexes to the cell surface 
(Trombetta and Mellman, 2005). Importantly, maturing DCs remodel their surface, 
typically expressing several membrane-associated costimulatory molecules, as detailed 
in section 1.3, including members of the B7, TNF and Notch families (Fujii et al., 
2004). Maturation of DCs has been demonstrated to involve the formation of MHC-
peptide complexes within the MHC class II and HLA-DM-positive compartments 
(Pierre et al., 1997). This is associated with high levels of CD86 expression in 
particular. Furthermore, the MHC-peptide complexes are found in clusters at the DC 
surface together with CD86, suggesting that high levels of MHC-peptide and 
costimulatory molecules, in a clustered distribution, initiate the formation of the 
immunological synapse (Turley et al., 2000). The definition of changes in DCs that link 
innate to adaptive immunity in vivo is still unknown- it has been suggested that the view 
of a combination of MHC-peptide (‘signal one’) and high CD86 expression being 
sufficient to drive T cell immunity is oversimplified (Steinman and Banchereau, 2007). 
To influence T cell differentiation, DCs have been shown to require the ability to 
produce cytokines such as IL-12 and type I interferons, or membrane-associated TNF 
family receptors- like CD40 (Fujii et al., 2004) and lymphotoxin receptors- and TNF 
family members- like CD70 and OX40L to induce TH1 (Soares et al., 2007) and TH2 
(Ito et al., 2005) cells respectively. 
 
It has been suggested that DC maturation can be induced by signals provided by 
invading pathogens, tissue inflammation or injury (Janeway, 1992; Matzinger, 1994)- 
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thus healthy tissues may act as de facto privileged sites because they lack pro-
inflammatory or ‘danger’ signals (Matzinger, 1994; Medzhitov and Janeway, 2002). In 
general, any tissue insult induces some degree of local inflammation, consisting of the 
influx and activation of immune cells, increased cytokine production, altered cell 
differentiation and metabolic stress responses, and perhaps unmasking of normally 
cryptic antigens. However, inflammation does not automatically promote an immune 
response- some forms of inflammation appear to actively suppress antigen-specific 
responses by the adaptive immune system (Mellor and Munn, 2008). For example, 
during infections, TLR ligands signal the presence of microorganisms. But the immune 
system must discriminate between pathogenic invasion and beneficial commensal 
microorganisms at mucosal surfaces (Sansonetti and Di Santo, 2007)- both induce 
inflammation and introduce foreign antigens and TLR ligands, yet in some settings TLR 
ligands provoke immunosuppressive and tolerogenic responses (Mellor et al., 2005; 
Wingender et al., 2006). This process of discrimination is not well understood, and may 
reflect subtle features of inflammation (e.g. the type and variety of TLRs engaged), or 
modulation of outcomes by pathogen-specific regulatory T cells. It has also been 
proposed that, in the steady state, DCs have the capacity for the induction of T cell 
tolerance to those self and environmental proteins that are readily processed (Steinman 
et al., 2000). This would ensure that DCs selectively present microbial proteins rather 
than proteins derived from dying self-tissue. 
 
DCs contain a specialised endocytic system (Guermonprez et al., 2002; Trombetta and 
Mellman, 2005), having many uptake receptors that deliver antigen to processing 
compartments (Dudziak et al., 2007). DCs then present peptides from processed 
proteins to CD4+ and CD8+ T cells, and self and microbial glycolipids to NKT cells 
(Banchereau et al., 2000). Although exogenous antigens are generally considered to be 
processed through the endosomal pathway leading to presentation of peptides via MHC 
class II (Rudensky et al., 1991; Chicz et al., 1993), a class I pathway for presentation of 
exogenous antigens has been described for DCs (Safley and Ziegler, 1994; Wick and 
Ljunggren, 1999; Castellino et al., 2000). Following uptake of antigen, DCs are able to 
‘cross-present’ antigens on MHC class I to elicit CD8+ cytotoxic T cells (Albert et al., 
1998; Jung et al., 2002; Heath et al., 2004). During cross-presentation, non-replicating 
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protein antigens are internalised and gain access to the cytoplasm before being 
processed by the proteasome for peptide presentation on MHC class I. Critical steps 
seem to occur from less-acidic compartments. Cross-presentation allows DCs to induce 
CD8+ cytotoxic T cell responses to immune complexes, non-replicating forms of 
microbes and vaccines, and dying cells. 
 
Three subsets of CD11chi DCs have been identified in the spleen and lymph nodes of 
mice: CD8α+ DCs, CD4+CD8- DCs and CD4-CD8- DCs (Vremec et al., 2000; Ardavin, 
2003). In the steady state, CD8α+ DCs constitute 20-30% of the CD11chi DC population 
in the spleen, are semi-mature APCs and reside within the T cell areas. The remaining 
CD8- DCs are immature, located mostly in the marginal zone and throughout the red 
pulp of the spleen, and migrate to the T cell areas in response to stimulation by the 
presence of microbial antigens. Skin-derived DCs (Langerhans cells) and tissue 
interstitial DCs, that arrive from the periphery through the lymphatic circulation, also 
constitute DC populations in lymph nodes (Henri et al., 2001). The thymus is populated 
mostly by CD8α+ DCs (Corcoran et al., 2003). It is well recognised that thymic DCs 
induce tolerance to self antigens in vivo through the clonal deletion of CD4+CD8+ 
thymocytes (Brocker et al., 1997). CD8α+ DCs are restricted to murine DCs as human 
DCs as do not express CD8. Human DCs that have been most extensively studied are 
derived from peripheral-blood monocytes. Several subtypes of human DCs, including 
myeloid and plasmacytoid DCs in addition to epidermal Langerhans cells, have been 
described both in vitro and in vivo (Shortman and Liu, 2002). Plasmacytoid DCs have 
also been identified in mice (Asselin-Paturel et al., 2001; Nakano et al., 2001)- they do 
not express markers of T-, B- or myeloid lineages, but exhibit plasma cell-like 
morphology in the steady state, and similar to other DC subtypes, are of BM origin. Due 
to the relatively low numbers of DCs present within secondary lymphoid organs of 
mice, the ability to generate large numbers of DCs from murine BM cultures has been 
of immense use to immunologists for in vivo studies (Inaba et al., 1992). For use in 
murine and human DC studies, it has been suggested that culture-generated DCs might 
be more like the immunogenic type of DC that is generated in vivo in response to 
microbial infections, whereas DCs freshly isolated from infected mice might be 
involved in the steady-state maintenance of self-tolerance (Shortman and Liu, 2002). 
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1.3. Costimulation and T Cell Activation 
 
In addition to antigen recognition through the T cell receptor (TCR), which accounts for 
the specificity of a T cell response (‘signal one’), the APC / DC - T cell interaction also 
involves the engagement of costimulatory molecules on the T cell (‘signal two’) 
[Figure 3]. The most important of these is CD28, which engages B7.1 (CD80) and B7.2 
(CD86) on the DC (Gimmi et al., 1991; Harding et al., 1992), though other interactions 
(e.g. ICOS and PD-1) are important in controlling the process of T cell activation 
(Okazaki et al., 2002; Sharpe and Freeman, 2002). It has been suggested that the two-
signal model oversimplifies the contribution of each signal because the strength of the 
TCR signal has a quantitative influence on T cell activation and differentiation (Sloan-
Lancaster et al., 1993; Viola and Lanzavecchia, 1996). T cell activation might occur in 
the absence of signal two if the TCR signal is very strong. Furthermore, T cell 
activation has also been shown to occur in the absence of signal one after binding of 
CD28 by ‘superagonist’ antibodies (described in section 1.3.1).  
1.3.1. The CD80/CD86 – CD28/CTLA4 Costimulation Pathway 
 
CD80 and CD86 are both upregulated on mature DCs (Freeman et al., 1991; Boussiotis 
et al., 1993; Freeman et al., 1993a; Freeman et al., 1993b; Freeman et al., 1993c; 
Walunas et al., 1994) and were the first described members of what is now recognised 
as the larger B7 subfamily. Members of the B7 subfamily belong to the 
immunoglobulin superfamily of proteins. Both CD80 and CD86 have dual specificity 
for two CD28 family members, the stimulatory receptor CD28 and the inhibitory 
receptor cytotoxic T lymphocyte antigen-4 (CTLA4). On most APC populations, CD86 
is expressed constitutively at low levels and is rapidly upregulated, whereas CD80 is 
inducibly expressed later after activation (Freeman et al., 1993c; Hathcock et al., 1994). 
The earlier expression of CD86 indicates that this molecule is the more important 
costimulator for initiating immune responses and this has been confirmed by analysis of 
knockout mice. CD80 and CD86 provide important costimulatory signals to augment 
and sustain a T cell response via an interaction with CD28 (Lenschow et al., 1996). 
CD28 transmits a signal that synergises with the TCR signal to promote T cell 
activation (Lanzavecchia et al., 1999). With the exception of the use of superagonist 
antibodies (see below), CD28 engagement does not usually have a physiological effect  
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Figure 3. Costimulatory Molecule Expression during Dendritic Cell-T Cell Interactions. 
In addition to MHC-peptide recognition through the TCR, which accounts for the specificity of the 
response, the DC : T cell interaction involves the engagement of costimulatory molecules on the T cell: 
Two members of the B7 family which are expressed by the DC, CD80 (B7-1) and CD86 (B7-2), have dual 
specificity for two CD28 family members, the stimulatory receptor CD28 and the inhibitory receptor CTLA4. 
CTLA4 is the higher affinity receptor for CD80 and CD86. On most DC populations, CD86 is expressed 
constitutively at low levels and is rapidly upregulated, whereas CD80 is inducibly expressed later after 
activation. CD28 is constitutively expressed on the surface of T cells, whereas CTLA4 expression is rapidly 
upregulated following T cell activation. In contrast to CD28, ICOS is not expressed constitutively on naïve 
T cells but is induced rapidly on T cells after TCR engagement, indicating that ICOS might provide 
costimulatory signals to activated T cells. PD-1 is expressed by activated, but not by unstimulated T cells. 
PD-1 is a receptor for two novel B7 homologues, PD-L1 and PD-L2. CD28 family members are 
immunoglobulin superfamily members with a single immunoglobulin V-like domain. CD28 and CTLA4 have 
a MYPPPY motif that is essential for binding CD80 and CD86, whereas ICOS has a FDPPPF motif and 
binds ICOSL but not CD80 and CD86. PD-1 only binds PD-L1 and PD-L2, and the PD-1 ligands do not 
bind to additional CD28 superfamily members. Abbreviations: CTLA4, Cytotoxic T Lymphocyte Antigen 4; 
ICOS, Inducible T Cell Costimulator; ICOSL, ICOS Ligand; MHC, Major Histocompatibility Complex; PD-1, 
Programmed Death 1; PD-L1, PD-L2, PD-1 Ligands 1 and 2; TCR, T Cell Receptor. 
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in the absence of TCR signalling. Early studies demonstrated that the main effects of 
CD28 costimulation are to augment and sustain T cell responses initiated by antigen-
receptor signalling by promoting T cell survival and thereby enabling cytokines to 
initiate T cell clonal expansion and differentiation (Thompson et al., 1989; Shahinian et 
al., 1993; Lucas et al., 1995; Sperling et al., 1996). CD28 signalling has also been 
described to regulate the threshold for T cell activation and significantly decrease the 
number of TCR engagements needed for effective T cell activation (Viola and 
Lanzavecchia, 1996). CD28 also optimises the responses of previously-activated T 
cells, promoting the production of IL-2 and T cell survival. Some responses are also 
independent of CD28 although it is not fully clear whether these responses are 
costimulation-independent because of strong antigenic stimuli or whether there is a 
dependence on other costimulatory pathways. 
 
Approximately 12 years ago, a new group of CD28 antibodies, later called CD28 
superagonists, were described (Tacke et al., 1997). In contrast to conventional CD28 
antibodies, CD28 superagonists are capable of triggering the activation of rat, mouse 
and human T cells upon binding to CD28 alone. How CD28 superagonists induce 
polyclonal T cell activation (and thus provide signal one and two simultaneously) is still 
not completely understood, one hypothesis being that CD28 superagonist might induce 
massive clustering of CD28, thereby generating signalling patches within the membrane 
(Schraven and Kalinke, 2008). Another hypothesis is that CD28 superagonists induce T 
cell activation by amplifying tonic signals that emanate from the unligated TCR and 
(Schraven and Kalinke, 2008). Soon after their discovery, it was recognised that these 
superagonist antibodies can induce a preferential activation and expansion of 
immunosuppressive regulatory T cells in rats and mice (Lin and Hunig, 2003), and that 
these particular properties can be used to ameliorate the onset, progression and clinical 
course of experimental autoimmune disease (Hunig, 2007). On the basis of these 
promising findings, it seemed possible to deploy CD28 superagonist for in vivo 
modulation of human autoimmune disease. Consequently, after an enormous amount of 
preclinical data had been collected (including experiments involving cynomolgus and 
rhesus monkeys), a phase I trial was conducted in which the humanised CD28 
superagonist TGN1412 was administered to six healthy volunteers. Unfortunately, 
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however, TGN1412 induced a rapid and massive cytokine storm that caused severe and 
life-threatening adverse effects in all six volunteers (Suntharalingam et al., 2006), 
leading to immediate suspension of the trial and re-evaluation (at the international level) 
of how trials are regulated. 
 
As stated earlier, CTLA4 is the higher-affinity receptor and alternative ligand for CD80 
and CD86 (Linsley et al., 1992a; Linsley et al., 1994; Peach et al., 1994)- CTLA4 is 
upregulated on activated T cells, binds with higher affinity to CD80/86 than CD28 and 
serves to control T cell activation (Walunas et al., 1994). Whereas CD28 is 
constitutively expressed on the surface of T cells (Gross et al., 1992), CTLA4 
expression is rapidly upregulated following T cell activation (Linsley et al., 1996). A 
strong inhibitory role for CTLA4 is demonstrated by the phenotype of CTLA4-deficient 
mice, which develop a massive lymphoproliferative disorder characterised by 
polyclonal T cell proliferation and early lethality (Tivol et al., 1995; Waterhouse et al., 
1995). CTLA4 modulates the threshold of signals needed for T cell cytokine production 
and proliferation (Chambers et al., 1997; Thompson and Allison, 1997). Furthermore, 
ligation of CTLA4 can lead to negative regulation of the cell cycle and inhibition of the 
transcription factors NF-κB, nuclear factor of activated T cells (NF-AT) and activator 
protein-1 (AP-1) (Fraser et al., 1999; Olsson et al., 1999). Several mechanisms have 
been reported for CTLA4-mediated inhibition of T cell activation, such as ectodomain 
competition for CD28 binding to CD80 and CD86 (Masteller et al., 2000), disruption of 
CD28 localisation at the immunological synapse, modulation of TCR signalling by the 
phosphatases SH2 domain-containing protein tyrosine phosphatase (SHP-2) and the 
serine-threonine phosphatase PP2A (Cilio et al., 1998; Chuang et al., 1999; Chuang et 
al., 2000), as well as interference with the expression or composition of lipid rafts on 
the surface of T cells (Martin et al., 2001; Darlington et al., 2002; Chikuma et al., 2003). 
CTLA4 has a crucial role in regulating peripheral T cell tolerance, which might be 
induced not because of the absence of CD80/86-mediated costimulation, but as a 
consequence of CTLA4-CD80/86 interactions (Perez et al., 1997; Greenwald et al., 
2001). Despite the fact that the affinity of the interaction of CD80 and CD86 with 
CTLA4 is at least one log higher than their interaction with CD28, the costimulatory 
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function of CD80/86 often dominates in vitro and in vivo (Chambers et al., 2001; 
Salomon and Bluestone, 2001). 
 
Despite its potent effects on T cell function, CTLA4 is primarily an intracellular antigen 
whose surface expression is tightly regulated by restricted trafficking to the cell surface 
and rapid internalisation (Alegre et al., 1996; Linsley et al., 1996). After initial 
transcription and translation, the CTLA4 protein associates with the clathrin adaptor 
complex AP-1 and is found predominantly in intracellular vesicles (Schneider et al., 
1999). A substantial amount of the CTLA4 protein is transported to the cell surface 
following TCR stimulation, however, it is rapidly endocytosed by a second clathrin 
adaptor complex, AP-2 (Shiratori et al., 1997). This is important because minor changes 
in surface expression levels could have major effects on the outcome of T cell 
activation. Furthermore, induction of CTLA4 surface expression after stimulation is 
temporarily restricted, and frequencies of CTLA4-expressing cells do not increase in 
later generations (Maszyna et al., 2003). In T cells, CTLA4 mRNA is first detected 1 
hour after TCR ligation, and peaks around 24-36 hours after stimulation when CTLA4 
is also detectable at the cell surface (Lindsten et al., 1993; Perkins et al., 1996). The 
stability of CTLA4 mRNA is linked to TCR signalling and costimulation. CD28 
costimulation increases the half-life of CTLA4 mRNA twofold compared with TCR 
engagement alone (Finn et al., 1997). 
 
Dependent on the cell type and activation status, CTLA4 is expressed at different levels. 
A characteristic of CTLA4 is its elevated level in activated T cells compared with naïve 
T cells. In naïve human T cells, intracellular CTLA4 is detectable only at low levels, 
whereas in murine naïve T cells, CTLA4 is not expressed (Wang et al., 2001; Jago et 
al., 2004). On the other hand, human memory T cells show significant amounts of 
intracellular CTLA4 (Jago et al., 2004). In these cells, CTLA4 is rapidly expressed on 
the cell surface upon activation compared with naïve T cells. Furthermore, CTLA4 is 
retained on the surface of memory T cells for a considerably longer time than in the case 
of activated naïve T cells (Jago et al., 2004). Intracellular CTLA4 is found in the trans-
Golgi network (Leung et al., 1995; Mead et al., 2005; Valk et al., 2006), as well as in 
endosomes, secretory granules (Linsley et al., 1996) and lysosomal vesicles (Iida et al., 
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2000). The localisation and translocation of CTLA4 represents a highly dynamic 
process and is a prerequisite for its function. CTLA4 localises to lipid rafts in the 
immunological synapse under conditions of APC-dependent TCR-CTLA4 coligation 
and T cell inactivation (Darlington et al., 2002). Its accumulation at the immunological 
synapse is regulated by the strength of the TCR signalling, and differences occur in the 
absence of an increase in total expression levels, suggesting that CTLA4 translocation is 
regulated by a post-translational mechanism. The strength of the TCR signal thus 
determines the extent of CTLA4 surface expression (Egen and Allison, 2002).  
 
Crystal structures of the molecules demonstrate that CD80 exists as a dimer with two 
CD28- or CTLA4-binding sites, creating the possibility of an ordered latticework of 
molecules at the site of T cell-APC contact (Ikemizu et al., 2000). Recent analysis of 
CD86 in solution or crystallised without CTLA4, however, has indicated that CD86 is 
unlikely to make stable dimers (Collins et al., 2002; Zhang et al., 2003). Furthermore, 
although it has been well documented that CD28 is a homodimer, recent evidence 
suggests that this dimer might only possess a single binding site for ligands, contrasting 
with the bivalent nature of the CTLA4 homodimer (Collins et al., 2002). This indicates 
that CD80 is probably a more potent ligand for CTLA4, based not only on its higher 
affinity but also its enhanced avidity. Despite having a weaker affinity for CD28, CD86 
is probably a more effective ligand for CD28 than CD80, in some circumstances, 
because its effects appear less opposed by CTLA4. The biophysical data described 
above has given rise to suggestions that are contrary to the general perception that 
CD80 and CD86 are interchangeable costimulators with differences mainly in kinetics 
of expression (which does not offer a satisfactory solution as to how the fate of T cell 
activation is regulated by CD28 and CTLA4). It has now been suggested that CD80 and 
CD86 have distinct preferences in engagement of their receptors and that CD80 is the 
major ligand for CTLA4 (Sansom et al., 2003). For example, in two unrelated tumour 
models, CD80-transfected tumours were significantly less immunogenic than those 
transfected with CD86 (Martin-Fontecha et al., 2000; LaBelle et al., 2002). In addition, 
in studies using vascularised cardiac allografts, CD80 was identified as the ligand for 
CTLA4 responsible for prolonged allograft survival (Judge et al., 1999; Yamada et al., 
2001b). It has thus been suggested that CD80-CTLA4 interactions occur more 
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effectively in the absence of CD86 expression, for example in the maintenance of 
homeostasis to autoantigens, and that on an immature DC, CD80 preferentially interacts 
with CTLA4 (e.g. expressed constitutively on Tregs), which in a non-inflammatory 
context, restricts T cell activation and acts to increase the threshold for activation 
(Sansom et al., 2003). However, there is also overwhelming evidence for CD86-CD28 
interactions being the initial interactions in this system followed later by CD80 and 
CTLA4 (Sharpe and Freeman, 2002), as described above. 
1.3.2. The ICOSL – ICOS Costimulation Pathway 
 
ICOS ligand (ICOSL) is another member of the B7 family and is expressed 
predominantly on B cells in addition to macrophages, DCs and several non-lymphoid 
tissues (Okazaki et al., 2002). The expression of ICOSL is upregulated by 
proinflammatory cytokines (such as TNFα and IFNγ) or LPS, and ICOSL binds to the 
inducible ICOS molecule expressed solely on activated T cells (Swallow et al., 1999; 
Yoshinaga et al., 1999). The MYPPPY motif, which is essential for binding of CD28 
and CTLA4 to CD80/86 ligands (Peach et al., 1994), is not conserved in ICOS but is 
instead FDPPPF, which is important for ICOSL binding (Hutloff et al., 1999). There is 
no detectable binding of CD80 or CD86 to ICOS (Yoshinaga et al., 1999; Beier et al., 
2000; Ling et al., 2000). In addition, CD28 has a consensus SH3-kinase binding site 
(PYAP) that is crucial for proliferation and IL-2 production (Holdorf et al., 2000), but 
ICOS lacks this site, indicating a structural basis for the distinct function of these 
receptors. In contrast to CD28, ICOS is not expressed constitutively on naïve T cells but 
is induced rapidly on T cells after TCR engagement (Hutloff et al., 1999; Yoshinaga et 
al., 1999), which indicates that ICOS might provide costimulatory signals to activated T 
cells. ICOS expression is influenced by both TCR and CD28 signals (Beier et al., 2000; 
Coyle et al., 2000; Mages et al., 2000; McAdam et al., 2000). CD28 costimulation 
enhances ICOS expression, and ICOS upregulation is markedly reduced in the absence 
of CD80 and CD86 (Aicher et al., 2000; McAdam et al., 2000), indicating that some of 
the functions ascribed to CD28 might be due in part to ICOS signalling. Studies 
undertaken with ICOS-/- mice demonstrate severely deficient Th cell responses- there 
were decreased levels of the TH2-dependent antibody isotype IgG1 and TH1-dependent 
antibody isotype IgG2a in the serum of the animals. Studies suggest an impaired T cell-
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dependent B cell response dependent on ICOS expression- with one study 
demonstrating ICOS-ICOSL interations facilitating downstream CD40-CD40L 
interactions (Dong et al., 2001; McAdam et al., 2001; Tafuri et al., 2001). Furthermore, 
there were defective immune responses characterised by an absence of T cell IL-4 
secretion but a normal TH1 cellular response demonstrated by T cell IFNγ secretion 
after immunisation. It has been demonstrated that blocking ICOS-ICOSL interactions 
by the used of ICOS-Ig can attenuate both acute and chronic rejection (Ozkaynak et al., 
2001). 
1.3.3. The PD-L1/L2 – PD-1 Costimulation Pathway 
 
In contrast to the restricted expression of CD28 and CTLA4 predominantly in T cells, 
Programmed Death-1 (PD-1), is expressed by activated T cells, B cells and myeloid 
cells (Agata et al., 1996). Similar to CTLA4, PD-1 appears to have a negative 
regulatory role on T cells (Freeman et al., 2000). PD-1 lacks both the MYPPPY motif 
found in CD28 and CTLA4, and the additional cysteine that allows these structures to 
homodimerise (Ishida et al., 1992; Shinohara et al., 1994; Vibhakar et al., 1997). The 
cytoplasmic domain of PD-1 contains two tyrosines, one of which forms part of an 
immunoreceptor tyrosine-based inhibition motif (ITIM) motif. Two novel B7 
homologues, PD-L1 and PD-L2, are ligands for PD-1 (Dong et al., 1999; Freeman et al., 
2000; Latchman et al., 2001; Tseng et al., 2001). PD-L1 and PD-L2 have been shown to 
share 20% and 88% homology with CD80/86 respectively, although expression patterns 
differ markedly (Freeman et al., 2000; Latchman et al., 2001). PD-1 only binds PD-L1 
and PD-L2, whereas PD-L1 has recently been demonstrated to interact with CD80 
specifically to inhibit T cell activation (Butte et al., 2007). PD-1 was isolated by 
subtractive hybridisation of a T cell hybridoma undergoing programmed cell death, 
hence the name PD-1 (programmed death 1) (Ishida et al., 1992). There is a 
hyperproliferative phenotype displayed by PD-1-/- mice that is consistent with the 
interpretation that PD-L1/L2-PD-1 interaction transduces an inhibitory signal that is 
required for lymphocyte homeostasis (Chambers et al., 1998; Nishimura et al., 1999). 
There is a delay in the onset of the phenotype in PD-1-/- mice which suggests that PD-1 
is not the primary inhibitory signal for T cells, and that the presence of PD-1 does not 
protect CTLA4-/- mice from developing severe lymphoproliferation. The converse is 
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also true, although a defect in B cells has been implicated in the disease observed in 
PD-1-/- mice. 
 
1.4. Alloantigen Recognition Pathways and Transplant Rejection 
 
Two major pathways of alloantigen recognition may contribute to graft sensitisation and 
effector mechanisms leading to graft rejection. These are known as the direct and 
indirect pathways of allorecognition. A third pathway, termed the semi-direct pathway, 
has also been described more recently. 
1.4.1. The Direct Pathway of Allorecognition 
 
T cells activated through the direct pathway encounter alloantigens presented by MHC 
molecules expressed on the donor APCs of the graft [Figure 4(a)]. In the case of MHC-
matched donors/recipients, the alloantigens may be peptides corresponding to minor 
MHC. Furthermore, alloantigens can be allogeneic donor MHC molecules in the case of 
an MHC-mismatched allograft. It is generally accepted that the direct pathway 
predominates in the immediate aftermath of transplantation, when graft-resident APCs, 
or ‘passenger leukocytes’, migrate to the surrounding lymphoid tissue. DCs are central 
to the direct pathway of allorecognition as they are specialised passenger leukocytes 
expressing costimulatory molecules with the capacity for activation of alloreactive 
CD4+ T cells. Two theories have been proposed to account for the high frequency of 
(previously unprimed) alloreactive T cells that induce a potent 
allorecognition/allorejection response: (i) multiple specificities comprise the 
alloresponse- a large number of differing MHC-peptide complexes are each recognised 
by T cell clones with different TCRs (Matzinger and Bevan, 1977) and (ii) individual 
allogeneic MHC determinants are expressed at a high density on a single APC, resulting 
in the activation of a large number of T cell clones varying in affinity for a particular 
allodeterminant (Bevan, 1984). Evidence of T cells participating in the direct pathway 
of allorecognition has been demonstrated in several models. For example, the 
reconstitution of severe combined immunodeficiency (SCID) or Rag1-/- mice with 
syngeneic CD4+ T cells allowed for rejection of MHC class II+ cardiac allografts but not 
MHC class II- grafts. In addition, MHC class II- Rag1-/- mice rejected allogeneic cardiac  
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Figure 4. Pathways of Alloantigen Presentation. 
The direct, indirect and semi-direct pathways of allorecognition. (a) In the direct pathway, recipient T cells 
engage with complexes of intact allogeneic MHC molecules and bound peptide (red circle) on the surface 
of donor DCs. (b) In the indirect pathway, alloantigens are either shed from the donor cell surface (as 
soluble MHC) or are taken up as dying or apoptotic allogeneic cells by responder DCs (e.g. immature 
DCs). Peptides derived from allogeneic MHC molecules are re-presented on the self-MHC molecules, 
especially MHC class II, of the recipient DCs, similar to conventional antigens. Helper cells that recognise 
donor MHC class I or II peptides on responder MHCs then help the formation and function of CD8+ T cells 
that directly recognise donor allogeneic MHC (e.g. by releasing IL-2 or other cytokines). (c) In chronic 
allograft rejection, recipient CD8+ T cells, stimulated directly by donor DCs or parenchymal cells, receive 
help from CD4+ T cells primed indirectly by recipient DCs after processing of donor antigens. Thus, in the 
semi-direct pathway of allorecognition, recipient DCs acquire and present intact donor MHC class I 
molecules to direct pathway CD8+ T cells, and simultaneously present internalised and processed donor 
MHC molecules as peptides to CD4+ T cells with indirect allospecificity. 
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allografts when reconstituted with CD4+ T cells (Pietra et al., 2000). The lack of CD8+ T 
cells in these mice in addition to the incapacity for MHC class II-restricted indirect 
pathway allorecognition indicate that CD4+ T cells with direct pathway allospecificity 
are sufficient to mediate rejection. 
1.4.2. The Indirect Pathway of Allorecognition 
 
An alternative pathway of allorecognition can be demonstrated by a study in which the 
prevention of direct pathway sensitisation (using animals in which graft-resident donor 
APCs were replaced by recipient-derived APC using chimeric animals that were created 
by BM transplantation) resulted in the prolongation of murine cardiac allograft survival 
(Krasinskas et al., 2000). However, prevention of direct pathway allorecognition did not 
prevent chronic rejection (demonstrated by the development of allograft vasculopathy) 
in all recipients, demonstrating that although the direct pathway may play a role in acute 
rejection, it is not essential for the development of chronic rejection. 
 
The indirect pathway of allorecognition refers to the presentation of an allogeneic 
determinant (e.g. a peptide derived from MHC or non-MHC molecules) by an APC of 
the host/recipient immune system [Figure 4(b)]. As a result of the indirect pathway, 
CD4+ T cells have the capacity for recognition of both MHC class I- and II-derived 
peptides presented by MHC class II expressed on the surface of recipient APCs. As 
donor-derived APCs are relatively short lived, the indirect pathway of allorecognition is 
generally believed to predominate as the alloresponse progresses (Chiffoleau et al., 
2003). Initial experiments demonstrating the substantial contribution of the indirect 
pathway to allograft rejection involved the depletion of donor APCs in transplanted 
tissues. Rejection was still observed suggesting an alternative pathway mediating 
transplant rejection (Talmage et al., 1976; Bowen et al., 1980; Lechler and Batchelor, 
1982a). Experiments with MHC class I-/- recipient mice that rejected skin grafts from 
MHC class II-/- donor mice provided strong evidence that the indirect pathway alone is 
sufficient to mediate allograft rejection (Auchincloss et al., 1993; Grusby et al., 1993). 
The recipient mice lack CD8+ T cells capable of direct recognition of MHC class I. 
Thus, the CD4+ T cells in the recipient mice can only be stimulated subsequent to 
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recognition of MHC class I presented indirectly in the context of recipient MHC 
class II. 
 
Allograft rejection mediated by the indirect pathway of alloantigen presentation 
involves the internalisation and processing of antigens from apoptotic, donor-derived 
cells (including secreted/shed antigens), and subsequent presentation by MHC 
molecules expressed on recipient DCs. As described in section 1.2, it was demonstrated 
that immature DCs are able to phagocytose apoptotic or necrotic cells and present 
peptides via MHC class I and class II (thus inducing alloreactive CD8+ and CD4+ T cell 
responses respectively) through a process confirmed later as cross-presentation (Albert 
et al., 1998; Inaba et al., 1998). 
 
The contribution of the indirect pathway to allorecognition is also demonstrated 
(indirectly) by several studies demonstrating that tolerance cannot be induced in the 
absence of the indirect pathway (Wise et al., 1998; Yamada et al., 2001a; Yamada et al., 
2003). For example, in one of the studies (Yamada et al., 2001a), treatment of MHC 
class II-/- recipient mice with anti-CD40L antibody, CTLA4-Ig and anti-CD8 antibody 
induced long-term survival of skin allografts. Tolerance was demonstrated by the 
capacity of the recipient T cells to protect a skin graft from the same donor strain 
subsequent to adoptive transfer. This was in contrast to the rejection of skin grafts 
observed if the same immunosuppressive protocol was used in a T cell response that 
was confined to the direct pathway (as a result of the use of recipient mice with MHC 
class II expression in the thymus but not peripheral APCs). This study demonstrates the 
necessity for tolerance induction to the indirect pathway for the maintenance of long-
term allograft tolerance. 
1.4.3. The Semi-Direct Pathway of Allorecognition 
 
The generation of a pathogen-specific cytotoxic CD8+ T cell response usually requires 
helper CD4+ T cells activated by the same APC to be effective (Ridge et al., 1998): this 
has been referred to as the ‘linked’ help or ‘three-cell’ model. The priming of naïve 
CD8+ T cells with direct allospecificity is considered to be less dependent on CD4+ T 
cells. However, several studies observed that CD4+ T cells with indirect donor 
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allospecificity can amplify effector CD8+ T cells with direct anti-donor allospecificity 
(Lee et al., 1994). These observations presented a challenge, in that they suggested 
‘unlinked’ help by which CD8+ T cells, activated directly by donor APCs, receive help 
from CD4+ T cells that are primed indirectly by recipient APCs. This has been referred 
to as the ‘four-cell problem’ (Jiang et al., 2004). Similarly, in transplantation tolerance 
models, it has been observed that CD4+ Tregs with indirect donor allospecificity 
induced by non-depleting anti-CD4 and anti-CD8 antibody treatment could regulate 
effector CD8+ T cells with direct pathway allospecificity for donor alloantigens, so long 
as the cells of the grafts carry both alloantigens. This appears to be a result of linked 
suppression (see section 1.7). A study demonstrating the transfer of intact MHC 
molecules from endothelium to DCs both in vitro and in vivo helped to resolve the 
‘four-cell’ problem and proposed a third mode of allorecognition- the ‘semi-direct’ 
pathway [Figure 4(c)] (Herrera et al., 2004). 
 
Although the transfer of intact MHC molecules between cells was demonstrated more 
than two decades ago (Sharrow et al., 1981), and MHC acquisition by mature CD8+ and 
CD4+ T cells from APCs has also been reported (Huang et al., 1999), it was 
demonstrated only recently that DCs are capable of acquiring significant levels of MHC 
class I and II molecules from other DCs and endothelial cells (Herrera et al., 2004). DCs 
have also been shown to acquire MHC molecules or allopeptides from other cells by the 
transfer of vesicles or fragments of the plasma membrane (Thery et al., 2002), a process 
which has been referred to as cell ‘nibbling’. Through the semi-direct pathway, recipient 
DCs were shown to acquire and present intact donor MHC class I molecules to direct 
pathway CD8+ T cells, and simultaneously present internalised and processed donor 
MHC molecules as peptides to CD4+ T cells with indirect allospecificity (Herrera et al., 
2004). This observation has thus provided a potential link between T cells with direct 
and indirect allospecificity. 
1.4.4. Donor Microchimerism as a Mechanism of Tolerance Induction to the Direct 
or Indirect Pathway 
 
Several models have been described in which donor-derived leukocytes are required for 
the induction of tolerance subsequent to donor antigen exposure, and that donor-derived 
Chapter 1: Introduction 
Adnan Khan, Department of Immunology, Division of Medicine, Imperial College London 41 
DCs may be required to amplify regulatory cells primed initially by antigen treatment. It 
has also been suggested that distinct subsets of tolerogenic DCs exist and are 
differentially distributed in different organs (Banchereau et al., 2000). Another study 
describing the role of donor DCs in transplantation tolerance concerns the phenomenon 
of donor microchimerism (Starzl et al., 1996). Donor cells were detected in several 
peripheral sites and in the thymus following organ transplantation. It has been argued 
that donor microchimerism is essential in the induction of donor-specific tolerance. 
However, it is unclear whether the persistence of donor leukocytes in tolerant recipients 
is the cause or effect of tolerance. It is also unclear whether donor microchimerism is a 
mechanism for the induction of tolerance to the direct or indirect pathway. Donor-
derived DCs may be required for the development of tolerance induced by donor 
antigen pre-treatment (Josien et al., 1998b), and exposure to immature DCs can prolong 
allograft survival. 
1.4.5. Cell-Mediated Effector Mechanisms 
 
Cell-mediated effector mechanisms of tissue/allograft destruction can either be direct 
(cytolytic) or indirect via a cytokine-mediated mechanism. Whereas a variety of 
cytokines have been implicated in allograft rejection, regulatory cytokines contributing 
to allograft tolerance have also been defined. CD4+ T cell responses include the two 
general classes already described in section 1.2: TH1 cells (which are associated with 
potent cellular immune responses) produce IL-2, IFNγ and TNFα whereas TH2 cells 
(associated with the downregulation of TH1 activity and upregulation of humoral 
immunity) produce IL-4, IL-5, IL-6, IL-10, IL-13 and IL-25 (Mosmann and Sad, 1996). 
IL-12 has a substantial role in driving TH1 responses and IL-4 in the induction of TH2 
responses. Furthermore, whereas TH1-associated cytokines have been implicated in 
allograft rejection in both experimental and clinical studies (Qin et al., 1993; Sayegh et 
al., 1995), TH2 cytokines have been implicated in studies demonstrating both the 
induction of allograft tolerance (Ganschow et al., 2001) and allograft rejection (Chan et 
al., 1995; Zheng et al., 1995; Strom et al., 1996; Minguela et al., 1999). 
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1.5. Corneal Transplantation and the Indirect Pathway of 
Allorecognition 
 
Corneal transplantation is the oldest and most commonly performed transplant (Larkin, 
1994). Eduard Zirm performed the first successful corneal transplant on 7 December, 
1905 on Alois Gloger, a day labourer from the Czech Republic who had been blinded in 
both eyes while slaking lime [Figure 5(a-b)]. The donor corneas were obtained from an 
11 year-old boy named Karl Brauer who was brought to Zirm’s clinic due to a blinding 
accident. To overcome the lack of microscopy and fine sutures, Zirm used strips of the 
conjunctiva, prising up one end of a strip and using it to ‘tape down’ the new cornea 
(Armitage et al., 2006). The current practice of corneal transplantation, however, is 
carried out under a microscope and involves the use of continuous or discontinuous 
sutures to secure the donor cornea into the recipient corneal bed [Figure 5(c)]. The 
cornea comprises three main layers: (1) a six- or seven-layer epithelium on the anterior 
surface and resting on Bowman’s zone that is continually regenerated from stem cells 
located in the limbal region; (2) the stroma, which makes up approximately 90% of the 
cornea and contains collagen fibres that are precisely arranged so as to be transparent 
and also contains scattered keratocytes; and (3) an endothelial monolayer on the 
posterior surface which is attached to Descemet’s membrane [Figure 5(d)]. Endothelial 
cells have the vital role of pumping water out of the stroma and maintain integrity of the 
cornea [Figure 5(e)]. Human corneal endothelial cells are arrested in the G1 stage of the 
cell cycle and are thus essentially non-replicative (Joyce et al., 1996). Corneal 
endothelial cells are of neural crest origin and are thus distinct from vascular endothelial 
cells. 
 
Corneal transplantation has always been considered to be successful and is typically 
carried out without systemic immunosuppression or HLA matching. This is because the 
cornea and anterior chamber of the eye form an immunologically privileged site 
(Streilein, 1999). There are several mechanisms that are responsible for this privilege, 
which can be divided into those that lead to ignorance of the foreign antigen and those 
that actively suppress or deviate immunological responses. An early study showed that 
allografts and even xenografts often survived for long periods in the anterior chamber of 
the eye (Greene, 1943). However, it was Sir Peter Medawar who fully analysed the 
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(a)                                                                   (b)
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Figure 5. Corneal Transplantation and Anatomy. 
(a) Dr. Eduard K Zirm (pictured on the operating table) performed the first successful human organ 
transplant on 7 December, 1905.  He performed corneal transplantation on (b) Alois Gloger, a day labourer 
from the Czech Republic who had been blinded in both eyes a year earlier while slaking lime. The corneas 
were obtained from an 11 year-old boy named Karl Brauer who was brought to Zirm’s clinic due to a 
blinding accident. To overcome problems due to the lack of microscopy and fine sutures, Zirm used strips 
of the conjunctiva, prising up one end of a strip and using it to ‘tape down’ the new cornea. Although 
complications affected one eye, the other remained clear allowing Glogar to return to work on his farm 
within three months. He retained his eyesight for the rest of his life. (c) The current practice of corneal 
transplantation is carried out under a microscope and involves (1) the scoring and removal of the cornea 
with a trephine, (2) the removal of a donor cornea and insertion into the corneal bed, and (3) the use of 
continuous (shown) or discontinuous sutures to secure the donor cornea. [Figures (a-c) adapted from 
(Ryan, 2005)]. (d) The cornea forms the transparent front surface of the eye, forming the anterior boundary 
of the anterior chamber and comprising three major layers. The anterior surface is formed by epithelial 
cells with a thickness of 6-8 cells, resting on Bowman’s zone. The majority of the stroma consists of 
collagen fibres that are precisely arrayed so as to preserve transparency, together with scattered 
keratocytes. The posterior surface is formed by the endothelial monolayer, which is attached to 
Descemet’s membrane. (e) Corneal endothelial cells are readily visible using in vivo specular microscopy, 
and form a monolayer of roughly hexagonal cells. The death of any endothelial cells will cause the 
migration and enlargement of surrounding cells into the denuded space. [Figures (d-e) adapted from 
(George and Larkin, 2004)]. 
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 reasons for this apparent dispensation in rabbits, and found that although small 
fragments of allogeneic skin survived well, previous and specific systemic sensitisation 
led to destruction provided that the grafts had been vascularised. They can and do, 
however, often survive in an avascular state and this, together with the absence of 
lymphatic drainage, prevents them from activating the immune response (Medawar, 
1948). He concluded that the unvascularised corneal transplant “cannot succumb to an 
immune reaction even if it can initiate one.” These data suggest that the anatomical 
location of the cornea, lack of blood supply, poor lymphatic drainage and paucity of 
DCs in the central cornea contribute toward the lack of immunorecognition of 
alloantigens (Niederkorn, 1999). There is also strong evidence of active suppression and 
deviation of the immune response in the cornea as a result of mechanisms such as the 
induction of apoptosis in CD95+ (alloreactive) lymphocytes by CD95L-expressing cells 
in the anterior chamber (Griffith et al., 1995; Stuart et al., 1997; Yamagami et al., 
1997). 
 
Immune deviation, frequently termed anterior chamber acquired immune deviation 
(ACAID) describes the phenomenon that a systemic immune response can be deviated 
from a cytotoxic, inflammatory response to a non-cytotoxic one if the antigen had 
previously been introduced into the anterior chamber of the eye (Streilein et al., 1980; 
Niederkorn, 1999). The mechanisms of ACAID include the exposure of APCs/DCs in 
the anterior chamber to cytokines such as TGF-β (Obritsch et al., 1992). It would be 
expected from the immune privilege mechanisms described here that corneal allografts 
are not rejected. However, this is not the case as approximately 25% of all grafts are lost 
within 5 years of transplant, predominately because of immunological rejection 
(Williams et al., 1992; Williams et al., 2008). In addition, there is a group of patients 
who are at high risk of graft rejection- these include those with previous grafts [recipient 
corneas in these patients contain high numbers of DCs and associated levels of MHC 
class I and class II- experimental induction of APC migration into donor cornea prior to 
transplantation results in a more rapid rejection (Ross et al., 1991), and adhesion 
molecule expression on the corneal endothelium, stroma and basal epithelium], 
paediatric recipients and those with ongoing inflammation or infection (Williams et al., 
1992; Comer et al., 2001). 
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Being composed of three major layers (as discussed above), corneal allograft rejection 
is described as either an epithelial, stromal or endothelial rejection (George and Larkin, 
2004). While epithelial rejection involves the anterior layer of the cornea, stromal 
rejection is associated with the migration of leukocytes through this layer. In endothelial 
rejection, endothelial cells are destroyed as a result of alloreactive cells passing through 
the anterior chamber and adhering to the posterior (endothelial) surface. This 
mechanism of rejection has the greatest effect on the function and stability of the 
corneal graft as any damage to endothelial cells is irreversible due to the cells being 
non-replicative. Endothelial rejection thus has major implications on corneal 
transparency. As the epithelial layer is capable of regeneration (and will eventually be 
replaced by recipient cells derived from the limbus), rejection in this layer is clinically 
not as important. Similarly, stromal rejection is associated with minor symptoms and 
does not involve aqueous inflammation (Larkin, 1994) 
 
In addition to the clinical necessity, and the long term potential for translation into 
clinical trials, corneal transplantation offers several useful features for experimentation 
in transplantation immunology. Allorecognition in corneal transplantation is primarily 
through the indirect pathway (Sano et al., 1999; Boisgerault et al., 2001; Illigens et al., 
2002), because of the paucity of resident MHC class II+ DCs in the donor (Gillette et al., 
1982). However, recent data has also demonstrated the presence of atypical (MHC class 
II negative) DCs present in the cornea which, upon grafting, migrate to the lymph nodes 
and express MHC class II. The role of these cells in corneal allograft rejection is still 
unclear (Hamrah et al., 2002; Liu et al., 2002). Additionally, rejection of corneal grafts 
is predominately through a CD4+ T cell-mediated pathway- depletion experiments 
demonstrate that CD4+ T cells are vital for graft rejection, with no clear role for CD8+ T 
cells (He et al., 1991; Illigens et al., 2002). As a result of corneal allograft rejection 
being mediated via the indirect pathway of allorecognition, matching for MHC class II 
would not be expected to prolong graft survival and in contrast with solid organ 
transplants, the beneficial effect of MHC class I matching on corneal graft survival is 
small (Vail et al., 1994). Murine corneal transplantation is thus an excellent model in 
which to test tolerance induction protocols specific for the indirect pathway of 
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allorecognition. The transparency of the cornea allows early and continuing monitoring 
of the immunological response, and it is relatively easy to obtain aqueous humour for 
measuring cytokines or infiltrating cells (Larkin et al., 1997; Rayner et al., 2000). 
Murine experimental corneal transplantation has been developed successfully, with graft 
survival being monitored daily by inspection and the use of established scoring systems 
for graft opacity and neovascularisation. Histology is performed to confirm rejection 
and to determine if there are any differences in the nature of rejection between different 
groups (George and Larkin, 2004). 
 
Topical glucocorticoid treatment is the mainstay of immunosuppression in corneal 
transplant recipients with the exception of those patients with a recognised risk of high 
rejection (Hill et al., 1991). Although topical steroid treatment has been demonstrated to 
prevent or reverse rejection episodes (Hudde et al., 1999), it is much less effective in 
preventing graft failure in high-risk patients (the criteria of which are described above) 
(Hemady et al., 1991). This has provided the impetus for the development of 
immunomodulatory approaches which would not involve systemic immunosuppression. 
There have been no reported clinical trials of immunomodulatory proteins in patients 
with corneal graft rejection, mainly due to a lack of clear cut, long-term graft survival in 
animal models (George and Larkin, 2004). Modification of corneal endothelial cells by 
gene therapy is an attractive alternative to the systemic use of immunomodulatory 
proteins (Fu et al., 2008). Ex vivo transduction of the cornea with gene transfer vectors 
has been demonstrated to be feasible using adenoviral, lentiviral, herpes and adeno-
associated viral vectors in a range of different species (Larkin et al., 1996; George et al., 
2000; Hudde et al., 2000). These vectors have been used for the expression of molecules 
that can prolong the survival of allografts, including IL-10 (Klebe et al., 2001), soluble 
TNF receptors (Rayner et al., 2001), CTLA4-Ig (Comer et al., 2002) and IL-4 (Pleyer et 
al., 2000). However, while viral vectors are highly efficient, they can be immunogenic 
and pro-inflammatory, and in at least one study vector controls have shortened graft 
survival when compared with untreated corneal grafts (Rayner et al., 2001). This 
demonstrates the need for lentiviral transduction of specific lymphopoietic cells (e.g. 
APCs such as DCs) with immunomodulatory molecules such that the cornea itself is not 
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transduced, a process which has been implicated in the premature destruction of the 
corneal endothelium, thus overcoming the beneficial effects of the transgene. 
 
1.6. Peripheral Tolerance, Anergy and Suppression 
 
Rodent studies have demonstrated that it is possible to exploit the mechanisms that 
normally maintain immune homeostasis and tolerance to autoantigens in order to induce 
tolerance to alloantigens (Waldmann, 2001). Central tolerance results from intrathymic 
deletion of T cells with high avidity for thymically-expressed antigens. Experimental 
methods to induce transplantation tolerance have thus included mechanisms of central 
tolerance. For example, BM transplantation has been used as a means to induce 
haematopoietic chimerism (Nikolic and Sykes, 1997). This results in the coexistence of 
donor- and recipient-derived lymphoid and myeloid cells. As a result, developing T 
cells that are reactive against the donor are deleted before they can exit the thymus, in 
the same manner as autoreactive T cells. 
 
Peripheral tolerance to autoantigens is maintained by a dynamic process involving 
several different mechanisms that restrict the development of a potentially destructive 
autoaggressive T cell response. These mechanisms include T cell depletion through 
activation-induced cell death, immunological ignorance of autoantigens (i.e. the 
apparent absence of antigen recognition), and the induction of T cell anergy (Lechler et 
al., 2001a; Lechler et al., 2003; Walsh et al., 2004b). Activation of the TCR in the 
absence of costimulation may result in the induction of T cell anergy (Schwartz, 1990). 
For example, without CD28 engagement the T cell that recognises the DC is not 
activated, but will undergo apoptosis or become anergic (Chai and Lechler, 1997). The 
capacity of anergic T cells to act as regulatory T cells means that costimulation-
defective antigen recognition can contribute to a sustained state of tolerance (Lombardi 
et al., 1994; Chai et al., 1999). The anergic state has often been associated with the lack 
of IL-2 production, and can be overcome by providing exogenous IL-2 stimulation 
(Schwartz, 1992). In addition, anergy of T cells has been demonstrated to be associated 
with TCR downregulation (Rocha and von Boehmer, 1991), although this phenomonen 
has not been observed in all examples of T cell anergy. In order to demonstrate the 
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induction of true anergy, it is necessary to show that T cells specific for the donor 
antigen are still present in the unresponsive population and that the donor-specific 
unresponsiveness is not due to a suppressive mechanism. In an early animal study, T 
cell unresponsiveness after TCR crosslinking was demonstrated after transplantation of 
I-E+ donor islets into I-E- recipients subsequent to anti-CD4 monoclonal antibody 
treatment (Charlton et al., 1994). 
 
Although T cell anergy, deletion and ignorance are important in the maintenance of self-
tolerance, they are by themselves not sufficient, as there is a need for active 
suppression/regulation of autoreactive cells- a mechanism that in transplantation 
tolerance is referred to as ‘dominant tolerance’ as unresponsiveness to a given set of 
antigens is actively maintained (Graca et al., 2005).  
 
The concept of suppressor T cells emerged when it was shown by experiments 
performed in London in the late 1960s that stimulation of the immune system by 
thymus-dependent antigens could give rise to the production of suppressor T cells that 
downregulate the differentiation of helper cells or antigen-specific T cells (Gershon and 
Kondo, 1970). A large number of studies were subsequently carried out with the aim of 
characterising the phenotype of suppressor T cells and their mode of action. Various 
conclusions were reached at that time, with their many flaws in interpretation which led 
to the discrediting of the whole concept (Moller, 1988). However, new evidence, in the 
context of the lessons that were learnt from this ‘black period’ indicated that T cell-
mediated suppression might indeed have a role in modulating immune responses (Bach, 
2003). Studies of ‘regulatory’ cells have identified multiple populations (which can be 
antigen-specific or non-specific) with different cell surface phenotypes and, to some 
extent, with different mechanisms of action (Jonuleit and Schmitt, 2003). CD4+CD25+ 
regulatory T cells (Tregs) are a naturally-occurring population of CD4+ T cells that 
constitutively express the IL-2 receptor α-chain (Sakaguchi et al., 1995; Sakaguchi, 
2004). These Tregs develop in the thymus and constitute approximately 5-10% of 
mature CD4+CD8- thymocytes and approximately 10% of peripheral CD4+ T cells (Itoh 
et al., 1999; Jordan et al., 2001). This specific population of cells have been shown to be 
potent suppressors of activated T cells in vitro (Thornton and Shevach, 1998; Piccirillo 
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and Shevach, 2001), and to be essential for the control of autoreactive T cells 
(Sakaguchi et al., 1995) and of the effector function of alloreactive CD4+ and CD8+ T 
cells in transplantation models in vivo (van Maurik et al., 2002). This fraction of CD4+ 
T cells has been shown to mediate tolerance on adoptive transfer into a naïve host 
(Sakaguchi, 2000; Hara et al., 2001; Waldmann and Cobbold, 2001; Graca et al., 
2002a). Furthermore, whereas adoptive tolerance of Tregs from long-term survivors to 
naïve recipients has resulted in the induction of tolerance, the removal of these cells 
from normal mice have been shown to enhance allograft rejection (Sakaguchi et al., 
1995). Additionally, CD4+ T cells with a regulatory function have been shown to play a 
critical role in the maintenance of transplantation tolerance (Qin et al., 1989).  
 
The forkhead/winged helix transcription factor FoxP3 was shown to be uniquely 
expressed by naturally-occurring CD4+CD25+ Tregs, and is thought to act as a master 
switch controlling Treg differentiation, especially in murine Tregs (Fontenot et al., 
2003; Hori et al., 2003). CD4+CD25+ Tregs have been shown to express high levels of 
CTLA4, although the relevance of this molecule to Treg effector function is still a topic 
of debate. It has been suggested that CTLA4 expressed by Tregs preferentially binds 
CD80/86 and prevents CD28-mediated signalling that might otherwise abrogate the 
suppressive function of Tregs (Takahashi et al., 2000). CTLA4 has also been implicated 
in the upregulation of FoxP3 expression induced by TGF-β, leading to the generation of 
adaptive CD4+CD25+ Tregs (Zheng et al., 2006). Furthermore, ligation of CTLA4 may 
increase TGF-β production, which in turn induces FoxP3 expression (Chen et al., 1998; 
Chen et al., 2003). It has recently been shown that enhanced CTLA4 signalling 
promotes the generation of CD4+CD25+FoxP3+ and CD4+CD25-TGF-β1+ Tregs (TH3 
cells) (Li et al., 2007). Although CTLA4-/- mice still produce functional naturally-
occurring Tregs, the induction of FoxP3 expression and generation of adaptive Tregs by 
TGF-β is abrogated in these mice, which might contribute to the severe 
lymphoproliferative phenotype in these mice (Zheng et al., 2006). Although the exact 
mechanism by which naturally-occurring Tregs exert their immunosuppressive effect is 
still being elucidated, these cells are known to suppress effector T cell proliferation in 
vitro through a cell contact-dependent mechanism that is largely cytokine independent 
(Takahashi et al., 1998; Suri-Payer and Cantor, 2001; Piccirillo et al., 2002). In addition 
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to CTLA4, the glucocorticoid-induced TNF receptor family-related receptor (GITR) 
expressed on the surface of Tregs has also been implicated in the function of these cells 
(Shimizu et al., 2002). This contact-dependent mechanism is in contrast to the 
suppression observed with in vivo models, where blockade of both IL-10 and TGF-β has 
been reported to abrogate Treg-mediated unresponsiveness to alloantigens (Josien et al., 
1998a; Hara et al., 2001). There is evidence that crosslinking of CTLA4 on activated T 
cells results in the expression/secretion of TGF-β (Chen et al., 1998; Nakamura et al., 
2001). This is relevant because TGF-β and its precursor can be detected on the surface 
of CD4+CD25+ Tregs but not CD4+CD25- cells, and the demonstration that the use of an 
anti-TGF-β monoclonal antibody can abrogate the suppressive capacity of Tregs also 
suggests the effector function of Tregs being mediated by cytokines (Nakamura et al., 
2001). Other cell surface markers in naturally-occurring Tregs, such as CD45RB, 
CD122, CD103 (αEβ7), CD127, CD134 (OX40), and CD62 (L-selectin), whose relative 
expression levels (or lack thereof in the case of CD127) can be used to define and 
isolate this Treg population in humans have been identified (Wood and Sakaguchi, 
2003). 
 
However, several cytokines and costimulatory molecules have been shown to play a 
role in Treg homeostasis. For example, CD4+CD25+ Tregs are absent in IL-2-/- mice 
(Papiernik et al., 1998) and are substantially reduced in CD28-/-, CD80/86-/- and 
CD40L-/- mice (Salomon et al., 2000). Despite a deficiency in the number of Tregs in 
CD28-/- or CD40L-/- mice, these cells retain their regulatory activity both in vitro and in 
vivo suggesting that these molecules are not required in Treg function. It has also been 
demonstrated that CD4+CD25+ Tregs do not proliferate or secrete IL-2 in response to 
TCR ligation yet suppress CD4+ and CD8+ T cell proliferation (Takahashi et al., 1998; 
Thornton and Shevach, 1998). Activated Tregs do not require further TCR ligation and 
inhibit T cell proliferation in a non-specific manner. Suppression by CD4+CD25+ Tregs 
can be mediated via direct T cell : T cell interaction. There is sufficient evidence that 
the initial activation of Tregs requires interaction with APCs and that Tregs (Cederbom 
et al., 2000) and anergic T cells (Taams et al., 2000; Vendetti et al., 2000) can modulate 
the expression of CD80/86 on APCs.  
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A role for naturally-occurring Tregs in the induction of transplantation tolerance was 
first demonstrated by their ability to suppress GVHD in murine models of BM 
transplantation. While transfer of allogeneic CD4+CD25- naïve or effector T cells 
normally leads to GVHD, cotransfer of purified CD4+CD25+ Tregs along with the 
CD4+CD25- T cells significantly delayed the onset of the disease (Taylor et al., 2001). 
Furthermore, in solid organ and tissue transplantation, cotransfer of CD4+CD25+ T cells 
into T cell-deficient mice along with naïve CD4+CD25- were shown to block the ability 
of the latter cell subset to reject minor or MHC-mismatched allogeneic skin grafts 
(Graca et al., 2002b). It has been demonstrated that alloantigen-specific CD4+CD25+ 
Tregs can be expanded in vitro by repeated stimulation of CD4+CD25+ T cells with 
stimulator cells in the presence of a high dose of exogenous IL-2 (Sakaguchi et al., 
2001). Furthermore, Tregs can been induced ex vivo after culturing with TGF-β 
(Yamagiwa et al., 2001). 
 
In addition to the naturally-occurring Tregs (which undergo development in the thymus 
and have inherent suppressive capabilities), populations of ‘induced’ Treg subsets 
whose immunosuppressive activity is induced/acquired in the periphery have also been 
identified [Figure 6(a)]. While these induced subsets are largely contained within the 
CD4+ T cell compartment, they are distinct from their naturally-occurring CD4+CD25+ 
counterparts. There are two major populations of inducible Tregs that are significant in 
the context of transplantation tolerance: TH3 cells and TR1 cells. The TH3 cell subset 
was first identified because of their role, via secretion of TGF-β, in the development of 
immune tolerance following oral tolerance (Chen et al., 1994). Although similar to TH3 
cells, TR1 cells secrete large amounts of IL-10 and were first characterised on the basis 
of their role in preventing autoimmune colitis (Groux et al., 1997). The induction of 
Tregs depends on peripheral factors including the maturity or type of the stimulating 
APC and the availability of cytokines such as TGF-β (Steinman et al., 2003). Whereas 
naturally-occurring Tregs exert their suppressive function through a cell contact-
dependent mechanism (as described above), both TH3 cells and TR1 cells appear to 
function independently of cell-to-cell contact and suppress immune responses through 
the secretion of immunosuppressive cytokines such as IL-10 and TGF-β (Stassen et al., 
2004). In addition, while TR1 cells have been demonstrated to migrate towards sites of  
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Figure 6. Natural and Inducible Regulatory T Cells. 
(a) Natural regulatory T cells (Tregs) express the cell surface marker CD25 and the transcriptional 
repressor FoxP3 (Forkhead box P3). These cells mature and migrate from the thymus and constitute 5-
10% of peripheral T cells in normal mice. Other populations of Ag-specific Tregs can be induced from 
naïve CD4+CD25- or CD8+CD25- T cells in the periphery under the influence of semi-mature dendritic cells, 
and the regulatory cytokines IL-10 and TGF-β. The inducible populations of Tregs include distinct subtypes 
of the CD4+ T cell: T regulatory 1 (TR1) cells, which secrete high levels of IL-10, no IL-4 and no or low 
levels of IFN-γ; and T helper 3 (TH3) cells, which secrete high levels of TGF-β. Although CD8+ T cells are 
normally associated with cytotoxic T-lymphocyte function and IFN-γ production, these cells or a subtype of 
these cells can secrete IL-10 and have been designated CD8+ regulatory T cells. (b) There has recently 
been a revision of the bimodal concept of fully mature DCs as inducers of immunity as opposed to 
immature DCs as promoters of T cell tolerance. It is now understood that DCs integrate a variety of 
incoming signals and decide whether protective immunity or Ag-specific unresponsiveness develops. 
Cytokine-modulated semimature DCs promote the conversion of naïve T cells into TR1 cells or TH3 cells 
that inhibit effector T cell responses via the cytokines described above. The inability to produce detectable 
amounts of bioactive IL-12p70 coupled with enhanced IL-10 release are unique features of cytokine-
modulated, semimature tolerogenic DCs. However, mature DCs might be critical in the expansion of 
preformed Tregs (as demonstrated in studies performed with bone marrow-derived GM-CSF-modulated 
DCs and by in vivo treatment with complete Freund adjuvant (CFA) and GM-CSF-differentiated DCs). 
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inflammation, naturally-occuring CD4+CD25+ Tregs are found predominantly within 
lymphoid organs (Cottrez and Groux, 2004). There have, however, been demonstrations 
of CD4+CD25+ Tregs present within tolerated allografts (Graca et al., 2002a). Another 
major difference between induced Tregs and their naturally-occurring counterparts is 
the expression of the transcription factor FoxP3. While FoxP3 is expressed by 
CD4+CD25+ Tregs, the regulation of TH3 or TR1 cell development by this transcription 
factor is debatable (Sakaguchi, 2003), although TGF-β has been shown to convert 
nonregulatory CD4+CD25- T cells into CD4+CD25+ Tregs that has been associated with 
the induction of FoxP3 expression (Chen et al., 2003). 
 
The induction of a Treg phenotype in otherwise alloreactive T cells has been suggested 
as a major contributing factor for the maintenance of tolerance generated using select 
mechanisms (Waldmann and Cobbold, 2001). For example, the repetitive stimulation of 
naïve T cells with immature allogeneic DCs has been shown to induce the development 
of a suppressive phenotype in responding T cells (Jonuleit et al., 2000). The maturation 
status and types of DCs present in the grafted tissue is a critical factor in determining 
the outcome of an alloreactive response [Figure 6(b)]. As will be discussed further in 
section 1.10, immature DCs do not stimulate optimal effector T cell responses owing to 
low costimulatory molecule and proinflammatory cytokine expression (e.g. IL-12)- such 
cells are often capable of inducing a Treg phenotype in responding T cells (Walsh et al., 
2004a). As discussed earlier, in order to silence T cells to autoantigens, short-lived 
immature, migratory DCs might transfer tissue-derived peptides to longer-lived 
tolerogenic DCs upon reaching the lymph node (Steinman et al., 2000). Interestingly, 
autoantigen transport, processing and presentation for tolerance induction by DCs have 
been shown to require partial maturation (Lutz and Schuler, 2002). In the absence of 
inflammation or TLR triggering, DCs will not produce IL-12, and DCs will be arrested 
at a semimature stage. Furthermore, the residence of DCs in a tolerising milieu (e.g. in 
mucosal or immune-privileged sites) affects their capacity for priming Tregs. DCs 
isolated from Peyer’s patches, lungs or the anterior chamber of the eye display a mature 
phenotype, secrete IL-10 but not IL-12, and drive the development of TR1 cells (Lutz 
and Schuler, 2002). More intriguingly, fully mature, immunologically-competent DCs 
have been demonstrated to generate ‘tolerogenic peptides’ upon processing of an 
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autoantigen, thyroid peroxidase (Quaratino et al., 2000). Accordingly, antigen-loaded, 
mature DCs can expand CD4+CD25+ Tregs with a retained ability to suppress the 
proliferation of nonregulatory T cells (Yamazaki et al., 2003). There is a growing body 
of evidence and suggestion that DC maturation is neither a distinguishing feature of 
immunogenic or tolerogenic DCs, or a control point for initiating immunity (Rutella et 
al., 2006). Furthermore, in addition to their maturation state, the multiplicity of existing 
DC subtypes have been demonstrated to induce Treg (e.g. TH3 or TR1) phenotypes 
irrespective of their maturation state (Lavelle et al., 2003; Wakkach et al., 2003). 
 
DCs, either at an immature or semimature stage, can induce both naturally-occurring 
CD4+CD25+ Tregs and TR1 cells either in vitro or in vivo (Vigouroux et al., 2004; 
Battaglia et al., 2006), and upregulation of Jagged-1 (Notch ligand) on DCs has been 
shown to induce TH3 cells (Yvon et al., 2003). TNF-α has been used in a study to 
generate murine semimature IL-12- DCs that express high levels of MHC class II and 
costimulation but do not themselves secrete IL-12 (Verginis et al., 2005). Such 
thyroglobulin-pulsed, TNF-α-matured/semimature DCs were shown to induce IL-10-
secreting CD4+CD25+FoxP3+ Tregs capable of suppressing thyroglobulin-specific T 
cells in a cell contact-dependent manner (Verginis et al., 2005). In cases of GVHD after 
BM transplantation, experimental evidence generated in vitro has indicated that the 
tolerising capacity of semimature DCs might be restricted to antigen-specific CD4+ T 
cells while CD8+ T cell effector functions remain unaffected (Kleindienst et al., 2005). 
As described above, mature DCs have been shown to expand CD4+CD25+ Tregs with 
retained suppressive activity and are capable of preventing the onset of diabetes in NOD 
mice (Yamazaki et al., 2003; Tarbell et al., 2004; Brinster and Shevach, 2005). These 
studies thus highlight that mature DCs might be critical for the restimulation and/or 
expantion of functional Tregs. 
 
In addition to regulatory cells within the CD4+ compartment, the presence of CD8+ 
Tregs, TCR+CD4-CD8- T cells and NK Tregs have also been reported and demonstrated 
to play a role in different models of transplantation tolerance (Zhang et al., 2000; Seino 
et al., 2001; Zhou et al., 2001; Gilliet and Liu, 2002). 
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1.7. Regulatory T Cells in the Mediation of Linked Suppression and 
Infectious Tolerance 
 
As described earlier using various theories (section 1.4), owing to the high frequency of 
T cells that are able to recognise and respond to alloantigens (primarily the products of 
genes encoded within the MHC), it is believed that the large-scale deletion of 
alloreactive T cells is required in order to achieve transplantation tolerance (Suchin et 
al., 2001). Complete deletion of alloreactive cells would ensure that even in the 
presence of the immunological stimuli in the allograft-bearing recipient, an alloresponse 
could not be generated (Sykes, 2001). In humans that would require haematopoietic cell 
transplantation after myeloablation in order to induce tolerance resulting from 
intrathymic clonal deletion of thymocytes with TCRs specific for antigens of the 
transplanted haematopoietic cells (Ramsdell and Fowlkes, 1990). As described in 
section 1.1, two recent reports have described renal transplant recipients in whom 
allografts have maintained good function for upto five years without 
immunosuppressive treatment (Kawai et al., 2008; Scandling et al., 2008). The authors 
attributed the successful outcome in their patients to the cotransplantation of donor stem 
cells after total lymphoid irradiation. In the case of peripheral tolerance strategies, data 
derived from numerous studies with experimental animals suggests that following 
depletion, the ‘maintenance’ phase of tolerance requires the presence of Tregs that can 
act on any remaining alloreactive T cells in addition to new thymic emigrants (Walsh et 
al., 2004b). 
 
CD4+CD25+ Tregs have been shown to play a crucial role in dominant transplantation 
tolerance. While induced Tregs represent a subset distinct from naturally-occurring 
CD4+CD25+ Tregs, there is evidence indicating that CD4+CD25+ Tregs play an 
important role in the induction of these cells, promoting otherwise potentially graft-
destructive effector T cells to adopt a TR1 suppressor phenotype (Dieckmann et al., 
2002; Jonuleit et al., 2002). The adoption of a CD4+CD25- suppressor phenotype in 
non-regulatory T cells has also been demonstrated under the influence of TGF-β (Chen 
et al., 2003). This mechanism might involve either direct cell-cell interaction, 
involvement of a third cell (such as an APC), soluble mediators, or a combination of the 
three factors. TGF-β has been found in tolerated grafts, which suggests that induced 
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Tregs may develop and exert their influence directly at the site of the graft (Josien et al., 
1998a). A study has also demonstrated that CD4+CD25+ Tregs can develop from CD25- 
precursors in thymectomised mice (Karim et al., 2004) and that these Tregs can prevent 
the rejection of skin allografts. The data suggests that inducible Tregs might prolong 
allograft survival without newly-generated innate Tregs entering the periphery. A role 
for CD4+CD25+ Tregs in the induction of a regulatory phenotype in otherwise 
nonsuppressive T cells brings together observations from numerous studies concerning 
the role of naturally-occuring and inducible Treg subsets in the induction of 
transplantation tolerance (Cottrez and Groux, 2004; Waldmann et al., 2004). These two 
subsets can thus act in a cooperative fashion to suppress potential alloreactive T cell 
responses. 
 
As explained in detail in section 1.4, it is believed that indirect allorecognition 
predominates over direct pathway allorecognition with increasing duration of 
engraftment. Alongside studies demonstrating a requirement for the continuous 
presence of antigen for the maintenance of transplantation tolerance (Chen et al., 1996; 
Onodera et al., 1998), the increasing role of the indirect pathway with the progression of 
an alloresponse suggests that it is this pathway that is the predominant mode of 
allorecognition by Tregs (Scully et al., 1994). As described in section 1.4, this was 
demonstrated very elegantly in a study exploring the relative contributions of the direct 
and indirect pathways of allopresentation to transplantation tolerance. The results 
demonstrated that transplantation tolerance could be achieved using costimulatory 
blockade in the absence of direct allorecognition (using mice deficient in MHC class II) 
but difficult to achieve in the absence of indirect allorecognition [resulting from 
transgenic expression of MHC II on thymic epithelium (Yamada et al., 2001a)]. The 
major question of how Tregs recognising only a small subset of graft-derived antigens 
via the indirect pathway of allorecognition can block the response to all graft-derived 
antigens has been painstakingly investigated for over a decade. For example, 
transplantation tolerance was achieved in a rat model through the oral administration of 
multiple MHC-derived peptide alloantigens (Sayegh et al., 1992). The tolerance 
observed in the study was attributed to immunoregulatory T cells in a subsequent study 
(Hancock et al., 1993). Furthermore, it was shown that allograft tolerance could be 
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achieved through oral administration of a single alloantigen present in the graft (Niimi 
et al., 2001). 
 
The tolerising potential of a single alloantigen, which can subsequently confer 
responsiveness in a dominant manner against all other antigens present within the graft 
has been termed ‘linked suppression’ and is dependent on the action of Tregs [Figure 7] 
(Waldmann and Cobbold, 2001). Linked suppression occurs when a potentially 
alloreactive T cell comes under the tolerising influence of a Treg as both cells recognise 
their respective alloantigens presented by the same APC (Davies et al., 1996; Honey et 
al., 1999; Stassen et al., 2004). This effectively leads to the ‘re-education’ of the 
potentially destructive alloreactive T cell with the induction of a Treg phenotype. More 
importantly, this newly-generated Treg can in turn induce other naïve CD4+ T cells to 
adopt a regulatory phenotype, thus propagating the tolerant state. (Walsh et al., 2004b). 
Such mechanisms are thought to explain some seminal observations regarding 
‘suppressive’ T cells and transplantation tolerance made nearly three decades ago 
(Kilshaw et al., 1975). It was only recently that the term ‘infectious tolerance’ was 
coined, by H Waldmann and colleagues, to describe the transferable nature of allograft 
tolerance from one recipient to another. Tolerance achieved after a short course of 
nondepleting anti-CD4 and anti-CD8 antibodies prior to transplantation of minor 
histocompatibility-mismatched skin grafts was associated with the development of a 
Treg phenotype within the recipient (Qin et al., 1993). Transfer of CD4+ cells from 
these tolerised mice could prevent graft rejection in naïve recipients. Furthermore, and 
more strikingly, the regulatory cells from the tolerised mice induced new Tregs in the 
naïve-transplanted recipients, and these secondary Tregs had the capacity to do the same 
if transferred to ‘tertiary’ recipients, which illustrates the infectious nature of the 
process. This occurrence was confirmed by subsequent studies using more stringent 
models of transplant tolerance, including cardiac allografts across major MHC barriers, 
leading to a general acceptance of this phenomenon (Yin and Fathman, 1995; Chen et 
al., 1996). The generation of these Treg subsets has also been implicated in tolerance 
induced through numerous strategies including costimulatory blockade (Larsen et al., 
1996; Graca et al., 2000). Evidence indicates that the immunosuppressive cytokines 
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Figure 7. Infectious Tolerance and Linked Suppression Induced by CD4+CD25+ Tregs. 
CD4+CD25+ Tregs can suppress alloreactive CD4+ T cells either directly via cell contact or secretion of IL-
10 and TGF-β or alternatively by influencing the stimulating APC (see figure 8). Linked suppression arises 
when tolerance generated against a specific antigen (Ag-Y) leads to tolerance against unrelated or third-
party antigens (Ag-X and Ag-Z), providing that these unrelated antigens are expressed on the surface of 
the same APC. The secretion of IL-10 and TGF-β by Tregs has been implicated in this process, which is 
thought to reinforce the infectious nature of transplantation tolerance. 
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 IL-10 and TGF-β play an important role in the mechanism by which infectious 
tolerance is mediated by CD4+ regulatory T cells (Cobbold and Waldmann, 1998; Graca 
et al., 2003). 
 
Evidence demonstrating significant roles for both naturally-occurring and induced Treg 
subsets in the development of allograft tolerance achieved through costimulatory 
blockade or otherwise has led to an increasing number of suggestions that clinical 
transplantation tolerance protocols that target alloreactive T lymphocytes for deletion 
need to specifically spare Tregs (Lechler et al., 2003). For example, a study has 
demonstrated that selective lysis of nonregulatory CD25+ alloreactive T cells and 
persistence of Tregs could be achieved through administration of an agonistic IL-2-Fc 
receptor fusion protein. Administration of this fusion protein in combination with 
selective blockade of IL-15 signalling, which is important for effector T cell 
proliferation and membory generation, resulted in allograft acceptance in a very 
rigorous transplantation model (Zheng et al., 2003).  
 
1.8. Nature’s Perfect Allograft: Indoleamine 2,3-Dioxygenase and the 
Foetus 
 
The induction of maternal immunological tolerance to paternal alloantigens expressed 
by the foetus during pregnancy have inspired scientists to develop tolerance-induction 
protocols (to prevent allograft rejection) that are based on mechanisms used by the 
foetus, sometimes referred to as ‘nature’s perfect allograft’ (Brent, 1997). The idea of 
maternal-foetal tolerance was first recognised and discussed in depth by Sir Peter 
Medawar. In his publication “Some immunological and endocrinological problems 
raised by the evolution of viviparity in vertebrates,” he proposed three mechanisms for 
maternal immunological tolerance (Medawar, 1953): He suggested either (1) the 
physical separation of (i.e. an anatomic barrier between) maternal and foetal tissues; (2) 
the antigenic immaturity of the foetal tissues; or that (3) the maternal immune system is 
suppressed or modified. Although the first two explanations have not held up [the 
maternal-foetal interface is not an impassible barrier- there is extensive microchimerism 
between mother and foetus- and both foetal and placental cells have been demonstrated 
to bear MHC (although a minority of these being classical MHC) molecules (Bonney 
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and Matzinger, 1998; Nelson, 2003)], the third explanation has been the subject of 
numerous studies. 
 
In human placentation foetus-derived extravillous trophoblast cells infiltrate the decidua 
and replace the endothelium of the uterine spiral arteries to ensure the development of 
an adequate blood supply to the foetal-maternal unit (Moffett-King, 2002). The 
implantation site is richly populated by maternal leukocytes in humans, which comprise 
approximately 70% natural killer (NK) cells of a unique uterine type (uNK) in addition 
to approximately 10% T cells and approximately 20% myelomonocytic cells (Moffett-
King, 2002; Trowsdale and Betz, 2006). As the placenta is intimately associated with 
the mother’s decidua, it constitutes the main target for immunological attack, and many 
foetal immune evasion mechanisms have evolved to generate a non-specific dampening 
of both the innate and adaptive arms of the immune respone in the uterine tissue during 
pregnancy. Key mechanisms of maternal-foetal tolerance have been conserved 
throughout mammalian evolution. Medawar’s hypotheses laid the foundation for the 
idea that, similar to the testes, eyes and brain, which are examples of tissues that are 
thought to prevent access to cells of the immune system by setting up anatomical and 
physiological barriers, the gravid uterus might constitute an immune-privileged site that 
promotes immunological ignorance by non-specific suppression of the cells of both the 
innate and adaptive immune system (Streilein, 1996; Ferguson and Griffith, 1997).  
 
One of the most important immune evasion strategies is the absence of the classical 
MHC alloantigens on the trophoblast. MHC class II alloantigens are completely absent 
on extravillous trophoblast cells in both humans and rodents (Mattsson, 1998), and 
cannot be induced by stimuli such as IFNγ, which suggests that antigen presentation via 
MHC class II is prevented even in the context of inflammation (Peyman et al., 1992). In 
addition, human trophoblasts do not express classical MHC class I HLA-A and HLA-B 
molecules but do express classical HLA-C and non-classical HLA-E and HLA-G MHC 
class I molecules (Goodfellow et al., 1976). HLA-G expression is restricted mainly to 
the extravillous trophoblast, so it is assumed to be involved in relation to placental 
implantation, through modulation of maternal decidual leukocytes (Kovats et al., 1990). 
CD56hi uterine NK cells are not cytotoxic, unlike their peripheral circulation 
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counterparts, but express considerable levels of cytokines (Moffett-King, 2002). HLA-C 
is important for the interaction of human NK cells through killer Immunoglobulin 
receptors (KIRs). All uterine NK cells express receptors for HLA-E and HLA-G. 
Receptors for the HLA-E molecule differ on uNK cells versus peripheral blood NK 
cells. All uNK cells have high expression of the inhibitory heterodimer CD94-NKG2A, 
a C lectin-like receptor for HLA-E. A proposed ligand for HLA-G is the unique KIR 
KIR2DL4, which is expressed by all NK cells (Rajagopalan and Long, 1999). 
Interaction of soluble HLA-G from the foetus with KIR2DL4 on uNK cells contributes 
to vascularisation of the maternal decidua during pregnancy. Thus, both HLA-C and 
HLA-G MHC class I-related ligand may be involved in implantation by shaping the 
vascular adaptation of maternal tissue by binding to KIR molecules. DCs also bind with 
HLA-G with a high affinity- DCs that interact with HLA-G are unable to stimulate T 
cells, have reduced expression of the costimulatory molecules CD80/86 and are 
associated with the generation of CD4+CD25+ Tregs (Chang et al., 2002). Therefore, 
engagement of inhibitory leukocyte immunoglobulin-like receptors on decidual DCs by 
placental HLA-G could act to downregulate maternal T cell-mediated responses during 
pregnancy. 
 
Another mechanism of maternal-foetal tolerance is the expression of CD95L (Fas 
ligand) by the foetal trophoblast, which promotes apoptosis of activated lymphocytes 
expressing CD95 (Fas). Pregnancy in gld mice, a natural mutant strain lacking 
functional CD95L, is characterised by extensive infiltration of lymphocytes and 
necrosis at the interface of the decidua with the placenta (Hunt et al., 1997). The gld 
strain suffers from small litters and an increase in the resorption of foetuses even if the 
pregnancy is a result of a homozygous mating, demonstrating that in this scenario, the 
maternal immunity lacks an allogeneic target and has a basic function during pregnancy 
(but it does not excluding the possibility of involvement of CD95L in the dampening of 
antigen-specific responses). Another mechanism is function of the complement inhibitor 
Crry (Xu et al., 2000). Lack of this protein in mice leads to gestational failure due to 
complement deposition at the maternal-foetal interface, and resorption of foetuses in 
Crry-/- mice shows some of the features of immunological rejection such as complement 
deposition and infiltration of the extraembryonic tissue with PMN cells. Similar to 
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CD95L, an effect on pregnancy can be found in syngeneic mating lacking paternal 
alloantigen. There are similar counterparts to Crry in humans (Rooney et al., 1993). The 
expression and secretion of leukaemia inhibitory factor (LIF) by the maternal 
endometrium and later by the decidua has been suggested to contribue to a localised 
immune suppressive environment (Piccinni et al., 1998). LIF is essential in blastocyst 
implantation, although its involvement in promoting maternal-foetal tolerance by 
shifting the TH1-TH2 balance is less well understood. However, complications of human 
pregnancy such as spontaneous foetal loss has been associated with a shift in the 
mother’s serum from a TH2-biased to a TH1-biased cytokine profile (Lin et al., 1993).  
 
Another mechanism employed by the maternal immune system is the generation of 
CD4+CD25+ Treg populations, which can be found in both allogeneic and syngeneic 
pregnancies, suggesting that it is independent of exposure to paternal alloantigen 
(Aluvihare et al., 2004). It has been demonstrated that during pregnancy Tregs 
accumulate in the uterus, where they represent about a third of all CD4+ T cells. This 
influx of Tregs into the uterus is associated with a significant increase in FoxP3 
transcripts among total uterine mRNA. An absence of CD4+CD25+ Tregs leads to early 
failure of gestation after implantation in allogeneic but not syngeneic pregnancies 
(Aluvihare et al., 2004). In addition, studies have described both systemic and decidual 
expansion of FoxP3+ Tregs in the first two trimesters of pregnancy (Heikkinen et al., 
2004; Sasaki et al., 2004). In mice, these cells suppress the population of T cells ex vivo. 
The finding that the proportion of Tregs in the decidua of spontaneous abortions is 
much lower than that in elective abortions is consistent with a requirement for their 
presence at the maternal-foetal interface (Sasaki et al., 2004). 
 
In recent years, the role of indoleamine 2,3-dioxygenase (IDO) in the regulation of 
immune responses has been increasingly recognised (Grohmann et al., 2003b). IDO is a 
monomeric, intracellular enzyme that catabolises tryptophan, an essential amino acid. It 
directly leads to an opening of the indole ring of tryptophan, thus forming N-
formylkynurenine, which is then converted into various downstream metabolites 
(kynurenines) [Figure 8(a)] (Stone and Darlington, 2002; Moffett and Namboodiri, 
2003). IDO catalyses the initial, rate-limiting step in this pathway, but the pattern of  
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Figure 8. Indoleamine 2,3-Dioxygenase and Dendritic Cells. 
(a) Indoleamine 2,3-Dioxygenase (IDO) is an enzyme that catalyzes the oxidative cleavage of tryptophan, 
an essential amino acid. The cleavage of the indole ring of tryptophan (the initial and rate-limiting step) by 
IDO forms N-forymylkynurenine, which rapidly degrades to L-kynurenine. (b) Cytotoxic T Lymphocyte-
associated Antigen 4 (CTLA4) expressed either as a fusion protein/chimera with the human 
immunoglobulin Fc fragment (CTLA4-Ig) or in a physiological environment by CTLA4+ Tregs and other cell 
types (e.g. placental fibroblasts) acts as a ligand for CD80/86 on DCs. Signalling through CD80/86 causes 
DCs to release IFNγ, which acts in an autocrine or paracrine fashion to activate IDO expression 
transcriptionally. Local changes in the availability of tryptophan and the presence of proapoptotic 
kynurenines result in decreased clonal expansion and the increased deletion of T cells. 
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subsequent metabolites is determined by the particular set of downstream enzymes that 
are expressed by the various cell types (Werner-Felmayer et al., 1989). IDO is produced 
by the maternal uterine mucosa (decidua) and by the foetal syncytiotrophoblast, which 
invades the uterus (Kamimura et al., 1991). The expression of high levels of IDO in the 
placenta is now considered to be a major factor associated with its immune privilege 
(Mellor and Munn, 1999). Treatment of pregnant mice carrying a syngeneic or 
allogeneic foetus with the pharmacological inhibitor of IDO, 1-methyl-tryptophan (1-
MT), resulted in the loss of only the allogeneic foetus (Munn et al., 1998). By studying 
matings among normal, immunocompetent and transgenic mice, the authors showed 
that abortions only occurred if the mother had an intact immune system. However, a 
mouse lacking IDO has been shown to undergo normal pregnancy, a finding that 
remains to be fully resolved (Baban et al., 2004). Tryptophan is one of several amino 
acids that are essential in mammals (i.e. it cannot be synthesised de novo). It is the rarest 
of all amino acids, accounting for ~1% of total amino acids in cellular proteins. 
Incorporation of tryptophan into protein is initiated by tryptophanyl-transfer RNA 
synthetase (WRS). WRS is the only aminoacyl synthetase that responds to 
inflammatory mediators, such as IFNγ (Frolova et al., 1993), and overexpression of 
WRS has been postulated to help cells that express IDO compensate for the reduction in 
intracellular tryptophan. It might therefore be important that T cell lines do not show 
induction of WRS expression in response to IFNγ (Fleckner et al., 1995). The basal 
level of tryptophan in the serum is controlled principally by the enzyme 
tryptophan 2,3-dioxygenase (TDO). TDO is expressed in the liver and seems to be a 
homeostatic or housekeeping enzyme and does not respond to immunological signals. 
In contrast, IDO is highly responsive to signals from the immune system and can be 
induced by such signals in various cell types. However, as will be discussed in section 
1.9, expression of IDO, and factors that regulate it are highly cell type-specific. The 
crucial role of IDO in maintaining maternal-foetal tolerance during pregnancy has only 
in the past decade led to numerous studies investigating its potent T cell 
immunosuppressive mechanisms and strategies to manipulate its expression for 
therapeutic purposes (e.g. transplantation and tumour immunology). 
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1.9. Indoleamine 2,3-Dioxygenase and Dendritic Cells 
 
The depletion of tryptophan, and/or possibly the signalling properties of kynurenines 
have been demonstrated to inhibit T cell responses (Frumento et al., 2002; Terness et 
al., 2002). In addition to being expressed in immune privileged sites, IDO is also 
expressed by DCs and cells of the monocytic lineage. Furthermore, constitutive 
expression of the enzyme has been detected in a subset of human DCs with a 
CD123+CCR6+ phenotype (Munn et al., 2002). IDO can be induced on both human and 
murine DCs by IFNγ (Grohmann et al., 2003b), which is the strongest known inducer of 
IDO in cultured fibroblasts, macrophages and several tumour cell lines (Carlin et al., 
1989; Dai and Gupta, 1990; Taylor and Feng, 1991). As will be discussed below, the 
release of IFNγ from murine DCs can be induced by the crosslinking of CD80/86 on the 
surface of DCs with CTLA4-Ig (Grohmann et al., 2002), and previous murine studies 
have demonstrated that crosslinking of CD80/86 by CTLA4 expressed on the surface of 
CD4+CD25+ Tregs can induce the expression of IDO [Figure 8(b)] (Fallarino et al., 
2003).  
 
The toxic metabolites of tryptophan have a prominent role in mediating the 
immunosuppressive effects of IDO (Grohmann et al., 2003b). Although the downstream 
metabolites of IDO are known to be biologically active, the molecular mechanisms for 
these effects are only starting to emerge. There are two known amino-acid-responsive 
signal transduction pathways by which T cells might sense decreased levels of free 
tryptophan. Essential amino acid deficiency antagonises signalling through the 
mammalian target of rapamycin (mTOR) kinase pathway (Rohde et al., 2001; Gao et 
al., 2002). mTOR signalling is required for normal ribosomal translation. This pathway 
is important for growth factor-signalling, and T cells are particularly sensitive to 
inhibitors of mTOR, such as the immunosuppressant drug rapamycin (Grolleau et al., 
2002). A second amino acid pathway is initiated by general control non-depressible 2 
(GCN2) kinase, which contains a binding domain that is specific for the uncharged form 
of transfer RNA (tRNA) (Harding et al., 2000a; Zhang et al., 2002). Deprivation of any 
amino acid causes activation of the kinase domain, resulting in the phosphorylation of 
eukaryotic translation-initiation factor-2α (eIF-2α) and repression of translation. Amino 
acid catabolism by APCs that express IDO has been demonstrated to stimulate the 
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cellular GCN2 kinase-dependent stress response in naïve T cells in addition to mature, 
functionally quiescent Tregs, leading to active bystander suppression (Munn et al., 
2005; Fallarino et al., 2006b; Sharma et al., 2007). A limited set of mRNA transcripts 
for stress-response genes have internal ribosome entry site (IRES) sequences that allow 
them to bypass this generalised translational repression, and these genes show selective 
upregulation in response to GCN2 (Harding et al., 2003). It is currently unknown how 
activating this stress-response pathway or inhibiting the mTOR pathway might affect 
the programme of T cell activation. However, translational control is a fundamental 
regulatory process, and alterations can affect cellular activation and cell-cycle 
progression in marked ways (Calkhoven et al., 2002). Such translational control 
mechanisms are distinct from simple starvation and can be highly gene-specific- e.g. 
tryptophan deprivation blocks IFNγ-induced expression of nitric oxide synthase by 
macrophages, but expression of tumour necrosis factor (TNF) by the same cells is 
unaffected (Chiarugi et al., 2003). It is thus possible that a period of tryptophan 
deprivation early in T cell activation might fundamentally alter the proliferation and 
differentiation programme of the responding cells. 
 
There is a strong correlation between inflammation, IFNγ and induced IDO expression, 
but IFNγ is not essential for IDO expression. Lipopolysaccharide (LPS) and the 
inflammatory cytokine IL-1 and TNF act synergistically with IFNγ to enhance IDO 
expression in vitro (Babcock and Carlin, 2000; Robinson et al., 2003). However, in 
vivo, responsiveness to LPS crucially depends on TNF, but does not require IFNγ 
(Fujigaki et al., 2001), indicating the existence of an IFNγ-independent pathway for the 
induction of IDO expression. Additional signalling pathways and cytokines have 
demonstrated to modulate IDO expression by specific cell types (MacKenzie et al., 
1999; Fallarino et al., 2003). Thus, the control of IDO transcription is complex and cell-
type specific. As described above, soluble CTLA4-Ig is an artificial means of inducing 
IDO expression in DCs through the ligation of cell surface CD80/86 (Grohmann et al., 
2003b). This role for CD80/86 molecules has been confirmed in both mouse and human 
DCs in several model systems (Fallarino et al., 2003; Mellor et al., 2003; Mellor et al., 
2004; Munn et al., 2004b). In some systems, IFNγ was required for the induction of 
IDO expression, but in others, ligation of CD80/86 induced functional IDO expression 
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by IFNγ-receptor-deficient DCs, demonstrating that IFNγ signals are not essential for 
CD80/86-induced upregulation of IDO expression by these DCs (Mellor et al., 2004). 
IDO seems to function as the downstream mediator for certain tolerogenic effects of 
CTLA4-Ig (Grohmann et al., 2002). 
 
It has been suggested that the physiological signal that normally fulfils the artificial 
mechanism of IDO upregulation via ligation of DC surface CD80/86 using recombinant 
CTLA4-Ig might be the CTLA4-expressing subset of Tregs (Finger and Bluestone, 
2002; Grohmann et al., 2003b). This hypothesis is strengthened by the observation that 
mouse CD4+CD25+ Tregs and a CTLA4-transfected cell line both induced IDO activity 
in mouse DCs in vitro, in a CTLA4-dependent manner (Fallarino et al., 2003). 
Additionally, a cloned CD4+CD25+ T cell line expressing surface CTLA4 induced IDO 
expression by B220+ (plasmacytoid) and CD8α+ subsets of DCs, and in this particular 
model, the regulatory functions of these T cells completely depended on their ability to 
induce functional IDO expression by the DCs (Mellor et al., 2004). Tregs can therefore 
become an important upstream mechanism of IDO expression; and conversely IDO 
becomes one of the potential downstream effector mechanisms by which Tregs can 
mediate their inhibitory effects. 
 
A model has been proposed whereby IDO-mediated immune regulation first requires an 
immature (unactivated) DC that can express IDO (Mellor and Munn, 2004)- it is unclear 
whether this would be a specific DC subset or a certain developmental stage of many 
types of DC. During (or perhaps, after) maturation, the IDO-competent cell can receive 
two types of ‘conditioning’ signal that lead to different phenotypes [Figure 9(a)]. 
Tolerogenic signals, such as CD80/86 ligation by CTLA4+ Tregs, would induce IDO 
expression, thereby eliciting the full, functionally tolerogenic/regulatory phenoype. In 
contrast, immunogenic signals, such as CD40 ligation by TH cells or exposure to pro-
inflammatory cytokines, would promote a non-suppressive phenotype and downregulate 
expression of IDO (Grohmann et al., 2001a; Grohmann et al., 2001b). Both pathways 
could lead to fully mature DCs- it is a surprising characteristic of IDO-expressing DCs 
that potent IDO-mediated suppression can be maintained even while the underlying DC 
function undergoes maturation (Munn et al., 2004b). In studies using the IDO inhibitor  
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Figure 9. Generation of IDO-Competent DCs and Potential Downstream Mechanisms. 
(a) DC maturation has traditionally been viewed as a linear process leading from an immature (tolerogenic) 
phenotype to a mature (immunogenic) phenotype. However, some IDO-expressing DCs seem to be both 
mature and tolerogenic, which suggests that maturation and the capacity to express IDO might be 
separate processes or that there might be two different maturation pathways for IDO-competent DCs. Pro-
inflammatory maturation signals such as CD40 ligation might act to downregulate functional IDO 
expression, whereas tolerogenic signals such as CTLA4 expressed on Tregs (acting in combination with 
other maturation signals) result in differentiation of mature IDO+ DCs that suppress T cell proliferation. (b) 
There has been speculation regarding the bystander effects observed with IDO+ DCs. Studies have 
indicated that even small numbers of IDO+ DCs can have widespread immunosuppressive effects on T 
cells that recognise antigens presented by IDO- DCs. Mechanisms suggested for the bystander effects of 
IDO+ DCs include toxic metabolites (such as L-kynurenine breakdown products), widespread local 
tryptophan depletion or IDO-induced Tregs and associated regulatory cytokines. It has been proposed that 
neighbouring cells (e.g. macrophages and regulatory T or B cells) might be similarly induced by IDO-
responsive signalling pathways to secrete regulatory cytokines. Naïve T cells might be biased by IDO+ 
DCs to adopt a regulatory phenotype. Any of these effects could then suppress nearby T cells responding 
to IDO- DCs. The effect of IDO would thus be to convert the local tissue microenvironment into a tolerising 
milieu, even for antigens presented by other, normally immunogenic APCs. (c) The figure shows a 
proposed model of a self-amplifying regulatory network involving interactions between IDO+ DCs and 
Tregs. The generation of Tregs by IDO+ DCs could be a potent mechanism as these Tregs might in turn 
create other tolerogenic DCs through the induction of IDO expression by CTLA4 interactions. This could 
provide a possible molecular mechanism for epitope spreading and infectious tolerance. 
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1-MT and IDO-deficient mice, it seems that the only difference between an 
immunogenic and a tolerogenic phenotype is IDO expression (Munn et al., 2004a). It 
can thus be hypothesised that both immunogenic and tolerogenic phenotypes are fully 
competent, mature DCs but specialised for opposing functions (Mellor and Munn, 
2004). 
 
It is important to state that IDO protein can be expressed without functional enzymatic 
activity. Isolated mouse splenic CD8α+ DCs were found to catabolise tryptophan when 
exposed to IFNγ, whereas other (CD8α-) DCs did not, even though both subsets 
expressed comparable amounts of IDO protein as analysed by western blot (Fallarino et 
al., 2002). In parallel, human CD123+CCR6+ DCs can constitutively express 
immunoreactive IDO protein as shown by western blot, yet it does not have functional 
enzymatic activity until these cells are activated by IFNγ and CD80/86 ligation (Munn 
et al., 2004b). Although it was originally proposed (and subsequently confirmed) that 
IDO activity seemed to preferentially segregate with the CD8α+ subset of DCs after 
IFNγ treatment in vitro (as described above), (Grohmann et al., 2001a; Grohmann et al., 
2001b), it was also possible to induce IDO expression by CD8α- DCs, by exposing them 
to CTLA4-Ig or CTLA4+ Tregs (Fallarino et al., 2003; Grohmann et al., 2003a). 
Additionally, in a recent in vivo study to investigate the expression of IDO after 
treatment with CTLA4-Ig, the upregulation of immunoreactive IDO was restricted 
mainly to cells in the B220+ (plasmacytoid) population of splenic DCs, in addition to 
the CD8α+ population described above (Mellor et al., 2003). Subsequent studies with 
APC fractions that were isolated from mice treated with CTLA4-Ig confirmed that IDO-
dependent T cell suppression was confirmed to specific DC subsets that express these 
markers (Mellor et al., 2004). More recently, a small subpopulation of DCs (known as 
IDO+CD19+ DCs) found in the mouse spleen has been found to synthesise large 
amounts of IDO and downregulate T cell function (Baban et al., 2005). IDO+CD19+ 
DCs are found in the red pulp of the spleen, are CD11chi and show characteristics of 
mature APCs in the steady state. IDO+CD19+ DCs increase their production of IDO 
following CD80/86 ligation by CTLA4 [either in the form of the soluble CTLA4-Ig 
protein or membrane-bound CTLA4 on the surface of Tregs (Mellor et al., 2004)] or 
TLR9 ligation, a phenomenon that requires the autocrine release of IFNα (Mellor et al., 
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2005). This observation was supported by a detailed analysis of IDO-mediated T cell 
suppression in tumour-draining lymph nodes (Munn et al., 2004a) demonstrated that 
although a significant fraction of DCs expressed detectable levels of IDO protein (as 
determined by immunohistochemistry), the functional IDO-mediated suppression was 
mediated almost entirely by the CD19+ population, a subset of B220+ plasmacytoid 
DCs. The study demonstrates that the biologically-relevant population of IDO-
expressing DCs might be a minor subset within a DC population. It should be noted that 
IDO+ DCs do not sequester antigens or fail to present them. Instead IDO activity in DCs 
alters the context in which antigens are presented, so that activated T cells die (by 
apoptosis), become anergic or differentiate into Tregs instead of undergoing clonal 
expansion and differentiating into effector cells (Munn et al., 2004a; Munn et al., 2005; 
Fallarino et al., 2006b; Sharma et al., 2007). 
 
It has been observed that IDO-mediated suppression can act in a dominant manner by 
suppressing T cell responses to antigens that are presented by neighbouring, IDO- 
APCs. This effect can be dramatic in vivo, where small populations of IDO+ DCs 
efficiently suppress all T cell responses to a particular antigen, despite the fact that the 
same antigen was presented by many other IDO- APCs (Mellor et al., 2003; Mellor et 
al., 2004; Munn et al., 2004a). Linked suppression has been described in vitro using 
defined IDO+ and IDO- APC populations, simultaneously presenting two different 
antigens in the same MLR (Munn et al., 2004a). These effects occurred in a defined, 
local context (i.e. affecting two antigens presented by the same DC or by closely 
adjacent DCs), and so are reminiscent of the antigen-driven linked suppression model 
(described in section 1.7) by Waldmann and colleagues (Fairchild and Waldmann, 
2000; Waldmann and Cobbold, 2004). Such a mechanism would have to exist for IDO 
to serve as a downstream mechanism of suppression for Tregs. Dominant (bystander) 
suppression might also be due to the local effects of IDO- depletion of tryptophan or 
production of diffusible solube factors such as toxic tryptophan metabolites or 
immunoregulatory cytokines, might affect T cells responding to antigens presented by 
nearby DCs [Figure 9(b)]. On the other hand, it is theoretically possible that IDO 
expression by the DC might affect nearby (non-APC) cell types, causing them to 
produce factors that indirectly regulate local T cell responses. Lymphoid tissues contain 
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macrophages, which are potential immunoregulatory cells (Munn and Mellor, 2003), as 
well as Tregs and regulatory B cells (Fillatreau et al., 2002), all with the capacity for 
producing immunosuppressive cytokines. Several studies have indicated that a 
relatively small number of IDO+ DCs can suppress potent T cell responses in vivo 
(Mellor et al., 2004) and promote systemic tolerance (Grohmann et al., 2000; Grohmann 
et al., 2001b). It has thus been suggested that the original DCs somehow recruited 
secondary mechanisms that indirectly enhanced suppression. One possibility is that 
IDO+ DCs might promote Treg development. No published data address this hypothesis 
with respect to IDO+ DCs, but there is considerable evidence that some types of 
regulatory DCs can induce CD4+CD25+ T cells (Bilsborough et al., 2003; Mahnke et al., 
2003), IL-10-producing TR1 cells (Wakkach et al., 2003), and CD8+ Tregs (Gilliet and 
Liu, 2002; Faunce et al., 2004). If IDO+ DCs can be demonstrated to have a similar role, 
it would raise the possibility that IDO-competent DCs might collaborate with CTLA4-
expressing Tregs in a self-reinforcing network [Figure 9(c)]- see section 1.13. Although 
it is unlikely that IDO participates in the development of naturally-occurring Tregs that 
arise in the thymus (Bluestone and Abbas, 2003), as IDO-deficient mice do not develop 
spontaneous lethal autoimmunity (Mellor et al., 2003) [unlike mice deficient in 
naturally-occuring Tregs (Khattri et al., 2003)], IDO+ cells might have a role in 
generating acquired/adaptive Tregs that arise extrathymically and drive acquired 
peripheral tolerance. The generation of Tregs by IDO-expressing DCs could be a potent 
mechanism, as these Tregs might in turn create other tolerogenic DCs through the 
induction of IDO expression by CTLA4 interactions. This could provide one possible 
molecular mechanism for epitope spreading and ‘infectious’ tolerance as described in 
other systems. 
 
Together with the landmark study demonstrating the role of IDO in maternal-foetal 
tolerance- see section 1.8 (Munn et al., 1998), studies investigating mechanisms of 
IDO-mediated T cell suppression have pointed to modulation of IDO expression in DCs 
as a strategy to prevent allograft rejection. In experimental transplantation studies, the 
inhibition of IDO with 1-MT has been demonstrated to prevent the prolongation of graft 
survival following CTLA4-Ig administration (Grohmann et al., 2002). Transduction of 
pancreatic islet cells with a gene encoding IDO has been shown to prolong allograft 
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survival (Alexander et al., 2002) and data from studies with skin fibroblasts have 
demonstrated that IDO acts as a local suppressor in the acceptance of allogeneic skin 
fibroblasts (Carlin et al., 1989; Dai and Gupta, 1990; Taylor and Feng, 1991; Ghahary 
et al., 2004). A recent study has also detected (i) the expression of functional IDO in the 
normal cornea; (ii) the upregulation of IDO expression following corneal 
transplantation; and (iii) the prolongation of corneal allograft survival after 
overexpression of IDO in donor grafts (Beutelspacher et al., 2006). IDO overexpression 
has previously been shown to result in immunosuppression and tolerance. For example, 
IDO-transfected cell lines suppressed antigen-specific T-cell responses in vitro (Mellor 
et al., 2002), and IDO overexpression in mouse tumour cell lines rendered them 
resistant to immune rejection in vivo. Adenoviral-mediated IDO gene transfer into 
pancreatic islet cells has also prolonged their survival in allogeneic hosts (Alexander et 
al., 2002), and IDO transfection protected allogeneic lung transplants from rejection 
(Swanson et al., 2004). 
1.9.1. Indoleamine 2,3-Dioxygenase-2 (IDO2) 
 
Since the 1970s, the belief that the first and rate-limiting step in the kynurenine pathway 
is performed by either of two enzymes, TDO or IDO (depending on the tissue and cell 
type), was recently overturned when a gene with homology to IDO was reported 
(Murray, 2007) and then subsequently demonstrated by three groups to encode an 
enzyme with the ability to catabolise tryptophan (Ball et al., 2007; Metz et al., 2007; 
Yuasa et al., 2007). The enzyme has been referred to as indoleamine 2,3-dioxygenase-2 
(IDO2) on the basis of its structural similarity to IDO [which in turn has recently been 
referred to as IDO1 (Ball et al., 2009)] and its enzymatic activity. The IDO1 and IDO2 
proteins share significant identity at the amino acid level (43% for human and mouse 
proteins) (Ball et al., 2009), and the tryptophan-catabolising activity of IDO2 expressed 
in intact mammalian cells has been demonstrated. As the discovery of the IDO2 enzyme 
is so recent, its biological role is still yet to be defined but its expression pattern in the 
kidney, reproductive system and a dendritic cell line suggest its involvement in kidney 
function, fertility and immunomodulation (Ball et al., 2009). 
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1-methyl-D-tryptophan was found to be selective for inhibition of IDO2 compared with 
IDO1 activity, whilst its stereoisomer 1-methyl-L-tryptophan was more selective for 
IDO1 (Metz et al., 2007). The selective inhibition of IDO2 by 1-methyl-D-tryptophan 
points to one biological function for the enzyme. IDO expression in DCs within tumour-
draining lymph nodes has been correlated with suppression of T cell responses and poor 
prognosis (Munn et al., 2004a). IDO inhibition enhanced anti-tumour immunity in 
combination with other anti-cancer agents (Hou et al., 2007). However, it has been 
difficult to explain why the D-stereoisomer of 1-MT has more potent anti-tumour 
effects compared with the L-stereoisomer, given that 1-methyl-L-tryptophan is a more 
potent inhibitor of IDO1 activity (Lob et al., 2008; Lob et al., 2009). The discovery of 
IDO2, its possible expression in DCs (Lob et al., 2008), and its inhibition by 1-methyl-
D-tryptophan, suggest that the IDO2 enzyme may be involved in immune evasion by 
tumours (Metz et al., 2007). The lack of an anti-tumour effect with the D-stereoisomer 
in IDO1-/- mice (Hou et al., 2007), which still express IDO2, suggests that IDO1 is still 
involved in some way and raises the possibility that the two enzymes interact in 
suppressing T cell responses to tumours. 
1.10. The Tolerogenic Dendritic Cell 
 
Immature DCs expressing low constitutive levels of MHC class II and costimulatory 
molecules have been demonstrated in numerous studies to be incapable of activating 
naïve T cells that are reactive against the DC antigen(s), instead causing them to 
become anergic (Banchereau and Steinman, 1998; Steinman et al., 2000; Lechler et al., 
2001b; Steinman et al., 2003). This is regarded to be not only an important mechanism 
for the induction of peripheral tolerance to autoantigens but also a strategy to induce 
antigen-specific tolerance in an experimental setting. For example, in a human study, 
subcutaneous injection of autologous, monocyte-derived immature DCs pulsed with an 
influenza-matrix peptide led to a reduction in antigen-specific CD8+ T cells that 
secreted IL-10, and memory CD8+ T cells that had impaired IFNγ section and cytolytic 
function (Dhodapkar et al., 2001). This is a proof-of-principle study demonstrating that 
immature autologous DCs pulsed with nominal antigen can induce antigen-specific T 
cell tolerance in healthy volunteers. 
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Disruption of the engagement of costimulatory molecules with their ligands represents a 
potential set of strategies to induce tolerance. The administration of CTLA4-Ig blocks 
the interaction of CD28 with CD80/86 and has been shown to prolong graft survival and 
in some settings induce tolerance (Lenschow et al., 1992; Linsley et al., 1992b; Pearson 
et al., 1994). Using a cellular approach, the administration of parenchymal cells, which 
express the appropriate antigens but do not express ligands for CD28 or other co-
stimulatory molecules, can be used to induce T cell anergy (Marelli-Berg et al., 1997; 
Marelli-Berg and Lechler, 1999). Hence, as the most efficient professional APC, DCs 
are increasingly being used as the basis on which to design tolerance-induction 
protocols. 
 
DCs have also been observed to respond actively to tolerogenic signals such as 
interleukin-10 (IL-10) and transforming growth factor-β1 (TGF-β1), or to signals that 
are delivered in an antigen-specific manner by the adaptive immune system subsequent 
to the generation of Tregs (Steinbrink et al., 1997; Powrie and Maloy, 2003). 
‘Tolerogenic’ DCs can thus be defined as immature, maturation-resistant or 
‘alternatively-activated’ DCs that have low constitutive expression of surface MHC 
molecules, have a low ratio of costimulatory to inhibitory signals (such as PD-L1), and 
an impaired capacity to synthesise TH1 cell-driving cytokines such as interleukin-12p70 
(IL-12p70) (Morelli and Thomson, 2007). In an effort to generate tolerogenic DCs, in 
vitro-propagated DCs have been modified after exposure to various antinflammatory 
and immunosuppressive agents that target DC differentiation and function by various 
mechanisms (Hackstein and Thomson, 2004). Similar to the incubation of DCs in vitro 
with the immunoregulatory cytokines IL-10 and TGF-β1, strategies used to induce 
tolerance via the pharmacological route are also aimed at preventing the maturation 
and/or activation of DCs, or impairing the capacity of the DCs to produce IL-12p70. For 
example, incubation of DCs with the glucocorticoid dexamethasone ‘freezes’ the cells 
in an immature phenotype and renders them relatively resistant to activation (Mirenda et 
al., 2004). Other agents include inducers of cyclic AMP (cAMP) such as prostaglandin 
E2, histamine, β2 agonists, neuropeptides, the vitamin D3 metabolite 1α,25-
dihydroxyvitamin D3 [1α,25(OH)2D3] (the active form of  vitamin D3) and its 
analogues, glucosamine, the antioxidant N-acetyl-L-cysteine, ligands for inhibitory 
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immunoglobulin-like transcript receptors (such as the MHC class 1b molecule HLA-G), 
and cobalt protoporphyrin for the induction of haem oxygenase-1 (HO-1) expression 
(Morelli and Thomson, 2007). Furthermore, several clinically approved or experimental 
immunosuppressive drugs such as corticosteroids, cyclosporine, tacrolimus, rapamycin, 
aspirin, deoxyspergualin (DSG), mycophenolate mofetil (MMF) and sanglifehrin A 
have been used to target the differentiation and function of DCs. Subsequent to studies 
demonstrating that 1α,25(OH)2D3 inhibits the differentiation and maturation of DCs in 
vitro (Griffin et al., 2000; Penna and Adorini, 2000), it has been shown that a 
combination of 1α,25(OH)2D3 and dexamethasone induces human and mouse naïve T 
cells to differentiate into IL-10-producing Tregs (Barrat et al., 2002). Similarly, the 
tolerogenic properties of DCs induced by 1α,25(OH)2D3 treatment in combination with 
MMF have been demonstrated in vivo by the induction of tolerance to mouse pancreatic 
islet allografts following administration of the donor-derived DCs after treatment with 
the two agents. The induction of allograft tolerance was associated with the generation 
of donor-specific Tregs (Gregori et al., 2001). To date, several reports have 
demonstrated a stable phenotype of cytokine-modulated DC preparations, indicating 
that tolerogenic DCs differentiated in the presence of G-CSF, IL-21, vasoactive 
intestinal peptide (VIP) or low-dose GM-CSF might be resistant to further maturation-
inducing stimuli (Lutz and Schuler, 2002; Rutella et al., 2004; Chorny et al., 2005). 
Concern regarding the maturation of ‘alternatively activated’ DCs has been mitigated by 
recent findings that endogenous modulators produced at sites of inflammation, for 
example PGE2, and histamine, might interfere with DC maturation and promote DC 
tolerogenicity (Mazzoni et al., 2001; Yang et al., 2003). 
 
Murine BM-derived immature DCs have been demonstrated to induce alloantigen-
specific T cell anergy in vitro (Fu et al., 1996; Lutz et al., 2000) and drive de novo 
differentiation of naturally-occuring Tregs or TR1 cells (Wakkach et al., 2003; Cong et 
al., 2005). It has also been shown that BM-derived DCs are more efficient than their 
immature counterparts at inducing the proliferation of Tregs (Yamazaki et al., 2003), 
and have been used in vitro to expand antigen-specific Tregs that suppress GVHD 
(Yamazaki et al., 2006) and autoimmunity (Tarbell et al., 2004). Initial observations that 
murine splenic CD8α+ DCs suppress allogeneic T cell responses suggested that CD8α+ 
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DCs participate in T cell homeostasis (Suss and Shortman, 1996). Under steady-state 
conditions antigen presentation by splenic CD8α+ DCs leads to T cell tolerance, 
whereas under the influence of DC maturation stimuli it leads to T cell-mediated 
immunity (Belz et al., 2002). It was demonstrated that splenic CD8α+ DCs inhibit the 
presentation of self-peptides by immunogenic CD8- DCs in vivo, and this inhibitory 
effect was ascribed to their IDO activity (Grohmann et al., 2001b). In a recent 
transplantation study, pre-treatment of recipient mice with donor splenic CD8α+ 
immature DCs (freshly isolated) or mature CD8α+ DCs (cultured with GM-CSF) from 
animals treated with the growth FLT3L prolonged the survival of vascularised allografts 
(O'Connell et al., 2002) 
 
Tolerogenic DCs that express both self and donor MHC molecules have been generated 
from the BM precursors of semi-allogeneic [donor x recipient] F1 mice or by the fusion 
of DCs of different MHC haplotypes. As described earlier, dexamethasone-treated 
immature DCs have been shown to induce T cell anergy in vitro, and administration of 
dexamethasone-treated DCs- expressing self and allogeneic MHC molecules- has been 
shown to be effective at inducing tolerance to rat kidney grafts by inducing Tregs with 
indirect pathway allospecificity (Mirenda et al., 2004). Through the phenomenon of 
linked suppression, there was inhibition of activation of anti-donor T cells that 
recognised intact donor MHC molecules on the same semi-allogeneic DC through the 
direct pathway. A recent study demonstrated that the injection of DCs from [BALB/c x 
C57BL/6] F1 mice that express viral IL-10 and CC-chemokine receptor 7 (CCR7- for 
the enhancement of homing to secondary lymphoid tissue) 7 days prior to 
transplantation resulted in the indefinite surivival of heart grafts from F1 mice in >80% 
of C57BL/6 recipients (Garrod et al., 2006). Additionally, in an in vitro study, donor-
recipient DC-DC hybrids were created by the fusion of a CD95L-transduced DC line 
with allogeneic splenic DCs to induce the selective apoptosis of donor-reactive T cells 
recognising alloantigen through each pathway of allorecognition (Matsue et al., 2001). 
The CD95L-transduced ‘killer’ DC hybrids suppressed allospecific T cell responses 
against both parental strains without affecting responses to third-party antigen, thus 
excluding the possibility of non-specific cytotoxic activity of the hybrids due to 
transgenic expression of CD95L. Intravenous administration of the CD95L-expressing 
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DC hybrids expressing both donor and recipient MHC haplotyes delayed the onset of 
GVHD in mice as a result of MHC-restricted, CD95L-mediated apoptosis of donor anti-
host CTLs (Matsue et al., 2001). 
 
As described earlier, in the steady state, DCs in blood and non-lymphoid tissues 
(including commonly transplanted organs) are phenotypically immature. These cells 
and their precursors can be expanded by the infusion of appropriate growth factors 
alone or in combination, such as granulocyte colony-stimulating factor (G-CSF), 
granulocyte/macrophage colony-stimulating factor (GM-CSF) or FMS-like tyrosine 
kinase 3 ligand (FLT3L) (Morelli and Thomson, 2007). Expansion of murine DCs in 
donor haematopoietic cell infusions which are administered in combination with 
cyclophosphamide and T cell-depleted donor BM, promotes donor-specific MHC-
mismatched skin transplant tolerance (Eto et al., 2002). Furthermore, FLT3L-expanded 
allogeneic BM cells markedly promote hamatopoietic-cell chimerism, in particular 
chimerism of donor DCs, but can prevent the therapeutic effect of donor BM cells in 
transiently immunosuppressed graft recipients (Antonysamy et al., 1998). In a recent 
study, bone-marrow-derived (myeloid) recipient DCs generated in vitro with GM-CSF, 
IL-10 and TGF-β1, and then pulsed with LPS (‘alternatively activated’ DCs), 
demonstrated regulatory properties and were used to prevent lethal GVHD following 
allogeneic BM transplantation in sublethally irradiated mice (Sato et al., 2003).  A 
single administration of host-matched tolerogenic DCs downregulated the anti-host 
reactivity of donor T cells and prevented GVHD in a donor-specific manner. This was 
associated with an increased incidence of naturally-occurring FoxP3+ Tregs. Not only 
was the inhibitory effect of the regulatory, host-matched DCs on the cytotoxic activity 
of donor CD8+ T cells sufficient to prevent acute GVHD, but the DCs did not restrain 
the capacity of the transplanted CD8+ T cells to mediate the beneficial graft-versus-
leukaemia effect (GVL), which is a distinct advantage of the tolerogenic DCs (Sato et 
al., 2003). Recently, autologous BM-derived DCs pulsed with allopeptides were used in 
a study to expand alloantigen-specific Tregs that induce donor-specific transplantation 
tolerance in a T cell-depleted skin transplant model in mice (Golshayan et al., 2007). In 
human studies, repetitive stimulation with monocyte-derived immature DCs pulsed with 
an HLA-A2-derived allopeptide was used to expand alloantigen-specific Tregs ex vivo 
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(Jiang et al., 2003). The Tregs that have indirect allospecificity downregulated the 
proliferation of T cells that recognised the allopeptide through the indirect pathway, and 
suppressed donor T cells that recognised the allopeptide through the direct pathway by 
bystander suppression and linked suppression. 
 
Whilst pharmacologically-treated immature DCs are relatively refractory to activation, 
they might be activated by high concentrations of cytokines or other stimuli. For 
example, in a study of tumour-infiltrating DCs, which have a similar immature 
phenotype to dexamethasone-treated DCs as a result of the local environment, the cells 
could be matured by addition of CpG immunostimulatory sequences and anti-IL10 
receptor antibody, but not LPS or IFNγ (Vicari et al., 2002). Intravenous administration 
of in vitro-generated, donor-derived immature DCs significantly (but not indefinitely) 
prolonged the survival of vascularised (heart) or non-vascularised (pancreatic islet) 
allografts in otherwise untreated recipient mice (Rastellini et al., 1995; Fu et al., 1996). 
The failure of the donor-derived DCs to induce indefinite graft survival was ascribed to 
late upregulation of costimulatory markers by the DCs, triggered through CD40-CD154 
(CD40L) interactions. This problem was only circumvented by combining the 
intravenous administration of immature, donor-derived DCs with CD40-CD154 
blockade, anti-T cell therapy or by using ‘maturation-resistant’ DCs (Lu et al., 1997; 
Lutz et al., 2000). This raises the possibility that some stimuli may be capable of 
maturing dexamethasone-treated DCs. The potential also exists wherein 
pharmacologically-treated immature DCs administered for tolerogenic therapy could be 
activated in vivo as a result of local inflammation. 
 
Genetic modification of DCs has resulted in the enhancement of the tolerogenic 
potential of DCs. There have been two broad approaches to this; one has been to 
transfect or transduce DCs with a gene encoding an immunomodulatory protein which 
then influences the environment the DC enters. Thus, DCs transduced with TGF-β1 
have been shown to induce T cell hyporesponsiveness both in vitro and in vivo (Asiedu 
et al., 2002; Sun et al., 2002). The second is to use a gene encoding a molecule that 
prevents DC activation, such as inhibiting the activation of NF-κB by expressing a 
dominant negative form of IκB-kinase 2 (IKK2) (Andreakos et al., 2003; Yoshimura et 
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al., 2003). This also results in DCs that induce T cell hyporesponsiveness in vitro and in 
vivo (Yoshimura et al., 2001). Other examples of using genetically-modified DCs 
include the induction and maintenance of T cell anergy by expressing PD-L1 in DCs or 
the deletion of antigen-specific T cells through the expression of CD95L or TNF-related 
apoptosis-inducing ligand (TRAIL) (Morelli and Thomson, 2003). Genetic modification 
provides long-term (for the life of the DC) modulation of cell function as a strategy to 
induce tolerance and has several advantages in vivo. The tolerogenic DCs would not 
only have the capacity for efficient antigen presentation to T cells, but would also be 
able to traffic rapidly to secondary lymphoid organs to encounter T cells (De Vries et 
al., 2003), and depending on the specific phenotypic and/or functional effect of the DC 
transgene, induce anergy. Furthermore, in comparison to the in vivo administration of 
soluble proteins (such as CTLA4-Ig or humanised antibodies specific for costimulatory 
markers), tolerogenic therapy based on administration of a DC population expressing a 
transgene would be donor-specific, due to expression on the DC surface of donor 
MHC:peptide complexes and absence of ‘signal two’, or costimulatory molecule 
expression. This would avoid current problems of generalised immunosuppression after 
administration of an agent that blocks engagement of costimulatory molecule(s) in an 
antigen non-specific manner.  
 
In addition to the generation of donor- or recipient-derived tolerogenic DCs in vitro to 
downregulate anti-donor T cell responses in transplantation, an alternative technique is 
based on the in situ delivery of alloantigen to quiescent DCs in the lymphoid organs of 
the recipient. This approach avoids activating the DCs, whilst maintaining or even 
enhancing their ability to induce T cell tolerance. Systemic administration of donor 
leukocytes undergoing apoptosis has been demonstrated to be a feasible approach for 
delivering donor allopeptides to recipient DCs in situ, without altering their quiescent 
status [moreso than targeting peptides to CD205/DEC205, a lectin expressed mainly by 
CD8α+ DCs in the T cell areas of lymphoid organs (Hawiger et al., 2001; Bonifaz et al., 
2002)]. The surface of apoptotic cells contains a series of ligands known as ‘apoptotic-
cell-associated-molecular-patterns’ (Larregina and Morelli, 2006), which are recognised 
by pattern recognition receptors expressed by DCs. Interaction of these ligands with the 
receptors results in the recognition and internalisation of the apoptotic cell by the DC. 
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An inhibitory signal is then delivered to the DC, which fails to mature in response to 
maturation / danger signals and remains tolerogenic (Morelli et al., 2003). For example, 
donor UVB-induced early apoptotic splenocytes injected intravenously in mice are 
captured and processed rapidly by splenic DCs. These host DCs remain quiescent, 
express low levels of costimulatory molecules and thus induce suboptimal activation, 
followed by apoptosis, of anti-donor T cells (Wang et al., 2006). When combined with 
CD40-CD154 blockade, systemic administration of donor apoptotic cells induces the 
indefinite survival of cardiac allografts in mice with the generation of donor-specific 
Tregs with minimal evidence of transplant vasculopathy (Wang et al., 2006). 
 
Simultaneous targeting of DCs and Tregs is also a desirable approach to induce 
transplantation tolerance- a self-maintaining regulatory loop has been described in a 
murine model of cardiac transplantation, where tolerogenic DCs induce Tregs that, in 
turn, generate further tolerogenic DCs (Min et al., 2003). DC administration has great 
potential as an effective method of tolerance induction. However, it has a number of 
logistic drawbacks. There would be a need to grow DCs for each patient, which will be 
costly and labour intensive under GMP conditions. In the context of cadaveric donor 
transplantation (which is likely to remain the mainstay of any organ transplantation 
programme) it may be difficult to obtain enough DCs in a short time period (Bluestone 
et al., 2007). 
 
1.11. Inhibition of Costimulation and Intracellular Fusion Proteins 
 
As described in detail above, disruption of CD80/86-CD28 costimulation represents a 
potential set of strategies to induce donor-specific tolerance- hence, the use of immature 
DCs expressing low constitutive levels of MHC class II and costimulatory molecules in 
numerous studies, resulting in the induction of donor-specific regulation and 
prolongation of allograft survival. Thus, the use of CTLA4-Ig (a synthetic fusion 
protein containing the extracellular domain / CD80/86-binding domain of CTLA4) 
(Linsley et al., 1992b) has been demonstrated to prolong the survival of allografts in 
several transplantation models (Lenschow et al., 1992; Blazar et al., 1994; Bolling et al., 
1994; Pearson et al., 1994; Tepper et al., 1994; Lane et al., 1996; Gainer et al., 1997; 
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Graser et al., 1997; Kirk et al., 1997; Gainer et al., 1998a; Gainer et al., 1998b; Fu et al., 
1999a; Fu et al., 1999b; Rastellini et al., 1999). Furthermore, it has also been 
demonstrated that tolerance induced by the administration of CTLA4-Ig alone is a result 
of a TH1 to TH2 cytokine profile shift rather than the induction of donor-specific anergy 
(Sayegh et al., 1995). The in vivo administration of CTLA4-Ig or a monoclonal 
antibody specific for CD154 (CD40L) alone or in combination has also been shown to 
prolong allograft survival. This was particularly the case when administration of 
CTLA4-Ig (Lenschow et al., 1992) and/or CD154 (Hancock et al., 1996) was combined 
with donor specific therapy, such as the injection of donor-derived cells (Larsen et al., 
1996). In the absence of concomitant donor specific therapy, allografts are eventually 
rejected due to the development of atherosclerosis in transplants. 
1.11.1. Intracellular Retention of CD80/86: CTLA4-KDEL 
 
The endoplasmic reticulum (ER) is the gateway of proteins into the intracellular 
secretory system. There are a number of soluble proteins, membrane proteins and 
molecular chaperones which are involved in folding, glycosylation, assembly and 
maturation of nascent proteins (Vitale and Denecke, 1999). The soluble chaperone 
proteins such as BiP, calreticulin, calnexin and isomerase located in the ER lumen have 
the retention signal, KDEL or HDEL at C terminus (Munro and Pelham, 1987; Pelham, 
1989) and this signal is known to be recognised by the KDEL receptor on the Golgi 
complex, which mediates the retrieval of the KDEL-tail protein to the ER. Newly-
synthesised proteins interact with ER molecular chaperones to become folded and 
assembled into mature protein complexes for transport along the secretory pathways. 
ER chaperones participate in a mechanism to prevent misfolded proteins (or those 
incapable of transport) from being exported out of the ER (Hammond and Helenius, 
1995; Ellgaard et al., 1999). ER chaperones act on the retained proteins either for 
further maturation or for degradation, protecting the ER from protein aggregation 
(Gething and Sambrook, 1992). Such degradation termed ER-associated degradation 
(ERAD) is accomplished by translocation of proteins to the cytosol through 
translocation channels, followed by ubiquitination and degradation via the proteosome 
system (Brodsky and McCracken, 1999). The pathway that is responsible for the 
retrieval of KDEL-expressing proteins involves the binding of the KDEL receptor 
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ERD2 which is an integral membrane protein located in the Golgi and ER (Lewis and 
Pelham, 1990; Semenza et al., 1990). Binding to ERD2 returns KDEL-expressing 
proteins to the ER via COP1 coated transport intermediates (Orci et al., 1997), where 
they are released from the receptor- possibly as a consequence of changes in the pH 
(Wilson et al., 1993; Cabrera et al., 2003). 
 
A method has recently been developed to render DCs incapable of activating T cells that 
relies on inhibiting expression of costimulatory molecules without altering other aspects 
of DC maturation (Tan et al., 2005c). A novel genetic construct has been produced 
consisting of the extracellular domain of CTLA4 fused to the KDEL (Lys-Asp-Glu-
Leu) peptide (CTLA4-KDEL). As stated above, the KDEL peptide serves as a signal 
that retains or retrieves proteins to the ER (Munro and Pelham, 1987). As a 
consequence when CTLA4-KDEL is expressed in a cell it is confined to the 
endoplasmic reticulum. There it can bind to CD80 and CD86, preventing their passage 
through the Golgi apparatus to the cell surface. The CD80/86 that is thus retained in the 
ER is degraded [Figure 10]. The approach of using KDEL fused to the extracellular 
part of a cell surface protein is similar in some respects to the use of intracellular 
antibodies and intrakines when similar KDEL fusions between either antibody 
fragments or chemokines have been used to block the expression of cell surface 
molecules (Richardson et al., 1995; Chen et al., 1997; Yang et al., 1997; Sepp et al., 
1999). The way in which complexes between KDEL-expressing proteins and their 
ligands are degraded has been characterised. Aside from the compartment where they 
are expressed, intrabodies are naturally diverted to the proteasome pathway. This has 
been demonstrated not only for nuclear and cytoplasmic intrabodies but also for 
secretory intrabodies. In the first case, they tend to aggregate and coalesce into 
aggresome structures, whereas in the second case they are retrotranslocated from the 
ER, ubiquitinated and, finally, proteasome-degraded (Cardinale et al., 2001; Cardinale 
et al., 2003; Cardinale and Biocca, 2008). It has also been demonstrated that proteasome 
inhibitors inhibit the degradation of CD80/86 (after retention in the ER by CTLA4-
KDEL), which suggests a retrograde transport of the CTLA4-KDEL-CD80/86 complex 
from the ER to the cytosol (Tan et al., 2005c). 
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Figure 10. Intracellular Retention of CD80/86 by CTLA4-KDEL. 
Proteins resident to a cell’s Endoplasmic Reticulum (ER) are retained there due to a C-terminal four amino 
acid peptide called KDEL. The KDEL peptide serves as a signal that retains or retrieves proteins to the 
ER. The pathway responsible for the retrieval of KDEL-expressing proteins involves the binding of KDEL to 
its receptor ERD2, which is an integral membrane protein located in the Golgi and ER. Binding to ERD2 
returns KDEL-expressing proteins to the ER via COP1 coated transport intermediates. An intracellular 
mechanism that prevents CD80/86 costimulation has been developed based on this retention mechanism: 
A fusion protein consisting of the extracellular domain of CTLA4 and the KDEL peptide is expressed in 
DCs. The CTLA4-KDEL binds to CD80/86 in the ER and prevents expression of these proteins on the DC 
surface. 
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Initial studies in a human in vitro system have demonstrated that transfection with 
CTLA4-KDEL inhibits the surface expression of CD80/86 on a range of human APCs, 
including B lymphocytes and DCs, without affecting the expression of other surface 
markers (Tan et al., 2005c). The advantage of using a cell surface molecule such as 
CTLA4, rather than antibodies or siRNA, is that the construct is capable of blocking 
expression of all of its ligands (in this case CD80 and CD86), rather than a separate 
antibody or siRNA construct for each target. Furthermore, if siRNA were to be used for 
the pupose of inhibiting surface CD80/86 expression, two siRNA constructs would have 
to be transfected into cells (a difficult procedure in practice), or one construct 
expressing both siRNA specific for CD80 and CD86 under separate promoters would 
have to be used. Immunogenicity of the CTLA4-KDEL construct would be minimal, as 
the CTLA4 construct would be derived from human sequences (in a clinical scenario), 
or murine sequences for the purpose of in vivo studies. This is particularly significant, 
as proteosome-dependant degradation of CTLA4-KDEL has been demonstrated (Tan et 
al., 2005c), suggesting that the molecules are likely to enter the antigen-processing 
machinery. An advantage of modifying DCs such that they express CTLA4-KDEL 
ensures (at an optimised transfection/transduction efficieny) the presence of populations 
of cells that do not express surface CD80/86 as a result of intracellular retention in the 
ER. Above all, the CTLA4-KDEL approach has a major advantage over the 
administration of soluble proteins such as CTLA4-Ig (described above) in that it would 
be specific to the antigens expressed by the DCs and so will not induce generalised 
immunosuppression. 
 
1.12. Lentiviral Vector-Mediated Modification of Dendritic Cells 
 
As described in section 1.10, genetic modification of DC function is an attractive 
approach to treat disease, either using mature DCs to immunise patients, or immature 
DCs to induce tolerance. DCs are important targets for novel genetic interventions to 
induce transplantation tolerance as they are regarded not only as the initiators or 
regulators of the immune response but also as a powerful tool for the therapeutic 
manipulation of allorecognition and thus, allograft survival. Non-viral vectors are 
relatively inefficient at targeting the nucleus for gene therapy (Tan et al., 2006). 
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Movement of DNA through the cytoplasm towards the nucleus occurs by diffusion, a 
relatively slow process during which the DNA must be protected. Hence, coating with 
lipid/polymer agents such as PEG can stabilise plasmid DNA and protect it from 
degradation in the cytosol (Lee and Huang, 1997). Nuclear entry of exogenous DNA is 
controlled by the nuclear pore complex (NPC). Passive entry is restricted to 50-60 kDa 
particles as the diameter of the nuclear pores is less than 10 nm. Entry of a larger size 
requires appropriate nuclear localisation signals (NLSs) to recognise importins in the 
cytoplasm. The importins allow docking on the nuclear envelope prior to an energy-
dependent translocation event (Goldfarb et al., 1986; Zanta et al., 1999). The first 
nuclear localisation signal identified was that of the SV40 large T-antigen (Kalderon et 
al., 1984). Alternative non-viral approaches have struggled to achieve efficiencies 
similar to those obtained using viruses. For example, in recent study by Tan and 
colleagues, human monocyte-derived DCs were transfected using a novel approach- 
monocytes were transfected using a non-viral vector system in which liposomes were 
targeted to the transferrin receptor (Tan et al., 2001; Tan et al., 2003; Tan et al., 2005a), 
resulting in a 20-30% transfection efficiency. Drug selection during the differentiation 
of the monocytes into DCs subsequently ensured that all of the surviving cells contained 
the gene of interest. The cells were demonstrated to retain their immature phenotype 
(unless activated). It is interesting to note that that at early periods post transfection (48 
hours) of murine bone-marrow DCs, expression of cell surface molecules is affected in 
a non-specific manner (PH Tan, unpublished), most likely due to upregulation of the ER 
stress-responsive protein PERK and subsequent activation of elF2 α (Welihinda et al., 
1999; Harding et al., 2000a). However, at 72 hours no activation of the PERK/elF2α 
system is seen, and the expression of all cell surface proteins returns. Interestingly, no 
activation of the PERK/elF2α pathway is seen in human DCs (Tan et al., 2005c). There 
have been no reports of whether this transient expression of PERK and elF2α after non-
viral transfection has any long-term effects on the DCs that can have implications for in 
vivo studies. 
 
Viruses have evolved to deliver DNA efficiently to specific cell types without detection 
by immunosurveillance mechanisms in the host. A variety of retroviruses, for example, 
are able to integrate stably into the genome of the host cell (Hajihosseini et al., 1993). 
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Whereas the Murine Moloney Leukaemia Virus (MMLV)- a retrovirus- is unable to 
infect non-dividing cells, which limits its application and efficacy in cells such as DCs 
(Okano and Rich, 1969; Augenlicht and Halsey, 1985), lentiviral vectors are able to 
infect non-dividing cells (Bukrinsky et al., 1993; Freed and Martin, 1994). Similar to 
lentiviruses, adenovirus- (Guzman et al., 1993), Herpes Simplex virus (HSV)- (Nilaver 
et al., 1995), and adeno-associated virus (AAV)-based vectors (Zhou et al., 1994) are 
also able to infect non-dividing cells (with the vector genome existing principally in 
episomal form) and express transgenes at relatively high levels [Figure 11]- the 
mechanisms used by lentiviruses to infect non-dividing cells is discussed below. The 
development over the last three decades of viral vectors that do not express viral gene 
products are proving to be especially useful in the context of gene therapy and 
transplantation. Virus entry into target cells involves two initial events: binding to the 
cell surface followed by internalisation. Viruses generally enter the cytoplasm either by 
fusion of the viral envelope and cell membrane (as occurs with retroviruses) or by 
recepter-mediated endocytosis (e.g. the influenza virus) (Knipe, 1996). Upon binding, 
the viral fibres dissociate and the viral particles are internalised via vesicles. The 
particles are then able to escape into the cytoplasm by lysis of the endosomal membrane 
(Seisenberger et al., 2001). Lysis has been demonstrated to be mediated by changes in 
pH (the acid-activated, lytic activity of two capsid components, the hexon or penton-
base proteins) (Greber et al., 1994). Uncoating of virus particles occurs at the cell 
surface or inside the cell (in the cytoplasm or at the nuclear pores). 
 
Viral vectors developed for gene therapy rely on the generation of recombinant viruses, 
consisting of viral genomes packaged into true viral particles. In the majority of 
systems, replication-deficient vector particles are generated using a ‘packaging’ cell line 
(Thomas et al., 2003). Recombinant viruses are generated in the producer cells via a 
‘trans-complementation’ process in which some of the viral genes are deleted such that 
the viral particles are rendered replication-deficient (see below for details) and 
accommodate the transgene / gene of interest. The producer cells provide the viral 
sequence in trans, thus generating particles that are capable of transferring the transgene 
into the host genome without the capacity for replication (Thomas et al., 2003). To drive 
the expression of exogenous DNA requires a strong promoter and and enhancer  
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Figure 11. Properties of Viral Vectors used for Gene Transfer. 
Retroviral particles are lipid-enveloped and comprise a homodimer of linear, positive-sense, single-
stranded RNA of upto 12 kb. Following entry into the target cells, the RNA genome is retro-transcribed into 
linear double-stranded DNA and integrated into the cell chromatin. The Retroviridae include the 
mammalian and avian C-type onco-retroviruses, the lentiviruses the spumaviruses and Murine Moloney 
Leukaemia Virus (MMLV). The lentiviral family can be derived from primate (such as HIV or SIV) and non-
primate viruses such as feline immunodeficiency virus (FIV) and the Equine Infectious Anaemia Virus 
(EIAV). The lentivirus differs from MMLV in that it does not require a breakdown of the nuclear membrane 
to allow transfer of the pre-integration complex, but makes use of an active transfer mechanism which 
enables efficient transduction of non-dividing cells. 
*Replication-Defective. #Amplicon. §Helper-Dependent. AAV, Adeno-Associated Viral vector; dsDNA, 
Double-Stranded DNA; HSV-1, Herpes Simplex Virus-1; ss(+)RNA, Single-Stranded positive-sense RNA; 
ssDNA, Single-Stranded DNA. 
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upstream of the transgene. Viral promoters generally result in uncontrolled expression 
of transgenes and the human cytomegalovirus (CMV) promoter has been used 
extensively to drive the expression of transgenes in mammalian cells (Boshart et al., 
1985). 
 
Adenoviral transduction is an efficient method to introduce a transgene into DCs, 
although it results in the activation of immature DCs and also results in a somewhat 
reduced capacity of the mature DCs to stimulate a MLR, due to the modulatory effects 
of the virus (Tan et al., 2005a). In contrast, with human immature DCs, a transduction 
efficiency of approximately 70% has been obtained using retroviral vectors with 
minimal cell activation (Tan et al., 2005b). Retroviral vectors, specifically lentiviral 
vectors based on the Equine Infectious Anaemia Virus (EIAV) and Human 
Immunodeficiency Virus-1 (HIV-1), are promising for future gene therapy (Thomas et 
al., 2003); Examples of retroviral vectors used in gene therapy, and the disease(s) 
associated with the wild-type form of the virus are given in Figure 12. Retroviral 
particles are lipid-enveloped and comprise a homodimer of linear, positive-sense, 
single-stranded RNA of up to 12kb. Following entry into the target cells, the RNA 
genome is retro-transcribed into linear double-stranded DNA and integrated into the cell 
chromatin. As described earlier, of particular interest is the capacity of lentiviruses to 
transduce quiescent and terminally differentiated cells such as DCs as these viruses do 
not require a breakdown of the nuclear envelope to allow transfer of the pre-initiation 
complex, but make use of an active transfer mechanism- nuclear targeting (Thomas et 
al., 2003)- this is discussed below. It was demonstrated in a recent study that the 
majority of EIAV and HIV-1 integration sites were within a gene, and both vectors 
favoured AT-rich regions (Hacker et al., 2006). Sites within genes were examined using 
a model to determine the influence of gene-specific parameters, gene region, and 
transcriptional activity. Both EIAV and HIV-1 preferentially integrated within active 
genes. Unlike the gammaretrovirus MLV, EIAV and HIV-1 vectors do not integrate 
preferentially into the promoter region or the 5’ end of the transcription unit (Hacker et 
al., 2006). The long-term expression by integration into the host cell genome, along 
with an overall minimal vector-induced immunogenity, renders the lentivirus an 
attractive option for the treatment of diseases requiring stable transgene expression. 
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RETROVIRUS DISEASE
Alpharetroviruses
Avian Leukosis Virus
Moloney Murine Leukaemia Virus (MMLV)
Lymphoid leukaemia and wasting syndromes in chickens
T-cell leukaemia in mice/rats
Betaretroviruses
Mouse Mammary Tumour Virus Epithelial mammary tumours in mice
Gammaretroviruses
Feline Leukaemia Virus Feline Immunodef iciency/Lymphoid Leukaemia in cats
Deltaretroviruses
Human T-cell Lymphotrophic Virus-1 (HTLV-1)
Human T-cell Lymphotrophic Virus-2 (HTLV-1)
Bovine Leukaemia Virus
Adult T-cell Leukaemia in human
Hairy-cell leukaemia in humans; CNS disease
T-cell leukaemia in cattle
Lentiviruses
Human Immunodef iciency Virus 1 and 2 (HIV-1 and HIV-2)
Simian Immunodef iciency Virus (SIV)
Feline Immunodef iciency Virus (FIV)
Equine Infectious Anaemia Virus (EIAV)
Caprine Arthritis-Encephalitis Virus
Visna/maedi Virus
Acquired Immune Def iciency Syndrome; CNS disease
Non pathogenic in monkeys, immunodef iciency in old-world primates
Immunodef iciency in cats
Chronic haemolytic anaemia in horses
Arthritis, pneumonia and wasting in goats
Pneumonia, wasting and paralysis in sheep
Spumaviruses
Human Foamy Virus (HFV) No pathogenicity def iciency identified
 
 
 
Figure 12. Commonly Studied Retroviruses and Associated Diseases. 
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Recent studies have demonstrated that EIAV is more efficient than an HIV-1 based 
construct in the transduction of terminally differentiated cells such as DCs (Tan et al., 
2005b) and human corneal endothelial cells (quiescent cells in the cornea- compromise 
of corneal endothelial cell number results in the loss of corneal allografts- see section 
1.5) (Beutelspacher et al., 2005). EIAV-based lentiviral vectors that have been 
developed for use in research are pseudotyped with the vesicular stomatitis virus 
glycoprotein (VSV-G) envelope and contain a marker transgene under the control of an 
internal CMV promoter. The VSV-G modification confers an extremely broad host 
range and markedly stabilises the vector particles, allowing the vector stocks to be 
concentrated to high titres. EIAV entry into cells has recently been demonstrated to 
occur through clathrin-mediated endocytosis (Brindley and Maury, 2008). As described 
earlier, in the interest of safety early lentiviral vectors were produced by transient 
transfection with three plasmids (Naldini et al., 1996a). Safety was further guaranteed 
by deleting genes not required for the generation of functional vector particles and by 
making the vector self-inactivating (SIN), mainly by modifying transcriptional enhancer 
and promoter regions in the 3’U3-Long Terminal Repeats (LTR) (Zufferey et al., 1998). 
The modified U3 which is transferred to the 5’-LTR during reverse transcription, causes 
transcriptional inactivation of the LTR in integrated proviruses, while the activity of the 
promoter internal to the LTR regions remains unaffected (Miyoshi et al., 1998; Zufferey 
et al., 1998). Reverse transcription of the retroviral RNA genome occurs in the 
cytoplasm, and unlike C-type retroviruses, the lentiviral cDNA complexed with other 
viral factors- known as the pre-initiation complex (PIC)- is able to translocate across the 
nuclear membrane and transduce non-dividing cells. A structural feature of the viral 
cDNA – a DNA ‘flap’- seems to contribute to efficient nuclear import. This flap is 
dependent on the integrity of a central polypurine tract (cPPT) that is located in the viral 
polymerase gene, so most lentiviral vectors now retain this cPPT sequence (Zennou et 
al., 2000). 
1.12.1. Titration of Lentiviral Vectors Lacking a Reporter Gene 
 
There are several methods that can be used to titre lentiviral stocks for experimental 
studies. A recent comparision of three methods of titre assessment (Sastry et al., 2002), 
including (i) the detection of vector RNA sequences in viral supernatant; (ii) viral DNA 
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sequences in transduced cells (i.e. integrated within the genomic DNA of the cell) and 
(iii) vector expression in transduced cells (using a vector expressing a reporter protein 
such as GFP). It was concluded that of the three methods tested, titres assessed by the 
detection of viral DNA sequences in transduced cells provide the most reliable estimate 
of functional titres as these are least likely to be influenced by factors such as defective 
interfering particles and vector expression levels. It was also concluded that real-time 
PCR offers a reproducible method for lentiviral titration (Sastry et al., 2002). For 
example, RNA dot-blot assays are still used to estimate vector RNA from viral 
supernatants. This method, although helpful, is semi-quantitative. Real-time PCR 
technology is a more sensitive and accurate method (Martin-Rendon et al., 2002). 
 
The use of lentiviral vectors for basic research and prospective clinical applications 
requires methodologies that can accurately determine lentiviral titres and monitor viral 
transgene expression within target cells beyond the context of reporter genes typically 
used for this purpose. Ideally, gene transfer vectors used in clinical protocols should 
only express the gene of interest. So far most vectors have contained marker genes to 
aid their titration. There is concern about the immunogenic potential of these genes in 
animal models and clinical trials (Thomas et al., 2003). Accordingly, scientists have 
preferred to remove marker genes from viral vector genomes. A recent study has 
described a quantitative/real-time PCR-based method that achieves both goals stated 
above using primer sequences that are specific for the woodchuck hepatitis 
posttranscriptional regulatory element (WPRE) (Lizee et al., 2003). Mammalian 
hepadnaviruses such as hepatitis B virus (HBV) and woodchuck hepatitis B virus 
(WHV) contain a conserved post-transcriptional regulatory element (PRE) that is 
required for the cytoplasmic accumulation of mRNAs encoding the virion surface 
antigen. These PREs confer enhanced gene expression when linked with heterologous 
transcription units and PRE derived from WHV (WPRE) has proven to be particularly 
effective (Donello et al., 1998). The WPRE has been incorporated into a number of viral 
vectors, including those based on retroviruses, adeno-associated viruses and lentiviruses 
with significant beneficial effects on transgene expression (Zufferey et al., 1999). It is 
incorporated in the 3’UTR of nascent transgene transcripts to enhance transgene 
expression (Lizee et al., 2003). In research undertaken with EIAV the incorporation of 
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WPRE into a number of vectors has resulted in enhanced expression of the gene-of-
interest (Bienemann et al., 2003; O'Rourke et al., 2003). Similar to the methods 
described above, quantitative/real-time PCR based on WPRE detection allows for rapid 
and accurate assessment of lentiviral vector titres at three levels: vector supernatant 
RNA, integrated proviral DNA, and lentiviral gene (mRNA) expression in transduced 
cells (Lizee et al., 2003). In a recent study, although the detection of integrated proviral 
DNA was concluded to be the most reliable/reproducible method for lentiviral titration 
based on WPRE detection, there was a much wider discrepancy in mRNA levels among 
three separate vectors than would have been anticipated from titre estimates based on 
DNA integration events (Lizee et al., 2003). 
 
1.13. Aims, Approaches and Hypotheses of Study 
 
The principle aim of the study was to investigate the potential of the intracellular fusion 
protein CTLA4-KDEL and the immunoregulatory enzyme IDO1 (referred to throughout 
the study as IDO) to render murine DCs tolerogenic and subsequently induce donor-
specific transplantation tolerance. Whereas in vivo data regarding the intracellular 
strategy of CD80/86 retention by DCs expressing CTLA4-KDEL was unavailable 
before this study, numerous studies have been published emphasising the beneficial 
effect of IDO expression by donor grafts (Mellor and Munn, 2004), [but very few 
regarding IDO expression by BM-derived DCs (Terness et al., 2002)]. It was thus 
interesting to compare a novel mechanism of costimulation inhibition with an enzymatic 
mechanism of immunoregulation that has been applied widely in transplant, 
autoimmune and tumour (where mechanisms to inhibit IDO function are utilised) 
settings, both in vitro and in vivo. Lentiviral (EIAV) vectors encoding either murine 
CTLA4-KDEL or murine IDO were used to transduce BM-derived DCs, as opposed to 
the use of a non-viral system.  This is because transfection efficiencies equivalent to 
those obtained with lentiviral vectors are generally difficult to attain using non-viral 
methods (Tan et al., 2006), unless (antibiotic) selection is used. As described in the 
previous section, the WPRE sequence in an EIAV construct contains the tripartite 
element that has been demonstrated to be essential for enhanced gene expression. A 
previously-reported quantitative/real-time PCR system (based on detection of WPRE) 
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was used that allowed for the rapid and accurate titration of lentiviral vectors lacking a 
reporter gene, yielding a value for the concentration (in transducing units/ml) of viral 
vector supernatant (Lizee et al., 2003). Using lentiviral technology, the study aimed to 
investigate whether EIAV CTLA4-KDEL- or EIAV IDO-transduced murine DCs can 
induce donor-specific tolerance in vitro and in vivo (after intravenous administration of 
transduced DCs into mice). The effect of both populations of EIAV-transduced DCs on 
corneal allograft survival was also assessed. In addition, the efficiency and mechanisms 
of tolerance observed using CTLA4-KDEL- or IDO-expressiong DCs was compared. 
 
It was hypothesised that the use of CTLA4-KDEL-expressing DCs to induce tolerance 
would have several advantages over pharmacologically-treated (e.g. dexamethasone-
treated) immature DCs. First, CTLA4-KDEL- or IDO-expressing DCs could be 
activated by the addition of LPS prior to administration. In the case of CTLA4-KDEL-
expressing DCs, these transduced DCs would be identical to their untransduced 
counterparts with the exception that they do not express CD80/86 but express high 
levels of MHC class II, with subsequent enhanced efficiency at presenting alloantigen to 
T cells (in order to induce anergy). Furthermore, activated DCs rapidly migrate to 
lymph nodes, unlike immature DCs which are much less motile and inefficient at 
homing to lymph nodes (De Vries et al., 2003). Therefore, it was expected that 
CTLA4-KDEL- or IDO-expressing DCs would be more successful than immature DCs 
at reaching secondary lymphoid organs where they would encounter allospecific naïve 
T cells. Although the mechanism of T cell anergy induction would differ from 
CTLA4-KDEL-transduced DCs, it was expected that DCs transduced with EIAV IDO 
would be more effective than dexamethasone-treated DCs for the induction of tolerance, 
largely due to data indicating that a relatively small number of IDO+ DCs can suppress 
potent T cell responses in vivo, and promote systemic tolerance- see section 1.9. 
1.13.1. Effect of Intracellular Retention of CD80/86 and Tryptophan Catabolism by 
Dendritic Cells on in vitro- and in vivo-Generated T Cell Alloreactivity and Allograft 
Survival 
 
Progressing from preliminary research undertaken with CTLA4-KDEL-expressing DCs 
in a human in vitro system (Tan et al., 2005c), an important aim of the study was to 
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assess, in a murine system, whether allogeneic CD4+ T cells that interact with 
CTLA4-KDEL- or IDO-expressing DCs proliferate or are rendered anergic. This was 
tested by the capacity of the CD4+ T cells to respond to a secondary challenge by donor-
derived DCs, and whether the T cells expressed cell cycle-associated kinase inhibitors 
that are restricted to expression in non-replicating / anergic T cells. CD4+ T cells 
exposed to CTLA4-KDEL- or IDO-expressing DCs were also rechallenged with third-
party DCs to investigate the induction of donor-specific anergy. For cell-based 
tolerogenic therapy to be efficient in transplantation medicine, it is critical that 
allogeneic T cells rendered anergic do not die but have the capacity to regulate the 
activity of alloreactive T cells. Therefore, by definition, T cell anergy would have to be 
reversible on addition of exogenous IL-2 to rechallenge cultures (Beverly et al., 1992; 
Kuniyasu et al., 2000). The study also investigated whether Tregs with the capacity for 
linked suppression are generated from CD4+ T cells that encounter CTLA4-KDEL- or 
IDO-expressing DCs. The induction of a Treg population would be important for the 
ultimate application of each strategy. 
 
In addition to in vitro experiments, it was important to investigate, using rechallenge 
assays, whether the interaction of alloreactive T cells with EIAV CTLA4-KDEL- or 
EIAV IDO- transduced DCs induces donor-specific anergy and regulation in vivo. 
Suppressor assays were used to assess whether anergic T cells generated in vivo (after 
encountering CTLA4-KDEL- or IDO-expressing DCs) are capable of acting as Tregs by 
suppressing the activation of alloreactive/effector T cells (Lombardi et al., 1994; Chai et 
al., 1999). The induction of a Treg population was confirmed, in part, by detection of 
FoxP3, a marker of murine CD4+CD25+ Tregs (Fontenot et al., 2003; Hori et al., 2003). 
The induction of linked suppression to third-party antigens (Qin et al., 1993; Davies et 
al., 1996) after treatment with CTLA4-KDEL- or IDO-expressing DCs was also 
investigated using rechallenge and suppressor assays. Studies have demonstrated that 
CD80/86 expression by APCs is required for the generation and survival (via CD28 
ligation) of Tregs in the mouse (Salomon et al., 2000; Sakaguchi, 2005)- see section 1.6. 
Furthermore, it has been suggested that CTLA4 probably has a role in T cells that is 
carried out via ligation of CD80/86 (Lohr et al., 2003). It was therefore crucial to 
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confirm that CTLA4-KDEL-expressing DCs do not prevent the generation of Tregs due 
to intracellular retention of CD80/86 in the ER by the transduced cells. 
 
Further to in vivo experiments, corneal transplantation was performed using strain 
combinations with full MHC mismatches. This allowed for the general applicability and 
potency of the CTLA4-KDEL and IDO systems to be tested, including the ability of the 
transduced DC populations to induce tolerance to the direct pathway and subsequent 
effects on corneal allograft rejection, a process mediated predominantly by the indirect 
pathway of allopresentation. Figure 13 illustrates the cellular interactions that were 
hypothesised to characterise donor-specific tolerance induction by CTLA4-KDEL-
expressing DCs. 
 
A crucial objective of this study was to investigate the effect of the EIAV-transduced 
DCs on the indirect pathway of allorecognition, as this is the predominant pathway of 
recognition during the chronic phase of allograft rejection- see section 1.4.2. In the 
clinical setting, induction of tolerance to the indirect pathway using recipient-derived 
DCs (presenting donor-derived peptide) would certainly be less challenging than 
obtaining donor-derived DCs (in the case of cadaveric donor transplantation). For both 
in vitro and in vivo experiments, the CBK→CBA strain combination was used to test 
the indirect pathway of allorecognition. The CBK mouse is derived from the CBA 
(H-2k) strain and is transgenic for the MHC class I Kb (Tarazona et al., 1996). As there 
are no class II differences between the two strains, and the only difference is in the 
addition of the Kb molecule, the CD4+ cells that lead to rejection are therefore 
obligatorily specific for the indirect pathway of allorecognition for Kb (Ensminger et al., 
2002). The use of the CBK→CBA strain combination allowed for experiments to be 
undertaken that tested the applicability of CTLA4-KDEL- or IDO-expressing DCs to 
the induction, in vivo, of tolerance to the indirect pathway. It has previously been 
demonstrated using the CBK→CBA strain combination that induction of tolerance to 
Kb alone can result in acceptance of a fully mismatched H-2b graft (Wong et al., 1996; 
Wong et al., 1997). The CBK→CBA system thus allowed for further assessment of any 
regulation of the indirect pathway (by Tregs with specificity for this pathway and the 
mediation of any observed linked suppression by these cells). 
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Figure 13. Illustrated Hypothesis for Cellular Reactions Characterising Donor-Specific Tolerance 
Induction by CTLA4-KDEL-Expressing DCs in Murine Corneal Transplantation. 
Cellular reactions characterising the alloresponse in murine corneal transplantation: the relative paucity of 
MHC II+ donor DCs in the cornea (most are MHC II-) suggests that donor DCs trafficking through the 
draining lymph nodes of the recipient to elicit a direct alloresponse is relatively minor. However, these DCs 
provide a vehicle for the supply of donor histocompatibility antigens to recipient DCs. Migrant recipient 
DCs trafficking back through the graft also have the opportunity to capture alloantigens, before egress 
back to the lymph nodes. Such alloantigens are then able to evoke an indirect alloresponse, involving 
CD4+ T cells interacting with DCs through MHC class II molecules and, to a lesser extent, CD8+ T cells 
interacting with cross-presenting DCs through MHC class I molecules (although CD8+ T cells are 
understood not to play a significant role in corneal allograft rejection). The unique ability of DCs to prime 
naïve T cells and to mediate cross presentation places them at the centre of the indirect alloresponse, 
which is thought to contribute mainly to chronic allograft rejection. (a) In this study, it is predicted that the 
intravenous administration of CTLA4-KDEL-transduced donor-derived DCs or CTLA4-KDEL-transduced 
F1 DCs expressing both donor and recipient MHC prior to murine corneal transplantation (as opposed to 
Untransduced or Mock-transduced DCs) will (b) induce Tregs with direct and indirect pathway 
allospecificity. The indirect pathway-specific Tregs will suppress effector CD4+ T cells induced by recipient 
DCs expressing donor peptide after alloantigen capture and presentation through the indirect pathway. 
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Investigation of the CTLA4-KDEL system was of scientific and therapeutic value as it 
has the potential to be engineered such that it is effective for specific antigens. The 
strategy could be developed as a therapeutic tool for use in tolerance induction regimes 
not only for graft recipients, but also for the treatment of antigen-specific diseases (both 
allergy and autoimmune disease). The study would also result in a greater understanding 
of the role and potency of IDO in the regulation of allospecific responses and in the 
control of allograft rejection. 
1.13.2. Effect of Tryptophan Catabolism on the Generation and/or Maintenance of 
Tregs: Can IDO+CD80/86+ or IDO+CD80/86- DCs and CTLA4+ Tregs Induce a 
Regulatory Amplification Cycle / Positive Feedback Loop? 
 
It is known that interaction of alloreactive T cells with CTLA4-Ig-treated DCs results in 
the induction of an anergic phenotype in the cells (Linsley et al., 1992b; Pearson et al., 
1994). These anergic cells can then act as Tregs and suppress the response of other 
alloreactive T cells. However, it is not known whether the induction of this regulatory 
phenotype is a result of costimulation blockade or the expression of IDO by the DCs. 
As mentioned in section 1.9 it has been suggested that the possible effect of IDO is to 
induce apoptosis rather than anergy or regulation. It was important to verify this during 
this study since the advantage of IDO as a therapeutic agent to block transplant rejection 
would be increased if T cells became regulatory as the effect would ‘spread’ to T cells 
that do not contact the IDO+ DCs (linked suppression). Furthermore, it has already been 
demonstrated that DCs lacking cell surface expression of CD80/86 (due to ER retention 
by CTLA4-KDEL) do not express IDO (Tan et al., 2005c). However, incubation of 
these human DCs with alloreactive T cells results in the induction of an anergic and 
subsequent Treg phenotype in vitro, which indicates that IDO is not essential for the 
induction of T cell regulation. In addition, as described in section 1.9, there has been 
wide speculation into the role of IDO in T cell regulation, and whether IDO+ DCs can 
induce expression of the enzyme in neighbouring IDO- DCs via induction of Tregs as a 
mechanism of infectious tolerance. 
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An important aim of the study was therefore to investigate whether expression of IDO 
(and the resulting tryptophan depletion in the microenvironment) can promote the 
induction and/or expansion of a Treg population (possibly by enhancing the effects of 
costimulation blockade), murine DC populations differing in surface CD80/86 
costimulation and IDO expression were used in cocultures with T cells consisting of 
specific ratios of induced CTLA4+CD4+CD25+FoxP3+ Tregs and CFSE-labelled 
CD4+CD25- T cells. The experiments were performed using a temperature-sensitive, 
immortalised dendritic cell line (tsDC) (Volkmann et al., 1996)- described further in 
section 2.5.4- that were transduced with EIAV to create several stable DC lines. The 
results of these experiments were duplicated using primary BM-derived DCs. The five 
stable cell lines and primary DC populations used were as follows: 
 
1. Wild-type tsDCs, or primary untransduced DCs (+costimulation, -IDO) 
2. Stable CD80/86- tsDC line expressing CTLA4-KDEL, or primary DCs 
transduced with EIAV CTLA4-KDEL (-costimulation, -IDO) 
3. Stable IDO+ tsDC line expressing IDO, or primary DCs transduced with EIAV 
IDO (+costimulation, +IDO) 
4. Stable CD80/86-IDO+ tsDC line expressing both IDO and CTLA4-KDEL, or 
primary DCs either incubated with high concentrations of CTLA4-Ig or double-
transduced with EIAV CTLA4-KDEL and EIAV IDO (-costimulation, +IDO). 
5. Stable tsDC line expressing an irrelevant/mock (GFP), or primary EIAV GFP-
transduced DCs. 
 
As explained in section 1.9, IDO has been demonstrated in several studies to have a 
dominant immunosuppressive role in vitro and in vivo. The five primary DC 
populations and stable tsDC lines (including the untransduced/wild-type tsDCs) 
numbered above were used to dissect the immunosuppressive role of IDO and 
investigate whether the expression of IDO by DCs (in the presence or absence of 
costimulation expression) can induce Treg populations from CFSE-labelled CD4+CD25- 
T cells, or expand populations of pre-induced CTLA4+ Tregs. This would determine the 
possibility of an amplification cycle (positive cascade) in which IDO+ DCs induce or 
expand CTLA4+ Tregs that have the capacity to upregulate IDO in IDO- DCs via 
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CD80/86 ligation [Figure 9(c)]. This would provide a possible mechanism for the 
dominant immunosuppressive role of IDO- even when a few IDO-expressing DCs are 
present (Mellor and Munn, 2004). 
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Chapter 2: MATERIALS AND METHODS 
 
2.1. Mice 
 
BALB/c (H-2d), C3H/He (H-2k), C57BL/6 (H-2b), CBA/Ca (H-2k), B10.A - H-2a 
(H-2a), CB6F1 [(BALB/c)x(C57BL/6)F1], B6CBF1 [(C57BL/6)x(CBA/Ca)F1] and 
CBACF1 [(CBA/Ca)x(BALB/c)F1] mice were purchased from Harlan Olac (Bicester, 
United Kingdom). CBK (CBA/Ca bearing a transgenic Kb molecule) mice (Yeoman and 
Mellor, 1992) were a kind gift from Professor Giovanna Lombardi and Professor Robert 
Lechler (Department of Nephrology and Transplantation, Guy’s Hospital Campus, 
King’s College London). 
 
All experimental procedures were performed on female mice (donor and recipient 
strains were sex-matched) aged between 6 and 10 weeks. Animals were maintained in a 
pathogen-free facility (CBS, Imperial College London, Hammersmith Campus, United 
Kingdom) and treated in accordance with the United Kingdom government regulations 
for care of experimental animals (the 1986 Home Office Animals Scientific Procedures 
Act) and the ARVO Statement for the Use of Animals in Ophthalmic and Vision 
Research. 
 
2.2. Subcloning of CTLA4-KDEL into a Lentiviral Construct 
 
The murine CTLA4-KDEL sequence was generated previously (Jennifer Harper, 
unpublished). In brief, the gene for the extracellular domain of murine CTLA4 was 
inserted into the multiple cloning site of the pCMV/c-myc/ER vector (Invitrogen, 
Paisley, United Kingdom), see figure 15. The sequence for the extracellular domain of 
CTLA4 was identical to that used to produce CTLA4-Ig and was thus known to be 
functional (Brunet et al., 1987; Peach et al., 1994). 
 
For the purposes of this study, an EIAV lentiviral construct containing the murine 
CTLA4-KDEL gene was generated. The CTLA4-KDEL gene was amplified from the 
aforementioned pCMV/c-myc/ER vector by polymerase chain reaction (PCR) with the 
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primers 5’-ATCGAAGCTTAATGGGATGGAGCTGTATCATC-3’ (forward) and 5’-
ATCGCTCGAGCTACAGCTCGTCCTTCTCGC-3’ (reverse), which were designed to 
include the restriction sites HindIII and XhoI respectively. 50 µl PCR reaction mixtures 
consisted of the following: 0.5 µl of a proofreading DNA polymerase- 
TaKaRa Ex Taq™ (Takara Bio Inc., Japan), 10 µl of 10X Ex Taq™ Buffer (included 
with TaKaRa kit), 8 µl of 2.5 mM dNTP mixture (included with kit), 5 µl each of 
1.0 µM (final conc.) sense and anti-sense primers, 5 µl (1 µg) of DNA Template 
(pCMV/CTLA4-KDEL/c-myc/ER) and 16.5 µl of DNA/RNA/nuclease-free water. The 
PCR conditions were as follows: 95°C for 5 minutes, followed by the addition of a 
proofreading DNA polymerase- TaKaRa Ex Taq™, (Takara Bio Inc., Japan) and 25 
cycles consisting of 95°C (denaturation), 58°C (annealing) and 72°C (elongation) for 30 
seconds each. The PCR was completed with a final 10-minute extension at 72°C. PCR 
products amplified with TaKaRa Ex Taq™ have one A (adenine) nucleotide added at 
3’-termini. The PCR product can thus be used directly for cloning into a linearised T-
vector. 
 
The PCR reactions were initially optimised for annealing temperature and MgCl2 
concentration (data not shown). This was important as the optimal annealing 
temperature allows the primers to bind specifically and with high stringency to the DNA 
sequence of interest. This is influenced by both the temperature and cation 
concentration, the latter of which can neutralise the negatively charged phosphate 
groups on the DNA and weaken the forces between the two strands, thus facilitating 
annealing between the primers and DNA. Purification of the PCR reaction (for recovery 
of amplified DNA) was undertaken using the QIAquick PCR purification kit (Qiagen, 
UK). The PCR product was visualised by electrophoresis using 1% agarose gels stained 
with Ethidium Bromide (EtBr). Using the TA Cloning® kit (Invitrogen, UK), the PCR 
product was introduced into pCR®2.1 (a TA Cloning® vector) using sticky-end ligation / 
T4 DNA ligase in accordance with the manufacturer’s instructions. Recovery of DNA- 
including amplified DNA from PCRs, and both insert and backbone DNA segments 
(after restriction enzyme digestion of plasmid vectors)- from 1% agarose NA 
electrophoresis gels was undertaken using the QIAquick Gel Extraction Kit (Qiagen, 
UK). Refer to sections 2.2.1-2.2.3 for descriptions of chemical transformation of 
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bacteria, plasmid amplification and purification. The CTLA4-KDEL insert was cloned 
into the EIAV plasmid pSMART2G (Oxford Biomedica Co, Oxford, UK) with HindIII 
and XhoI restriction enzymes (New England Biolabs, MA, USA) followed by ligation 
using the Quick Ligation™ kit (New England Biolabs), thus removing the enhanced 
GFP (eGFP) gene already present. The cloned murine CTLA4-KDEL insert was 
sequenced using the ABI PRISM dRhodamine Terminator Cycle Sequencing Ready 
Reaction Kit (Jefferiss Research Trust Laboratories Sequencing Service, Imperial 
College London, St Mary’s Campus), and the resulting plasmid was designated 
pSMART-CTLA4-KDEL. 
2.2.1. Chemical Transformation 
 
10 µl of (ligated) plasmid DNA (1 ng/µl) was added to 150 µl of chemically competent, 
DH5α™ strain E. Coli bacteria (Invitrogen, UK). The mixture was incubated on ice for 
30 minutes, and competent bacteria were encouraged to take up plasmid DNA by a heat 
shock method at 42°C for 2 minutes. The bacterial mixture was incubated for a further 
60 minutes in a 37°C shaking incubator in the presence of 1 ml of Super Optimal 
Catabolite (SOC) medium. The bacteria were then streaked onto dishes of LB agar 
(Sigma-Aldrich, UK) supplemented with 50 µg/ml ampicillin (Sigma-Aldrich) and 
incubated overnight at 37°C. The addition of ampicillin to the agar selected for 
transformants expressing the relevant plasmids used in this study that confer resistance 
to this antibiotic. 
2.2.1.1. X-Gal Staining 
 
After ligation of the initial PCR product (CTLA4-KDEL) into the TA cloning vector 
pCR®2.1, selection of transformants was undertaken by the spreading of 40 µl of 
40 mg/ml X-Gal (Invitrogen, UK) onto each agar plate. The pCR®2.1 vector contains 
the lacZα fragment which encodes the first 146 amino acids of β-galactosidase. 
Complementation in trans with the Ω fragment gives active β-galactosidase for blue-
white screening. The X-Gal solution was allowed to soak into the plates prior to the 
application of contents of the transformation vial.  After overnight incubation, at least 
10 white colonies were picked for plasmid isolation and restriction analysis. 
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2.2.2. Plasmid Amplification 
 
Plasmids were amplified in transformed DH5α™ strain E. Coli bacteria (Invitrogen, 
UK) previously picked from ampicillin-supplemented agar plates and confirmed to 
contain the relevant construct after restriction digest analysis. The bacteria were 
maintained in Luria-Bertani (LB) medium (Sigma-Aldrich, UK) supplemented with 
50 µg/ml ampicillin for selection of transformed (ampicillin-resistant) bacteria. 
2.2.3. Plasmid Purification 
 
Plasmids were purified after bacterial alkaline lysis using Qiagen plasmid purification 
kits.  Mini-, midi- and maxi-purification kits (Qiagen, UK) were used in accordance 
with the manufacturer’s instructions. DNA concentration and purity was measured by 
spectrophotometry. DNA was used when the ratio of OD260 to OD280 (DNA) was greater 
than 1.8. All plasmids were characterised using restriction enzyme digestion mapping. 
2.2.4. Transfection Protocols: Polyethylenimine (PEI) and LipofectAMINE 2000™ 
 
In order to confirm the successful subcloning of CTLA4-KDEL into pSMART2G (the 
EIAV-constituent plasmid described in section 2.2), transfection of HEK 293T cells 
with this newly generated plasmid- pSMART-CTLA4-KDEL- was undertaken in 6-well 
plates with two transfection agents: Polyethylenimine (PEI) (Sigma-Aldrich, UK), a 
cationic polymer with high efficiency of gene delivery into dividing cells (Godbey et 
al., 1999b; Godbey et al., 1999a; Gebhart and Kabanov, 2001), and a lipid-based vector, 
i.e. liposome, LipofectAMINE 2000™ (Invitrogen, UK). Transfected 293T cells were 
used for detection of the CTLA4-KDEL protein by western blotting. PEI transfection 
complexes were generated by mixing 2 µg of plasmid DNA in 500 µl of serum-free 
DMEM with PEI diluted 1:1000 in 500 µl of serum-free DMEM followed by incubation 
at room temperature for twenty minutes. Transfection medium was replaced with 
complete culture medium after 4-5 hours. For LipofectAMINE 2000™-mediated 
transfection, 4 µg of plasmid DNA diluted in 250 µl of Optimem I® was mixed with 4 µl 
of LipofectAMINE 2000™ diluted in 250 µl of Optimem I® in accordance with 
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manufacturer’s instructions. Complexes were incubated for 45 minutes at room 
temperature before addition to cells. Cells were transfected in the absence of antibiotics. 
 
2.3. Subcloning of IDO into Lentiviral Construct 
 
An EIAV lentiviral construct encoding murine IDO1 was generated previously using a 
slightly modified approach to the subcloning of CTLA4-KDEL into pSMART2G 
described in section 2.2 (Beutelspacher et al., 2006). In brief, the gene for murine IDO1 
(referred to throughout this study as IDO) was amplified from mature DCs by PCR 
using 5’-ATCGTTAATTAAGTGGGGGGTCAGTGGAGTAG-3’ (forward) and 5’-
ATCGGCTAGCCTGTGCCCTGATAGAAGTGG-3’ (reverse) as primers. Similar to 
the cloning strategy for CTLA4-KDEL, the plasmid pSMART2G (Bienemann et al., 
2003) was initially cut with HindIII, and XhoI restriction enzymes (New England 
Biolabs, Beverly MA), removing the eGFP gene originally present. However, as 
opposed to using a TA cloning vector, a linker oligonucleotide (forward 
AGCTTAGCGTTAATTAAAGCTGGTACCAGCTGCTAGCAGCTC, reverse 
TCGAGAGCTGCTAGCAGCTGGTACCAGCTTTAATTAACGCTA) containing 
HindIII, PacI, KpnI, NheI and XhoI-restriction sites was ligated into the plasmid using 
T4 ligase (New England Biolabs). The gene for IDO was inserted between the PacI and 
NheI sites. The cloned IDO insert was confirmed by sequencing as described in section 
2.2, and the resulting plasmid designated pSMART-IDO, which was used in the present 
study to generate EIAV IDO. 
 
2.4. Generation and Culture of Murine Bone Marrow-Derived 
Dendritic Cells 
 
DCs were generated from BM obtained from the hind limbs (both tibia and femur) 
(Inaba et al., 1992; Lutz et al., 1999) of several strains of mice used in this study. The 
hind limbs were collected in phosphate buffered saline (PBS) and the BM cavities 
flushed out with a 25G needle to obtain a homogenous cell suspension. The cells were 
pelleted by centrifugation and red blood cells lysed with Red Blood Cell (RBC) lysis 
solution (Flowgen, UK). After termination of lysis by dilution, cells were transferred 
through a 70 µM cell strainer, centrifuged again, and put in culture in Roswell Park 
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Memorial Institute (RPMI) 1640 medium (Gibco-Invitrogen, Paisley, UK) 
supplemented with 10% heat-inactivated foetal calf serum (FCS) (PAA, UK), 100 
units/ml penicillin, 100 µg/ml streptomycin (Cambrex Biosciences, Wokingham, UK), 2 
mM L-glutamine (Cambrex Biosciences) and 50 µM β-Mercaptoethanol (Gibco-
Invitrogen) in the presence of a 1:30 dilution of culture medium obtained from a 
GM-CSF-producing hybridoma (Zal et al., 1994)- see culture protocol of hybridoma 
below. DCs were cultured in T75 flasks, T150 flasks or 6-well plates at 37°C in a 
humidified atmosphere with 5% CO2 until day 7. The DC culture medium was replaced 
with fresh GM-CSF-containing medium (1:30 hybridoma supernatant dilution) on day 
3, and half of the culture medium was replaced with fresh GM-CSF-containing medium 
(1:60 hybridoma supernatant dilution) on day 6. In order to generate mature DCs, the 
cultures were stimulated for 16 hours with 1 µg/ml lipopolysaccharide (LPS) (Sigma-
Aldrich). DC generation, purity and maturation status was assessed on day 8 by flow 
cytometric analysis- see section 2.8. Flow cytometry was used to detect expression of 
the DC marker CD11c, and expression (and upregulation in the case of mature DCs) of 
I-Ad (MHC II), and the costimulatory markers CD80, CD86, ICOSL and CD40. Where 
applicable, murine BM-derived DCs were transduced on day 6 with EIAV for use in T 
cell proliferation assays (including suppressor assays), western blotting, flow cytometric 
analysis, and intravenous injection into mice for in vivo experiments. 
2.4.1. Culture of GM-CSF-producing Hybridoma 
 
A GM-CSF-producing hybridoma (Zal et al., 1994)- was cultured in Dulbecco’s 
Modified Eagles Medium (DMEM) that was purchased with supplemented glucose 
(Gibco-Invitrogen, Paisley, UK), in the presence of 10% heat-inactivated FCS, 2 mM L-
glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin and 1 mg/ml of G418 to 
ensure selection until GM-CSF-containing supernatant was ready to be collected. Cells 
were grown at 37°C in a humidified atmosphere with 5% CO2 to approximately 500 ml 
in volume in G418, centrifuged, washed twice in PBS and resuspended in medium 
without G418. The cells were then split every 2-3 days until 2 litres were attained, at 
which point the cells were grown to exhaustion in roller bottles (Falcon, UK) in order to 
achieve the highest activity. 
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2.5. Cell Lines 
 
Six cell lines, detailed below, were used during the study. All cell lines were tested for 
Mycoplasma organisms using the gel-based PCR Mycoplasma Test Kit (MD 
Biosciences, UK) and were confirmed to be free of contamination prior to use. 
2.5.1. (Human Embryonic Kidney- HEK) 293T Cells 
 
(HEK) 293T cells (National Institute for Medical Research, Mill Hill, London, UK) 
were used for: 1) PEI- and Lipofectamine 2000™-based transfection to confirm 
subcloning of CTLA4-KDEL into the lentiviral vector pSMART2G- see section 2.2.4; 
and 2) the propagation of VSV-G-pseudotyped EIAV lentiviruses using a three-plasmid 
co-transfection technique- see section 2.7. (HEK) 293T cells were routinely 
cultured/passaged in Dulbecco’s Modified Eagles Medium (DMEM) (Invitrogen, 
Paisley, UK) supplemented with 10% heat-inactivated FCS (PAA, UK), 100 units/ml 
penicillin, 100 µg/ml streptomycin (Cambrex Biosciences) and 2 mM L-glutamine 
(Cambrex Biosciences) at 37°C, 5% CO2. Routine subculture and harvesting of cell 
monolayers was performed using a 0.02% EDTA and 0.05% trypsin solution (Gibco-
Invitrogen). 293T cells were also transfected to ensure production of the CTLA4-KDEL 
protein after subcloning of the sequence into the pSMART2G (EIAV) construct. 
2.5.2. Canine Osteosarcoma Cells (D17) Cells 
 
Lentiviruses used in this study were titred using D17 cells transduced with serial 
dilutions of lentiviral stocks- see section 2.7.1. D17 cells were routinely cultured in 
DMEM supplemented with 10% heat-inactivated FCS, 100 units/ml penicillin, 
100 µg/ml streptomycin and 2 mM L-glutamine at 37°C, 5% CO2. Subculture and 
harvesting of cell monolayers was performed using a 0.02% EDTA and 0.05% trypsin 
solution (Gibco-Invitrogen). 
2.5.3. Chinese Hamster Ovary (CHO) Cells, CHO mB7.1 Cells, CHO mB7.1 / I-Ad 
Cells and CHO mB7.2 / I-Ad Cells 
 
CHO cells, CHO mB7.1 cells (CHO cell line transgenic for murine CD80), CHO mB7.1 
/ I-Ad cells (CHO cell line transgenic for murine CD80 and MHC class II) and CHO 
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mB7.2 / I-Ad cells (CHO cell line transgenic for murine CD86 and MHC class II) 
(Galvin et al., 1992; Razi-Wolf et al., 1992; Reiser et al., 1992) were cultured in DMEM 
supplemented with 10% heat-inactivated FCS, 100 units/ml penicillin, 100 µg/ml 
streptomycin and 2 mM L-glutamine at 37°C, 5% CO2. In addition, G418 selection 
antibiotic (Invitrogen) was added to cultures of CHO mB7.1 cells at a concentration of 
1 mg/ml; CHO mB7.1 / I-Ad cells were cultured in the presence of 1 mg/ml G418 and 
500 µg/ml Zeocin (Invitrogen) antibiotics; CHO mB7.2 / I-Ad cells were cultured in the 
presence of 1 mg/ml G418 and 1 µl/ml Puromycin (Invitrogen). Subculture and 
harvesting of cell monolayers was performed using a 0.02% EDTA and 0.05% trypsin 
solution (Gibco-Invitrogen). 
2.5.4. Temperature-Sensitive Dendritic Cells (tsDCs) 
 
A temperature-sensitive dendritic cell (tsDC) line was purchased from the European 
Collection of Cell Cultures (ECACC, UK). This is a conditionally immortalised DC line 
established from BM of CBA (H-2k) mice transgenic for a thermolabile mutant of the 
SV40 large T antigen under the control of the class I Kb promoter (Volkmann et al., 
1996). The advantage of this system is the conditional immortalisation of cells at the 
permissive temperatures of 33°C-37°C- the line divides in the absence of GM-CSF and 
is efficient at antigen processing and presentation. Upon transfer to 39°C, the transgene 
product (large T antigen) is rapidly degraded which arrests growth and results in 
upregulation of cell surface (including costimulatory) markers. Further upregulation of 
cell surface markers and functional maturity occur following contact with T cells and 
their cognate antigen. The tsDCs were thus cultured at 33°C in a humidified atmosphere 
with 5% CO2 in Iscove’s modified Dulbecco’s Medium (IMDM) (Invitrogen) 
supplemented with 5% heat-inactivated FCS, 100 units/ml penicillin, 100 µg/ml 
streptomycin and 5x10-5 M β-Mercaptoethanol. Cells were transferred to 39°C for 48 
hours to upregulate costimulatory markers prior to FACS experiments, or irradiated (at 
60 Gy) and transferred to 37°C for experiments entailing coculture with CD4+ T cells (a 
permissive temperature at which surface phenotype or functional capacity is not 
altered). Subculture and harvesting of both adherent and non-adherent fractions of the 
tsDCs was performed using cell-dissociation buffer (Gibco-Invitrogen, UK)- tsDCs 
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grow in a semi-adherent fashion similar to short-term BM-derived DCs, with dendritic 
processes extending from the cell surface. 
2.5.4.1. Generation of Stable tsDC Lines 
 
Four stable tsDC lines were generated for the purposes of this study. tsDCs were 
transduced with EIAV lentiviruses followed by limited dilution cloning. The stable 
tsDC lines generated are as follows: 1) CD80/86- tsDC line using EIAV CTLA4-KDEL, 
2) IDO+ tsDC line using EIAV IDO, 3) CD80/86-IDO+ tsDC line using both EIAV IDO 
and EIAV CTLA4-KDEL for the double-transduction of tsDCs, and 4) tsDC line 
expressing an irrelevant (mock) protein using EIAV GFP. Following transduction of 
tsDCs with the relevant viruses at a multiplicity of infection of 250, the cells were 
passaged on day 4 and clonally diluted in the basal medium described above. In order to 
provide growth-contact stimuli, tsDCs were cocultured (at 1:3 ratio) in the presence of 
irradiated, syngeneic (CBA) splenocytes. These cells acted as a feeder line to provide 
support to the transduced, diluted tsDCs. The clones were screened using a combination 
of real-time PCR for genomic DNA analysis [clones positive for the relevant proteins 
would have the transgene sequence, together with the viral Woodchuck Hepatitis Post 
Regulatory Element (WPRE) integrated within host/genomic DNA- see section 2.13.1 
for primers], western blots for protein analysis, and functional assays including 
L-kynurenine assays and MLRs. Screening of clones was performed after 3 weeks and 
the clones expressing high levels of the relevant DNA, mRNA and proteins were 
expanded further for use in phenotypic and functional assays. 
 
2.6. Exogenous Treatment of Dendritic Cell Cultures 
 
2.6.1. Induction of Indoleamine 2,3-Dioxygenase 
 
Where appropriate, immature primary DCs were stimulated for 48 hours with IFNγ or 
treated with murine recombinant CTLA4-Ig on day 7 of culture for the induction of 
IDO expression (Mellor et al., 2004). This was followed by a 16-hour stimulation with 
LPS on day 8. Recombinant murine IFNγ (PeproTech EC, London UK) was added 
directly to DC cultures at a final concentration of 60 ng/ml. Recombinant Mouse 
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CTLA-4/Fc Chimera (Extracellular domain of mouse CTLA4 fused to the Fc region of 
human IgG1) (R&D Systems, UK) was added directly to DC and tsDC cultures at 
concentrations ranging from 50 µg/ml to 100 µg/ml. Lower concentrations of murine 
CTLA4-Ig were used for upregulation of IDO only, whilst higher concentrations were 
used for both upregulation of IDO and total CD80/86 costimulation blockade. This was 
determined by T cell proliferation assays in the presence and absence of the IDO 
inhibitor 1-Methyl-D,L-Tryptophan- see section 3.8. 
2.6.2. Exogenous Treatment of DC Cultures for Proliferation Assays and Western 
Blotting 
 
Dexamethasone (Sigma-Aldrich, UK) was added to DC cultures at a concentration of 
10-7 M from day 6 of culture to render the DCs resistant to maturation (Mirenda et al., 
2004). Thapsigargin (Sigma-Aldrich) was added to DC cultures on day 7 at a 
concentration of 140 µM. Tunicamycin (Sigma-Aldrich) was added to DC cultures on 
day 7 at a concentration recommended by the manufacturer. Both Thapsigargin- and 
Tunicamycin-treated DCs were used as positive controls for the expression of 
phosphorylated-PERK (an endoplasmic reticulum stress marker) in western blots. poly-
IC (Sigma-Aldrich) was added to DC cultures on day 7 at a concentration of 10 µg/ml. 
The poly-IC-treated DC population was used as a positive control for phosphorylated-
PKR expression in western blotting. 
 
2.7. Replication-Defective Lentivirus (EIAV) Production, Titration and 
Transduction 
 
VSV-G-pseudotyped EIAV lentiviruses were propagated by a three-plasmid co-
transfection technique in Human Embryonic Kidney (HEK) 293T cells (Naldini et al., 
1996b). The self-inactivating lentiviral plasmids (described below) were amplified in 
transformed, DH5α strain E. Coli bacteria using ampicillin-supplemented LB medium 
for selection of the resistant bacteria- see section 2.2.2. The plasmids were purified 
using the Endotoxin Free (EndoFree) Plasmid Giga Kit (Qiagen, UK), which was used 
in accordance with the manufacturer’s instructions. The DNA concentration and purity 
were measured by spectrophotometry. Transfections were performed using 
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polyethylenimine (PEI) (Sigma-Aldrich, UK) in 14 cm tissue culture dishes. The 293T 
cells were transfected at a confluency of approximately 70%. For each plate transfected 
a DNA mixture consisting of 24 µg of an EIAV gag/pol-expressing plasmid (pONY3.1) 
(Yuan and Krug, 2001), 12 µg of an EIAV env-expressing plasmid (pRV67) (Zhou and 
Tedder, 1996; Bienemann et al., 2003) and 24 µg of either the vector construct 
pSMART2G (for EIAV GFP production), pSMART-CTLA4-KDEL (for EIAV 
CTLA4-KDEL production) or pSMART-IDO (for EIAV IDO production) (Bienemann 
et al., 2003), was added to 7.5 ml serum-free DMEM. A 10 mM PEI solution was 
diluted 1:1000 in serum-free DMEM, of which 500 µl was added to 7 ml serum-free 
DMEM. The DNA and PEI solutions were combined and vortexed vigorously for 30 
seconds. Prior to transfection, the DNA/PEI solution was kept for 15 minutes at room 
temperature to allow complex formation. 15 ml of the DNA/PEI solution was added to 
each 14 cm plate which was then incubated at 33°C for 4-5 hours. The DNA/PEI 
solution was replaced with full tissue culture medium and the plates incubated at 37°C. 
After 72 hours, supernatant of the 293T cells was collected, cleared by low-speed 
centrifugation (1200 x g, 5 min) and filtered through 0.45 µm filters (Millipore, UK). 
Vector particles were then concentrated by ultracentrifugation at 17000 x g for 100 
minutes at 4°C. The virus pellet was resuspended on ice in serum-free DMEM, snap-
frozen and maintained in liquid nitrogen until use. 
2.7.1. Titration of Lentiviral Stocks 
 
EIAV eGFP virus stocks were titred using D17 cells seeded on 48-well plates at 2x104 
cells per well and incubated at 37°C, 5% CO2 overnight. Viral stocks were serially 
diluted 10-fold (10-1 – 10-7) in serum-free medium. 150 µl of each dilution was added to 
the wells in triplicate. Transduced cells were incubated for 3 days at 37°C, fixed in 4% 
formaldehyde and visualised by fluorescence microscopy (see section 2.14 below). 
Quantitative (real-time) PCR was carried out (see section 2.13.1) in conjunction with 
fluorescence microscopy (see section 2.14) in order to determine titres of stocks of 
EIAV CTLA4-KDEL and EIAV IDO, as the constructs of these viruses did not encode 
a reporter gene that would have allowed for direct visualisation of transduction of a 
reporter cell line (Lizee et al., 2003). 
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Titres calculated were of the order 1.5x108-1.5x109 infectious particles/ml. All plasmids 
used were a kind gift from Oxford Biomedica Co. (Oxford, UK). 
 
2.8. Flow Cytometry 
 
Several populations of cells were stained routinely throughout this study to assess 
expression (or lack thereof) of specific surface or intracellular markers by flow 
cytometric analysis: The phenotype of murine BM-derived DCs was assessed by flow 
cytometry on day 8 of culture to determine the purity (based on CD11c expression) of 
the population- see section 2.4. The purity of spleen-derived CD4+ T cells was also 
assessed in addition to the phenotype of CTLA4+Tregs induced by treatment of 
CD4+CD25+ bead-selected T cells with anti-CD3ε antibody in the presence of IL-2- see 
section 2.11.5 T cells acquired from MLRs and from DC : T cell cocultures were 
stained for intracellular markers as described below. 
 
In experiments where flow cytometry was used to investigate the phenotype of EIAV 
transduced DCs, cells were analysed 72 hours (3 days) post-transduction. This was 
determined by preliminary time-trial experiments in which maximum expression of the 
transgene was detected (data not shown). DC transgene expression and transduction 
efficiency was assessed by GFP expression subsequent to EIAV GFP transduction at a 
specified MOI. Inhibition of DC CD80/86 expression after EIAV CTLA4-KDEL 
transduction was assessed prior to the use of these cells in further functional assays 
described in this study. Similar to DCs, the phenotypic and functional confirmation of 
subcloning of the CTLA4-KDEL sequence into the pSMART2G (EIAV) construct was 
undertaken after 72 hours using flow cytometric analysis of pSMART-CTLA4-KDEL 
transfected- or EIAV transduced-CHO cell lines. The establishment of GFP- and 
CD80/86-/CTLA4-KDEL+ tsDC clones and subsequent cell lines was also assessed 
functionally by flow cytometry. 
 
Flow cytometric analysis was carried out on a FACSCalibur flow cytometer (Becton 
Dickinson, Mountain View, CA) equipped with CellQuest v4.0 software (Becton 
Dickinson). EIAV GFP-transduced DCs were detected directly on FL1 during analytic 
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flow cytometry scans. The emission from FITC-, PE- and APC-conjugated antibodies 
was detected on FL1, FL2, and FL4 respectively. Graphical representation and analysis 
of flow cytometry data, specifically the analysis of EIAV transduced DCs, is described 
in section 2.8.4. 
2.8.1. Cell Surface Staining 
 
Prior to staining, tissue culture plastic-adherent cells were harvested using a method 
dependant upon the cell type: CHO cell lines were harvested using a 0.02% EDTA and 
0.05% Trypsin solution (Gibco-Invitrogen); tsDCs and EIAV transduced DCs were 
harvested using cell-dissociation buffer (Gibco-Invitrogen). Primary BM-derived DCs 
were obtained from the non-adherent fraction of day 7-8 cultures- semi-adherent cells 
were harvested by gentle rinsing of the DC tissue culture flasks/plates with PBS. 
Similarly, semi-adherent primary CD4+ T cells acquired from 24-well plates after a 
72 hour-coculture with EIAV transduced DCs were harvested by gentle pipetting of 
wells with PBS. 
 
Cells harvested for analysis were pelleted by centrifugation at 400 g for 5 minutes at 
4°C and washed twice with cold PBS, followed by counting and assessment of viability; 
- in this study, a minimum of 0.5x106 cells were stained with antibody per test sample 
for the flow cytometric detection of surface markers. After counting, the cells were then 
pelleted again by centrifugation at 400 g/5 minutes/4°C and resuspended in 100 µl of 
cold PBS supplemented with 5% FCS (FACS buffer). Staining of cells for the detection 
of surface markers was performed either directly, using fluorochrome-conjugated 
antibodies, or indirectly using a combination of unconjugated/purified primary 
antibodies (listed in the table in section 2.8.1.1) and FITC- or PE-conjugated secondary 
antibodies (listed in the table in section 2.8.1.2). Cells were incubated with a 
fluorochrome-conjugated/unconjugated antibody in 100 µl of FACS buffer for 30 
minutes at 4°C (on ice). 2 µg of antibody was added per 0.5x106 cells unless a specific 
dilution factor was recommended by the manufacturer. It was determined during this 
study that the use of CD16/32 functional antibodies to block Fc receptors on DCs was 
not required. After 30 minutes of incubation, cells were washed three times in 200 µl of 
FACS buffer and resuspended in 200 µl of PBS for analysis. If unconjugated primary 
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antibodies were used, the cells were incubated for a further 30 minutes at 4°C with a 
fluorochrome-conjugated secondary antibody. This was followed by three subsequent 
washes in FACS buffer as described above, and resuspension in 200 µl of PBS as 
described above. 
 
2.8.1.1. Cell Surface Staining: Primary Antibodies 
 
All primary- purified and fluorochrome-conjugated- antibodies used for flow cytometric 
analysis are listed in the table below (all antibodies were specific for murine 
determinants; monoclonal antibodies are described with the associated clones from 
which they were derived): 
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Determinant (Clone) Isotype-Conjugate Source (Company) 
CD3 (17A2) Rat IgG2b-Purified eBioscience/Insight 
CD4 (RM4-5) Rat IgG2a-Purified eBioscience/Insight 
CD8 (53-6.7) Rat IgG2a-Purified eBioscience/Insight 
CD11c (N418) Hamster IgG-Purified Serotec 
CD11c (N418) Hamster IgG-PE Serotec 
I-A / I-E (MHC II) (M5/114.15.2) Rat IgG2b-Purified BD Biosciences- Pharmingen 
CD16/32 (93) Rat IgG2a-Purified eBioscience/Insight 
CD19 (1D3) Rat IgG2a-Purified eBioscience/Insight 
CD25 (IL-2Ra) (PC61.5) Rat IgG1-Purified eBioscience/Insight 
CD40 (3/23) Rat IgG2a-Purified Serotec 
CD80 (B7.1) (RMMP-1) Rat IgG2a-Purified Caltag/Invitrogen 
CD80 (B7.1) (16-10A1) Hamster IgG2-FITC BD Biosciences- Pharmingen 
CD86 (B7.2) (RMMP-2) Rat IgG2a-Purified Caltag/Invitrogen 
CD86 (B7.2) (GL1) Rat IgG2a-FITC BD Biosciences- Pharmingen 
CD275 (ICOSL) (HK5.3) Rat IgG2a-Purified eBioscience/Insight 
Isotype Control (A19-3) Hamster IgG1-Purified BD Biosciences- Pharmingen 
Isotype Control (B81-3) Hamster IgG2-FITC BD Biosciences- Pharmingen 
Isotype Control Hamster IgG-PE Serotec 
Isotype Control Rat IgG1-Purified eBioscience/Insight 
Isotype Control (54447) Rat IgG2a-Purified R&D Systems 
Isotype Control (R35-95) Rat IgG2a-FITC BD Biosciences- Pharmingen 
Isotype Control (141945) Rat IgG2b-Purified R&D Systems 
 
2.8.1.2. Cell Surface Staining: Secondary Antibodies 
 
All secondary antibodies used for flow cytometric analysis are listed in the table below: 
 
Determinant Conjugate Source (Company) 
Rat IgG Mouse anti-Rat IgG-FITC eBioscience/Insight 
Rat IgG Goat anti-Rat IgG-PE BD Biosciences- Pharmingen 
Hamster IgG Goat anti-Hamster IgG-FITC Caltag/Invitrogen 
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2.8.2. Intracellular Staining 
 
T cells acquired from rechallenge/two-stage MLRs and three-day DC : T cell cocultures 
were stained for FoxP3 and total levels of CTLA4 after treatment (fixation and 
permeabilisation) of cells for intracellular staining. 100 µl of 1x106 cells were first 
stained for relevant surface markers such as CD4 and CD25 using the surface staining 
protocol described above, and washed in cold FACS buffer. Cells were then fixed, 
permeabilised and stained using the intracellular staining set (eBioscience, USA) in 
accordance with manufacturer’s instructions. Briefly, 1x106 cells were resuspended in 
100 µl of cold Fixation/Permeabilisation solution (eBioscience), vortexed, and 
incubated at 4°C for 30 minutes in the dark. Cells were then washed twice in cold 
Permeabilisation Buffer (eBioscience) followed by staining with directly-conjugated 
antibody in the presence of 100 µl Permeabilisation Buffer 4°C for 30 minutes in the 
dark. Cells were washed twice again in cold Permeabilisation Buffer, centrifuged and 
resuspended in 200 µl of FACS buffer. Samples were then analysed within 24 hours by 
flow cytometry. The emissions from PE- and APC-conjugated antibodies were detected 
on FL2 and FL4 of a FACSCalibur flow cytometer (Becton Dickinson) respectively. 
All fluorochrome-conjugated antibodies used for intracellular staining are listed in the 
table below: 
 
Determinant (Clone) Isotype-Conjugate Source (Company) 
CD152 (CTLA-4) (UC10-4F10-11) Hamster IgG-PE BD Biosciences- Pharmingen 
FoxP3 (FJK-16s) Rat IgG2a-PE eBioscience/Insight 
FoxP3 (FJK-16s) Rat IgG2a-APC eBioscience/Insight 
Isotype Control Hamster IgG-PE Serotec 
Isotype Control (R35-95) Rat IgG2a-PE BD Biosciencs- Pharmingen 
Isotype Control Rat IgG2a-APC eBioscience/Insight 
 
2.8.3. Annexin V and 7-Amino-Actinomycin (7-AAD) Staining 
 
Apoptosis is characterised by specific morphological features, one of the earliest being 
the loss of plasma membrane asymmetry. In apoptotic cells, the membrane phospholipid 
phosphatidylserine (PS) is translocated from the inner to the outer leaflet of the plasma 
membrane, thereby exposing PS to the external cellular environment. Annexin V is a 
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Ca2+-dependent phospholipid-binding protein that has high affinity for PS, and binds to 
cells with exposed PS. Because externalisation of PS occurs in the earlier stages of 
apoptosis, Annexin V staining can identify apoptosis at this early phase. Annexin V 
staining precedes the loss of membrane integrity which accompanies the latest stages of 
cell death resulting from either apoptotic or necrotic processes. In order to identify early 
apoptotic cells, staining with Annexin V is used in conjunction with a dye such as 
7-AAD, which is a standard flow cytometric viability probe used to distinguish viable 
from nonviable cells. Viable cells with intact membranes exclude 7-AAD, whereas the 
membranes of dead and damaged cells are permeable to this dye. Cells that are either in 
the late stage of apoptosis, are undergoing necrosis or have already undergone an 
apoptotic or necrotic death will stain positive for both Annexin and 7-AAD. 
 
In this study, EIAV-transduced DCs (72 hours post-transduction), and T cells acquired 
from DC : T cell cocultures were stained with Annexin V and 7-AAD. Cells were 
washed three times with cold PBS and resuspended in Annexin V Binding Buffer (BD 
Biosciences Pharmingen, UK) at the standard concentration of 1x106 cells/ml. Cells 
were then stained with PE-conjugated Annexin V (BD Pharmingen) according to 
manufacturer’s instructions. Annexin V-PE-stained cells were detected on FL2 during 
flow cytometric analysis/acquisition. Cells from DC : T cell cocultures were stained 
with 7-AAD (BD Pharmingen) according to the manufacturer’s instructions. 
Fluorescent emission from 7-AAD is detected in the ‘far red’ range of the spectrum 
(650nm), and was therefore detected during flow cytometric acquisition and subsequent 
analysis on FL3. 
2.8.4. Flow Cytometric Analysis and Graphical Representation 
 
Flow cytometry data acquired using the FACSCalibur flow cytometer was subsequently 
analysed for this study using the Windows Multiple Document Interface for Flow 
Cytometry 2.8 (WinMDI 2.8) software (The Scripps Research Institute, USA). Results 
were expressed as the percentage of cells expressing the relevant marker using a 
threshold based on an isotype control. 
 
Chapter 2: Materials and Methods 
Adnan Khan, Department of Immunology, Division of Medicine, Imperial College London 118 
2.9. CFSE Labelling 
 
CD4+CD25- T cells were labelled with the intracellular dye Carboxyfluorescein 
diacetate succinimidyl ester (CFSE) in order to assess for the induction of a FoxP3+ 
Treg phenotype from the aforementioned/labelled population when cultured with 
IDO+CD80/86+ or IDO+CD80/86- DCs (in addition to other DC populations). CFSE 
labelling was also used to measure individual CD4+CD25- T cell proliferation in these 
experiments (Lyons, 2000). After three washes in PBS, the pelleted CD4+CD25- T cells 
were resuspended in 1 µM of CFSE using the Vybrant® CFDA SE Cell Tracer Kit 
(Molecular Probes- Invitrogen, Paisley, UK). Prior to addition of CFSE solution, the 
cells were maintained at room temperature, and 1 ml of 1 µM CFSE solution was added 
per 10x106 cells. The cells were incubated in the CFSE solution on a roller at room 
temperature for 10-15 minutes in the dark. Following incubation, the cells were washed 
once with cold PBS and twice with cold PBS supplemented with 10% FCS (FCS stops 
the CFSE reaction). The cells were then pelleted and resuspended at the required 
concentration and incubated with specific populations of DCs and 
CTLA4+CD4+CD25+FoxP3+ Tregs. Three days after coculture with populations of DCs 
and Tregs, CFSE-labelled CD4+CD25- cells were detected on FL1 during flow 
cytometric analysis on a FACScalibur flow cytometer. 
 
2.10. Immunoblot Analysis 
2.10.1. Protein Extraction and SDS Treatment 
 
Cells ready for extraction of proteins for western blotting were harvested using methods 
described in section 2.5 and washed three times in cold PBS prior to counting. The cells 
were then pelleted by centrifugation at 600 g for 5 minutes and the supernatant 
removed. Cell lysates were prepared by resuspending 1x106- 2x106 cells in 130 µl lysis 
buffer [1% NP-40, 150 mM NaCl, 5 mM MgCl2, 10 mM Hepes Buffer] supplemented 
with Protease Inhibitor Cocktail (PIC) (Sigma-Aldrich). Once resuspended the the 
cell/lysis buffer mixture was incubated on ice for 30 minutes, and the resulting cell 
debris was pelleted by centrifugation at 4000 g for 5 minutes. The supernatant 
containing the cell lysate / extracted proteins was used for the subsequent stage. A 30 µl 
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aliquot was taken from each sample of cell lysate for protein quantification using the 
Pierce® BCA protein assay kit (Perbio/Thermo Scientific, UK) according to the 
manufacturer’s instructions.  
 
The remainder of the cell lysate was diluted with an equal volume of 2X concentrated 
Laemmli Sample Buffer [125 mM Tris HCl pH 6.8, 10% β-Mercaptoethanol, 4% SDS, 
0.004% bromophenol blue, 20% glycerol] (Sigma-Aldrich) and boiled for 5 minutes 
(Laemmli, 1970). The β-Mercaptoethanol in the sample buffer reduces the intra- and 
inter-molecular disulphide bonds of proteins. Thus, reducing gels were used to carry out 
western blots in this study. SDS is a detergent that serves to denature the proteins and 
subunits and give an overall negative charge so that each will separate based on size. 
The bromophenol blue serves as a dye front that runs ahead of the proteins whilst the 
glycerol increases the density of the sample so that it will layer in the sample well. 
2.10.2. SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
Gels containing varying percentages of acrylamide were prepared from a 30% (w/v) 
acrylamide, 0.8% (w/v) N-N’-methylene bisacrylamide stock (Sigma-Aldrich). A 13% 
SDS-PAGE gel was used in the separation of c-myc-CTLA4-KDEL, indoleamine 2,3-
dioxygenase, p27Kip1, eIF2α, phospho-eIF2α [pS52], and β-actin; a 10% SDS-PAGE gel 
was used in the separation of cyclin E, PKR, phospho-PKR [pT451] and β-actin; a 7.5% 
SDS-PAGE gel was used in the separation of PERK and Phospho-PERK [pT980]. 
 
The resolving polyacrylamide gels were produced by mixing the following reagents 
prior to pipetting the resulting solution into gel casting modules: 2.3/3.3/4.3 ml of 30% 
acrylamide (for the production of a 7.5/10/13 percent polyacrylamide gel respectively), 
5/4/3 ml of H2O, 2.5 ml of 1.5 M Tris (pH 8.8) and 100 µl of 10% (w/v) SDS. 100µl of 
10% (w/v) ammonium persulphate and 4 µl of TEMED were added immediately prior 
to pipetting 4 ml of the resulting solution into the casting module. After polymerisation 
of the resolving gel, a 4% polyacrylamide stacking gel was produced. Each stacking gel 
was prepared by mixing 500 µl of 30% acrylamide, 2.1 ml of H2O, 380 µl of 1 M Tris 
(pH 6.8) and 30 µl of 10% (w/v) SDS. Similar to the production of the resolving gel, 
30 µl of 10% (w/v) ammonium persulphate and 3 µl of TEMED were added just prior to 
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pipetting 3 ml of acrylamide solution over the polymerised resolving gel. After protein 
quantification (described in section 2.10.1), 20-40 µg total protein was loaded into pre-
formed wells of the stacking gel, which together with the resolving gel was immersed in 
a running buffer [25 mM Tris-base, 192 mM glycine, 0.1% SDS] during 
electrophoresis. 
2.10.3. Western Blotting 
 
Following electrophoresis, SDS-polyacrylamide gels were equilibrated in a transfer 
buffer [25 mM Tris-base, 192 mM glycine, 20% (v/v) methanol]. Proteins separated by 
electrophoresis on the resolving gel were then electro-transferred onto Protran™ 
nitrocellulose membrane (Schleicher and Schuell Bioscience GmbH, Germany) using 
the Biorad Protean II™ electro-transfer equipment (Biorad Laboratories Ltd, UK). 
Electro-transfer was carried out for 1 hour at 200mA and 4°C. The temperature of the 
transfer buffer, which immersed the cassette (containing the SDS-PAGE gel and 
membrane) during electro-transfer, was preventing from increasing in temperature by 
the applied current using an ice block/compartment in the transfer tank. 
2.10.4. Immunodetection 
 
Following electro-transfer, as described in section 2.10.3, the protein-blotted 
nitrocellulose membrane was rinsed with PBS Tween [0.1% (w/v) Tween 20]. In order 
to block non-specific binding sites, the membrane was then immersed in newly prepared 
blocking solution 5% non-fat powdered milk in PBS Tween) for 1 hour at room 
temperature with constant agitation. After blocking, the membrane was incubated with 
primary antibody diluted in blocking solution (at a dilution recommended by the 
manufacturer) at 4°C overnight with constant agitation. This was followed by three 15-
minute washes in PBS Tween and further incubation with a secondary/HRP-conjugated 
antibody (in the presence of animal serum to reduce non-specific binding as described 
below) for 1 hour at room temperature at a dilution recommended by the manufacturer. 
Another 3x 20-minute washes in PBS Tween were carried out following the incubations 
with secondary antibody. 
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When nitrocellulose membranes were incubated with a secondary/HRP-conjugated 
goat-anti-mouse IgG antibody, goat serum (Sigma-Aldrich) was added to the 
antibody/PBST/BB2 solution at final concentration of 3% to reduce background 
staining. Similarly, when membranes were incubated with an HRP-conjugated rabbit 
anti-mouse / anti-goat IgG antibody, rabbit serum (DakoCytomation, UK) was added to 
the solution at 3% to minimise non-specific staining. 
 
Specific proteins labelled indirectly with HRP-conjugated secondary antibodies were 
visualised by enhanced chemiluminescence using the ECL™ plus Western Blotting 
detection system (Amersham Biosciences- GE Healthcare, UK) according to 
manufacturer’s instructions. Whereas most chemiluminescent detection reagents are 
based on the oxidation of the cyclic diacylhydrazide, luminol, ECL™ plus is based on 
the enzymatic generation of an acridinium ester, which produces a more intense long-
lasting chemifluorescent signal. ECL™ plus-treated membranes were exposed to an 
autoradiography film- Hyperfilm ECL™ (Amersham Biosciences- GE Healthcare)- that 
was then processed using a standard developer (AGFA, UK) after an optimal exposure 
time. The BenchMark™ Pre-Stained Protein Ladder (Invitrogen, UK), the Full-Range 
and High-Range Rainbow Molecular Weight Markers (Amersham Biosciences- GE 
Healthcare) were used to determine molecular weights of proteins (Invitrogen, UK) and 
were treated in accordance with manufacturer’s instructions. 
2.10.4.1. Immunodetection of Phosphorylated Proteins 
 
For detection of phosphorylated proteins by western blotting, a slightly modified 
method was applied for the blocking and staining of nitrocellulose membranes with 
primary and secondary antibodies. This was performed as follows: a 10X Blocking 
Buffer (BB) [0.5 M Tris pH 7.5, 1.5 M NaCl, 0.5% Triton X-100 (w/v)] was prepared 
prior to western blot detection of phosphorylated proteins. After SDS-PAGE and 
electro-transfer, the blotted nitrocellulose membrane was immersed in newly prepared 
Blocking Buffer 1 (BB1) [5% non-fat powdered milk in 1X Blocking Buffer] for 1 hour 
at room temperature with constant agitation on a shaker. After blocking, the membrane 
was incubated with the primary antibody diluted in Blocking Buffer 2 (BB2) [0.1% 
non-fat powdered milk in 1X BB] at 4°C overnight with constant agitation. This was 
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followed by 3x 20-minute washes in BB2 with vigorous shaking. Following washing, 
the nitrocellulose membrane was then incubated with a secondary/HRP-conjugated 
antibody (in the presence of animal serum to reduce non-specific binding as described 
below) for 1 hour at room temperature at a dilution recommended by the manufacturer. 
Another 3x 20-minute washes in BB2 were carried out following the incubations with 
secondary antibody. 
2.10.5. Antibody Stripping and Re-Probing of Membranes 
 
Where described, nitrocellulose membranes were re-probed (after immunodetection of 
the protein of interest) with antibodies specific for the ubiquitous murine β-actin 
cytoskeletal protein. Immunodetection for β-actin was performed only when the 
percentage of acrylamide gel used did not allow for a clear separation- and hence, 
distinction- between the fragments/bands of β-actin and the protein of interest (as a 
result of similar molecular weights). Re-probing the membrane for β-actin was carried 
out to confirm equal loading of cell lysates (into the wells of stacking gels) prior to 
electrophoresis. In order to ‘strip off’ the aforementioned primary antibodies for re-
probing with anti-murine β-actin antibodies, the nitrocellulose membrane was immersed 
in an antibody stripping solution [100 mM β-Mercaptoethanol, 2% SDS, 62.5 mM Tris 
pH 6.7] and incubated at 65°C for 30 minutes. The incubation was followed by 1 hour 
of blocking and indirect staining consisting of the primary β-actin antibody and a 
secondary HRP-conjugated antibody as described earlier. 
2.10.6. Positive Controls 
 
Where western blots were used to detect IDO protein, murine placental lysates were 
used as a positive control for IDO expression, and were a kind gift from Professor 
Matthias Merkenschlager (Clinical Sciences Centre, MRC, Imperial College London, 
UK). For the detection of cyclin E, a 3T3/A31 (murine fibroblast cell line) lysate was 
used as a positive control. This was provided by the company from which the rabbit 
polyclonal anti-cyclin E was purchased (Upstate/Millipore, Lake Placid, NY). 
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2.10.7. Primary Antibodies 
 
All primary antibodies used for western blotting are listed in the table below (all 
antibodies were specific for murine determinants, except where stated; monoclonal 
antibodies are described with the associated clones from which they were derived): 
 
Determinant (Clone) Isotype Source (Company) 
Indoleamine 2,3-Dioxygenase Rabbit Polyclonal IgG Cosmo Bio Co. Ltd. 
Human c-myc epitope tag* (4A6) Mouse IgG1 Upstate/Millipore 
Cyclin E Rabbit Polyclonal IgG Upstate/Millipore 
p27Kip1 (G173-524) Mouse IgG1 BD Biosciences 
Phospho-PERK [pT980] (16F8) Rabbit IgG Cell Signalling Tech 
PERK Goat Polyclonal IgG Santa Cruz Biotech 
Phospho-PKR [pT451] Rabbit Polyclonal IgG Biosource/Invitrogen 
PKR Rabbit Polyclonal IgG Santa Cruz Biotech 
Phospho-eIF2α [pS51] Rabbit Polyclonal IgG Cell Signalling Tech 
eIF2α Rabbit Polyclonal IgG Cell Signalling Tech 
β-Actin (AC-15) Mouse IgG1 Sigma-Aldrich 
 
*= The antibody used to detect human c-myc epitope tag was used to detect the human 
c-myc epitope expressed by the murine CTLA4-KDEL protein. 
2.10.8. Secondary Antibodies 
 
All secondary antibodies used for western blotting are listed in the table below: 
 
Determinant Conjugate (Source) Company 
Rabbit IgG Polyclonal Goat anti-Rabbit IgG HRP Dakocytomation 
Mouse IgG Polyclonal Rabbit anti-Mouse IgG HRP Dakocytomation 
Goat IgG Polyclonal Rabbit anti-Goat IgG HRP Dakocytomation 
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2.11. Murine T Cell Proliferation Assays and DC : T Cell Cocultures 
2.11.1. Murine CD4+ T Cell Purification 
 
A single-cell suspension was obtained by passing spleens and lymph nodes (mesenteric 
and inguinal), derived from either BALB/c (H-2d), C3H/He (H-2k) or CBA/Ca (H-2k) 
mice, through 70 µm cell strainers into cold RPMI 1640 medium supplemented with 
10% heat-inactivated FCS, 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM 
L-glutamine, 50 µM β-Mercaptoethanol and 10 units/ml DNAse- Pulmozyme/Dornase 
Alfa (Roche, UK). The cells were pelleted by centrifugation and red blood cells lysed 
with Red Blood Cell (RBC) lysis solution (Flowgen). Subsequent to lysis of 
erythrocytes, splenocytes were incubated on a horizontal roller at 4°C with supernatants 
of rat anti-mouse hybridoma cultures containing antibodies specific for murine 
CD45R/B220 (RA3-3A1, ATCC, Manassas, VA), murine CD8 (53.6.7, ATCC), H2-
Ek,d/Ab,d (M5/114.15.2, ATCC) and murine CD16/32 (2.4G2, ATCC). After treatment 
with the hybridoma supernatants, the cells were washed twice in serum 
free/unsupplemented RPMI 1640 medium and incubated with Sheep anti-Rat IgG 
Dynabeads® (Dynal Biotech, Bromborough, UK) for 30 minutes on a horizontal roller 
at 4°C before separation in a magnetic field for negative selection of CD4+ T cells. Cells 
expressing CD8, MHC class II, CD16/32 and B220 were selected and retained in the 
magnetic column due to Dynabead conjugation. The supernatant containing the 
population of negatively selected CD4+ T cells was removed for another round of 
selection in a magnetic field (for optimal purity of CD4-expressing cells). The purity of 
the negatively selected CD4 population was assessed to be greater than 90% by flow 
cytometry (the staining protocol of which is described in section 2.8.1). CD4+ T cells 
were either used in T cell proliferation assays, or further purified/depleted for 
CD4+CD25+ cells by positive selection for subsequent addition to suppressor assays and 
DC : T cell cocultures. 
2.11.2. Mixed Lymphocyte Response (MLR) 
 
Responder C3H (H-2k)-, CBA (H-2k)- or BALB/c (H-2d)-derived CD4+ T cells were 
cocultured for 5 days with stimulator cells- allogeneic BM-derived BALB/c DCs, CBK 
(H-2k + Kb) DCs or tsDCs respectively which were irradiated in specific experiments at 
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60 Gy- at a ratio of 5:1 or 2:1 (25x104 CD4+ T cells: 5x104 DCs or 2x105 CD4+ T cells: 
1x105 DCs) in triplicate wells of a 96 well plate.  The cells were cultured in RPMI 1640 
medium supplemented with 10% FCS, 100 units/ml penicillin, 100 µg/ml streptomycin, 
2 mM L-glutamine and 50 µM β-Mercaptoethanol (Gibco-Invitrogen). In order to 
measure proliferation of the responder T cell population, each MLR well of the 96 well 
plate was pulsed on day 4 (in addition to day 2 and day 6 for a CBK-CBA MLR) with 
[methyl-3H] tritiated thymidine that was diluted in serum free/unsupplemented-RPMI 
1640 medium to a working concentration of 1 µCi/well (Tsang et al., 2003) [stock 
concentration 37 MBq/ml, 1 mCi/ml (Amersham Biosciences- GE Healthcare, UK)]. 
MLR plates were harvested 17 hours later and T cell proliferation determined using a 
Wallac MicroBeta TriLux Scintillation Counter (Wallac, UK). 
2.11.3. Functional Inhibition of IDO: 1-Methyl-Tryptophan and Excess Tryptophan 
 
In several MLRs and DC/tsDC : T cell cocultures the IDO inhibitor, 1-methyl-
tryptophan, was added from day 0 (the start of coculture) at a final concentration of 
250 µM (Mellor et al., 2004). Two stereoisomers of 1-methyl-tryptophan [1-methyl-D-
tryptophan and 1-methyl-L-tryptophan (Sigma-Aldrich)] have recently been shown to 
have differential effects on the inhibition of tryptophan catabolism in human cells and 
tissues (Metz et al., 2007; Lob et al., 2008). 1-methyl-D-tryptophan was found to be 
selective for inhibition of IDO2 compared with IDO1 activity, whilst it’s stereoisomer 
1-methyl-L-tryptophan was more selective for IDO1 (Metz et al., 2007). 
 
The three isomers were dissolved according to manufacturer’s instructions and added 
into cultures to assess the effects on tryptophan catabolism by the murine IDO protein 
expressed by EIAV IDO-transduced DCs in this study. The stereoisomer of choice was 
1-methyl-DL-tryptophan. 
 
L-tryptophan (Sigma-Aldrich) was added as a supplement in certain experiments to 
final concentrations of 122.5 µM or 245 µM, equivalent to 5x or 10x the original 
concentration (24.5 µM) in RPMI 1640 (Mellor et al., 2004). 
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2.11.4. Murine CD4+CD25+ T Cell Purification or Depletion 
 
CD25+ T cells were purified or depleted from BALB/c (H-2d), C3H (H-2k) or CBA 
(H-2k) CD4+ T cell populations prior to incubation with DCs in several MLRs, 
suppressor assays and DC : T cell cocultures for this study. CD25+ cells were 
magnetically labelled and selected using the MACS® CD25 MicroBead Kit (Miltenyi 
Biotec GmbH, Bergisch Gladbach, Germany). In brief, CD4+ T cells that were purified 
by negative selection using Dynabead separation (as described in section 2.11.1) were 
subsequently incubated with anti-CD25 PE (isotype: Rat IgM; clone: 7D4) and anti-PE 
MicroBeads included in the MACS® kit according to manufacturer’s instructions. The 
labelled cells were then isolated by magnetic separation- the cells were loaded onto a 
MACS® MS column (Miltenyi Biotec GmbH) which was placed in the magnetic field of 
a MACS® separator (Miltenyi Biotec GmbH). The labelled CD4+CD25hi cells were 
retained on the column, while the unlabelled CD25- cells were collected in the flow 
through. After removal of the column from the magnetic field, the retained CD25+ cells 
were eluted out. The positively selected cells were greater than 95% pure on flow 
cytometric analysis. The CD4+CD25hi cells were subsequently added to suppressor 
assays (described in section 2.11.7), stained for cell surface and intracellular markers, or 
treated with anti-CD3ε antibodies in the presence of murine recombinant IL-2 for the 
induction of CTLA4+FoxP3+ Tregs. In several experiments, the CD4+CD25- fraction of 
T cells that were collected in the flow through of the MACS® MS columns were used in 
CD25+ T cell-depleted two-stage MLRs. 
2.11.5. Generation of CTLA4+FoxP3+ Regulatory T Cells in vitro and Coculture with 
DCs or tsDCs 
 
To address whether IDO expression by DCs (and the resulting tryptophan depletion) 
can promote the induction and/or expansion of a Treg population, T cells consisting of 
specific ratios of induced CTLA4+CD4+CD25+FoxP3+ Tregs and CFSE-stained 
CD4+CD25- T cells were cocultured with murine DC populations differing in CD80/86 
and IDO expression. To induce CTLA4+CD4+CD25+FoxP3+ Tregs, CD4+CD25+ 
BALB/c (H-2d) T cells were purified from the spleens of BALB/c mice using a 
combination of negative selection for CD4+ T cells using Dynabeads®, and subsequent 
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positive selection of CD4+CD25+ T cells using the MACS® CD25 MicroBead Kit (as 
explained in sections 2.11.1 and 2.11.4 respectively). The CD4+CD25+ T cells were then 
stimulated in 24-well plates with 5 µg/ml plate-bound anti-CD3ε antibody (clone 145-
2C11; Armenian Hamster IgG1 Isotype; BD Biosciences- Pharmingen) (Schwartz et al., 
1989; Jenkins et al., 1990) in the presence of 100 units/ml of recombinant murine IL-2 
(Roche Biosciences, UK) for 24 hours at 37°C with 5% CO2 (McHugh et al., 2002; 
Fallarino et al., 2003). Using intracellular staining (see section 2.8.2), the treated 
CD4+CD25+ T cells were assessed for FoxP3 and total CTLA4 expression by flow 
cytometric analysis and were found to be greater than 90% pure. 
 
Five primary CBA (H-2k) DC populations or five irradiated (60 Gy), stable tsDC lines 
were each incubated in 24-well plates at a 1:1 ratio with BALB/c CD4+ T cells for 72 
hours at 37°C, 5% CO2. The CD4+ T cells consisted of ratios of induced 
CTLA4+CD4+CD25+FoxP3+ Tregs (CTLA4+ Tregs) : CFSE+CD4+CD25- T cells. These 
ratios (x parts CTLA4+ Tregs : y parts CFSE+CD25- T cells) were as follows: 0:4, 1:3, 
2:2, and 3:1. After 72 hours of coculture, the DC/tsDC : T cell cocultures were 
harvested and the T cells analysed by flow cytometry for intracellular CTLA4 and 
FoxP3. 
2.11.6. Two-Stage MLR (Rechallenge Assay) for Induction of Anergy 
 
Throughout the study, a two-stage MLR, or rechallenge assay, was widely used as a 
functional assay to investigate whether T cells that encounter alloreactive CTLA4-
KDEL- or IDO-transduced DCs are subsequently rendered anergic and demonstrate 
donor allospecificity. Rechallenge assays were performed in this study after slight 
modifications and optimisation of established protocols designed to investigate the 
induction of anergy both in vitro (Schwartz, 1990; Marelli-Berg et al., 1999; Tan et al., 
2005c) and in vivo (Schwartz, 1990; Mirenda et al., 2004; Mirenda et al., 2005). In 
order to assess donor specificity, T cells that encountered alloreactive 
modified/transduced DCs either in vitro in a primary MLR or in vivo after injection of 
allogeneic DC populations into mice were then subsequently ‘rechallenged’ in vitro 
with both donor-derived and third-party DCs as detailed below. In addition, T cells were 
also rechallenged with DCs expressing both donor and third-party (self and allogeneic) 
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MHC (Mirenda et al., 2004) in order to demonstrate the induction of linked suppression 
/ infectious tolerance and thus the induction of a donor-specific Treg population. After 
enumeration of T cell proliferation by tritiated thymidine incorporation, the kinetics of 
primary versus secondary (memory) T cell responses was analysed. In addition, an 
assay was designed and performed to confirm the induction of donor-specific Tregs 
from alloreactive T cells encountering modified (for the induction of tolerance) DCs, 
which is described in section 2.11.7. 
2.11.6.1. Rechallenge Assay for Induction of Anergy and Linked Suppression in vitro 
 
To investigate the induction of anergy in vitro, populations of BALB/c (H-2d) or CBK 
(H-2k+Kb) DCs were incubated in 24-well plates with C3H (H-2k) or CBA/Ca (H-2k) 
CD4+ T cells respectively in a total volume of 4 ml for 10 days at 37°C, 5% CO2. The 
DCs were incubated with allogeneic CD4+ T cells at a ratio of 1:10 (2x105 DCs : 2x106 
T cells). The 10-day MLR was optimised to include a period in which the CD4+ T cells 
were rested subsequent to clonal proliferation in response to the primary DC challenge. 
The T cells were harvested from the primary MLR, washed 2x in PBS, counted and 
subsequently rechallenged with DCs in 96-well plates at a ratio of 1:2 (1x104 DCs: 
2x104 T cells). In preliminary experiments, it was confirmed by flow cytometric 
analysis that there was no carry-over of viable CD11c+ DCs from the 10-day primary 
MLR into the rechallenge culture (this would correspond to day 19 of culture of the 
terminally-differentiated murine BM-derived DCs, which survive for a maximum of 15 
days). It was also confirmed by thymidine incorporation that T cells were no longer 
undergoing clonal proliferation from the primary allogeneic DC challenge at the end of 
the 10-day incubation. C3H-derived CD4+ T cells that were originally exposed to 
BALB/c DCs were rechallenged with donor BALB/c DCs, third-party C57BL/6 (H-2b) 
DCs, CB6F1 [(C57BL/6xBALB/c)F1] DCs expressing both donor and third-party MHC 
(to test the induction of linked suppression), and B6CBF1 [(C57BL/6xCBA)F1] DCs 
expressing third-party and self MHC, but not donor MHC, which were used as a F1 DC 
control. CBA/Ca-derived CD4+ T cells that were originally exposed to CBK DCs to test 
the indirect pathway were rechallenged with donor CBK DCs, third-party B10.A (H-2k 
+ Dd) DCs, B6CBF1 [(C57BL/6xCBA)F1] DCs expressing both donor and third-party 
MHC (to test the induction of linked suppression), and CB6F1 [(C57BL/6xBALB/c)F1] 
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DCs expressing only third-party MHC which were used as a F1 DC control. All 
rechallenge assays that were preceded by a 10-day primary MLR as described above 
were harvested on days 3, 5 and 7, and proliferation of T cells measured with thymidine 
incorporation as described in section 2.11.2 above. 
2.11.6.2. Rechallenge Assay for Induction of Anergy and Linked Suppression in vivo 
 
To investigate the induction of anergy in vivo, populations of 2.5x106 BALB/c or CBK  
DCs were injected intravenously via the tail vein into C3H or CBA/Ca mice 
respectively. 10 days later, CD4+ T cells were purified from the spleen and lymph nodes 
of the injected animals by negative selection as described in section 2.11.1. The purified 
T cells were subsequently rechallenged with DCs in 96-well plates at a ratio of 1:10 
(2x103 DCs: 2x104 T cells). Similar to rechallenge assays performed to test anergy 
induction in vitro, CD4+ T cells purified from C3H mice that were previously injected 
with BALB/c DCs were rechallenged in vitro with donor BALB/c DCs, third-party 
C57BL/6 DCs, CB6F1 DCs expressing both donor and third-party MHC (to test the 
induction of linked suppression), and B6CBF1 DCs expressing third-party and self 
MHC, but not donor MHC, which were used as a F1 DC control. CD4+ T cells purified 
from CBA/Ca mice that were previously injected with CBK DCs to test the indirect 
pathway were rechallenged with donor CBK DCs, third-party B10.A DCs, B6CBF1 
DCs expressing both donor and third-party MHC (to test the induction of linked 
suppression), and CB6F1 DCs expressing only third-party MHC which was used as a 
F1 DC control. All rechallenge assays in which CD4+ T cells were purified from mice 
previously injected intravenously with DC populations as described above were 
harvested on days 3, 5 and 7 and proliferation of T cells measured with thymidine 
incorporation as described in section 2.11.2 above. 
2.11.6.3. Reversibility of Anergy and Regulation of Allogeneic T Cell Proliferation by 
CD4+CD25+ T Cells 
 
Assessment of CD4+ T cell viability was undertaken in rechallenge assays to establish 
whether anergy was observed (as opposed to T cell death). This was carried out by 
demonstrating reversibility of T cell anergy by the addition of exogenous IL-2 directly 
to the rechallenge cultures (Beverly et al., 1992). CD4+ T cells purified from the spleens 
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and lymph nodes of DC-injected mice were rechallenged in vitro with various strains of 
DCs (as described in section 2.11.6.2) in the presence of 100 U/ml of recombinant 
murine IL-2 (Roche Biosciences) (Takahashi et al., 1998). 
 
It was necessary to investigate whether anergy observed in rechallenge assays was the 
result of alloreactive T cell regulation by the CD25+ T cell compartment of CD4+ T 
cells. CD4+ T cells were purified by negative selection from the spleens and lymph 
nodes of DC-injected mice. The CD4+ T cells were then magnetically labelled for CD25 
expression using the MACS® CD25 Microbead kit (as described in section 2.11.4) and 
the subpopulation of CD25+ T cells depleted prior to rechallenge of the CD4+ T cells in 
vitro with various strains of DCs similar to the rechallenge of non-CD4+CD25+-depleted 
T cells. 
2.11.7. Suppressor Assays for Induction of Regulatory T Cells 
2.11.7.1. Suppressor Assay for Induction of Regulatory T Cells in vitro 
 
Functional suppressor assays (Tan et al., 2005c) were carried out to investigate the in 
vitro-induction of Tregs from CD4+ T cells incubated with modified (for the induction 
of tolerance) DCs in a primary 10-day MLR (the primary MLR is described above in 
section 2.11.6.1). CD4+ T cells were harvested on day 10 of the primary MLR. Similar 
to rechallenge assays to detect in vitro anergy induction, it was confirmed that there was 
no carry-over of viable DCs from the primary MLR when T cells were harvested. The 
CD4+ T cells were irradiated (50 Gy) and added in increasing numbers (0 to 100,000) to 
‘fresh’ primary MLRs with a 1:5 ratio of DCs : T cells (2x104 DCs : 1x105  T cells). 
Irradiated CD4+ T cells derived from 10-day MLRs consisting of BALB/c DCs and C3H 
T cells were subsequently added to primary MLRs consisting of new C3H T cells and 
the following DCs: BALB/c DCs to test for donor-specific Treg-mediated suppression; 
C57BL/6 DCs as a third-party control; CB6F1 to test for linked suppression; and 
B6CBF1 DCs as a F1 DC control. CD4+ T cells derived from 10-day MLRs consisting 
of CBK DCs and CBA T cells were subsequently added to primary MLRs consisting of 
new CBA T cells and the following DCs: CBK DCs to test for donor-specific Treg-
mediated suppression; B10.A DCs as a third-party control; B6CBF1 to test for linked 
suppression; and CB6F1 DCs as a F1 DC control. 
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2.11.7.2. Suppressor Assay for Induction of Regulatory T Cells in vivo 
 
The induction of Tregs in vivo was also investigated by carrying out functional 
suppressor assays using CD4+CD25+ T cells purified from mice that were previously 
injected with modified BALB/c or CBK DC populations. 10 days after intravenous DC 
injection, CD4+CD25+ T cells were purified from the spleens and lymph nodes using a 
combination of negative selection for CD4+ T cells followed by positive selection of 
CD25+ T cells using the MACS® CD25 Microbead kit (as described in sections 2.11.1 
2.11.4 respectively). The CD4+CD25+ T cells were irradiated (50 Gy) and added in 
increasing numbers (0 to 100,000) to primary MLRs with a 1:5 ratio of DCs : T cells 
(2x104 DCs : 1x105  T cells). Irradiated CD4+CD25+ T cells purified from BALB/c DC-
injected C3H mice were added to primary MLRs consisting of new C3H T cells and the 
following DCs: BALB/c DCs to test for donor-specific Treg-mediated suppression; 
C57BL/6 DCs as a third-party control; CB6F1 to test for linked suppression; and 
B6CBF1 DCs as a F1 DC control. CD4+CD25+ T cells derived from CBA mice were 
added to primary MLRs consisting of new CBA T cells and the following DCs: CBK 
DCs to test for donor-specific Treg-mediated suppression; B10.A DCs as a third-party 
control; B6CBF1 to test for linked suppression; and CB6F1 DCs as a F1 DC control. 
 
2.12. RNA Extraction and Reverse Transcription (RT-PCR) 
2.12.1. RNA Extraction 
 
Cellular mRNA was extracted from both primary cells and cell lines used in this study 
using TRIzol™ Reagent (Invitrogen). Briefly, 2x106-4x106 cells were centrifuged and 
resuspended in 1ml of TRIzol™ Reagent for nucleoprotein dissociation. This was 
followed by the addition of 200 µl of chloroform (Sigma-Aldrich) and subsequent 
(immediate), vigorous shaking of the solution and centrifugation at 13,000 rpm for 15 
minutes. 500 µl of isopropanol was added to the aqueous phase, which was mixed 
thoroughly and centrifuged again at 13,000 rpm for 30 minutes. The RNA pellet was 
washed in 75% ethanol (4°C), centrifuged, air-dried (to evaporate any excess ethanol 
remaining after removal) and resuspended in a maximum volume of 30 µl of DEPC-
treated molecular biology H2O (BioChemika, Fluka, UK). RNA was quantified by 
spectrophotometry and used when ratio of OD260 to OD280 (RNA) was greater than 1.7. 
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2.12.2. Reverse Transcription (RT-PCR) for First-Strand cDNA Synthesis 
 
Prior to reverse transcription, RNA was treated with RNAse-free DNase (RQ RNase-
free DNAse, Promega, Madison, WI, USA) for 30 minutes to eliminate potentially 
contaminating genomic DNA. 5 µg of extracted RNA (quantified by spectrophotometry 
as described above) was first incubated at 65°C for 10 minutes with 1 µl of 10 µg/ml 
Oligo(dT) Primer (Promega Corporation, UK) and DEPC-treated molecular biology 
H2O (BioChemika, Fluka, UK) to make up a final volume of 16.25 µl. The Oligo(dT) 
primer hybridises to the poly(A) tail of mRNA and is suitable for first-strand cDNA 
synthesis with a reverse transcriptase. The incubation at 65°C was followed by 
incubation of the mixture on ice for two minutes. Subsequently, the RNA was subjected 
to reverse transcription using Moloney Murine Leukaemia Virus Reverse Transcriptase 
(M-MLV RT) (Promega). After Oligo(dT) primer hybridisation and subsequent 
incubation of the RNA tube on ice, 1 µl of 200 units/µl of M-MLV RT, 5 µl of first 
strand / 5x Reaction Buffer (Promega), 1 µl of 10 mM dNTPs (Bioline, UK) and 0.75 µl 
of 30U RNasin® Ribonuclease Inhibitor (Promega) for the inhibition of RNAse. The 
mixture was incubated at 42°C for 1 hour for the synthesis of first-strand cDNA. DTT 
was omitted from the reaction mix due to its effect on real-time PCR [DTT was found 
to reduce its efficiency and did not result in any difference in cDNA formation 
(Beutelspacher et al., 2006)]. The RT-PCR products were double diluted so that a 
greater volume could be added to the PCR reaction mixture to reduce any mechanical 
errors during pipetting. 
 
2.13. Quantitative (Real-Time) PCR 
 
Real-Time PCR for mRNA production was performed subsequent to RNA extraction 
and reverse transcription for first-strand cDNA synthesis using the protocol described 
above in section 2.12. 
 
The PCR protocol comprised an initial denaturation step at 95°C for 3 minutes followed 
by 40 cycles of amplification. The conditions were denaturation at 95°C for 5 seconds, 
annealing at 56°C for 10 seconds, elongation at 72°C for 13 seconds, and quantification 
at 81°C (once). Amplification was performed using a LightCycler machine (Roche 
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Molecular Biochemicals, Hertfordshire, UK) and the SYBR® Green Taq ReadyMix™ 
for Quantitative PCR, Capillary Formulation (Sigma-Aldrich), according to the 
manufacturer’s instructions. Specificity for the amplification was assessed by the 
melting temperature of the product which was determined using the LightCycler 
machine and its associated software (Roche, UK). Quantitative, real-time PCR data was 
also analysed using the LightCycler software. 
 
Quantification of IDO1 mRNA was carried out using the paired primers 5’-
TGGCAAACTGGAAGAAAAAG-3’ (forward) and 5’-
AATGCTTTCAGGTCTTGACG-3’ (reverse) spanning 197bp of the IDO1 gene. 
Transcripts were normalised to levels of hypoxanthine phosphoribosyl transferase 
(HPRT) mRNA, using a plasmid encoding a fragment of the HPRT gene. This plasmid 
was previously obtained by amplification of a 176bp fragment of the HPRT gene from a 
plasmid-encoding HPRT gene (King et al., 2000) using the following primers 3’-
GTAATGATCCAGTCAACGGGGGAC-5’ (forward) and 3’-
CCAGCAAGCTTGCAACCTTAACCA-5’ (reverse). The PCR product was purified 
using the Roche DNA purification kit and cloned into the pCMV script vector 
(Stratagene) by blunt end cloning (Beutelspacher et al., 2006). The same primers were 
used for quantification of HPRT mRNA. 
2.13.1. Use of Quantitative (Real-Time) PCR for Determination of Viral Titre 
 
As stated in section 2.7.1, in order to determine titres for EIAV IDO and EIAV CTLA4-
KDEL lentiviral stocks, quantification of a DNA sequence found in the woodchuck 
hepatitis postregulatory element (WPRE) of the lentiviral constructs had to be 
undertaken as a reporter gene is not present in the constructs to allow for direct 
visualisation (Martin-Rendon et al., 2002; Lizee et al., 2003). The following paired 
primers were used for the detection by real-time PCR of WPRE in genomic DNA 
extracted directly from EIAV-transduced D17 cells- forward 3’-
CCGTTGTCAGGCAACGTG-5’; reverse 3’-AGCTGACAGGTGGTGGCAAT-5’ 
(Lizee et al., 2003). Genomic DNA was extracted using the DNeasy Tissue Kit 
(Qiagen).  
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2.13.2. Use of Quantitative (Real-Time) PCR for Screening of tsDC Clones 
 
As explained in section 2.5.4.1, four tsDC clones were generated for the purposes of 
this study. The clones were screened using a combination of real-time PCR for genomic 
DNA analysis [clones positive for the relevant proteins would express the viral 
Woodchuck Hepatitis Post Regulatory Element (WPRE) integrated within host/genomic 
DNA] and real-time PCR for mRNA of the relevant proteins. Screening of clones was 
performed after 3 weeks and the clones expressing high levels of the relevant DNA and 
mRNA were expanded further for use in phenotypic and functional assays. Detection of 
WPRE by q-PCR was performed using the primers described in section 2.13.1. 
Detection of mRNA for IDO was performed with the IDO and HPRT primers described 
above, whilst detection of CTLA4-KDEL mRNA in the tsDC clones was performed 
using the following paired primers spanning 150bp (including a fragment of the 
extracellular domain of CTLA4- not expressed by DCs) of the CTLA4-KDEL gene: 
forward 5’-GGCAGACAAATGACCAAATG-3’; reverse 5’-
CCGTGTCAACAGCTCTCAGT-3’. 
 
2.14. Fluorescence Microscopy 
 
Accurate determination of viral titres after each cycle of replication-defective EIAV 
production (EIAV GFP, EIAV CTLA4-KDEL and EIAV IDO) relied, in part, upon the 
counting of the number of foci of infection present after transduction of canine 
osteosarcoma (D17) cells by serial dilutions of EIAV GFP stocks. As described in 
section 2.7.1, fluorescence microscopy was used in conjunction with real-time PCR in 
order to determine titres for EIAV CTLA4-KDEL and EIAV IDO, the DNA constructs 
of which did not encode a reporter gene that would have allowed for direct visualisation 
of transduction like EIAV GFP stocks. Counting of the number of foci of infection in 
the GFP-transduced D17 cells was undertaken using a Nikon Eclipse TE2000-S (Nikon, 
UK) and Olympus CK40 (Olympus, UK) fluorescence microscope. 
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2.15. L-Kynurenine Assay for IDO Function 
 
The biological activity of IDO was evaluated colourimetrically by measuring levels of 
the tryptophan metabolite L-kynurenine in culture medium (Takikawa et al., 1988; Lee 
et al., 1998). 500 µl of tissue culture medium was collected from DC cultures grown and 
transduced in 6-well plates. 100 µl of 30% (w/v) trichloroacetic acid (TCA) was added 
for the precipitation of proteins, followed by incubation of the medium at 50°C for 30 
minutes for the hydrolysis of N-formylkynurenine produced by IDO to kynurenine. The 
reaction mixture was then centrifuged for 20 minutes at 3000 g to remove sediment. To 
500 µl of the supernatant, an equal volume of Ehrlich’s reagent was added. The 
constituents of Ehrlich’s reagent (Takikawa et al., 1988) are as follows: 3.0g 
p-dimethylaminobenzaldehyde (Sigma-Aldrich, UK), 12.4 ml n-propanol (Sigma-
Aldrich), 5.2 ml 70% perchloric acid (Sigma-Aldrich) and 2.4 ml distilled water. The 
samples were incubated for a further 15 minutes at 65°C, then cooled. Absorption of the 
resulting solution was measured at 490 nm by spectrophotometry within 2 hours of the 
addition of Ehrlich’s reagent. The values of kynurenine in conditioned medium were 
calculated by a standard curve with defined levels (0.39-200 µM) of purified 
L-kynurenine (Sigma-Aldrich) concentrations (20.82 mg of L-kynurenine- FW 208.21- 
was dissolved in 5 ml of tissue culture medium to yield an initial 20 mM L-kynurenine 
solution that was subsequently serially diluted). 
 
In specific experiments, 100 µl of supernatant could be collected (as opposed to 500 µl 
described above), and the protocol was slightly modified to take account of the smaller 
volume: 20 µl of 30% TCA was added to precipitate proteins, followed by incubation 
for 30 minutes at 50°C. After centrifugation of the reaction mixture, 50 µl of 
supernatent was mixed with an equal volume of Ehrlich’s reagent, followed by 
incubation for 15 minutes at 65°C. Absorption of the resulting solution was analysed as 
above using a microplate spectrophotometer. 
 
2.16. ELISA for Immunoregulatory Cytokine Production 
 
Immunoregulatory cytokine levels in the supernatants of two-stage mixed lymphocyte 
responses (rechallenge assays) were detected using the Mouse IL-10 ELISA Ready-
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SET-Go! Kit® (eBioscience, USA) and Mouse TGF-beta1 (TGF-β1) ELISA Ready-
SET-Go! Kit® (eBioscience, USA)- both are 2-site sandwich ELISAs. The IL-10 kit 
(with a sensitivity of 30 pg/ml) and the TGF-β1 kit (with a sensitivity of 60 pg/ml) 
allowed for the accurate and precise detection of low levels of the respective cytokines 
in 100 µl of culture supernatant taken from wells of a 96-well plate rechallenge assay. In 
order to activate latent TGF-β1 to the immunoreactive form, the samples (but not the 
standards provided with the kit) were acidified, and then neutralised: 20 µl of 1 N HCl 
was added to 100 µl of sample, followed by incubation for 10 minutes at room 
temperature and neutralisation with 20 µl of 1 N NaOH (when final concentrations were 
calculated, this was corrected to the dilution factor of 1.4). After the addition of pre-
titrated detection enzyme (Avidin-HRP), substrate solution (tetramethylbenzidine-
TMB) and stop solution, ELISA plates were read at 450 nm using a microplate 
spectrophotometer. Samples were assayed in triplicate and were quantitated by 
comparison with standard curves obtained with purified recombinant cytokines 
provided with the ELISA kits. Results are presented as the means and standard 
deviations of triplicates. 
 
2.17. Orthotopic Corneal Transplantation and Criteria for Graft 
Rejection 
 
Mice were injected intravenously (via the tail vein) with 2.5x106 DCs (transduced with 
EIAV or left untransduced) 10 days prior to corneal transplantation. As stated earlier, 
BALB/c mice receiving a C3H/He corneal transplant were injected with donor-derived 
(C3H/He) DCs whereas BALB/c mice receiving a CBA/Ca corneal transplant were 
injected with CBACF1 [(CBA/Ca)x(BALB/c)F1] DCs. In addition, to investigate the 
role of CD8+ T cells in corneal allograft rejection, in vivo-depletion was carried out by 
intraperitoneal injection of CD8-depleting- YTS169.4- antibody (2 x 250 µg/mouse) 
(AbD serotec) prior to separate experiments to investigate the effect of intravenous 
tolerogenic DC injection on corneal allograft rejection. 
 
Murine corneal transplantation was performed in the right eye of female BALB/c 
(H-2d), C3H/He (H-2k) and CBA/Ca (H-2k) mice (all 8-10 weeks of age) using an 
established protocol (Zhang et al., 1996) with minor modifications (Ardjomand et al., 
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2003). Anaesthesia and neuroleptanalgesia was induced in the animals using a 
combination of Hypnorm (Fentanyl Citrate and Fluanisone) (VetaPharma Ltd, Leeds, 
UK) and Hypnovel (Midazolam) (Roche, Welwyn Garden City, UK). Prior to 
transplantation of the cornea, pupils were dilated using 1% tropicamide and 10% 
phenylephrine hydrochloride sterile eye drops (Minims, UK). The donor cornea and the 
recipient corneal bed were marked with a 2.5 mm and 2.0 mm trephine respectively 
(Geuder AG, Heidelberg, Germany), and subsequently cut on the trephine marking 
using an ophthalmic diamond knife (Duckworth and Kent, UK). A continuous 11-0 
nylon suture (Ethicon/Johnson and Johnson, USA) was used to suture a 2.5 mm donor 
corneal graft (derived from C3H/He or CBA/Ca mice for BALB/c recipients, or CBK 
mice for CBA recipients) into a 2.0 mm recipient corneal bed. After completion of the 
procedure, chloramphenicol ointment (Martindale Pharmaceuticals, Brentwood, UK) 
was applied to the cornea. The eyelid was sutured closed with a 7-0 Vicryl suture 
(Ethicon) to protect the cornea for the initial 48 hours, after which the 7-0 suture was 
removed and the eyes examined by operating microscope (Carl Zeiss Microimaging 
GmbH, Germany) every two days thereafter. Technically satisfactory grafts had  corneal 
opacity grades 0 to 1 at all times until corneal suture removal on day 7. All other graft 
recipients and those with intraocular haemorrhage or cataract were excluded from 
further analysis. 
 
Corneal transparency is an indicator of corneal endothelial function and of graft 
endothelial injury. The grading of corneal opacity and the onset of graft rejection was 
determined using minor modifications to an established protocol (Sonoda and Streilein, 
1993). Graft rejection was diagnosed when corneal opacity increased to grade 3 (no iris 
blood vessels visible). The full grading is as follows: 0, completely transparent cornea; 
1, minimal corneal opacity, iris vessels easily visible; 2, moderate corneal opacity, iris 
vessels still visible; 3, moderate corneal opacity, iris vessels no longer visible, only 
pupil margin visible; 4, complete corneal opacity, pupil no longer visible. Grading of 
graft transparency was undertaking by an examiner masked to the treatment group of 
each animal.  
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2.18. Statistical Analyses 
 
A mean value for triplicate values and associated Standard Deviation (SD) are given for 
all T cell proliferation and L-kynurenine assay data. When stated, statistical differences 
were calculated using a two-tailed t-test. A Mann-Whitney U test was used for 
calculating statistical differences in corneal graft opacity scores. Differences in graft 
survival were analysed using a log rank test and plotted according to the Kaplan-Meyer 
method. All graphical representation of data and statistical analyses were performed 
using GraphPad Prism version 4.00 for Windows, (GraphPad Software, San Diego, 
CA). A value of p<0.05 was regarded as statistically significant. 
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Chapter 3: RESULTS 
 
3.1. Subcloning of CTLA4-KDEL and IDO Genes into Lentiviral 
Constructs 
3.1.1. Self-Inactivating Lentivirus Production using a Three-Plasmid Cotransfection 
Technique and Highly Efficient Transduction of an Immortalised Cell Line 
 
As described in section 1.12, lentiviral vectors are particularly attractive for gene 
delivery, the primary rationale being that the vectors integrate efficiently into host 
chromosomal DNA, resulting in stable transmission and high levels of transgene 
expression. At present one of the most efficient methods for genetic modification of 
DCs (for subsequent use in transplantation medicine or otherwise) is to use viral vectors 
(Tan et al., 2005b; Tan et al., 2006). This was demonstrated at the start of this study by 
the efficient transduction of a CHO cell line with an EIAV lentiviral vector 
incorporating the eGFP protein at MOI 20 (MOI derivation discussed in section 3.2 
below) as assessed by flow cytometry. The transduction efficiency attained was greater 
than 95%, and was calculated as the percentage of CHO cells expressing GFP after 
EIAV GFP transduction relative to expression after transduction by EIAV Mock to 
correct for any non-specific DC autofluorescence after viral transduction. The VSV-G-
pseudotyped, self-inactivating EIAV GFP lentivirus was propagated by a three-plasmid 
co-transfection technique using pONY3.1, an EIAV/HIV gag/pol-expressing construct, 
pRV67 (the EIAV VSV-G-expressing construct) and pSMART2G (the EIAV vector 
construct with the eGFP expression cassette) [Figure 14(a-d)]. The EIAV Mock 
lentivirus was propagated using the pSMART-IDO (see section 3.1.3) construct 
substituted for the pSMART2G construct. 
3.1.2. Subcloning of CTLA4-KDEL into EIAV Lentiviral Construct (pSMART2G) 
 
As the primary objective in this study was to use a genetic approach to confer 
tolerogenic properties on murine DCs, a lentiviral construct containing the murine 
CTLA4-KDEL gene was generated for use in subsequent experiments (both in vitro and 
in vivo) [Figure 15]. Prior to the study, the gene sequence encoding the extracellular 
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(a) (b)
(c) (d)pSMART2G: EIAV Vector Construct with eGFP Expression Cassette:
pONY3.1: EIAV/HIV Gag/Pol-Expressing Construct: pRV67: EIAV VSV-G Env-Expressing Construct:
Three-Plasmid Viral Vector (EIAV GFP) 
Production & Transduction of CHO Cell Line
Mock-Transduced
GFP-Transduced
 
 
 
Figure 14. Self-Inactivating EIAV Lentivirus Production using a Three-Plasmid Cotransfection 
Technique and Highly-Efficient Transduction of an Immortalised Cell Line. 
Lentiviral vectors integrate efficiently into host chromosomal DNA, resulting in stable transmission and high 
levels of transgene expression (see text). The VSV-G-pseudotyped, self-inactivating / third-generation 
EIAV GFP lentivirus was propagated by a three-plasmid co-transfection technique using the following 
plasmids: (a) pONY3.1 (EIAV/HIV gag/pol-expressing construct), (b) pRV67 (EIAV VSV-G-expressing 
construct) and (c) pSMART2G (EIAV vector construct with the eGFP expression cassette). (d) CHO cells 
were transduced with EIAV GFP (generated using the three-plasmid co-transfection technique described 
above) at MOI 20 and transduction efficiency assessed by flow cytometry 72 hours later. Transduction 
efficiency was calculated as the percentage of CHO cells expressing GFP after EIAV GFP transduction 
relative to expression after transduction by EIAV Mock (to correct for any non-specific DC 
autofluorescence after viral transduction). 
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Figure 15. Subcloning of CTLA4-KDEL into EIAV Lentiviral Construct (pSMART2G): Strategy. 
Prior to the study, the gene sequence encoding the extracellular domain of murine CTLA4 was inserted 
between the SalI and NotI restriction sites (located in the multiple cloning site) of the pCMV/c-myc/ER 
vector to generate CTLA4-KDEL (Miss Jennifer Harper, unpublished). In this study, the CTLA4-KDEL gene 
was subsequently amplified from the pCMV/c-myc/ER vector by polymerase chain reaction (PCR) with 
primers designed to include the restriction sites HindIII and XhoI. The CTLA4-KDEL insert was subcloned 
first into a TA cloning vector, and subsequently into the EIAV plasmid pSMART2G using a HindIII and XhoI 
restriction digest reaction followed by a ligation reaction (thus removing the enhanced GFP gene already 
present). Subcloning of the murine CTLA4-KDEL insert into the lentiviral construct was confirmed by 
sequencing and the resulting plasmid designated pSMART-CTLA4-KDEL. 
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domain of murine CTLA4 was inserted between the SalI and NotI restriction sites 
(located in the multiple cloning site) of the pCMV/c-myc/ER vector to generate the 
sequence for the CTLA4-KDEL fusion protein (Miss Jennifer Harper, unpublished). For 
the purpose of this investigation, the pSMART2G (EIAV GFP) plasmid was first cut 
with HindIII and XhoI restriction enzymes to isolate the 8kb pSMART2G backbone and 
773bp eGFP insert [Figure 16(a)]. The CTLA4-KDEL gene was subsequently 
amplified from the pCMV/c-myc/ER vector by polymerase chain reaction (PCR) with 
primers designed to include the restriction sites HindIII and XhoI, and subcloned into a 
TA cloning vector. Successful insertion of the CTLA4-KDEL gene into the TA vector 
backbone was confirmed by screening clones (after TA ligation) using gel 
electophoresis. The ligated TA vector was cut using HindIII and XhoI restriction 
enzymes followed by gel electrophoresis of the reaction products to isolate the 3kb TA 
vector backbone and 616bp CTLA4-KDEL insert [Figure 16(b)]. Following TA 
cloning, the CTLA4-KDEL insert was subcloned into the pSMART2G construct. 
Similar to TA cloning stage, successful insertion of the CTLA4-KDEL gene into the 
pSMART2G backbone was also confirmed by screening clones (after ligation reactions) 
using gel electrophoresis. The ligated pSMART-CTLA4-KDEL construct was cut with 
HindIII and XhoI restriction enzymes followed by gel electrophoresis to isolate the 8kb 
pSMART2G backbone and 616bp CTLA4-KDEL insert [Figure 16(c)]. The 
CTLA4-KDEL insert was thus subcloned first into a TA cloning vector and 
subsequently into the EIAV plasmid pSMART2G using a series of HindIII and XhoI 
restriction digest and ligation reactions to replace the enhanced GFP gene originally 
present in the pSMART2G construct with the murine CTLA4-KDEL gene. 
 
Subcloning of the murine CTLA4-KDEL insert into the lentiviral construct was 
confirmed by sequencing and the resulting plasmid designated 
pSMART-CTLA4-KDEL. The pSMART-CTLA4-KDEL construct would be used to 
generate the EIAV CTLA4-KDEL lentivirus (using the three-plasmid cotransfection 
technique) for long-term, stable expression of the transgene after integration into the 
host cell (DC) genome [Figure 17]. As discussed previously, in addition to the 
propagation of lentiviral vectors by transient transfection with three constituent 
plasmids, safety of the 3rd-generation pSMART lentiviral vectors was guaranteed by the  
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Figure 16. Subcloning of CTLA4-KDEL into EIAV Lentiviral Construct (pSMART2G). 
(a) The pSMART2G (EIAV GFP) plasmid was cut with HindIII and XhoI restriction enzymes to remove the 
773 bps eGFP insert from the 8 kb pSMART2G backbone. (b) The CTLA4-KDEL insert was subcloned 
from the pCMV/c-myc/ER vector into a TA cloning vector. Confirmation of subcloning was undertaken by 
screening clones using gel electophoresis- the ligated TA vector was cut using HindIII and XhoI restriction 
enzymes to confirm successful insertion of the 616 bps CTLA4-KDEL insert into the 3 kb TA vector 
backbone. (c) Following TA cloning, the CTLA4-KDEL insert was subcloned into the pSMART2G 
construct. Following ligation reactions, clones were screened using gel electrophoresis- the ligated 
constructs were cut with HindIII and XhoI restriction enzymes to confirm successful insertion of the 
616 bps CTLA4-KDEL insert into the 8 kb pSMART2G backbone to generate pSMART-CTLA4-KDEL. 
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Figure 17. Transcriptional Sequences in the pSMART CTLA4-KDEL Construct and Integrated Virus. 
(a) Long-term, stable transgene expression by integration into the host cell genome renders the EIAV virus 
an attractive option for genetic modification. In addition to production of lentiviral vectors by transient 
transfection with three plasmids, safety has been further guaranteed by deleting genes not required for the 
generation of functional vector particles. This has also been achieved by making the vector self-
inactivating (SIN), mainly by modifying transcriptional enhancer and promoter regions in the 3’U3-LTR. The 
modified U3 which is transferred to the 5’-LTR during reverse transcription, causes transcriptional 
inactivation of the LTR in integrated provirus, while the activity of the CMV promoter internal to the LTR 
regions remains unaffected. There is usually a transcriptional override caused by the LTR: LTR 
interference acts to silence the promoter downstream of the LTR. This is seen in non-U3 depleted 
retroviruses since the transcriptional control elements are localised within the U3. Depletion of the 
transcriptional elements within the U3 region is one of the targets in the construction of a self-inactivation 
vector for reasons of bio-safety, resulting in a single infectious cycle with one event of stable integration 
into the host genome. Furthermore, this eliminates transcription of any viral sequences within the 
transduced cell. (b) Before integration of EIAV into the host genome, the U3 region is copied to the 5’ end 
such that the integrated virus genome is flanked by U3-U5-R. 
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deletion of genes not required for the generation of functional vector particles [and 
hence making the vector self-inactivting (SIN)]. 
3.1.3. Subcloning of IDO into EIAV Lentiviral Construct (pSMART2G) 
 
Similar to the use of the CTLA4-KDEL intracellular fusion protein in lentiviral gene 
transfer, it was also investigated whether the immunomodulatory enzyme IDO could be 
used to render DCs tolerogenic (for the subsequent induction of donor-allospecific 
tolerance) after lentiviral gene transfer of the enzyme. An EIAV lentiviral construct 
encoding murine IDO1 (referred to throughout the study as IDO) was generated in a 
previous study to prolong corneal allograft survival after transduction of murine corneal 
endothelial cells (Beutelspacher et al., 2006) [Figure 18(a)]. This involved amplifying 
the gene for murine IDO from mature DCs by PCR and cutting the plasmid 
pSMART2G with HindIII, and XhoI restriction enzymes, removing the eGFP gene 
originally present. A linker oligonucleotide containing HindIII, PacI, KpnI, NheI and 
XhoI restriction sites was ligated into the plasmid using T4 ligase. The gene for IDO 
was inserted between the PacI and NheI sites. The cloned IDO insert was confirmed by 
sequencing and the resulting plasmid designated pSMART-IDO. In this study, the 
ligated pSMART-IDO construct was cut with HindIII and XhoI restriction enzymes to 
isolate the 8 kb pSMART2G backbone and the 1244 bps IDO insert to ensure successful 
cloning [Figure 18(b)]. Similar to the generation of EIAV CTLA4-KDEL, the 
pSMART-IDO construct would be used to generate the EIAV IDO lentivirus for long-
term, stable expression of the transgene after integration into the host cell (DC) genome 
[Figure 18(c)]. 
3.1.4. CTLA4-KDEL Protein Expression and Inhibition of Surface CD80/86 
Expression 
 
Prior to the generation of functional, replication-deficient EIAV lentiviral vectors 
encoding GFP (EIAV GFP/Mock), CTLA4-KDEL (EIAV CTLA4-KDEL) or IDO 
(EIAV IDO), it was necessary to confirm that transfection (non-viral) of the newly-
generated pSMART-CTLA4-KDEL plasmid alone into 293T cells using the cationic 
polymer polyethylenimine (PEI) induced expression of the fusion protein. Expression of 
the 20 kDa CTLA4-KDEL protein in the lysates of 293T cells transfected with the  
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Figure 18. Subcloning of IDO into EIAV Lentiviral Construct (pSMART2G). 
(a) An EIAV lentiviral construct encoding murine IDO was generated previously (plasmid shown). The 
gene for murine IDO was amplified from mature DCs by PCR and the plasmid pSMART2G cut with HindIII, 
and XhoI restriction enzymes, removing the eGFP gene originally present. A linker oligonucleotide 
containing HindIII, PacI, KpnI, NheI and XhoI restriction sites was ligated into the plasmid using T4 ligase. 
The gene for IDO was inserted between the PacI and NheI sites. The cloned IDO insert was confirmed by 
sequencing and the resulting plasmid designated pSMART-IDO. (b) The ligated pSMART-IDO construct 
was cut with HindIII and XhoI restriction enzymes to isolate the 8 kb pSMART2G backbone and the 
1244 bps IDO insert to ensure that the IDO gene was indeed inserted successfully into the pSMART2G 
backbone. (c) The figure shows a schematic diagram of the transcriptional sequences in the pSMART-IDO 
construct after integration of EIAV IDO into the host genome (see figure 17). 
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pSMART2G (Mock) or pSMART CTLA4-KDEL construct was determined by western 
blotting 72 hours after transfection with PEI [Figure 19(a)]. The CTLA4-KDEL protein 
was detected using an antibody directed against the human c-myc protein tag 
incorporated in the construct. The 20 kDa c-myc-CTLA4-KDEL protein was detected 
only in 293T cells transfected with pSMART-CTLA4-KDEL- predictably, the fusion 
protein was not expressed in 293T cells that were either untransfected or transduced 
with pSMART2G (Mock). Expression of CTLA4-KDEL was detected relative to 293T 
cell expression of the 42 kDa β-actin housekeeping protein. 
 
After demonstrating expression of the fusion protein in 293T cells using the newly-
generated construct, it was the aim (for the progression of the study) to investigate 
whether transfection of three CHO-derived cell lines [i) CHO mB7.1 cells (CHO cells 
transgenic for murine CD80), ii) CHO mB7.1 / I-Ad cells (CHO cells transgenic for 
murine CD80 and MHC class II) and iii) CHO mB7.2 / I-Ad cells (CHO cells transgenic 
for murine CD86 and MHC class II)] with pSMART-CTLA4-KDEL affected surface 
expression of transgenic CD80/86 costimulatory molecules. The optimal transfection 
efficiency of PEI and Lipofectamine 2000 (both non-viral vectors) was first determined 
using an (unmodified) CHO cell line. CHO cells were transfected with the pSMART2G 
construct using either PEI or Lipofectamine 2000, and the transfection efficiency 
assessed by flow cytometry 72 hours later [Figure 19(b)]. The transfection efficiency 
with either of the non-viral vectors did not exceed 35%. It would thus have been 
unlikely that transfection of the three CHO cell lines [each of which expressed high 
levels (>95%) of transgenic costimulatory molecules- see below] with pSMART-
CTLA4-KDEL would have had a considerable impact on phenotype such that a 
conclusion could have been drawn about the functional effect of the fusion protein- 
namely the intracellular retention of CD80/86 within the ER of transfected cells. In light 
of the results, the functional effect of the newly-generated pSMART-CTLA4-KDEL 
construct was investigated after the generation of EIAV CTLA4-KDEL vector particles 
(subsequent to propagation using the three-plasmid cotransfection technique). EIAV 
Mock and EIAV CTLA4-KDEL were used to transduce CHO B7.1 (CD80)- [Figure 
19(c)], CHO B7.1 (CD80) / I-Ad- [Figure 19(d)] and CHO B7.2 (CD86) / I-Ad cells 
[Figure 19(e)] at MOI 20. The transduction efficiency achieved with each of the cell  
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Figure 19. CTLA4-KDEL Protein Expression and Inhibition of Surface CD80/86 Expression. 
(a) Expression of the 20 kDa CTLA4-KDEL protein in the lysates of 293T cells transfected with the 
pSMART2G (Mock) or pSMART CTLA4-KDEL construct was determined by western blotting 72 hours 
after transfection with polyethylenimine (PEI). The CTLA4-KDEL protein was detected using an antibody 
directed against the human c-myc protein tag incorporated in the construct. Expression of CTLA4-KDEL is 
shown relative to expression of the 42 kDa β-actin protein. (b) CHO cells were transfected with the 
pSMART2G construct using either PEI or Lipofectamine 2000, and the transfection efficiency assessed by 
flow cytometry for GFP expression 72 hours later. EIAV Mock and EIAV CTLA4-KDEL were used to 
transduce (c) CHO B7.1 (CD80)-, (d) CHO B7.1 (CD80) / I-Ad- and (e) CHO B7.2 (CD86) / I-Ad cells at 
MOI 20. Histograms show the transduction efficiency achieved with each of the cell lines at MOI 20 as 
assessed by GFP expression after EIAV GFP transduction (left panel), the expression of CD80 or CD86 
(middle panel) and the expression of I-Ad on CHO B7.1 / I-Ad- and CHO B7.2 / I-Ad cells (right panel) as 
assessed by flow cytometric analysis 72 hours after EIAV transduction. 
Chapter 3: Results 
Adnan Khan, Department of Immunology, Division of Medicine, Imperial College London 150 
lines at MOI 20 was greater than 90% as assessed by GFP expression 72 hours after 
EIAV GFP transduction (left panel). The expression of CD80, CD86 and/or I-Ad (as 
applicable) on CHO B7.1 (CD80), CHO B7.1 (CD80) / I-Ad- and CHO B7.2 (CD86) / 
I-Ad cells was analysed by flow cytometry 72 hours after EIAV transduction. There was 
complete inhibition of surface CD80 expression in CHO B7.1 (CD80) and CHO B7.1 
(CD80) / I-Ad cells transduced with EIAV CTLA4-KDEL relative to cells that were 
either untransduced or transduced with EIAV Mock. In addition, there was complete 
inhibition of surface CD86 expression in CHO B7.2 (CD86) / I-Ad cells transduced with 
EIAV CTLA4-KDEL relative to cells that were either untransduced or transduced with 
EIAV Mock. Furthermore, transduction of both CHO B7.1 (CD80) / I-Ad and CHO 
B7.2 (CD86) / I-Ad cells with EIAV CTLA4-KDEL did not affect expression of I-Ad, 
demonstrating specificity of CTLA4-KDEL for CD80 and CD86. The results of 
experiments undertaken in this section therefore demonstrate the inhibition of surface 
CD80 and CD86 expression in murine CTLA4-KDEL-expressing cells. 
 
3.2. Lentivirus Titration by Real-Time (Quantitative) PCR and 
Fluorescence Microscopy 
 
Throughout the study, in vitro and in vivo experiments requiring the lentiviral 
transduction of DCs were a predominant and recurring feature. Consistency in the 
number of infectious units (or concentration of virus) used to transduce DCs was 
achieved by titrating lentiviral stocks immediately after production. The number of 
infectious particles (or transducing units) per ml of virus stock was calculated after 
titration of viral stocks, and DCs subsequently transduced at an identical multiplicity of 
infection (MOI) corresponding to optimal transduction efficiency with EIAV as 
discussed later in section 3.4. EIAV stocks were titred using a combination of 
fluorescence microscopy and quantitative (real-time) PCR. Fluorescence microscopy of 
EIAV GFP-transduced cells was used in conjunction with real-time PCR of genomic 
DNA extracted from transduced cells to determine titres for EIAV CTLA4-KDEL and 
EIAV IDO stocks. Real-time PCR was used as the pSMART CTLA4-KDEL and 
pSMART IDO constructs do not encode a reporter gene that allows for direct 
visualisation of transduced cells (the GFP sequence present in the pSMART2G 
construct was replaced by sequences encoding either CTLA4-KDEL to generate 
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pSMART CTLA4-KDEL or IDO to generate pSMART-IDO). The real-time PCR was 
adapted from a method described in a recent study in which a DNA sequence found in 
the woodchuck hepatitis postregulatory element (WPRE) was quantified using qPCR 
(Lizee et al., 2003). As mentioned earlier, the WPRE is incorporated into a number of 
lentiviral vectors in the 3’UTR of nascent transgene transcripts to enhance transgene 
expression, and is common to the three lentiviral constructs used in this study. 
 
To calculate lentiviral titres, canine osteosarcoma (D17) cells were seeded on 48-well 
plates at 2x104 cells per well. EIAV stocks were serially diluted 10-fold (10-1 – 10-7) in 
serum-free medium and 150µl of each dilution was added to the seeded wells in 
triplicate. The D17 cells were subsequently visualised by fluorescence microscopy 72 
hours after transduction with the serial dilutions of EIAV GFP stocks. A graph of the 
number of foci of infection visualised per well at each of the five dilutions (10-3 – 10-7) 
was generated with the Y-axis (foci of infection) converted to a Log scale for 
linearisation of the curve [Figure 20(a-c)]. The value used for the number of foci of 
infection per well at each dilution was an estimate, derived from dividing the area of 
each well into 100 equal sections, counting the number of foci in one section, and 
approximating (linearly) the total number in the entire well. The graph was generated 
from values derived from the titration of EIAV GFP lentiviral stocks on five separate 
occasions. Similar to methods used for fluorescence microscopy, D17 cells transduced 
with EIAV IDO and EIAV CTLA4-KDEL (in addition to EIAV GFP) were harvested 
72 hours post-transduction and genomic DNA extracted for real-time PCR analysis. 
Real-time PCR was used to quantify WPRE DNA sequences in order to report a D17 
cell lentivirus transduction event. The WPRE copy number was normalised to ½ of the 
HPRT copy number to account for two copies of the HPRT gene in the diploid genome. 
A graph of normalised WPRE copy numbers from the genomic DNA of EIAV 
transduced D17 cells at each dilution of EIAV GFP stock was generated with a line of 
best fit applied [Figure 20(d)]. The same curve was derived for EIAV CTLA4-KDEL- 
and EIAV IDO-transduced D17 cells. A line of best fit applied to the EIAV GFP 
standard curve [Figure 20(b)] was used to unite the normalised WPRE copy number (of 
EIAV CTLA4-KDEL- and IDO-transduced D17 cells) to a value of foci of infection 
value for EIAV GFP-transduced D17 cells (using the log 10 dilution as the connecting  
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Figure 20. Lentivirus Titration by Real-Time (Quantitative) PCR and Fluorescence Microscopy. 
EIAV stocks were titred using a combination of fluorescence microscopy and quantitative (real-time) PCR. 
Fluorescence microscopy of EIAV GFP-transduced cells was used in conjunction with real-time PCR of 
genomic DNA extracted from transduced cells to determine titres for EIAV CTLA4-KDEL and EIAV IDO 
stocks. Real-time PCR was used as the pSMART CTLA4-KDEL and pSMART IDO constructs do not 
encode a reporter gene that allows for direct visualisation of transduced cells. (a-c) Canine osteosarcoma 
(D17) cells were seeded on 48-well plates at 2x104 cells per well. EIAV stocks were serially diluted 10-fold 
(10-1 – 10-7) in serum-free medium and 150µl of each dilution was added to the seeded wells in triplicate. 
EIAV GFP-transduced D17 cells were visualised by fluorescence microscopy 72 hours later (c). A graph of 
the number of foci of infection visualised per well at each of the five dilutions is shown (a) with the Y axis in 
Log scale (b). The graph was generated from values derived from the titration of EIAV GFP lentiviral 
stocks on five separate occasions. Results shown are the Mean ± SD of triplicate wells from the five 
occasions of fluorescence microscopy. Similar to methods used for fluorescence microscopy, D17 cells 
transduced with EIAV IDO and EIAV CTLA4-KDEL (in addition to EIAV GFP) were harvested 72 hours 
post-transduction and genomic DNA extracted for real-time PCR analysis. Real-time PCR was used to 
quantifiy woodchuck hepatitis postregulatory element (WPRE) DNA sequences in order to report a D17 
cell lentivirus transduction event. The WPRE copy number was normalised to ½ of the HPRT copy 
number. (d) A graph of normalised WPRE copy numbers from the genomic DNA of EIAV transduced D17 
cells at each dilution of EIAV GFP stock is shown with a line of best fit applied. The same curve was 
derived for EIAV CTLA4-KDEL- and EIAV IDO-transduced D17 cells. A line of best fit applied to the EIAV 
GFP standard curve (shown in part b) was used to unite the normalised WPRE copy number (of EIAV 
CTLA4-KDEL- and IDO-transduced D17 cells) to a foci of infection value for EIAV GFP-transduced D17 
cells (using the log 10 dilution as the connecting value). The number of infectious particles per ml each 
lentiviral stock was then deduced from the estimated foci of infection value. 
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value). The number of infectious particles per ml each lentiviral stock was then deduced 
from the estimated foci of infection value. The EIAV GFP curve [figure 20(b)] was thus 
used as a standard to deduce the number of foci of infection from the real-time PCR 
data used to detect WPRE after transduction of cells with EIAV CTLA4-KDEL or 
EIAV IDO, which both lack the reporter gene in their respective DNA constructs. 
 
3.3. Generation of Functional Murine Bone Marrow-Derived DCs 
 
The primary aim of the study was to investigate whether DCs transduced with either 
EIAV CTLA4-KDEL or EIAV IDO were subsequently rendered tolerogenic and had 
the capacity for donor-allospecific, Treg-mediated tolerance induction both in vitro and 
in vivo in a murine system. It was thus vital to ensure that pure populations of murine 
BM-derived DCs were generated in the lab with the capacity to induce allogeneic CD4+ 
T cell proliferation in a variety of functional assays (including mixed lymphocyte 
responses) that would be used throughout this study. 
3.3.1. Generation of CD11c+ Bone Marrow-Derived Dendritic Cells 
 
Protocols were thus developed to generate pure populations of murine DCs in vitro. BM 
cells obtained from BALB/c mice were cultured and differentiated in the presence of 
supernatant derived from a murine GM-CSF-producing hybridoma. The BM-derived 
cells were stimulated with LPS on day 7 for 16 hours to induce maturation. The cell 
surface expression of CD11c, CD80, CD86, MHC II (I-A, I-E), and ICOSL was 
analysed by flow cytometry for detection of both unstimulated/immature [Figure 21 top 
row] and LPS-stimulated/mature [Figure 21 bottom row] cells. Indicative of the 
immunophenotype of immature DCs, unstimulated cells expressed high levels of CD11c 
and MHC II (I-Ad), and low levels of the co-stimulatory markers CD80, CD86, and 
ICOSL. Furthermore, consistent with DC maturation, there was upregulation of the 
costimulatory markers CD80 and CD86 and constitutive expression of ICOSL after 
stimulation with LPS. 
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Figure 21. Generation of CD11c+ Bone Marrow-Derived Dendritic Cells. 
Bone marrow cells obtained from BALB/c mice were cultured and differentiated in the presence of 
supernatant derived from a murine GM-CSF-producing hybridoma. The bone marrow-derived cells were 
stimulated with LPS on day 7 for 16 hours to induce maturation. The cell surface expression of CD11c, 
CD80, CD86, MHC II (I-A, I-E), and ICOSL was analysed by flow cytometry for detection of both 
unstimulated/immature (top row) and LPS-stimulated/mature (bottom row) cells. 
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Figure 22. Purification of Murine Spleen-Derived CD4+ T Cells. 
CD4+ T cells were purified from the spleens of C3H/He mice by negative selection using magnetic beads. 
Purity of the CD4+ T cells was assessed by flow cytometry immediately after negative selection from the 
whole spleen cell population. Purified CD4+ T cells were analysed for cell surface expression of CD3, CD4, 
CD8, CD19, MHC II (I-A, I-E) and CD16/CD32. 
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3.3.2. Capacity of Dendritic Cells to Stimulate Allogeneic T Cells in a Mixed 
Lymphocyte Response 
 
Murine DCs generated in vitro (as demonstrated by immunophenotypic analysis in 
figure 21) were subsequently tested for their ability to induce proliferation of allogeneic 
CD4+ T cells in a functional MLR. CD4+ T cells were first purified from the spleens of 
C3H/He mice by negative selection using magnetic beads. Purity of the CD4+ T cells 
was assessed by flow cytometry immediately after negative selection from the whole 
spleen cell population. Purified CD4+ T cells were analysed for cell surface expression 
of CD3, CD4, CD8, CD19, MHC II (I-A, I-E) and CD16/CD32 [Figure 22]. Greater 
than 90% of the negatively-selected cells expressed both CD3 and CD4, consistent with 
the phenotype of a ‘helper’ CD4+ T cell population in addition to expressing negligible 
levels of the ‘cytotoxic’ T cell marker CD8, the B cell marker CD19, the APC marker 
MHC II and the CD16/32 (FcγRIII/ FcγRII). 
 
To assess the functional capacity of the in vitro-generated murine BALB/c-derived 
DCs, cultures were stimulated with LPS on day 7 of culture for 16 hours to induce 
maturation. Both unstimulated/immature and LPS-stimulated/mature DCs were 
subsequently tested for their ability to induce allogeneic T cell proliferation in an MLR. 
1x104 and 5x104 BALB/c (H-2d) DCs were incubated with complete MHC-disparate 
C3H/He (H-2k) CD4+ T cells at increasing ratios of DC : T cells. T cell proliferation 
was detected by thymidine incorporation on day 5 [Figure 23(a)] and day 6 [Figure 
23(b)] of the MLR. CD4+ T cells demonstrated significant clonal proliferation (a 
primary response) after both a 5-day and 6-day coculture with allogeneic BALB/c DCs 
that increased with the ratio of DCs : T cells, indicating the generation of functional 
murine CD11c+ DCs in vitro after culture of BM-derived cells in the presence of GM-
CSF. As a result of the robust CD4+ T cell response observed after 5 days of coculture, 
primary (one-stage) MLRs that were subsequently performed throughout this 
investigation with BALB/c-derived DCs as stimulators and C3H-derived CD4+ T cells 
as responders (with a 1:5 DC : T cell ratio), were harvested on day 5 subsequent to 
thymidine incorporation. 
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Figure 23. Capacity of Dendritic Cells to Stimulate Allogeneic CD4+ T Cells in a Mixed Lymphocyte 
Response. 
Murine BALB/c DCs were stimulated with LPS on day 7 of culture for 16 hours to induce maturation. Both 
unstimulated/immature and LPS-stimulated/mature DCs were subsequently tested for their ability to induce 
allogeneic T cell proliferation in an MLR. 1x104 and 5x104 BALB/c (H-2d) DCs were incubated with 
complete MHC-disparate C3H/He (H-2k) CD4+ T cells at increasing ratios of DC : T cells. T cell 
proliferation was detected by thymidine incorporation on (a) day 5 and (b) day 6 of the MLR. Results 
shown are the Mean ± SD of triplicate wells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Lentiviral Transduction Efficiency of Murine DCs and Multiplicity of Infection (MOI). 
Murine BALB/c DCs were transduced on day 6 with EIAV GFP and EIAV Mock at specific MOIs ranging 
from 0-350. 72 hours post-transduction, EIAV DC transduction efficiency was assessed by flow cytometry. 
Results are expressed as a percentage of DCs expressing GFP using a threshold based on DCs 
transduced with EIAV Mock. Results shown are the Mean ± SD of percentage values obtained from three 
separate experiments/occasions.N.B. Unless otherwise stated, a MOI of 300 (>90% transduction 
efficiency) was applied for all subsequent experiments where EIAV-based DC transduction is used for the 
modification of DCs with a mock protein (Mock), CTLA4-KDEL, or IDO. 
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3.4. Lentiviral Transduction Efficiency of Murine DCs and 
Multiplicity of Infection (MOI) 
 
In order to ensure consistency throughout all experiments requiring EIAV-based 
transduction of DCs, it was vital that an identical multiplicity of infection (MOI) value 
(corresponding to optimal DC transduction efficiency with EIAV) was used in all 
subsequent experiments. Murine BALB/c DCs were therefore transduced on day 6 with 
EIAV GFP at specific MOIs ranging from 0-350. 72 hours post-transduction, EIAV DC 
transduction efficiency was assessed by flow cytometry [Figure 24]. Results were 
expressed as the percentage of DCs expressing GFP using a threshold based on DCs 
transduced with EIAV Mock. The experiment was performed on five occasions with the 
mean and standard deviation being graphed. Using a MOI of 300, a DC transduction 
efficiency of greater than 90% was achieved. 
 
N.B. DCs were transduced at an MOI of 300 in all subsequent experiments (throughout 
the study) such that modified DCs expressed either a mock protein (Mock), CTLA4-
KDEL for the inhibition of surface CD80/86 expression, or IDO for the catabolism of 
tryptophan, equivalent to a transduction efficiency greater than 90% as assessed by GFP 
expression. 
 
3.5. Inhibition of Surface CD80/86 Expression after Lentiviral 
Transduction of DCs with CTLA4-KDEL 
 
Subsequent to the propagation of the lentiviruses generated at the beginning of the study 
(EIAV CTLA4-KDEL and EIAV IDO, in addition to EIAV GFP) and the generation of 
murine BM-derived DCs (as demonstrated in section 3.3), the effect of EIAV 
transduction on the immunophenotype of murine DCs was investigated. Murine 
BALB/c DCs were transduced on day 6 with EIAV Mock (IDO) or EIAV 
CTLA4-KDEL at MOI 300. Both transduced and untransduced DC populations were 
stimulated with LPS on day 7 of culture for 16 hours to induce maturation. Expression 
of the 20 kDa CTLA4-KDEL protein in the lysates of DCs was determined by western 
blotting 72 hours after transduction [Figure 25(a)]. The CTLA4-KDEL protein was 
detected using an antibody directed against the human c-myc tag incorporated in the  
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Figure 25. Inhibition of Surface CD80/86 Expression after Lentiviral Transduction of DCs with 
CTLA4-KDEL. 
Murine BALB/c DCs were transduced on day 6 with EIAV Mock or EIAV CTLA4-KDEL at MOI 300. Both 
transduced and untransduced DC populations were stimulated with LPS on day 7 of culture for 16 hours to 
induce maturation. (a) Expression of the 20 kDa CTLA4-KDEL protein in the lysates of DCs was 
determined by western blotting 72 hours after transduction. The CTLA4-KDEL protein was detected using 
an antibody against the human c-myc tag incorporated in the fusion protein. Expression of CTLA4-KDEL is 
shown relative to DC expression of the 42 kDa β-actin protein. (b) Histograms show EIAV DC transduction 
efficiency achieved at MOI 300 as assessed by flow cytometry (top histogram). Transduction efficiency 
was assessed by DC GFP expression after transduction with EIAV GFP (relative to transduction with EIAV 
Mock). The percentage of DCs undergoing either apoptosis or necrosis after EIAV CTLA4-KDEL 
transduction at MOI 300 was assessed relative to viable DCs by Annexin V staining (middle histogram) 
and 7-AAD staining (bottom histogram) respectively. (c) Histograms show the surface expression of CD80, 
CD86, ICOSL and CD40 on EIAV transduced DCs as assessed by flow cytometry 72 hours after EIAV 
transduction. 
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fusion protein. The 20 kDa c-myc-CTLA4-KDEL protein was detected only in DCs 
transduced with EIAV CTLA4-KDEL- predictably, the fusion protein was not 
expressed in DCs that were either untransduced or transduced with EIAV Mock. 
Expression of CTLA4-KDEL was detected relative to DC expression of the 42 kDa β-
actin housekeeping protein. As expected from optimisation experiments undertaken in 
section 3.4, flow cytometric analysis undertaken on DCs 72 hours after transduction 
with EIAV GFP at MOI 300 revealed a transduction efficiency greater than 90% 
[Figure 25(b)- top histogram]. Similar to the transduction events demonstrated in 
section 3.4, DC transduction efficiency was assessed by GFP expression after 
transduction with EIAV GFP (relative to transduction with EIAV Mock). The 
percentage of DCs undergoing either apoptosis or necrosis after transduction with EIAV 
CTLA4-KDEL at MOI 300 was assessed (relative to viable DCs) by flow cytometry 
using Annexin V staining [Figure 25(b)- middle histogram] and 7-AAD staining 
[Figure 25(b)- bottom histogram] respectively, and found to be negligible. DCs 
transduced with EIAV GFP were not used to determine the induction of apoptosis and 
necrosis due to the toxicity associated with GFP expression in DCs (72 hours after 
transduction). 
 
The effect of CTLA4-KDEL expression on DC immunophenotype was investigated by 
flow cytometry. FACS was used to analyse the surface expression of several markers, 
including CD80, CD86, ICOSL and CD40 on DCs 72 hours after transduction with 
EIAV [Figure 25(c)]. There was complete inhibition of surface CD80/86 expression in 
DCs transduced with EIAV CTLA4-KDEL relative to untransduced DCs. In contrast, 
DCs transduced with EIAV Mock expressed higher levels of CD80 relative to 
untransduced DCs. As expected, the expression of CD86 was considerably high on 
mature, untransduced DCs. Furthermore, transduction of DCs with EIAV CTLA4-
KDEL did not affect the expression of other surface markers as demonstrated by 
unchanged levels of ICOSL and CD40 relative to untransduced and EIAV Mock-
transduced DCs. In addition, there was no change in the expression of MHC II and 
CD11c in DCs transduced with EIAV CTLA4-KDEL (data not shown). The data thus 
demonstrates the specific inhibition of surface CD80/86 expression on DCs transduced 
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with EIAV CTLA4-KDEL due to retention of the costimulatory molecules within the 
ER. 
 
3.6. DC Expression of Functional IDO after Lentiviral Gene Transfer 
 
As discussed in section 1.13, a major aim of the study was to harness the 
immunosuppressive capacity of IDO and investigate whether lentiviral gene transfer of 
the enzyme into DCs renders the cells tolerogenic with the capacity for induction of 
donor-allospecific transplantation tolerance. It therefore had to be assessed from the 
outset whether transduction of DCs with EIAV IDO (generated after subcloning the 
murine IDO sequence into the pSMART2G lentiviral plasmid- described in section 
3.1.3) resulted in the expression of functional/active IDO by transduced DCs (and thus 
the catabolism of tryptophan into kynurenines). Murine BALB/c DCs were transduced 
on day 6 with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO at MOI 300. L-
tryptophan was added as a supplement to the culture media of DCs on day 6 to a final 
concentration of 245 µM, equivalent to 10x the original concentration (24.5 µM) in 
RPMI 1640. Tryptophan was supplemented due to catabolism of all the available 
tryptophan (at the original concentration of 24.5 µM) in preliminary experiments 
undertaken with IDO-expressing DCs. Untransduced, immature DCs were stimulated on 
day 7 with either IFNγ (60 ng/ml) or treated with CTLA4-Ig (10, 50 and 100 µg/ml) for 
the induction of DC IDO expression. Both transduced, untransduced, IFNγ- and 
CTLA4-Ig-treated DCs were subsequently stimulated with LPS on day 8 of culture for 
16 hours to induce maturation. 
 
Expression of the 45 kDa IDO protein in the lysates of DCs was determined by western 
blotting using an antibody directed against murine IDO (72 hours after EIAV 
transduction or 48 hours after treatment with IFNγ or 50 µg/ml CTLA4-Ig. Expression 
of IDO was detected relative to expression of the 42 kDa β-actin housekeeping protein. 
The 45 kDa IDO protein was detected in DCs transduced with EIAV IDO, in contrast to 
untransduced DCs and DCs transduced with either EIAV Mock or EIAV CTLA-KDEL. 
As a positive control for the antibody, murine placental lysate was probed and 
expressed the protein as expected (syncytiotrophoblastic cells are the source of placental 
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IDO, as described in section 1.8 and 1.9) [Figure 26(a)]. The IDO protein was also 
detected in DCs treated with IFNγ or CTLA4-Ig, relative to untransduced DCs 
[Figure 26(b)]. 
 
DCs transduced with EIAV or treated with either IFNγ or CTLA4-Ig were also 
harvested on day 9 for real-time PCR analysis to assess for IDO mRNA expression 
[Figure 26(c)]. IDO mRNA copy numbers were normalised to those of HPRT to correct 
for errors arising from cellular RNA extraction/purification and reverse transcription in 
vitro. As expected from western blot observations, DCs transduced with EIAV IDO 
expressed markedly elevated levels of IDO mRNA (relaive to HPRT expression) 
compared to DCs that were untransduced or expressed either a mock protein or CTLA4-
KDEL subsequent to EIAV transduction. Elevated levels of IDO mRNA were also 
detected in DCs stimulated with 60 ng/ml IFNγ (though the detection was not as marked 
as levels achieved with DCs transduced with EIAV IDO), which supports earlier studies 
demonstrating IFNγ as a potent inducer of IDO expression. DCs stimulated with 
increasing concentrations of CTLA4-Ig (10, 50 and 100 µg/ml) also expressed 
considerably increased levels of IDO mRNA relative to DCs that were unstimulated. 
 
IDO activity was assessed by an L-kynurenine assay on DC culture supernatants that 
were either supplemented with tryptophan as described above, or unsupplemented 
[Figure 26(d)]. Substantially increased activity of IDO was detected in DCs transduced 
with EIAV IDO relative to DCs transduced with EIAV Mock, as demonstrated by the 
increased concentration of L-kynurenine in the culture medium of the DCs 72 hours 
after transduction. The concentration of L-kynurenine in the medium of EIAV IDO-
transduced DCs was considerably enhanced when the culture medium was 
supplemented with tryptophan. A significant increase in the activity of IDO was not 
observed with this assay in DCs transduced with EIAV Mock or EIAV CTLA4-KDEL. 
An interesting feature of these results is the lack of correlation in the upregulation of 
IDO mRNA expression as detected by real-time PCR and the associated increase in 
L-kynurenine concentration in the medium of DCs that were either treated with IFNγ or 
increasing concentrations of CTLA4-Ig. This suggests that although IDO expression is  
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Figure 26. DC Expression of Functional IDO after Lentiviral Gene Transfer. 
Murine BALB/c DCs were transduced on day 6 with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO at MOI 
300. L-tryptophan was added as a supplement to the culture media of DCs on day 6 to a final 
concentration of 245 µM, equivalent to 10x the original concentration (24.5 µM) in RPMI 1640. 
Untransduced, immature DCs were stimulated on day 7 with either IFN-γ (60 ng/ml) or treated with 
CTLA4-Ig (10, 50 and 100 µg/ml) for the induction of DC IDO expression. Both untransduced, transduced, 
IFN-γ- and CTLA4-Ig-treated DCs were subsequently stimulated with LPS on day 8 of culture for 16 hours 
to induce maturation. Expression of the 45 kDa IDO protein in the lysates of DCs was determined by 
western blotting 72 hours after (a) transduction with EIAV or (b) treatment with IFN-γ and 50 µg/ml 
CTLA4-Ig using an antibody directed against murine IDO. Expression of IDO is shown relative to DC 
expression of the 42 kDa β-actin housekeeping protein. (c) DCs were harvested on day 9 for real-time 
PCR analysis to assess for IDO mRNA expression. IDO mRNA copy numbers were normalised to those of 
HPRT to correct for errors arising from cellular RNA extraction/purification and reverse transcription in 
vitro. (d) IDO activity was assessed by a kynurenine assay on DC culture supernatants that were either 
supplemented with tryptophan as described above, or unsupplemented. Results shown are the Mean ± SD 
of triplicate wells. 
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upregulated in these conditions, it is not necessarily associated with a linear increase in 
IDO activity. 
 
Since incubation of DCs with CTLA4-Ig has been demonstrated to induce expression of 
IDO via ligation of surface CD80/86 (Grohmann et al., 2002), it was necessary to 
investigate whether the intracellular ligation of CD80/86 within the ER by CTLA4-
KDEL also induced the expression of IDO. This is because the sequence of the 
extracellular domain of CTLA4 in the murine CTLA4-KDEL construct was taken from 
the corresponding sequence in the murine CTLA4-Ig/Fc chimera (see section 2.2). 
However, experiments undertaken in this section showing a lack of IDO mRNA and 
protein expression (as assessed by real-time PCR and western blotting respectively) in 
DCs transduced with EIAV CTLA4-KDEL (relative to DCs transduced with EIAV 
Mock) demonstrate that the intracellular ligation of CD80/86 within the ER does not 
lead to the upregulation of IDO. The L-kynurenine assay undertaken also demonstrates 
a lack of functional IDO expression (as shown by negligible concentrations of L-
kynurenine in the supernatants of DCs) in CTLA4-KDEL-expressing DCs. The results 
described here therefore demonstrate (considerably) elevated levels of IDO expression 
in murine DCs after transduction with EIAV IDO generated in the lab, as observed by 
real-time PCR for mRNA detection and western blot analysis for protein detection, and 
that this IDO is functionally active due to the elevated levels of L-kynurenine detected 
in culture supernatant. 
 
3.7. Lentiviral Transduction of DCs and Cellular Stress Pathways 
 
Eukaryotic Initiation Factor 2 (eIF2) is a protein that is ubiquitously expressed in many 
cell types. The protein is composed of three subunits (α, β and γ) and is one of the key 
molecules in the initiation of mRNA translation. eIF2 binds GTP and Met-tRNAi and 
transfers Met-tRNA to the 40S subunit to form the 43S preinitiation complex (de Haro 
et al., 1996; Kimball, 1999). For eIF2 to promote a new round of translation initiation, 
GDP must be exchanged for GTP, a reaction catalysed by eIF2β. In mammalian cells, 
stress induces the alpha subunit of eIF2 to be phosphorylated at serine 51 by at least 
three kinases: the double-stranded RNA-dependent protein kinase (PKR) and PERK 
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(both described below), in addition to GCN2 (activated by amino acid starvation) 
[Figure 27(a-b)]. Phosphorylation of eIF2α stabilises the eIF2-GDP-eIF2β complex, 
inhibiting the turnover of eIF2β, leading to inhibition of protein synthesis, growth 
suppression and apoptosis induction. The phosphorylation of eIF2α is an important 
regulatory process in protein synthesis. Stress provoked by depletion of endoplasmic 
reticulum calcium levels induces potent phosphorylation of eIF2α (Kaufman, 1999; 
Sheikh and Fornace, 1999). The expression of both the unphosphorylated and 
phosphorylated/active form of eIF2α was investigated by western blotting in DCs 
transduced with EIAV [Figure 27(c)]. DCs transduced with EIAV Mock, EIAV 
CTLA4-KDEL and EIAV IDO all expressed eIF2α and phosphorylated eIF2α (both 
38 kDa), and were thus expressing a marker indicative of cellular stress. However, the 
expression of the activated form of eIF2α was also expressed by untransduced DCs in 
addition to the virally-transduced populations. This may be explained by the fact that 
primary BM-derived DCs are terminally differentiated cells and have a limited lifespan 
[no longer than 12-15 days- antigen uptake, processing and presentation are suboptimal 
after day 9 (Ardavin, 2003)]. DCs were lysed for western blotting on day 9 of culture 
(72 hours subsequent to EIAV transduction), a late stage in the life of a DC at which 
point cellular stress pathways are likely to be activated. 
 
PERK is a type I transmembrane protein resident in the ER membrane and couples ER 
stress signals to translation initiation. ER stress increases the activity of PERK, which 
then phosphorylates eIF2α as described above. PERK activation during ER stress 
correlates with autophosphorylation of its cytoplasmic kinase domain. Phosphorylation 
of PERK at Thr980 can serve as a marker for its activation status (Shi et al., 1998; 
Harding et al., 1999; Harding et al., 2000b). Induction of the protein CHOP is induced 
by certain cellular stresses including starvation and the induced CHOP suppresses cell 
cycle progression from G1 to S phase (Barone et al., 1994). During ER stress, the level 
of CHOP expression is elevated and CHOP functions to mediate programmed cell death 
[Figure 27(a)] (Zinszner et al., 1998). In order to investigate whether the intracellular 
retention of CD80/86 within the ER subsequent to DC expression of CTLA4-KDEL 
upregulated the expression of the activated/phosphorylated form of PERK, DCs 
transduced with CTLA4-KDEL (amongst other DC populations) were lysed and the  
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Figure 27. Lentiviral Transduction of DCs and Cellular Stress Pathways. 
(a-b) The Eukaryotic initiation factor 2 (eIF2) protein is composed of three subunits (α, β and γ) and is one 
of the key molecules in the initiation of translation. For eIF2 to promote a new round of translation initiation, 
GDP must be exchanged for GTP, a reaction catalysed by eIF2β. Kinases activated by viral infection 
[double-stranded RNA-dependent protein kinase (PKR)], ER stress (PERK), amino acid deprivation 
(GCN2) and hemin deficiency (HRI) can phophorylate eIF2α. This phosphorylation stabilises the eIF2-
GDP-eIF2β complex (thus blocking the GDP-GTP exchange activity of eIF2β) and inhibits the turnover of 
eIF2β, leading to inhibition of protein synthesis, growth suppression, and apoptosis induction. PERK, an 
eIF2α kinase, is a type I transmembrane protein resident in the endoplasmic reticulum (ER) membrane 
and couples ER stress signals to translation initiation (ER stress increases the activity of PERK, which 
then phosphorylates eIF2α, resulting in reduced translation). PERK activation during ER stress correlates 
with autophosphorylation of its cytoplasmic domain. CHOP expression is induced by certain cellular 
stresses. During ER stress, the level of CHOP expression is elevated and CHOP functions to mediate 
programmed cell death. The role of CHOP in the programmed cell death of ER-stressed cells is correlated 
with its role promoting protein synthesis and oxidative stress inside the ER. BALB/c DCs were transduced 
either with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO. (c) Expression of the 38 kDa eIF2α protein and 
phosphorylated eIF2α (pS51) protein, (d) 125 kDa PERK protein and 170 kDa phosphorylated PERK 
(pT980) protein, and (e) 68 kDa PKR and phosphorylated PKR (pT451) protein, in the lysates of both 
transduced and untransduced DCs (relative to DC expression of the 42 kDa β-actin protein) was assessed 
by western blotting 72 hours after EIAV DC transduction. 
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expression of PERK and p-PERK analysed by western blotting [Figure 27(d)]. p-PERK 
was not expressed in CTLA4-KDEL-transduced DCs, confirming that the ER-retention 
of CD80/86 does not lead to ER stress and subsequent eIF2α activation. Thapsigargin-
treated DCs were used as a positive control for phosphorylated-PERK expression. 
Thapsigargin is a potent, cell-permeable, IP3-independent intracellular calcium releaser. 
It blocks the transient increase in intracellular Ca2+ induced by angiostatin and 
endostatin, and induces apoptosis by disrupting intracellular free Ca2+ levels (Treiman et 
al., 1998). Tunicamycin-treated DCs were also used as a positive control. Tunicamycin 
blocks the formation of protein N-glycosidic linkages by inhibiting the transfer of N-
acetylglucosamine 1−phosphate to dolichol monophosphate, thus causing an unfolded 
protein response, ER stress and p-PERK expression. 
 
PKR is a protein that is induced by IFN and double-stranded RNAs (dsRNAs) produced 
in virus-infected cells (Icely et al., 1991; Pataer et al., 2002). PKR in earlier literature is 
variously known as DAI, dsJ, PI kinase, p65, p67 or TIK for the mouse kinase; and p68 
or p69 for the human kinase. Two dsRNA-binding domains in the N-terminus allow it 
to undergo autophosphorylation and activation (Zhang et al., 2001). Once activated, 
PKR phophorylates the α subunit of eIF-2, leading to inhibition of protein synthesis, 
growth suppression and apoptosis induction (McCormack et al., 1992; Srivastava et al., 
1998; Vorburger et al., 2002). The phosphorylation of two sites in the activation loop of 
the kinase domain, threonines 446 and 451 is critical for high-level catalytic activity. 
The expression of the activated/phosphorylated form of PKR was investigated in EIAV-
transduced DCs by western blotting [Figure 27(e)]. Transduction of DCs with EIAV 
did not lead to upregulated p-PKR expression. This was expected as EIAV is a single-
stranded (+) RNA virus. Double-stranded RNA is not produced subsequent to lentivirus 
entry into a cell and the (+) sense RNA can directly be used as a template for reverse 
transcription. For western blotting, polyinosinic–polycytidylic acid (poly-IC)-treated 
DCs were used as a positive control for PKR expression. poly-IC is a double-stranded 
homopolymer that mimics double-stranded RNAs and thus leads to phosphorylated 
PKR expression. 
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3.8. Inhibition of Allogeneic T Cell Proliferation after DC Expression 
of CTLA4-KDEL or IDO 
 
A simple (one-stage) MLR was carried out to investigate whether murine DCs 
transduced with EIAV CTLA4-KDEL or EIAV IDO (in comparison to DCs transduced 
with EIAV Mock, treated with the glucocorticoid dexamethasone or stimulated with the 
IDO-inducible pro-inflammatory cytokine IFNγ) acquire the capacity to stimulate the 
proliferation of allogeneic CD4+ T cells. Murine BALB/c (H-2d) DCs were treated on 
day 6 with dexamethasone or transduced with EIAV Mock, EIAV CTLA4-KDEL or 
EIAV IDO at MOI 300. Untransduced, immature DCs were stimulated on day 7 with 
60 ng/ml IFNγ for 48 hours to induce IDO expression. All populations of DCs (except a 
specified ‘unstimulated’ population and one population treated with dexamethasone 
only) were subsequently stimulated with LPS on day 8 of culture for 16 hours to induce 
maturation. All DC populations were cocultured on day 9 with fully MHC-disparate 
spleen-derived C3H/He (H-2k) CD4+ T cells at a ratio of 1:5 DC : T cells. In order to 
demonstrate any effects resulting from DC expression of IDO, 250 µM 1-methyl-D,L-
tryptophan (1-MT), in combination with excess tryptophan, was added to the medium at 
the start of coculture. Proliferation of CD4+ T cells was detected by thymidine 
incorporation on day 5 of the MLR [Figure 28(a)]. 
 
Thymidine incorporation detected in the MLR demonstrated that DCs transduced with 
either EIAV CTLA4-KDEL or EIAV IDO do not retain the capacity to induce and/or 
sustain the proliferation of allogeneic CD4+ T cells in an MLR. This was in contrast to 
MLRs in which DCs were either untransduced or transduced with EIAV Mock (both 
populations of DCs induced considerable CD4+ T cell proliferation). The inhibition of 
allogeneic CD4+ T cell proliferation by IDO-expressing DCs (subsequent to EIAV 
transduction) was specifically due to the functional activity of the enzyme, as 
demonstrated by the restoration (considerable but not complete) of proliferation with the 
addition of 1-MT to the MLR cultures (P<0.005). IFNγ-stimulated DCs demonstrated a 
reduced capacity to stimulate allogeneic T cell proliferation that was also mediated by 
the expression of IDO, as shown by restoration of proliferation with the addition of 
1-MT to the MLR cultures. 
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Figure 28. Inhibition of Allogeneic T Cell Proliferation after DC Expression of CTLA4-KDEL or IDO. 
(a) Murine BALB/c (H-2d) DCs were treated on day 6 with dexamethasone (DEX) or transduced with EIAV 
Mock, EIAV CTLA4-KDEL or EIAV IDO at MOI 300. Untransduced, immature DCs were stimulated on day 
7 with 60 ng/ml IFN-γ for 48 hours to induce IDO expression. All populations of DCs (except a specified 
‘unstimulated’ DC population and one treated with dexamethasone only) were subsequently stimulated 
with LPS on day 8 of culture for 16 hours to induce maturation. All DC populations were cocultured on day 
9 with fully MHC-disparate spleen-derived C3H/He (H-2k) CD4+ T cells at a ratio of 1:5 DC : T cells. In 
order to demonstrate any effects resulting from DC expression of IDO, 250 µM 1-methyl-D,L-tryptophan (1-
MT), in combination with excess tryptophan, was added to the medium at the start of coculture. 
Proliferation of CD4+ T cells was detected by thymidine incorporation on day 5 of the MLR. (b) Murine 
BALB/c DCs were treated on day 7 with increasing concentrations of CTLA4-Ig (10, 50 and 100 µg/ml). 
The DC populations were cocultured 48 hours later with fully MHC-disparate C3H/He CD4+ T cells in the 
presence and absence 250 µM 1-MT, in combination with excess tryptophan. Proliferation of CD4+ T cells 
was detected by thymidine incorporation on day 5 of the MLR. (c) Murine BALB/c DCs were transduced on 
day 6 with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO at MOI 300. Increasing numbers of both 
transduced and untransduced DC populations (0-105) were cocultured with C3H CD4+ T cells. Proliferation 
of T cells was detected by thymidine incorporation on day 5 of the MLR. (*, # : P<0.005). All results shown 
are the Mean ± SD of triplicate wells and are representative of three independent experiments. 
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As discussed earlier, since incubation of DCs with CTLA4-Ig has been demonstrated to 
induce expression of IDO via ligation of surface CD80/86 (Grohmann et al., 2002) (see 
below), it was also investigated in this MLR, similar to experiments undertaken in 
section 3.6 with real-time PCR, western blotting and an L-kynurenine assay, whether 
ligation of CD80/86 within the ER by CTLA4-KDEL has an identical effect of inducing 
the expression of IDO, i.e. whether the inhibition of CD4+ T cell proliferation by 
CTLA4-KDEL-expressing DCs is dependent or independent of IDO expression. The 
reason for this is because, as explained in section 2.2, the sequence of the extracellular 
domain of CTLA4 in the murine CTLA4-KDEL construct was taken from the 
corresponding sequence in the murine CTLA4-Ig/Fc chimera. As described above, 
1-MT was added to block the activity of IDO (thus preventing the catabolism of 
tryptophan). It was demonstrated by the addition of 1-MT to MLR cultures that a 
considerable restoration of proliferation was observed only in MLR cultures in which 
DCs were transduced with EIAV IDO, as opposed to EIAV CTLA4-KDEL or EIAV 
mock. This suggests that the inhibition of CD4+ T cell proliferation observed after 
coculture with CTLA-KDEL expressing DC cultures does not result from the depletion 
of tryptophan as a result of IDO activity. The reversal of proliferation observed after the 
addition of 1-MT to MLR cultures in which CD4+ T cells were exposed to allogeneic 
EIAV IDO-transduced DCs does, however, demonstrate the expression of functional 
IDO. Findings from the one-stage MLR also demonstrate a considerable reduction in 
the proliferation of allogeneic CD4+ T cells when cocultured with dexamethasone-
treated DCs, but only in the absence of LPS stimulation. DCs incubated with 
dexamethasone and subsequently treated with LPS (prior to coculture with T cells) 
resulted in a minor, though statistically significant (P<0.05), reduction in allogeneic 
CD4+ T cell proliferation. 
 
As discussed earlier, it is known that by ligating CD80/86 on the DC surface, 
CTLA4-Ig has the dual effect of both costimulation blockade and the induction of IDO 
expression. This dual role of IDO was investigated further using increasing 
concentrations of CTLA4-Ig. Murine BALB/c DCs were treated on day 7 with 
increasing concentrations of CTLA4-Ig (10, 50 and 100 µg/ml). The DC populations 
were cocultured 48 hours later with fully MHC-disparate C3H/He CD4+ T cells in the 
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presence or absence of 250 µM 1-MT, in combination with excess tryptophan. 
Proliferation of CD4+ T cells was detected by thymidine incorporation on day 5 of the 
MLR [Figure 28(b)]. It was observed that high concentrations (at least 100 µg/ml) of 
CTLA4-Ig inhibited the MLR in both the presence and absence of 1-MT, whereas lower 
concentrations of CTLA4-Ig (10 and 50 µg/ml) only inhibited the MLR (completely) in 
the absence of 1-MT (P<0.005). Reversal of the MLR with the addition of 1-MT at the 
lower concentrations of CTLA4-Ig was only partial, indicating that costimulation 
blockade did have an effect on allogeneic CD4+ T cell proliferation. Inhibition of the 
MLR at the lower concentrations of CTLA4-Ig was expected as this fusion protein did 
not block costimulation adequately but did lead to the induction of IDO (see section 
3.6), whereas the high concentration (100 µg/ml) of CTLA4-Ig used in the MLR 
resulted in the expression of IDO in addition to total costimulation blockade (which is 
IDO independent). 
 
After demonstrating that CTLA4-KDEL- or IDO-expressing DCs do not have the 
capacity to induce and/or sustain the proliferation of allogeneic CD4+ T cell 
proliferation after coculture in a MLR (described above), a DC dose-response MLR was 
undertaken to investigate the effect of increasing numbers of DCs (either untransduced 
or transduced) on allogeneic CD4+ T cell proliferation. Murine BALB/c DCs were 
transduced on day 6 with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO at MOI 
300. Increasing numbers of both transduced and untransduced DC populations (0-105) 
were cocultured with C3H CD4+ T cells. Similar to previous experiments, in order to 
demonstrate any effects resulting from DC expression of IDO, 250 µM 1-MT, in 
combination with excess tryptophan, was added to the medium at the start of coculture. 
Proliferation of T cells was detected by thymidine incorporation on day 5 of the MLR 
[Figure 28(c)]. Following on from the results of the MLR shown in figure 28(a), 
thymidine incorporation counts from the DC dose-response MLR demonstrate a 
continuous inhibition of CD4+ T cell proliferation in the presence of increasing numbers 
of allogeneic DCs expressing either CTLA4-KDEL- or IDO-expressing DCs, in 
comparison to untransduced or mock protein-expressing DCs which induced CD4+ T 
cell proliferation in a dose-dependent manner. The addition of 1-MT to cultures 
containing EIAV IDO-transduced DCs resulted in the restoration (considerable but not 
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complete) of proliferation, suggesting that the inhibition of CD4+ T cell proliferation in 
IDO-expressing DC cultures resulted specifically from the depletion of tryptophan by 
the functional enzyme. Additionally, T cell proliferation was not restored with the 
addition of 1-MT to MLR cultures in which DCs were transduced with EIAV 
CTLA4-KDEL [Figure 28(a)], indicating that the functional effect of CTLA4-KDEL is 
independent of IDO and is due to inhibition of surface CD80/86 expression. 
 
3.9. Cell Cycle Arrest in T cells Cocultured with CTLA4-KDEL- or 
IDO-Transduced DCs 
 
Several models have postulated the existence of anergy-specific signals in T cells. The 
more tenable model is that unresponsiveness results from an incomplete array of 
activation signals, or a subthreshold effect. The most direct model of anergy induction 
proposes that the central gap is the failure to activate mediators of the cell cycle for 
progression from the G1 to S phase. It has been observed in the murine system that the 
induction of anergy (or its stimulus) results in a considerable and sustained increase in T 
cells in the G1 phase of the cell cycle, whereas productive stimulation causes induced 
cells to enter G1 after 12-16 hours, enter S phase by 18-24 hours and reach G2-M after 
48-72 hours (Gilbert and Weigle, 1993; Boussiotis et al., 2000). 
 
Cell cycling is a complex process with many participants that promote or inhibit 
different stages of the cycle [Figure 29(a)]. Central to the cell cycling are the Cdks, 
whose activities are positively regulated by binding to the cyclins. In resting cells, G1 
Cdks are relatively inactive because of the abundance of cyclin-Cdk2 inhibitors such as 
p27Kip1, which ensure that cell cycling is not triggered without a proper signal. The 
inhibitor p27Kip1 (which belongs to the Cip/Kip family of Cdk inhibitors) binds and 
inhibits cyclin E-Cdk2 complexes in late G1 phase. The irreversible progression of a 
cell to S phase entry occurs at the G1 restriction point and is characterised by activation 
of Cdk2 and synthesis of cyclin E (Sherr and Roberts, 1995). Cyclins E and A 
sequentially activate Cdk2 near the start of S phase, a process thought to be necessary 
for the initiation of DNA replication. The active cyclin E-Cdk2 holoenzyme mediates 
phosphorylation of the p27Kip1 Cdk inhibitor, which facilitates its ubiquitination and 
degradation (Vlach et al., 1997), and modifies components of the pre-initiation  
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Figure 29. Cell Cycle Arrest in T cells Cocultured with CTLA4-KDEL- or IDO-Transduced DCs. 
(a) Regulation of the cell cycle. Cells progress from G0 or G1 to S (DNA synthesis), G2 and mitosis. Cyclin 
E-Cdk2 complexes drive the transition from G1 to S, whereas cyclin A-Cdk2 and cyclin A-cyclin B-Cdk2 
complexes are involved in S and G2, respectively. The inhibitor p27Kip1 binds and inhibits cyclin E-Cdk2 
kinase, whereas Cdk2 can phosphorylate the serine at position 212 of Smad 3 (pS-212) and inhibit its 
transcription activity. Smad 3 increases p15 (Cdk2 inhibitor 2B) and inhibits IL-2 production (necessary for 
T cell proliferation). (b) A model has been proposed in which anergy and in vivo tolerance is induced by 
p27Kip1 binding and the inhibition of cyclin E-Cdk2 complexes, which leads to reduced inhibitory 
phosphorylation of Smad3. This results in increased Smad3 activity, increased p15 expression and 
inhibition of IL-2 production. Conversely, proliferation and clonal expansion results from a loss of p27Kip1 
expression and/or binding to cyclin E-Cdk2, leading to inhibitory phosphorylation of Smad3 and a reduction 
in p15 and upregulation of IL-2 production. BALB/c DCs were transduced either with EIAV Mock, EIAV 
CTLA4-KDEL or EIAV IDO, followed by stimulation with LPS. The transduced (and untransduced) DCs 
were subsequently incubated in vitro with C3H/He-derived CD4+ T cells (at a 1:10 DC : T cell ratio). (c) 
Expression of the 52 kDa Cyclin E protein in the lysates of CD4+ T cells incubated with both the 
transduced and untransduced DCs (relative to T cell expression of the 42 kDa β-actin protein) was 
determined by western blotting on day 4 of coculture. Expression of the p27Kip1 protein in the lysates of T 
cells (relative to T cell expression of the β-actin protein) was assessed by western blotting on both (d) day 
4 and (e) day 7 of coculture. 
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complexes to trigger DNA replication. Activated cyclin E-Cdk2 acts in synergy with D 
cyclins and their associated Cdk4 and Cdk6 molecules to phosphorylate Rb. Elevated 
p27 binds and inactivates cyclin D-Cdk4, 6 and cyclin E-Cdk2 complexes in a 
stoichiometric fashion, resulting in hypophosphorylation of pRB and subsequent cell 
cycle arrest (Stewart and Pietenpol, 2001). 
 
T cell proliferation is accompanied by downregulation of p27Kip1, resulting in increased 
Cdk-mediated phosphorylation of transcription factors Smad2 and Smad3 and the 
retinoblastoma (Rb) protein, leading to S-phase entry (Gan et al., 1997). 
Phosphorylation of Smad2 and Smad3 inhibits their transcriptional activity and 
antiproliferative effects. That antiproliferative function is partially mediated by 
increased transcription of the Cdk inhibitor p15. A recent study has documented a 
pathway involving p27Kip1 in the inhibition of Cdk2 and the maintenance of 
transcription Smad3 activity for the induction of in vivo tolerance (Li et al., 2006). The 
authors show that T cells tolerised by in vivo blockade of CD28 and CD40 have 
impaired Cdk2 kinase activity and consequently fail to phosphorylate the serine at 
position 212 of Smad 3 [Figure 29(b)]. Given the information on p27Kip1 and other 
inhibitors of the G1-to-S transition, these proteins have been viewed as prime potential 
effectors of anergy. Suboptimal activation with costimulatory-deficient APCs 
concurrently fails to downregulate p27Kip1 and induces anergy. CD28 and IL-2 both 
downregulate p27Kip1, allowing for Cdk activation. Furthermore, p27Kip1-deficient T 
cells are essentially resistant to anergy induction (Rowell et al., 2005). Conversely, 
forced upregulation of p27Kip1 induces both in vitro anergy and in vivo tolerance 
(Boussiotis et al., 2000), that may operate after the first cell division. 
 
The expression of cyclin E by T cells incubated with EIAV-transduced DCs used in this 
study was investigated [Figure 29(c)]. BALB/c DCs were transduced either with EIAV 
Mock, EIAV CTLA4-KDEL or EIAV IDO, followed by stimulation with LPS. The 
transduced (and untransduced) DCs were subsequently incubated in vitro with C3H/He-
derived CD4+ T cells. Whereas expression of the 52 kDa Cyclin E protein was not 
detected in the lysates of resting CD4+ T cells (T cells not cocultured with DCs), the 
protein was upregulated significantly in T cells cocultured with untransduced and EIAV 
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Mock-transduced DCs (relative to T cell expression of the 42 kDa β-actin housekeeping 
protein). More importantly, there was no induction of cyclin E synthesis in T cells 
cocultured with CTLA4-KDEL-transduced DCs. Additionally, T cells incubated with 
IDO-transduced DCs had minimal expression of cyclin E. Therefore, T cells incubated 
with CTLA4-KDEL-expressing DCs (and the majority of cells incubated with IDO-
transduced DCs) fail to progress through the restriction point into late G1 and are thus 
arrested at earlier stages of the G1 phase. 
 
Similar to cyclin E, the role of the inhibitor p27Kip1 was investigated in DCs transduced 
with EIAV CTLA4-KDEL and IDO [Figure 29(d)]. Incubation of T cells with CTLA4-
KDEL- and IDO-expressing DCs induced T cell expression p27Kip1 in contrast to 
untransduced and mock DCs (there was considerably enhanced levels of p27Kip1 in T 
cells incubated with CTLA4-KDEL DCs) which indicates an active mechanism 
responsible for upregulation of p27Kip1 during induction of anergy in these two 
populations of alloreactive T cells. Furthermore, it is of interest that p27Kip1 was 
expressed in T cells cocultured with CTLA4-KDEL- and IDO-expressing DCs during 
the active phase of clonal proliferation of T cells cocultured with allogeneic DCs on day 
4 of coculture. In contrast, by day 7 of coculture when most cells have completed the 
primary phase of clonal proliferation to an allogeneic stimulus and are subsequently in  
‘rest’ or the G1 phase, all T cells cocultured with the four populations of DCs expressed 
the p27Kip1 inhibitor [Figure 29(e)]. 
 
3.10. Two-Stage MLRs (Rechallenge Assays): Establishment of 
Kinetics for Primary vs. Secondary Responses 
 
In order to demonstrate the induction of donor-specific anergy and regulation, a range of 
functional T cell assays were used throughout the investigation. Most importantly, a 
two-stage DC : T cell MLR, or rechallenge assay, was widely to investigate whether T 
cells that encounter alloreactive CTLA4-KDEL- or IDO-expressing DCs (resulting from 
EIAV-based gene transfer) are subsequently rendered anergic and demonstrate donor 
allospecificity. In order to assess donor allospecificity, T cells that encountered 
alloreactive modified/transduced DCs either in vitro in a primary MLR or in vivo
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injection of allogeneic DC populations into mice were subsequently ‘rechallenged’ in 
vitro with both donor-derived and third-party DCs as detailed below. 
3.10.1. Optimisation of Rechallenge Assays for the Detection of in vitro- and in vivo-
Generated Allogeneic T Cell Responses 
 
Two-stage MLRs (rechallenge assays) were developed and optimised in order to detect 
donor-specific allogeneic T cell responses following a primary in vitro- or in vivo-
generated T cell response. The rechallenge assays were then used for the subsequent 
detection (throughout the study) of donor-specific anergy induced either in vitro- or in 
vivo as explained above.  Rechallenge assays were optimised from established protocols 
originally designed for this purpose: to investigate the induction of anergy both in vitro 
(Schwartz, 1990; Marelli-Berg et al., 1999; Tan et al., 2005c) and in vivo (Schwartz, 
1990; Mirenda et al., 2004; Mirenda et al., 2005). Thus, for the detection of an 
allogeneic T cell response following a primary MLR, murine BALB/c (H-2d) DCs were 
incubated in vitro with fully MHC-disparate C3H/He (H-2k)-derived CD4+ T cells (at a 
1:10 DC : T cell ratio). After 10 days, the T cells were harvested and rechallenged in 
vitro (at a 1:2 DC : T cell ratio) with donor BALB/c DCs [Figure 30(a)] or third-party 
C57BL/6 (H-2b) DCs [Figure 30(b)], and proliferation assessed by thymidine 
incorporation on days 3, 5 and 7. Harvesting of the assay was optimised such that 
rechallenge of CD4+ T cells in vitro with donor-derived DCs resulted in the kinetics of 
a secondary (memory) response with highest T cell proliferation on day 3, whereas 
rechallenge with third-party C57BL/6 DCs resulted in the kinetics of a primary response 
with highest T cell proliferation on day 5. This rechallenge assay was subsequently 
adapted to measure responses following a primary stimulation/challenge of T cells in 
vivo. 2.5x106 BALB/c DCs were injected intravenously into C3H/He mice. After 10 
days, spleen-purified CD4+ T cells from the injected mice were rechallenged in vitro (at 
a 1:10 DC : T cell ratio) with donor BALB/c DCs [Figure 30(c)] or third-party 
C57BL/6 DCs [Figure 30(d)], and proliferation assessed by thymidine incorporation on 
days 3, 5 and 7. Similar to the rechallenge assay used after a primary DC : CD4+ T cell 
MLR, a rechallenge assay was also utilised after primary exposure in vivo of CD4+ T 
cells to i.v.-injected DCs. The rechallenge assay was optimised such that rechallenge of 
CD4+ T cells in vitro with donor-derived DCs resulted in the kinetics of a secondary  
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Figure 30. Optimisation of Rechallenge Assays for the Detection of in vitro- and in vivo-Generated 
Allogeneic T Cell Responses. 
Two-stage DC : T cell MLRs (rechallenge assays) were developed in order to detect donor-specific 
allogeneic T cell responses following a primary in vitro- or in vivo-generated T cell response. The 
rechallenge assays would then be applied for the subsequent detection (throughout the study) of donor-
specific anergy induced either in vitro- or in vivo.  For the detection of an allogeneic T cell response 
following a primary challenge in vitro, murine BALB/c (H-2d) DCs were incubated in vitro with fully MHC-
disparate C3H/He (H-2k)-derived CD4+ T cells (at a 1:10 DC : T cell ratio). After 10 days, the T cells were 
harvested and rechallenged in vitro (at a 1:2 DC : T cell ratio) with (a) donor BALB/c DCs or (b) third-party 
C57BL/6 (H-2b) DCs, and proliferation assessed by thymidine incorporation on days 3, 5 and 7. This 
rechallenge assay was subsequently adapted to measure responses following primary stimulation of T 
cells in vivo. 2.5x106 BALB/c DCs were injected intravenously into C3H/He mice. After 10 days, spleen-
purified CD4+ T cells from the injected mice were rechallenged in vitro (at a 1:10 DC : T cell ratio) with (c) 
donor BALB/c DCs or (d) third-party C57BL/6 DCs, and proliferation assessed by thymidine incorporation 
on days 3, 5 and 7. Both assays (to detect in vitro or in vivo-generated donor-specific T cell responses) 
were optimised such that rechallenge of CD4+ T cells in vitro with donor-derived DCs resulted in the 
kinetics of a secondary (memory) response with optimal T cell proliferation on day 3, whereas rechallenge 
with third-party C57BL/6 DCs resulted in the kinetics of a primary response with optimal T cell proliferation 
on day 5. All results shown are the Mean ± SD of triplicate wells and are representative of three 
independent experiments. 
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(memory) response with highest T cell proliferation on day 3, whereas rechallenge with 
third-party C57BL/6 DCs resulted in the kinetics of a primary response with highest T 
cell proliferation on day 5. Both assays were subsequently used to detect anergy with 
direct pathway specificity, induced either in vitro or in vivo using the genetically-
modified DCs developed for this study. 
3.10.2. Optimisation of Rechallenge Assays for the Detection of in vitro- and in vivo-
Generated T Cell Responses with Indirect Allospecificity 
 
A CBK→CBA strain combination was used in this study to investigate the effect (and 
applicability) of the CTLA4-KDEL- and IDO-expressing DC populations to the indirect 
pathway of allorecognition. The CBK mouse is derived from the CBA (H-2k) strain and 
is transgenic for the class I Kb. As there are no class II differences between the two 
strains, and the only difference is in the addition of the Kb molecule, the CD4+ cells that 
lead to rejection are therefore obligatorily specific for the indirect pathway of 
allorecognition for Kb. As a third-party control, a B10.A - H-2a → CBA strain 
combination was used in all rechallenge assays using the CBK→CBA system to 
investigate the indirect pathway of allorecognition. The haplotype of the congenic 
B10.A - H-2a mouse strain consists of classical MHC (class I and II) alleles that are 
identical to those of the CBA mouse (H-2k) with the exception of the class I Dk allele, 
which is substituted at the H-2 locus with the Dd allele in the congenic strain 
(Stimpfling and Richardson, 1965; Klein, 1973; Klein et al., 1983). It is recognised that 
the B10.A - H-2a mouse strain was not the ideal third-party control for the CBK mouse 
as the former strain is not transgenic for a third-party class I allele at the K region, but 
consists of a third-party class I mismatch at the D region in the H-2 locus. However, 
similar to the CBK→CBA strain combination, there are no class II differences between 
the B10.A - H-2a and CBA strains, and the only difference is the class I Dd molecule. 
Thus the CD4+ cells that lead to rejection in the B10.A - H-2a → CBA strain 
combination are specific for the indirect pathway of allorecognition for Dd. This 
provided a suitable third-party, indirect-pathway control for the CBK→CBA strain 
combination. Taking these factors into consideration, when analysing figures for 
experimental results, DCs derived from the B10.A - H-2a congenic strain were termed 
‘B10.A  (H-2k + Dd)’ DCs to account for the mismatched class I (Dd) allele. 
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Firstly, in order to detect the period of highest proliferation (during a primary response) 
of CD4+ T cells specific for the indirect pathway of alloantigen presentation, CBA/Ca-
derived CD4+ T cells were incubated with CBK-derived (H-2k + Kb) DCs [Figure 
31A(i)] and B10.A-derived (H-2k + Dd) DCs [Figure 31A(ii)] at four ratios (2x105 
CD4+ T cells only) and proliferation assessed by thymidine incorporation on days 3, 5, 7 
and 9. Similar to the allogeneic response of C3H/He-derived CD4+ T cells when 
cocultured with MHC-disparate BALB/c DCs in a primary MLR, highest proliferation 
of the indirect pathway-specific CBA cells (when cocultured with either CBK- or 
B10.A-derived DCs) was detected on day 5. The results of these initial experiments 
allowed the measurement, in vitro, of T cells with indirect pathway allospecificity, 
normally a difficult process when syngeneic DC : T cell strain combinations are used 
that also requires DCs to be pulsed with peptide derived from allogeneic tissue. These 
intial results were subsequently used in the optimisation of rechallenge assays for use 
with the CBK→CBA / indirect pathway system.  
 
Similar to the rechallenge assays designed to investigate the direct pathway of 
alloantigen presentation (as a result of a strain combination with complete MHC 
disparity), rechallenge assays were developed to detect donor-specific allogeneic T cell 
responses with indirect allospecificity, following a primary stimulation of the indirect 
pathway-specific T cells either in vitro or in vivo. The rechallenge assays would then be 
applied for the subsequent detection (throughout the study) of indirect pathway-specific 
donor-specific anergy induced both in vitro- and in vivo. For the detection of an in vitro-
generated allogeneic T cell response with indirect pathway allospecificity, CBK DCs 
were incubated in vitro with CBA-derived CD4+ T cells (at a 1:10 DC : T cell ratio). 
After 10 days, the T cells were harvested and rechallenged in vitro (at a 1:2 DC : T cell 
ratio) with donor CBK DCs [Figure 31B(i)] or third-party B10.A DCs [Figure 31B(ii)], 
and proliferation assessed by thymidine incorporation on days 3, 5 and 7. This 
rechallenge assay was subsequently adapted to measure responses following primary 
stimulation of T cells in vivo. 2.5x106 CBK DCs were injected intravenously into 
CBA/Ca mice. After 10 days, spleen-purified CD4+ T cells from the injected mice were 
rechallenged in vitro (at a 1:10 DC : T cell ratio) with donor CBK DCs [Figure 31C(i)]  
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Figure 31. Optimisation of Rechallenge Assays for the Detection of in vitro- and in vivo-Generated 
T Cell Responses with Indirect Allospecificity. 
In order to detect optimal proliferation (during a primary response) of CD4+ T cells specific for the indirect 
pathway of alloantigen presentation, CBA/Ca-derived (H-2k) CD4+ T cells were incubated with [A(i)] CBK-
derived (H-2k + Kb) DCs and [A(ii)] B10.A-derived (H-2k + Dd) DCs and T cell proliferation assessed by 
thymidine incorporation on days 3, 5, 7 and 9. Two-stage DC : T cell MLRs (rechallenge assays) were 
developed in order to detect donor-specific allogeneic T cell responses with indirect allospecificity, 
following a primary stimulation of the indirect pathway-specific T cells either in vitro or in vivo. The 
rechallenge assays would then be applied for the subsequent detection (throughout the study) of anergy 
with indirect pathway allospecificity induced both in vitro- and in vivo.  For the detection of an in vitro-
generated allogeneic T cell response with indirect pathway allospecificity, CBK DCs were incubated in vitro 
with CBA-derived CD4+ T cells (at a 1:10 DC : T cell ratio). After 10 days, the T cells were harvested and 
rechallenged in vitro (at a 1:2 DC : T cell ratio) with [B(i)] donor CBK DCs or [B(ii)] third-party B10.A DCs, 
and proliferation assessed by thymidine incorporation on days 3, 5 and 7. This rechallenge assay was 
subsequently adapted to measure responses following primary stimulation of T cells in vivo. 2.5x106 CBK 
DCs were injected intravenously into CBA/Ca mice. After 10 days, spleen-purified CD4+ T cells from the 
injected mice were rechallenged in vitro (at a 1:10 DC : T cell ratio) with [C(i)] donor CBK DCs or [C(ii)] 
third-party B10.A DCs, and proliferation assessed by thymidine incorporation on days 3, 5 and 7. Both 
assays (to detect in vitro or in vivo-generated donor-specific T cell responses with indirect allospecificity) 
were optimised such that rechallenge of CD4+ T cells in vitro with donor-derived DCs resulted in the 
kinetics of a secondary response (highest T cell proliferation on day 3) whereas rechallenge with third-
party B10.A DCs resulted in the kinetics of a primary response (highest T cell proliferation on day 5). All 
results shown are the Mean ± SD of triplicate wells. 
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or third-party B10.A DCs [Figure 31C(ii)], and proliferation assessed by thymidine 
incorporation on days 3, 5 and 7. Harvesting of both assays (to detect in vitro or in vivo-
generated donor-specific T cell responses with indirect allospecificity) was optimised 
such that rechallenge of CD4+ T cells in vitro with donor-derived (CBK) DCs resulted 
in the kinetics of a secondary (memory) response with highest T cell proliferation on 
day 3, whereas rechallenge with third-party (B10.A) DCs resulted in the kinetics of a 
primary response with highest T cell proliferation on day 5. Both assays were 
subsequently used to detect anergy with indirect pathway specificity, induced either in 
vitro or in vivo using the genetically-modified DCs developed for this study. 
 
3.11. Dexamethasone- or CTLA4-Ig-Treated DCs Fail to Induce 
Donor-Alloantigen Specific T Cell Anergy in vitro or in vivo 
 
An important objective of the study was to investigate whether DCs treated with 
dexamethasone [demonstrated to ‘freeze’ DCs in an immature phenotype and render the 
cells relatively resistant to activation (Mirenda et al., 2004)- see section 1.10], or with 
CTLA4-Ig (for the induction of IDO expression and/or blockade of CD80/86 surface 
expression) induce donor-allospecific anergy in CD4+ T cells either in vitro and/or in 
vivo. BALB/c DCs were treated either with 10-7 M dexamethasone [the concentration 
used in an in vivo kidney transplantation study, albeit in the rat, in which the tolerogenic 
properties of dexamethasone-treated DCs were demonstrated (Mirenda et al., 2004)] or 
10-30 µg/ml of CTLA4-Ig, followed by stimulation with LPS. The treated (and 
untreated) DCs were subsequently incubated in vitro with C3H/He-derived CD4+ T 
cells (at a 1:10 DC : T cell ratio). After 10 days, the T cells were harvested and 
rechallenged in vitro (at a 1:2 DC : T cell ratio) with donor BALB/c DCs [Figure 32(a)] 
or third-party C57BL/6 DCs [Figure 32(b)], and proliferation assessed by thymidine 
incorporation on days 3, 5 and 7. It was demonstrated in section 3.8 that DCs treated 
with either dexamethasone alone (in the absence of subsequent LPS stimulation) or 
CTLA4-Ig cannot sustain allogeneic CD4+ T cell proliferation in a primary MLR. When 
these CD4+ T cells were rechallenged in a two-stage MLR with 
unmodified/unstimulated donor-derived DCs, it was expected that T cell anergy with 
donor-allospecificity (or even total T cell unresponsiveness) would be observed. 
However, this was not the case and inhibition of T cell proliferation on rechallenge with  
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Figure 32. Dexamethasone- or CTLA4-Ig-Treated DCs Fail to Induce Donor Alloantigen-Specific 
CD4+ T Cell Anergy in vitro or in vivo. 
BALB/c DCs were treated either with 10-7M dexamethasone or 10-30µg/ml of CTLA4-Ig, followed by 
stimulation with LPS. The treated (and untreated) DCs were subsequently incubated in vitro with C3H/He-
derived CD4+ T cells (at a 1:10 DC : T cell ratio). After 10 days, the T cells were harvested and 
rechallenged in vitro (at a 1:2 DC : T cell ratio) with (a) donor BALB/c DCs or (b) third-party C57BL/6 DCs, 
and proliferation assessed by thymidine incorporation on days 3, 5 and 7. Similarly, 2.5x106 BALB/c-
derived untreated, dexamethasone-treated or CTLA4-Ig-treated DCs were injected intravenously into 
C3H/He mice. After 10 days, spleen-purified CD4+ T cells from the injected mice were rechallenged in vitro 
with (c) donor BALB/c DCs or (d) third-party C57BL/6 DCs, and proliferation assessed by thymidine 
incorporation on days 3, 5 and 7. All results shown are the Mean ± SD of triplicate wells. 
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donor-derived DCs was not observed. The maximum reduction of T cell profileration 
observed after rechallenge with donor-derived BALB/c DCs was approximately 50%, 
achieved when dexamethasone-treated DCs were used for T cell stimulation in the 
primary-stage MLR. There was also a minor, though significant, reduction of 
proliferation in these CD4+ T cells when rechallenged with third-party C57BL/6 DCs, 
further demonstrating a lack of donor allospecificity in the reduction of CD4+ T cell 
proliferation on rechallenge with donor and third-party derived DCs. All other CD4+ T 
cell populations demonstrated a standard primary response on rechallenge with third-
party C57BL/6 DCs with highest proliferation on day 5. 
 
To assess whether DCs treated with dexamethasone or CTLA4-Ig induce donor-
allospecific anergy in CD4+ T cells in vivo, 2.5x106 BALB/c-derived untreated, 
dexamethasone-treated or CTLA4-Ig-treated DCs were injected intravenously into 
C3H/He mice. After 10 days, spleen-purified CD4+ T cells from the injected mice were 
rechallenged in vitro with donor BALB/c DCs [Figure 32(c)] or third-party C57BL/6 
DCs [Figure 32(d)], and proliferation assessed by thymidine incorporation on days 3, 5 
and 7. Although donor-specific T cell anergy was demonstrated in vivo in a rat 
transplantation study, intravenous administration of dexamethasone-treated DCs 
(without in vitro LPS stimulation) did not induce T cell anergy (either donor-
allospecific or generalised unresponsiveness) in this study. CD4+ T cells purified from 
the spleens of mice administered with dexamethasone-treated DCs exhibited a 
secondary (memory) response on rechallenge with donor-derived BALB/c DCs and a 
primary response on rechallenge with third-party C57BL/6-derived DCs. This 
demonstrates that the DCs ‘frozen’ into an immature phenotype after dexamethasone 
treatment in vitro were able to subsequently induce a primary T cell response in vivo. 
This gives a strong indication for the maturation of dexamethasone-treated DCs in vivo, 
a current disadvantage of using pharmacologically-modified DCs in vivo, as discussed 
in the introduction to this thesis. Similar to dexamethasone treatment, CTLA4-Ig-treated 
DCs were also unable to induce donor-specific T cell anergy. It can be speculated from 
these findings that CTLA4-Ig does not retain the capacity for surface CD80/86 ligation 
and/or induction of IDO expression after administration of the treated DCs in vivo. 
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3.12. Induction of Donor Alloantigen-Specific Tolerance Mediated by 
in vitro-Generated Tregs using CTLA4-KDEL-, but not IDO-
expressing DCs 
3.12.1. Induction of Donor Alloantigen-Specific T Cell Anergy in vitro 
 
The rechallenge assay optimised to detect in vitro-generated allogeneic T cell responses 
in section 3.10.1 was used to investigate whether CD4+ T cells that encounter 
CTLA4-KDEL- or IDO-expressing allogeneic DCs in vitro, subsequently demonstrate 
donor alloantigen-specific anergy. BALB/c DCs were transduced either with EIAV 
Mock, EIAV CTLA4-KDEL or EIAV IDO, followed by stimulation with LPS. The 
transduced (and untransduced) DCs were subsequently incubated in vitro with C3H/He-
derived CD4+ T cells (at a 1:10 DC : T cell ratio). After 10 days, the T cells were 
harvested and rechallenged in vitro (at a 1:2 DC : T cell ratio) with donor BALB/c DCs 
[Figure 33(a)] or third-party C57BL/6 DCs [Figure 33(b)], and CD4+ T cell 
proliferation assessed by thymidine incorporation on days 3, 5 and 7. The results of the 
rechallenge assays demonstrate a donor-allospecific inhibition of CD4+ T cell 
proliferation after previous exposure (in a primary MLR) to CTLA4-KDEL-transduced 
DCs in comparison to untransduced or Mock-transduced DCs: there was a total 
inhibition of CD4+ T cell proliferation on rechallenge with donor BALB/c-derived DCs 
whereas rechallenge with third-party C57BL/6-derived DCs resulted in a standard, 
primary C3H/He T cell response with highest proliferation on day 5. On rechallenge 
with donor- and third party-derived DCs, CD4+ T cells that were previously exposed to 
IDO-transduced DCs did not demonstrate donor allospecificity- thymidine 
incorporation counts from the two-stage MLRs demonstrate an inhibition of 
proliferation and total hyporesponsiveness in CD4+ T cells after a rechallenge with both 
donor BALB/c and third-party C57BL/6 DCs. Therefore, it can be stated that T cell 
anergy with direct pathway allospecificity was induced in vitro with CTLA4-KDEL-
transduced DCs, but not IDO-transduced DCs. 
3.12.2. Production of TGF-β and IL-10 in T Cell Rechallenge Assays 
 
It was important to investigate whether there is an association between the induction of 
donor alloantigen-specific anergy in vitro (observed with CD4+ T cells that were 
exposed to CTLA4-KDEL-expressing DCs), and the production of immunoregulatory  
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Figure 33. Induction of Donor Alloantigen-Specific T Cell Anergy in vitro. 
BALB/c DCs were transduced either with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO, followed by 
stimulation with LPS. The transduced (and untransduced) DCs were subsequently incubated in vitro with 
C3H/He-derived CD4+ T cells (at a 1:10 DC : T cell ratio). After 10 days, the T cells were harvested and 
rechallenged in vitro (at a 1:2 DC : T cell ratio) with (a) donor BALB/c DCs or (b) third-party C57BL/6 DCs, 
and CD4+ T cell proliferation assessed by thymidine incorporation on days 3, 5 and 7. All results shown are 
the Mean ± SD of triplicate wells. 
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Figure 34. Production of TGF-β and IL-10 in T Cell Rechallenge Assays. 
BALB/c DCs were transduced either with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO, followed by 
stimulation with LPS. The transduced (and untransduced) DCs were subsequently incubated in vitro with 
C3H/He-derived CD4+ T cells (at a 1:10 DC : T cell ratio). After 10 days, the T cells were harvested and 
rechallenged in vitro (at a 1:2 DC : T cell ratio) with donor BALB/c DCs. Culture supernatant from the 
rechallenge assay was harvested for detection of the immunoregulatory cytokines (a) TGF-β and (b) IL-10 
by ELISA. Results shown are the Mean ± SD of triplicate wells. 
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cytokines. Similar to the rechallenge assay protocol used in section 3.12.1, BALB/c 
DCs were transduced either with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO, 
followed by stimulation with LPS. The transduced (and untransduced) DCs were 
subsequently incubated in vitro with C3H/He-derived CD4+ T cells (at a 1:10 DC : T 
cell ratio). After 10 days, the T cells were harvested and rechallenged in vitro (at a 1:2 
DC : T cell ratio) with donor BALB/c DCs. Culture supernatant from the rechallenge 
assay was harvested for detection of the immunoregulatory cytokines TGF-β [Figure 
34(a)] and IL-10 [Figure 34(b)] by ELISA. Relative to concentrations of TGF-β and 
IL-10 in the culture supernatant of assays in which CD4+ T cells were rechallenged after 
previous exposure (in a primary MLR) to untransduced or Mock-expressing (donor-
derived) DCs, there were significantly higher concentrations of these immunoregulatory 
cytokines in supernatants when the T cells were previously exposed to CTLA4-KDEL-
expressing DCs. In contrast, TGF-β and IL-10 levels in supernatant taken from assays in 
which T cells were rechallenged with donor-derived DCs after previous exposure to 
IDO-expressing DCs were not significantly higher than if they were exposed to 
untransduced or Mock-expressing DCs. Hence, in addition to the demonstration of 
donor alloantigen-specific T cell anergy, the use of ELISA on supernatants taken from 
two-stage MLRs clearly demonstrates an induction of TGF-β and IL-10 production in T 
cells that are challenged in the primary MLR with EIAV CTLA4-KDEL-transduced 
DCs. 
3.12.3. Generation of Donor Alloantigen-Specific Tregs in vitro 
 
As explained in section 1.13 (Aims, Approaches and Hypotheses), for cell-based 
tolerogenic therapy to be efficient in transplantation medicine, it will be critical that 
allogeneic T cells rendered anergic do not die but have the capacity to regulate the 
activity of alloreactive T cells. To address this vital issue, suppressor assays were 
developed in order to investigate whether CD4+ T cells rendered anergic after 
interaction with CTLA4-KDEL-expressing DCs in vitro (as demonstrated in section 
3.12.1) are subsequently capable of donor-allospecific T cell regulation in a primary 
MLR between donor-derived DCs and freshly-isolated alloreactive CD4+ T cells. 
BALB/c DCs were transduced either with EIAV Mock, EIAV CTLA4-KDEL or EIAV 
IDO, followed by stimulation with LPS. The transduced (and untransduced) DCs were 
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subsequently incubated in vitro with C3H/He-derived CD4+ T cells (at a 1:10 DC : T 
cell ratio). After 10 days, the T cells were harvested, irradiated and added in increasing 
numbers (0-105 CD4+ T Cells) to a primary MLR between freshly-isolated C3H-derived 
CD4+ T cells and donor BALB/c DCs [Figure 35(a)] or third-party C57BL/6 DCs 
[Figure 35(b)] (at a 1:5 DC : T cell ratio). T cell proliferation was assessed by 
thymidine incorporation after 5 days. A dose-dependent inhibition of T cell proliferation 
was observed in the MLR between (donor) BALB/c DCs and freshly-isolated C3H/He 
CD4+ T cells in the presence of increasing numbers of syngeneic (C3H) CD4+ T cells 
harvested after coculture in vitro with donor BALB/c-derived, CTLA4-KDEL-
expressing DCs. Donor allospecificity was demonstrated as CD4+ T cell proliferation 
was not inhibited in a MLR between third-party C57BL/6 DCs and freshly-isolated 
C3H CD4+ T cells in the presence of syngeneic CD4+ T cells that were challenged (in a 
primary MLR) with CTLA4-KDEL-expressing DCs. A minimal, though significant, 
degree of donor-specific T cell regulation was observed in the suppressor assays with 
the addition of increasing numbers of CD4+ T cells derived from a coculture (primary 
MLR) with IDO-expressing DCs. At the highest number (105) of irradiated CD4+ T 
cells added (after exposure to IDO-expressing DCs), an inhibition of approximately 
40% was observed in the suppression MLR. This was in comparison to an inhibition of 
approximately 90% observed with the addition of half the number (50,000) of irradiated 
CD4+ T cells purifed from coculture with EIAV CTLA4-KDEL-transduced DCs. The 
results therefore demonstrate the generation of donor alloantigen-specific Tregs in vitro 
with CTLA4-KDEL-expressing DCs, in comparison to minimal generation of Tregs 
with the IDO-expressing DC system. 
3.12.4. Immunoregulatory Activity of Tregs Generated in vitro with CTLA4-KDEL-
Expressing DCs is Independent of FoxP3 Expression and Associated with Mild 
Upregulation of CTLA4 
 
Following the in vitro-generation of Tregs with CTLA4-KDEL-expressing DCs, it was 
necessary to investigate whether there is a relationship between the immunoregulatory 
activity observed in section 3.12.3 and expression of the intracellular marker FoxP3 (a 
transcription factor associated with naturally-occuring CD4+CD25+ Tregs). Expression 
of CTLA4, a negative costimulatory molecule implicated in the function of naturally- 
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Figure 35. Generation of Donor Alloantigen-Specific Tregs in vitro. 
BALB/c DCs were transduced either with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO, followed by 
stimulation with LPS. The transduced (and untransduced) DCs were subsequently incubated in vitro with 
C3H/He-derived CD4+ T cells (at a 1:10 DC : T cell ratio). After 10 days, the T cells were harvested, 
irradiated and added in increasing numbers (0-105 CD4+ T Cells) to a primary MLR between freshly-
isolated C3H-derived CD4+ T cells and (a) donor BALB/c DCs or (b) third-party C57BL/6 DCs (at a 1:5 DC 
: T cell ratio). T cell proliferation was assessed by thymidine incorporation after 5 days. All results shown 
are the Mean ± SD of triplicate wells. 
Chapter 3: Results 
Adnan Khan, Department of Immunology, Division of Medicine, Imperial College London 188 
occuring Tregs (see section 1.6), was also analysed to detect for upregulation of this 
marker by the in vitro-generated Tregs. BALB/c DCs were transduced either with EIAV 
Mock, EIAV CTLA4-KDEL or EIAV IDO, followed by stimulation with LPS. The 
transduced (and untransduced) DCs were subsequently incubated in vitro with C3H/He-
derived CD4+ T cells (at a 1:10 DC : T cell ratio). After 10 days, the T cells were 
harvested, stained and analysed by flow cytometry for expression of CD4, CD25, total 
(intracellular) CTLA4 and FoxP3 [Figure 36]. CD4+ T cells that were cocultured with 
CTLA4-KDEL-transduced DCs did not exhibit a marked upregulation of the surface 
marker CD25 or the intracellular marker FoxP3 relative to expression of these markers 
in T cells that were cocultured with either untransduced or Mock-transduced DCs. 
CTLA4+ Tregs generated in vitro (see section 3.16.4) were used as a positive control for 
the FoxP3 antibody. However, there was a mild upregulation of total (intracellular) 
CTLA4 in these CD4+ T cells. In addition to the production of immunoregulatory 
cytokines, as demonstated in section 3.12.2, this could suggest a mechanism for the 
immunoregulatory function observed with Tregs generated in vitro after coculture with 
CTLA4-KDEL-expressing DCs. As expected from the rechallenge and suppressor 
assays undertaken earlier, FoxP3+ and/or CTLA4+ T cells were not generated in vivo 
after administration of IDO-expressing DCs. 
3.12.5. Induction of Linked Suppression Mediated by in vitro-Generated, Donor 
Alloantigen-Specific Tregs 
 
Using suppressor assays, it was demonstrated in section 3.12.3 that coculture of CD4+ T 
cells with fully MHC-disparate CTLA4-KDEL-expressing DCs in a primary MLR 
resulted in the generation of Tregs in vitro. As the Treg population was specific for 
donor alloantigens, it would be expected that the cells are capable of mediating linked 
suppression of the alloresponse, so that tolerance to one epitope could spread to another. 
It has been suggested by previous studies that the possible effect of IDO is to induce T 
cell death rather than anergy or regulation (Mellor and Munn, 1999; Grohmann et al., 
2003b). It was important to verify this using assays designed to investigate the induction 
of Tregs and their functional capacity, specifically linked suppression, since the 
advantage of IDO (or CTLA4-KDEL) as a therapeutic agent to block transplant 
rejection would be increased if T cells became regulatory as the effect would ‘spread’ to  
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Figure 36. Functional Activity of Tregs Generated in vitro with CTLA4-KDEL-Expressing DCs is 
Independent of FoxP3 Expression and Associated with Mild Upregulation of CTLA4. 
BALB/c DCs were transduced either with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO, followed by 
stimulation with LPS. The transduced (and untransduced) DCs were subsequently incubated in vitro with 
C3H/He-derived CD4+ T cells (at a 1:10 DC : T cell ratio). After 10 days, the T cells were harvested, 
stained and analysed by flow cytometry for expression of CD4, CD25, intracellular (total) CTLA4 and 
FoxP3. 
Chapter 3: Results 
Adnan Khan, Department of Immunology, Division of Medicine, Imperial College London 190 
T cells that did not encounter the genetically-modified DCs. The induction and 
mediation of linked suppression by donor-specific Tregs would thus contribute to 
‘infectious tolerance’. 
 
In order to investigate the capacity of the in vitro-generated Tregs to mediate linked 
suppression, BALB/c DCs were transduced either with EIAV Mock, EIAV CTLA4-
KDEL or EIAV IDO, followed by stimulation with LPS. The transduced (and 
untransduced) DC populations were subsequently incubated in vitro with C3H/He-
derived CD4+ T cells (at a 1:10 DC : T cell ratio). After 10 days, the T cells were 
harvested and rechallenged in vitro (at a 1:2 DC : T cell ratio) with CB6F1 
[(BALB/c)x(C57BL/6)F1] DCs expressing both donor and third-party MHC [Figure 
37(a)] or B6CBF1 [(C57BL/6)x(CBA/Ca)F1] DCs expressing only third-party MHC 
[Figure 37(b)], and CD4+ T cell proliferation assessed by thymidine incorporation on 
days 3, 5 and 7. Thymidine incorporation counts from the rechallenge assays 
demonstrate donor-specific linked suppression by CD4+ T cells previously exposed in 
vitro to CTLA4-KDEL-transduced DCs, in comparison to those CD4+ T cells exposed 
to untransduced or Mock-transduced DCs. There was a considerable reduction of CD4+ 
T cell proliferation on rechallenge with CB6F1 DCs expressing both donor (H-2d) and 
third-party (H-2b) ‘linked’ alloantigens whereas rechallenge with B6CBF1 DCs 
expressing third-party H-2b aswell as syngeneic H-2k alloantigens resulted in a standard, 
primary C3H/He T cell response with highest proliferation on day 5. On rechallenge 
with CB6F1 and B6CBF1 DCs, CD4+ T cells that were previously exposed in vitro to 
IDO-transduced DCs did not demonstrate specific linked suppression: thymidine 
incorporation counts from the two-stage MLRs demonstrate a near-total CD4+ T cell 
hyporesponsiveness, with a significant reduction of CD4+ T cell proliferation after a 
rechallenge with both F1 DCs expressing donor and third party MHC, and F1 DCs 
expressing only third-party C57BL/6 antigens. 
 
T cells harvested from primary MLRs after 10 days were also irradiated and added in 
increasing numbers (0-105 CD4+ T Cells) to new primary MLRs between freshly-
isolated C3H-derived CD4+ T cells and CB6F1 DCs [Figure 37(c)] or B6CBF1 DCs 
[Figure 37(d)] (at a 1:5 DC : T cell ratio). T cell proliferation was assessed by  
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Figure 37. Induction of Linked Suppression Mediated by in vitro-Generated, Donor Alloantigen-
Specific Tregs. 
BALB/c DCs were transduced either with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO, followed by 
stimulation with LPS. The transduced (and untransduced) DCs were subsequently incubated in vitro with 
C3H/He-derived CD4+ T cells (at a 1:10 DC : T cell ratio). After 10 days, the T cells were harvested and 
rechallenged in vitro (at a 1:2 DC : T cell ratio) with (a) CB6F1 [(BALB/c)x(C57BL/6)F1] DCs expressing 
both donor and third-party MHC or (b) B6CBF1 [(C57BL/6)x(CBA/Ca)F1] DCs expressing only third-party 
MHC, and CD4+ T cell proliferation assessed by thymidine incorporation on days 3, 5 and 7. T cells 
harvested from primary MLRs after 10 days were also irradiated and added in increasing numbers (0-105 
CD4+ T Cells) to new primary MLRs between freshly-isolated C3H-derived CD4+ T cells and (c) CB6F1 
DCs or (d) B6CBF1 DCs (at a 1:5 DC : T cell ratio). T cell proliferation was assessed by thymidine 
incorporation after 5 days. All results shown are the Mean ± SD of triplicate wells. 
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thymidine incorporation after 5 days. A dose-dependent inhibition of T cell proliferation 
was observed in the MLR between CB6F1 DCs expressing both donor (H-2d) and third-
party (H-2b) ‘linked’ alloantigens and freshly-isolated C3H/He CD4+ T cells in the 
presence of increasing numbers of syngeneic (C3H) CD4+ T cells harvested after 
coculture in vitro with donor BALB/c-derived, CTLA4-KDEL-expressing DCs. The in 
vitro-generation of donor alloantigen-specific Tregs with the capacity for mediating 
linked suppression was demonstrated as CD4+ T cell proliferation was not inhibited in a 
MLR between B6CBF1 DCs expressing only third-party H-2b (in addition to syngeneic 
H-2k) alloantigens and freshly-isolated C3H CD4+ T cells in the presence of syngeneic 
CD4+ T cells that were challenged (in a primary MLR) with CTLA4-KDEL-expressing 
DCs. Donor-specific linked suppression, or even non-specific bystander suppression, 
was not observed in the suppressor assays with the addition of CD4+ T cells derived 
from coculture with IDO-expressing DCs. The results demonstrate the in vitro-
generation of donor alloantigen-specific Tregs with the capacity for mediating linked 
suppression. Tregs were generated after coculture of CD4+ T cells with DCs transduced 
to express CTLA4-KDEL rather than IDO. 
 
3.13. Induction of Tolerance Mediated by in vitro-Generated Tregs 
with Indirect Donor Allospecificity using CTLA4-KDEL-, but not 
IDO-expressing DCs 
3.13.1. Induction of T Cell Anergy in vitro with Indirect Donor Allospecificity 
 
The rechallenge assay optimised to detect in vitro-generated CD4+ T cell responses with 
indirect donor allospecificity in section 3.10.2 was employed to investigate (using the 
same CBK-CBA strain combination) whether indirect pathway-specific CD4+ T cells 
that encounter CTLA4-KDEL- or IDO-expressing allogeneic DCs in vitro, subsequently 
demonstrate anergy with indirect donor allospecificity. CBK (H-2k + Kb) DCs were 
transduced either with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO, followed by 
stimulation with LPS. The transduced (and untransduced) DCs were subsequently 
incubated in vitro with CBA/Ca-derived CD4+ T cells (at a 1:10 DC : T cell ratio). After 
10 days, the T cells were harvested and rechallenged in vitro (at a 1:2 DC : T cell ratio) 
with donor CBK DCs [Figure 38(a)] or third-party B10.A (H-2k + Dd) DCs [Figure 
38(b)], and CD4+ T cell proliferation assessed by thymidine incorporation on days 3, 5  
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Figure 38. Induction of T Cell Anergy in vitro with Indirect Donor Allospecificity. 
CBK (H-2k + Kb) DCs were transduced either with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO, followed 
by stimulation with LPS. The transduced (and untransduced) DCs were subsequently incubated in vitro 
with CBA/Ca-derived CD4+ T cells (at a 1:10 DC : T cell ratio). After 10 days, the T cells were harvested 
and rechallenged in vitro (at a 1:2 DC : T cell ratio) with (a) donor CBK DCs or (b) third-party B10.A (H-2k + 
Dd) DCs, and CD4+ T cell proliferation assessed by thymidine incorporation on days 3, 5 and 7. All results 
shown are the Mean ± SD of triplicate wells. 
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Figure 39. Production of TGF-β and IL-10 in T Cell Rechallenge Assays. 
CBK (H-2k + Kb) DCs were transduced either with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO, followed 
by stimulation with LPS. The transduced (and untransduced) DCs were subsequently incubated in vitro 
with CBA/Ca-derived CD4+ T cells (at a 1:10 DC : T cell ratio). After 10 days, the T cells were harvested 
and rechallenged in vitro (at a 1:2 DC : T cell ratio) with donor CBK DCs. Culture supernatant from the 
rechallenge assay was harvested for detection of the immunoregulatory cytokines (a) TGF-β and (b) IL-10 
by ELISA. Results shown are the Mean ± SD of triplicate wells. 
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and 7. The results of the rechallenge assays demonstrate an inhibition of CD4+ T cell 
proliferation with indirect donor allospecificity after previous exposure (in a primary 
MLR) to CTLA4-KDEL-transduced DCs in comparison to untransduced or Mock-
transduced DCs: there was a total inhibition of CD4+ T cell proliferation on rechallenge 
with donor CBK-derived DCs whereas rechallenge with third-party B10.A-derived DCs 
resulted in a standard, primary CBA/Ca T cell response with highest proliferation on 
day 5. On rechallenge with donor- and third party-derived DCs, indirect pathway-
specific CD4+ T cells that were previously exposed to IDO-transduced DCs did not 
demonstrate donor allospecificity. Thymidine incorporation counts from the two-stage 
MLRs demonstrate an inhibition of proliferation in CD4+ T cells after a rechallenge 
with both donor CBK and third-party B10.A DCs. Thus, similar to the rechallenge 
assays designed to investigate the direct pathway of alloantigen presentation, T cell 
anergy with indirect donor allospecificity was also induced in vitro with DCs expressing 
CTLA4-KDEL, but not DCs expressing IDO. 
3.13.2. Production of TGF-β and IL-10 in T Cell Rechallenge Assays 
 
After performing the rechallenge assays described in the previous section, a potential 
link between the observed induction of anergy with indirect donor allospecificity 
(demonstrated with CD4+ T cells that were exposed in vitro to CTLA4-KDEL-
expressing CBK DCs), and the production of immunoregulatory cytokines was 
investigated. Similar to the indirect pathway-specific rechallenge assay protocol used in 
section 3.13.1, CBK (H-2k + Kb) DCs were transduced either with EIAV Mock, EIAV 
CTLA4-KDEL or EIAV IDO, followed by stimulation with LPS. The transduced (and 
untransduced) DCs were subsequently incubated in vitro with CBA/Ca-derived CD4+ T 
cells (at a 1:10 DC : T cell ratio). After 10 days, the T cells were harvested and 
rechallenged in vitro (at a 1:2 DC : T cell ratio) with donor CBK DCs. Culture 
supernatant from the rechallenge assay was harvested for detection of the 
immunoregulatory cytokines TGF-β [Figure 39(a)] and IL-10 [Figure 39(b)] by 
ELISA. 
 
Relative to concentrations of TGF-β and IL-10 in the culture supernatant of assays in 
which indirect pathway-specific CD4+ T cells were rechallenged after previous 
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exposure (in a primary MLR) to untransduced or Mock-expressing (donor-derived) 
DCs, there were significantly higher concentrations of these immunoregulatory 
cytokines in supernatants when the T cells were previously exposed to CTLA4-KDEL-
expressing DCs. In contrast, TGF-β and IL-10 levels in supernatant taken from assays in 
which indirect pathway-specific T cells were rechallenged with donor-derived DCs after 
previous exposure to IDO-expressing DCs were not significantly higher than if they 
were exposed to untransduced or Mock-expressing DCs. The results were similar to 
findings observed with direct pathway-specific rechallenge assays. Therefore, in 
addition to the demonstration of T cell anergy with indirect donor allospecificity, the 
use of ELISA on supernatants taken from two-stage MLRs clearly demonstrates an 
induction of TGF-β and IL-10 production in indirect pathway-specific T cells that are 
challenged in a primary MLR with EIAV CTLA4-KDEL-transduced DCs. 
3.13.3. Generation of Tregs in vitro with Indirect Donor Allospecificity 
 
As the indirect pathway is the predominant pathway of alloantigen presentation during 
the chronic phase of allograft rejection, it will be critical that allogeneic T cells rendered 
anergic, as a result of DC-based tolerogenic therapy, are capable of regulating the 
activity of alloreactive T cells that exhibit indirect donor allospecificity. Suppressor 
assays were thus developed to investigate whether indirect pathway-specific CD4+ T 
cells rendered anergic after interaction with CTLA4-KDEL-expressing DCs in vitro (as 
demonstrated in section 3.13.1) are subsequently capable of donor allospecific  T cell 
regulation in a primary MLR between donor-derived DCs and freshly-isolated 
alloreactive CD4+ T cells with indirect donor allospecificity. CBK (H-2k + Kb) DCs 
were transduced either with EIAV Mock, EIAV CTLA4-KDEL, or EIAV IDO, 
followed by stimulation with LPS. The transduced (and untransduced) DCs were 
subsequently incubated in vitro with CBA/Ca (H-2k)-derived CD4+ T cells (at a 1:10 
DC : T cell ratio). After 10 days, the T cells were harvested, irradiated and added in 
increasing numbers (0-105 CD4+ T Cells) to a primary MLR between freshly-isolated 
CBA-derived CD4+ T cells and donor CBK DCs [Figure 40(a)] or third-party B10.A 
(H-2k + Dd) DCs [Figure 40(b)] (at a 1:5 DC : T cell ratio). T cell proliferation was 
assessed by thymidine incorporation after 5 days. 
Chapter 3: Results 
Adnan Khan, Department of Immunology, Division of Medicine, Imperial College London 196 
(a) (b)Functional Regulatory T Cell (Suppressor) Assay:Fresh Donor CBK DC : CBA T cell MLR
No
 
DC
s 
(Fre
sh
 
T C
ells
)
Un
tra
ns
du
ce
d D
Cs
Mo
ck
 
DC
s
CT
LA
4-K
DE
L D
Cs
IDO
 
DC
s
0
25
50
75
100
3 H
-
Th
ym
idi
ne
 
In
co
rp
or
at
ion
 
(C
PM
)
(x1
0^
3)
Functional Regulatory T Cell (Suppressor) Assay:
Fresh Third-Party B10.A DC : CBA T cell MLR
No
 
DC
s 
(Fre
sh
 
T C
ells
)
Un
tra
ns
du
ce
d D
Cs
Mo
ck
 
DC
s
CT
LA
4-K
DE
L D
Cs
IDO
 
DC
s
0
25
50
75
+0 Irradiated Cells
+25000
+50000
+100000
3 H
-
Th
ym
idi
ne
 
In
co
rp
or
at
ion
 
(C
PM
)
(x1
0^
3)
Day 9: Incubation of CBK DC 
Populations with CBA CD4+ 
T Cells in vitro
Day 0: CBK DC Culture
Day 6: Transduction with EIAV
10 Days
Day 19: T cell Harvest from Primary MLR, 
Irradiation and Addition to Fresh Donor
CBK-CBA and 3rd-Party B10.A-CBA MLRs.
Harvest on Day 5.
72 Hours
T Cells Fresh CBA CD4+
T Cells + Donor 
or 3rd-Party DCs
 
 
 
 
Figure 40. Generation of Tregs in vitro with Indirect Donor Allospecificity. 
CBK (H-2k + Kb) DCs were transduced either with EIAV Mock, EIAV CTLA4-KDEL, or EIAV IDO, followed 
by stimulation with LPS. The transduced (and untransduced) DCs were subsequently incubated in vitro 
with CBA/Ca (H-2k)-derived CD4+ T cells (at a 1:10 DC : T cell ratio). After 10 days, the T cells were 
harvested, irradiated and added in increasing numbers (0-105 CD4+ T Cells) to a primary MLR between 
freshly-isolated CBA-derived CD4+ T cells and (a) donor CBK DCs or (b) third-party B10.A (H-2k + Dd) DCs 
(at a 1:5 DC : T cell ratio). T cell proliferation was assessed by thymidine incorporation after 5 days. All 
results shown are the Mean ± SD of triplicate wells. 
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A dose-dependent inhibition of T cell proliferation was observed in the MLR between 
(donor) CBK DCs and freshly-isolated CBA/Ca CD4+ T cells in the presence of 
increasing numbers of syngeneic (CBA) CD4+ T cells harvested after coculture in vitro 
with donor CBK-derived, CTLA4-KDEL-expressing DCs. Indirect donor allospecificity 
was demonstrated as CD4+ T cell proliferation was not inhibited in a MLR between 
third-party B10.A DCs and freshly-isolated CBA CD4+ T cells in the presence of 
syngeneic CD4+ T cells that were challenged (in a primary MLR) with CTLA4-KDEL-
expressing DCs. T cell regulation (with indirect donor allospecificity or otherwise) was 
not observed in the suppressor assays with the addition of CD4+ T cells derived from a 
coculture (primary MLR) with IDO-expressing DCs. The results therefore demonstrate 
the generation of Tregs in vitro with indirect donor allospecificity when DCs were 
transduced to express CTLA4-KDEL rather than IDO. 
3.13.4. Induction of Linked Suppression Mediated by in vitro-Generated Tregs with 
Indirect Donor Allospecificity 
 
An overall aim of this study, the capacity of either CTLA4-KDEL- or IDO-expressing 
DCs to generate Tregs with indirect donor allospecificity that have the capacity for 
linked suppression is important for the ultimate application of each strategy. It was 
demonstrated in section 3.13.3 that coculture of indirect pathway-specific CD4+ T cells 
with CTLA4-KDEL-expressing DCs in a primary MLR resulted in the in vitro-
generation of Tregs with indirect donor allospecificity. It would thus be expected that 
the cells are capable of mediating linked suppression (even if the generated Tregs are 
specific for the indirect allopresentation of Kb alone). For example, it has previously 
been shown using the CBK→CBA strain combination that induction of tolerance to Kb 
alone can result in acceptance of a fully mismatched H-2b graft (Wong et al., 1996; 
Wong et al., 1997). 
 
In order to investigate the capacity of in vitro-generated Tregs with indirect donor 
allospecificity to mediate linked suppression, CBK (H-2k + Kb) DCs were transduced 
either with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO, followed by stimulation 
with LPS. The transduced (and untransduced) DCs were subsequently incubated in vitro 
with CBA/Ca-derived CD4+ T cells (at a 1:10 DC : T cell ratio). After 10 days, the T 
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cells were harvested and rechallenged in vitro (at a 1:2 DC : T cell ratio) with CB6F1 
[(BALB/c)x(C57BL/6)F1] DCs expressing only third-party MHC-peptide [Figure 
41(a)] or B6CBF1 [(C57BL/6)x(CBA/Ca)F1] DCs expressing both donor (Kb presented 
in the context of I-Ak/I-Ek) and third-party MHC-peptide [Figure 41(b)], and CD4+ T 
cell proliferation assessed by thymidine incorporation on days 3, 5 and 7. Thymidine 
incorporation counts from the rechallenge assays demonstrate donor-specific linked 
suppression of CD4+ T cell proliferation after previous exposure in vitro to 
CTLA4-KDEL-transduced DCs, in comparison to exposure to untransduced or Mock-
transduced DCs: there was a considerable reduction of CD4+ T cell proliferation on 
rechallenge with B6CBF1 DCs which have the capacity for indirect presentation of Kb 
in the context of I-Ak/I-Ek (donor peptide-MHC) and also express third-party ‘linked’ 
MHC class I and II alloantigens derived from H-2b. This is in contrast to rechallenge 
with CB6F1 DCs expressing only third-party alloantigens derived from H-2b and H-2d, 
which resulted in a standard, primary CBA/Ca T cell response with highest proliferation 
on day 5. On rechallenge with B6CBF1 and CB6F1 DCs, CD4+ T cells that were 
previously exposed in vitro to IDO-transduced DCs did not demonstrate specific linked 
suppression, but rather a non-specific hyporesponsiveness- thymidine incorporation 
counts from the two-stage MLRs show a substantial reduction of CD4+ T cell 
proliferation after a rechallenge with either F1 DCs expressing donor and third-party 
MHC-peptide, or F1 DCs expressing only third-party MHC-peptide. 
 
T cells harvested from primary MLRs after 10 days were also irradiated and added in 
increasing numbers (0-105 CD4+ T Cells) to new primary MLRs between freshly-
isolated CBA/Ca-derived CD4+ T cells and CB6F1 DCs [Figure 41(c)] or B6CBF1 
DCs [Figure 41(d)] (at a 1:5 DC : T cell ratio). T cell proliferation was assessed by 
thymidine incorporation after 5 days. A dose-dependent inhibition of T cell proliferation 
was observed in the MLR between B6CBF1 DCs expressing both donor (Kb presented 
in the context of I-Ak/I-Ek) and ‘linked’ third-party MHC-peptide, and freshly-isolated 
CBA/Ca CD4+ T cells in the presence of increasing numbers of syngeneic (CBA) CD4+ 
T cells harvested after coculture in vitro with donor CBK-derived, CTLA4-KDEL-
expressing DCs. The in vitro-generation of Tregs with indirect donor allospecificity and 
the capacity for mediating donor-specific linked suppression was demonstrated as CD4+  
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Figure 41. Induction of Linked Suppression Mediated by in vitro-Generated Tregs with Indirect 
Donor Allospecificity. 
CBK (H-2k + Kb) DCs were transduced either with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO, followed 
by stimulation with LPS. The transduced (and untransduced) DCs were subsequently incubated in vitro 
with CBA/Ca-derived CD4+ T cells (at a 1:10 DC : T cell ratio). After 10 days, the T cells were harvested 
and rechallenged in vitro (at a 1:2 DC : T cell ratio) with (a) CB6F1 [(BALB/c)x(C57BL/6)F1] DCs 
expressing only third-party MHC-peptide or (b) B6CBF1 [(C57BL/6)x(CBA/Ca)F1] DCs expressing both 
donor (Kb presented in the context of I-Ak/I-Ek) and third-party MHC-peptide, and CD4+ T cell proliferation 
assessed by thymidine incorporation on days 3, 5 and 7. T cells harvested from primary MLRs after 10 
days were also irradiated and added in increasing numbers (0-105 CD4+ T Cells) to new primary MLRs 
between freshly-isolated CBA/Ca-derived CD4+ T cells and (c) CB6F1 DCs or (d) B6CBF1 DCs (at a 1:5 
DC : T cell ratio). T cell proliferation was assessed by thymidine incorporation after 5 days. All results 
shown are the Mean ± SD of triplicate wells. 
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T cell proliferation was not inhibited in a MLR between CB6F1 DCs expressing only 
third-party MHC-peptide, and freshly-isolated CBA CD4+ T cells in the presence of 
syngeneic CD4+ T cells that were challenged (in a primary MLR) with CTLA4-KDEL-
expressing DCs. Donor-specific linked suppression (or general T cell suppression / non-
specific bystander suppression) was not observed in the suppressor assays with the 
addition of CD4+ T cells derived from coculture with IDO-expressing DCs. As 
demonstrated earlier, these CD4+ T cells exhibited almost total hyporesponsiveness in 
the rechallenge assays. 
 
The results demonstrate the in vitro-generation of Tregs with indirect donor 
allospecificity that are capable of mediating linked suppression: Tregs were generated 
after coculture of CD4+ T cells with DCs transduced to express CTLA4-KDEL. The 
generated Tregs specific for the indirect allopresentation of Kb alone were able to 
mediate suppression to linked alloantigens presented by F1 DCs. In contrast, T cells 
exposed in vitro to IDO-expressing DCs exhibited profound non-specific 
hyporesponsiveness with no immunoregulatory properties or significant effect on the 
indirect pathway-directed suppressor assay. 
 
3.14. Induction of Donor Alloantigen-Specific Tolerance Mediated by 
in vivo-Generated Tregs using CTLA4-KDEL-, but not IDO-
expressing DCs 
3.14.1. Induction of Donor Alloantigen-Specific T Cell Anergy in vivo 
 
As a major aim of the study, it was critical to assess whether CD4+ T cells that are 
exposed in vivo to CTLA4-KDEL- or IDO-expressing allogeneic DCs (subsequent to 
intravenous administration), subsequently demonstrate donor alloantigen-specific 
anergy. The rechallenge assay optimised to detect in vivo-generated allogeneic T cell 
responses in section 3.10.1 was applied to investigate anergy induction. 2.5x106 
BALB/c DCs (either untransduced, or transduced with EIAV Mock, EIAV 
CTLA4-KDEL or EIAV IDO) were injected intravenously into C3H/He mice. After 10 
days, CD4+ T cells purified from the spleens of injected mice were rechallenged in vitro 
(at a 1:10 DC : T cell ratio) with donor BALB/c DCs [Figure 42(a)] or third-party 
C57BL/6 DCs [Figure 42(b)], and CD4+ T cell proliferation assessed by thymidine  
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Figure 42. Induction of Donor Alloantigen-Specific T Cell Anergy in vivo. 
2.5x106 BALB/c DCs (either untransduced, or transduced with EIAV Mock, EIAV CTLA4-KDEL or EIAV 
IDO) were injected intravenously into C3H/He mice. After 10 days, CD4+ T cells purified from the spleens 
of injected mice were rechallenged in vitro (at a 1:10 DC : T cell ratio) with (a) donor BALB/c DCs or (b) 
third-party C57BL/6 DCs, and CD4+ T cell proliferation assessed by thymidine incorporation on days 3, 5 
and 7. All results shown are the Mean ± SD of triplicate wells. 
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incorporation on days 3, 5 and 7. The results of the rechallenge assays demonstrate a 
donor-allospecific inhibition of CD4+ T cell proliferation after previous exposure in vivo 
to CTLA4-KDEL-transduced DCs relative to DCs that were either untransduced or 
transduced with EIAV Mock: there was a considerable inhibition of CD4+ T cell 
proliferation on rechallenge with donor BALB/c-derived DCs in vitro whereas 
rechallenge with third-party C57BL/6-derived DCs resulted in a standard, primary 
C3H/He T cell response with highest proliferation on day 5. On rechallenge with donor- 
and third party-derived DCs, CD4+ T cells purified from mice that were injected 
intravenously with IDO-transduced DCs did not demonstrate donor allospecificity, but 
rather a non-specific hyporesponsiveness- thymidine incorporation counts from the two-
stage MLRs show significant inhibition of proliferation in CD4+ T cells after a 
rechallenge in vitro that is not restricted to a rechallenge with donor BALB/c DCs, but 
also third-party C57BL/6 DCs. The total number of CD4+ T cells purified from mice 
that were injected with IDO-transduced DCs was not significantly different to the 
number of cells from mice injected with other populations (EIAV-transduced and 
untransduced) DCs. It can thus be stated that T cell anergy with direct pathway donor 
allospecificity was induced in vivo with CTLA4-KDEL-transduced DCs, but not IDO-
transduced DCs. 
3.14.2. Production of TGF-β and IL-10 by CD4+CD25- T Cells in Rechallenge Assays 
It was important to investigate whether the observed induction of donor-allospecific 
anergy in vivo (demonstrated with CD4+ T cells purified from mice that were injected 
intravenously with CTLA4-KDEL-expressing DCs), is associated with the production 
of immunoregulatory cytokines TGF-β and IL-10. Similar to the rechallenge assay 
protocol used in section 3.14.1, 2.5x106 BALB/c DCs (either untransduced, or 
transduced with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO) were injected 
intravenously into C3H/He mice. After 10 days, whole CD4+ T cells and CD4+CD25- T 
cells (negatively selected after CD4+CD25+ T cell depletion ex vivo) purified from the 
spleens of injected mice were rechallenged in vitro (at a 1:10 DC : T cell ratio) with 
donor BALB/c DCs. Culture supernatant from the rechallenge assays (including CD25+ 
T cell depleted-rechallenge assays) were harvested for detection of the 
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immunoregulatory cytokines TGF-β [Figure 43(a)] and IL-10 [Figure 43(b)] by 
ELISA. 
Relative to concentrations of TGF-β and IL-10 in the culture supernatant of assays in 
which CD4+ T cells were rechallenged after purification from the spleens of mice that 
were injected with untransduced or Mock-expressing (donor-derived) DCs, there were 
significantly higher concentrations of these immunoregulatory cytokines in supernatants 
when the T cells were purified from mice that were injected with CTLA4-KDEL-
expressing DCs. Furthermore, the production of TGF-β and IL-10 was not restricted to 
rechallenge assays in which CD4+CD25+ T cells were present. On the contrary, there 
were high levels of these immunoregulatory cytokines in rechallenge assays that were 
depleted for CD4+CD25+ T cells prior to the start of coculture, indicating that 
CD4+CD25- T cells produced significant levels of the investigated cytokines. In contrast 
to the above observations, TGF-β and IL-10 levels in supernatant taken from assays in 
which T cells were rechallenged after previous exposure (in vivo) to IDO-expressing 
DCs were not significantly higher than if they were exposed to untransduced or Mock-
expressing DCs. Hence, in addition to the demonstration of donor alloantigen-specific T 
cell anergy induction in vivo, the use of ELISA on supernatants taken from two-stage 
MLRs clearly demonstrates an induction of TGF-β and IL-10 production in CD4+ T 
cells, including the CD25- compartment, that are exposed in vivo to EIAV CTLA4-
KDEL-transduced DCs. 
3.14.3. Generation of Donor Alloantigen-Specific Tregs in vivo 
 
After experimental results demonstrating the in vitro-generation of donor alloantigen-
specific Tregs from CD4+ T cells after coculture with EIAV CTLA4-KDEL-transduced 
DCs (section 3.12.3), and the subsequent in vivo-induction of donor alloantigen-specific 
T cell anergy (section 3.14.3), it was necessary to assess whether donor alloantigen-
specific Tregs could be generated in vivo from CD4+ T cells rendered anergic after 
administration of CTLA4-KDEL-expressing DCs. The outcome would have obvious 
implications for the application of DC-based tolerogenic therapy in the prevention of 
clinical allograft rejection. To address this vital issue, suppressor assays were developed 
similar to those designed to assess the generation of Tregs in vitro after coculture of 
CD4+ T cells with CTLA4-KDEL-expressing DCs. 2.5x106 BALB/c DCs (either  
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Figure 43. Production of TGF-β and IL-10 by CD4+CD25- T Cells in Rechallenge Assays. 
2.5x106 BALB/c DCs (either untransduced, or transduced with EIAV Mock, EIAV CTLA4-KDEL or EIAV 
IDO) were injected intravenously into C3H/He mice. After 10 days, whole CD4+ T cells and CD4+CD25- T 
cells (negatively selected after CD4+CD25+ T cell depletion ex vivo) purified from the spleens of injected 
mice were rechallenged in vitro (at a 1:10 DC : T cell ratio) with donor BALB/c DCs. Culture supernatant 
from the rechallenge assays (including CD25+ T cell depleted-rechallenge assays) were harvested for 
detection of the immunoregulatory cytokines (a) TGF-β and (b) IL-10 by ELISA. Results shown are the 
Mean ± SD of triplicate wells. 
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untransduced, or transduced with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO) 
were injected intravenously into C3H/He mice. After 10 days, CD4+CD25+ T cells 
purified from the spleens of injected mice were irradiated and added in increasing 
numbers (0-105 CD4+CD25+ T Cells) to a primary MLR between freshly-isolated C3H-
derived CD4+ T cells and donor BALB/c DCs [Figure 44(a)] or third-party C57BL/6 
DCs [Figure 44(b)] (at a 1:5 DC : T cell ratio). T cell proliferation was assessed by 
thymidine incorporation after 5 days. A dose-dependent inhibition of T cell proliferation 
was observed in the MLR between (donor) BALB/c DCs and freshly-isolated C3H/He 
CD4+ T cells in the presence of increasing numbers of syngeneic (C3H) CD4+CD25+ T 
cells purified from mice that were injected intravenously with donor BALB/c-derived, 
CTLA4-KDEL-expressing DCs. Donor allospecificity was demonstrated as CD4+ T cell 
proliferation was not inhibited in a MLR between third-party C57BL/6 DCs and 
freshly-isolated C3H CD4+ T cells in the presence of syngeneic CD4+CD25+ T cells 
purified from mice that were injected 10 days earlier with CTLA4-KDEL-expressing 
BALB/c DCs. T cell regulation (donor-specific or otherwise) was not observed in the 
suppressor assays with the addition of CD4+CD25+ T cells purified from mice that were 
administered with IDO-expressing DCs. The results therefore demonstrate the 
generation of donor alloantigen-specific Tregs in vivo after intravenous administration 
of DCs transduced to express CTLA4-KDEL rather than IDO. 
3.14.4. Generation of Tregs in vivo with CTLA4-KDEL-Expressing DCs is Associated 
with Upregulation of FoxP3 and CTLA4 Expression 
 
Subsequent to the in vivo-generation of Tregs after the intravenous administration of 
CTLA4-KDEL-expressing DCs, it was necessary to investigate whether there is a 
relationship between the immunoregulatory activity observed in section 3.14.3 and 
expression of the intracellular marker FoxP3 (a transcription factor associated with 
naturally-occuring CD4+CD25+ Tregs). Similar to experiments designed to investigate 
the immunophenotype of Tregs generated in vitro, expression of the negative 
costimulatory molecule CTLA4 was also analysed to detect upregulation of this marker 
by the in vivo-generated Tregs. 2.5x106 BALB/c DCs (either untransduced, or 
transduced with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO) were injected 
intravenously into C3H/He mice. After 10 days, CD4+CD25+ T cells purified from the  
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Figure 44. Generation of Donor Alloantigen-Specific Tregs in vivo. 
2.5x106 BALB/c DCs (either untransduced, or transduced with EIAV Mock, EIAV CTLA4-KDEL or EIAV 
IDO) were injected intravenously into C3H/He mice. After 10 days, CD4+CD25+ T cells purified from the 
spleens of injected mice were irradiated and added in increasing numbers (0-105 CD4+CD25+ T Cells) to a 
primary MLR between freshly-isolated C3H-derived CD4+ T cells and (a) donor BALB/c DCs or (b) third-
party C57BL/6 DCs (at a 1:5 DC : T cell ratio). T cell proliferation was assessed by thymidine incorporation 
after 5 days. All results shown are the Mean ± SD of triplicate wells. 
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spleens of injected mice were stained and analysed by flow cytometry for expression of 
CD4, CD25, total (intracellular) CTLA4 and FoxP3 [Figure 45]. CD4+CD25+ T cells 
purified from the spleens of mice injected with CTLA4-KDEL-transduced DCs 
exhibited a marked upregulation of the intracellular Treg marker FoxP3 (from 
approximately 6% of CD4+CD25+ T cells to approximately 20%) in comparison to T 
cells that were purified from mice that injected intravenously with untransduced or 
Mock-transduced DCs. There was also a marked upregulation of total (intracellular) 
CTLA4 in these CD4+CD25+ T cells. The number of percentage of CD4+ T cells 
coexpressing CD25 did not differ significantly between the five groups of mice. 
 
In addition to the production of immunoregulatory cytokines by CD4+CD25- T cells (as 
demonstrated in section 3.14.2), it could be speculated from the results that the 
induction of FoxP3+ Treg populations (resulting from either the expansion of naturally 
occurring CD4+CD25+ Tregs or induction from FoxP3- T cell precursors) contributed to 
the donor-specific immunoregulation observed with in vivo-generated Tregs after 
intravenous administration CTLA4-KDEL-expressing DCs. As expected from the 
rechallenge and suppressor assays undertaken earlier, FoxP3+ and/or CTLA4+ T cells 
were not generated in vivo after administration of IDO-expressing DCs. 
3.14.5. Induction of Linked Suppression Mediated by in vivo-Generated, Donor 
Alloantigen-Specific Tregs 
 
After experimental findings demonstrating that donor alloantigen-specific Tregs with 
the capacity for mediating linked suppression could be generated in vitro after coculture 
of CD4+ T cells with CTLA4-KDEL-expressing DCs (section 3.12.5), it was important 
to investigate whether the Tregs that were generated in vivo after intravenous 
administration of CTLA4-KDEL-expressing DCs (section 3.14.4), were also capable of 
mediating linked suppression. As described earlier, for DC-based tolerogenic therapy to 
be efficient in transplantation medicine, the induction of Tregs in vivo with the capacity 
for linked suppression would be essential as the regulatory/suppressive effect would 
‘spread’ to T cells that did not encounter the genetically-modified DCs. In order to 
investigate this, 2.5x106 BALB/c DCs (either untransduced, or transduced with EIAV 
Mock, EIAV CTLA4-KDEL or EIAV IDO) were injected intravenously into C3H/He  
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Figure 45. Generation of Tregs in vivo with CTLA4-KDEL-Expressing DCs is Associated with 
Upregulation of FoxP3 and CTLA4 Expression. 
2.5x106 BALB/c DCs (either untransduced, or transduced with EIAV Mock, EIAV CTLA4-KDEL or EIAV 
IDO) were injected intravenously into C3H/He mice. After 10 days, CD4+CD25+ T cells purified from the 
spleens of injected mice were stained and analysed by flow cytometry for expression of CD4, CD25, 
intracellular (total) CTLA4 and FoxP3. 
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mice. After 10 days, CD4+ T cells purified from the spleens of injected mice were 
rechallenged in vitro (at a 1:10 DC : T cell ratio) with CB6F1 
[(BALB/c)x(C57BL/6)F1] DCs expressing both donor and third-party MHC [Figure 
46(a)] or B6CBF1 [(C57BL/6)x(CBA/Ca)F1] DCs expressing only third-party MHC 
[Figure 46(b)], and CD4+ T cell proliferation assessed by thymidine incorporation on 
days 3, 5 and 7. Results of the rechallenge assays demonstrate donor-specific linked 
suppression of CD4+ T cell proliferation after previous exposure in vivo to 
CTLA4-KDEL-transduced DCs, in comparison to exposure to untransduced or Mock-
transduced DCs: there was a considerable reduction of CD4+ T cell proliferation on 
rechallenge with CB6F1 DCs expressing both donor (H-2d) and third-party (H-2b) 
‘linked’ alloantigens whereas rechallenge with B6CBF1 DCs expressing only third-
party H-2b (in addition to syngeneic H-2k) alloantigens resulted in a standard, primary 
C3H/He T cell response with highest proliferation on day 5. On rechallenge with 
CB6F1 and B6CBF1 DCs, CD4+ T cells that were previously exposed in vivo (after 
intravenous administration) to IDO-transduced DCs did not demonstrate specific linked 
suppression, but rather a non-specific hyporesponsiveness- thymidine incorporation 
counts from the two-stage MLRs demonstrate a significant reduction of CD4+ T cell 
proliferation after a rechallenge with either F1 DCs expressing donor and third party 
MHC, or F1 DCs expressing only third-party C57BL/6 (H-2b) antigens. 
 
CD4+CD25+ T cells purified from the spleens of injected mice were also irradiated and 
added in increasing numbers (0-100000 CD4+CD25+ T Cells) to new primary MLRs 
between freshly-isolated C3H-derived CD4+ T cells and CB6F1 DCs [Figure 46(c)] or 
B6CBF1 DCs [Figure 46(d)] (at a 1:5 DC : T cell ratio). T cell proliferation was 
assessed by thymidine incorporation after 5 days. A dose-dependent inhibition of T cell 
proliferation was observed in the MLR between CB6F1 DCs expressing both donor (H-
2d) and third-party (H-2b) ‘linked’ alloantigens and freshly-isolated C3H/He CD4+ T 
cells in the presence of increasing numbers of syngeneic (C3H) CD4+CD25+ T cells 
purified from mice that were injected intravenously with donor BALB/c-derived, 
CTLA4-KDEL-expressing DCs. The in vivo-generation of donor alloantigen-specific 
Tregs with the capacity for mediating specific linked suppression was demonstrated as 
CD4+ T cell proliferation was not inhibited in a MLR between B6CBF1 DCs expressing  
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Figure 46. Induction of Linked Suppression Mediated by in vivo-Generated, Donor Alloantigen-
Specific Tregs. 
2.5x106 BALB/c DCs (either untransduced, or transduced with EIAV Mock, EIAV CTLA4-KDEL or EIAV 
IDO) were injected intravenously into C3H/He mice. After 10 days, CD4+ T cells purified from the spleens 
of injected mice were rechallenged in vitro (at a 1:10 DC : T cell ratio) with (a) CB6F1 
[(BALB/c)x(C57BL/6)F1] DCs expressing both donor and third-party MHC or (b) B6CBF1 
[(C57BL/6)x(CBA/Ca)F1] DCs expressing only third-party MHC, and CD4+ T cell proliferation assessed by 
thymidine incorporation on days 3, 5 and 7. CD4+CD25+ T cells purified from the spleens of injected mice 
were also irradiated and added in increasing numbers (0-105 CD4+ T Cells) to new primary MLRs between 
freshly-isolated C3H-derived CD4+ T cells and (c) CB6F1 DCs or (d) B6CBF1 DCs (at a 1:5 DC : T cell 
ratio). T cell proliferation was assessed by thymidine incorporation after 5 days. All results shown are the 
Mean ± SD of triplicate wells. 
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only third-party H-2b (in addition to syngeneic H-2k) alloantigens and freshly-isolated 
C3H CD4+ T cells in the presence of syngeneic CD4+CD25+ T cells purified from mice 
injected 10 days earlier with CTLA4-KDEL-expressing BALB/c DCs. Donor-specific 
linked suppression (or general T cell suppression / non-specific bystander suppression) 
was not observed in the suppressor assays with the addition of CD4+CD25+ T cells 
purified from mice that were injected with IDO-expressing DCs. As demonstrated 
earlier, CD4+ T cells previously exposed in vivo to EIAV IDO-transduced DCs 
exhibited almost total hyporesponsiveness in the rechallenge assays. 
 
The results thus demonstrate the in vivo-generation of donor alloantigen-specific Tregs 
with the capacity for mediating linked suppression after intravenous administration of 
EIAV CTLA4-KDEL-transduced DCs. CD4+ T cells purified from mice that were 
injected with IDO-expressing DCs exhibited non-specific hyporesponsiveness with no 
immunoregulatory properties or significant effect on suppressor assays. 
3.14.6. Reversibility of T Cell Anergy Induced by CTLA4-KDEL-Expressing DCs 
 
As explained in section 1.13.1, it is critical that alloreactive T cells rendered anergic 
after encountering EIAV-transduced DCs do not die but instead acquire the capacity to 
regulate the activity of other alloreactive/effector T cells. Donor-specific tolerance 
would thus extend to T cells that do not encounter the modified DCs. It has been 
demonstrated that T cell anergy can be reversed by the addition of exogenous IL-2 
directly to T cell cultures (Beverly et al., 1992). Indeed, T cell anergy has been defined 
as a reversible, anti-proliferative state (Schwartz, 1992; Kuniyasu et al., 2000). The 
addition of high-dose IL-2 to the rechallenge assays performed in section 3.14.1 would 
determine whether the donor-allospecific or non-specific inhibition of T cell clonal 
proliferation, induced by CTLA4-KDEL-expressing DCs and IDO-expressing DCs 
respectively, is reversible. 
 
The CD4+ T cell hyporesponsiveness (donor-allospecific or otherwise) observed in 
section 3.14.1 with CTLA4-KDEL- and IDO-expressing DCs was therefore investigated 
further to determine if the CD4+ T cells are rendered anergic (in a reversible, anti-
proliferative state) or permanently hyporesponsiveness in vivo (and thus unresponsive to 
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high-dose IL-2 in vitro). 2.5x106 BALB/c DCs (either untransduced, or transduced with 
EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO) were injected intravenously into 
C3H/He mice. After 10 days, CD4+ T cells purified from the spleens of injected mice 
were rechallenged in vitro (at a 1:10 DC : T cell ratio) with donor BALB/c DCs [Figure 
47(a)], third-party C57BL/6 DCs [Figure 47(b)], CB6F1 [(BALB/c)x(C57BL/6)F1] 
DCs expressing both donor and third-party MHC [Figure 47(c)] or B6CBF1 
[(C57BL/6)x(CBA/Ca)F1] DCs expressing only third-party MHC [Figure 47(d)], in the 
presence of 100 U/ml exogenous IL-2. CD4+ T cell proliferation was assessed by 
thymidine incorporation on days 3, 5 and 7. Addition of exogenous IL-2 to rechallenge 
cultures did indeed result in reversal of the donor-specific T cell anergy that was 
demonstrated in after intravenous administration of CTLA4-KDEL-expressing DCs. On 
rechallenge (in vitro) with donor BALB/c- and third-party C57BL/6-derived DCs in the 
presence of 100 U/ml IL-2, C3H/He CD4+ T cells that were previously exposed in vivo 
to EIAV CTLA4-KDEL-transduced DCs demonstrated an enhanced (as a result of high-
dose IL-2 stimulation) primary T cell response with highest proliferation on day 5, in 
contrast to T cells that were exposed to untransduced or EIAV Mock-transduced DCs 
and subsequently demonstrated a secondary (memory) response with highest 
proliferation of day 3. The results confirm that T cells exhibiting donor alloantigen-
specific hyporesponsiveness after exposure to CTLA-KDEL-expressing DCs are 
anergic as represented by the restoration of clonal proliferation on rechallenge with 
donor DCs in the presence of exogenous IL-2. This is in stark contrast to T cells that 
demonstrated non-specific hyporesponsiveness in rechallenge assays after exposure in 
vivo to IDO-expressing DCs. In the presence of exogenous IL-2, these T cells still 
demonstrated considerable hyporesponsiveness on rechallenge with both donor-derived 
BALB/c and third-party C57BL/6 DCs. This demonstrates that stimulation of CD4+ T 
cells with IDO-expressing DCs most likely results in an unreversible anti-proliferative 
state (therefore likely to result in T cell deletion in vivo) as the majority of these CD4+ T 
cells do not proliferate on rechallenge with DCs in the presence of non-specific IL-2 
stimulation. 
 
The reversal of donor-allospecific T cell anergy- as observed on addition of exogenous 
IL-2 to assays in which T cells were previously exposed in vivo to EIAV 
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Figure 47. Reversibility of T Cell Anergy Induced by CTLA4-KDEL-Expressing DCs. 
2.5x106 BALB/c DCs (either untransduced, or transduced with EIAV Mock, EIAV CTLA4-KDEL or EIAV 
IDO) were injected intravenously into C3H/He mice. After 10 days, CD4+ T cells purified from the spleens 
of injected mice were rechallenged in vitro (at a 1:10 DC : T cell ratio) with (a) donor BALB/c DCs, (b) third-
party C57BL/6 DCs, (c) CB6F1 [(BALB/c)x(C57BL/6)F1] DCs expressing both donor and third-party MHC 
or (d) B6CBF1 [(C57BL/6)x(CBA/Ca)F1] DCs expressing only third-party MHC, in the presence of 
100 U/ml exogenous IL-2. CD4+ T cell proliferation was assessed by thymidine incorporation on days 3, 5 
and 7. All results shown are the Mean ± SD of triplicate wells. 
Chapter 3: Results 
Adnan Khan, Department of Immunology, Division of Medicine, Imperial College London 214 
 CTLA4-KDEL-transduced DCs- was also applicable to assays in which CD4+ T cells 
were rechallenged with F1 DCs expressing both donor and third-party MHC to 
demonstrate the induction of linked suppression. After stimulation of CD4+ T cells with 
CTLA4-KDEL-expressing DCs in vivo, results in section 3.14.5 demonstrated a 
considerable reduction in proliferation of CD4+ T cells on rechallenge with CB6F1 DCs 
expressing both donor (H-2d) and third-party (H-2b) ‘linked’ alloantigens whereas 
rechallenge with B6CBF1 DCs expressing only third-party H-2b alloantigens resulted in 
a primary C3H/He T cell response with highest proliferation on day 5. However, on 
addition of exogenous IL-2 to these cultures, there was a restoration in the proliferation 
of the CD4+ T cells when rechallenged with CB6F1 DCs, with highest proliferation on 
day 5 that is indicative of a primary response to the third-party antigens expressed by 
the CB6F1 DCs. Again, this is in contrast to CD4+ T cells that demonstrated (in section 
3.14.5) non-specific hyporesponsiveness when rechallenged in vitro with F1 DCs after 
exposure to IDO-expressing DCs. In the presence of exogenous IL-2, these T cells 
continued to demonstrate considerably-reduced proliferation on rechallenge with both 
CB6F1 and B6CBF1 DCs, demonstrating a lack of (reversible) anergy in CD4+ T cells 
that are exposed to IDO-expressing DCs. 
 
The reversibility of CD4+ T cell anergy induced by CTLA4-KDEL-expressing DCs 
might be unexpected at first, given that the in vivo-generation of donor-allospecific 
Tregs was demonstrated in section 3.14.3. This requires some description of the 
properties of natural FoxP3+CD4+CD25+ Tregs and experimentally-induced anergic T 
cells with suppressive/regulatory properties. After TCR crosslinking in vitro, Tregs are 
unable to proliferate or produce IL-2 but are able to inhibit proliferative responses and 
cytokine production by effector T cells (Fontenot and Rudensky, 2005). However, 
despite their apparent in vitro anergy, Treg populations are capable of robust expansion 
in vivo, so their description as anergic cells is misleading (Fontenot and Rudensky, 
2005). Natural Tregs undergo antigen-specific proliferation in vivo (after strong 
antigenic stimulation) or in vitro (after stimulation with antigen and high-dose IL-2), 
although to a lesser degree than the proliferation of effector T cells (Takahashi et al., 
1998; Thornton and Shevach, 1998; Klein et al., 2003; Walker et al., 2003; Nishimura et 
al., 2004). They are actually more proliferative than other T cells in the physiological 
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steady state through the recognition of autoantigens (Fisson et al., 2003; Setoguchi et 
al., 2005). IL-2 is vital for the in vitro and in vivo activation of natural Tregs and for 
sustaining their CD25 expression (Furtado et al., 2002; Malek and Bayer, 2004; 
Thornton et al., 2004). The main source of IL-2 responsible for the in vivo maintenance 
and activation of CD4+CD25+ Tregs has been suggested to be other T cells, including 
autoreactive T cells, in the physiological steady state (Setoguchi et al., 2005). Thus IL-2 
has been described to mediate a feedback control between responder T cells and Tregs; 
that is IL-2 secreted by responder T cells maintains and activates Tregs, which in turn 
inhibit IL-2 production in responder T cells (Sakaguchi, 2005). It could thus be 
expected that IL-2 would conserve the suppressive capacity of the FoxP3+CD4+CD25+ 
Tregs generated in vivo after administration of CTLA4-KDEL-expressing DCs. 
 
However, natural CD4+CD25+ Tregs are functionally distinct from experimentally-
induced suppressive T cells, including anergy-induced suppressive T cells or regulatory 
T cells secreting a particular immunoregulatory cytokine (Chen et al., 1994; Lombardi 
et al., 1994; Powrie et al., 1996; Groux et al., 1997; Taams et al., 1998; Chai et al., 
1999). Both early and recent reports have indicated that natural or adaptive Treg-
mediated in vitro suppression can be overridden by provision of large amounts of IL-2 
(Takahashi et al., 1998; Li et al., 2007), that is the addition of high doses of IL-2 to 
in vitro T cell stimulation cultures not only breaks the anergic state of CD4+CD25+ T 
cells, but also abrogates their suppressive activity simultaneously. Importantly, the 
anergic/suppressive state of CD4+CD25+ Tregs has been demonstrated to be their basal 
default condition, since removal of IL-2 from the culture milieu allows them to revert to 
the original anergic/suppressive state (Takahashi et al., 1998). This contrasts markedly 
with usual anergic T cells which will never revert to an anergic state spontaneously 
once their anergic state is abrogated (Essery et al., 1988). In addition, suppression by 
natural CD4+CD25+ Tregs is antigen-nonspecific in the effector phase, which is similar 
to linked suppression (Davies et al., 1996). Furthermore, they suppress the 
activation/proliferation of both CD4+ and CD8+ T cells (Takahashi et al., 1998). This is 
in contrast to antigen-specific suppression by experimentally-induced anergy (Lombardi 
et al., 1994; Taams et al., 1998; Chai et al., 1999). It has been suggested that one aspect 
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of immunologic self-tolerance is maintained by this unique CD4+CD25+ naturally 
anergic/suppressive T cell population (Takahashi et al., 1998). 
 
Experiments undertaken in sections 3.14.1-3.14.5 have shown the in vivo-generation of 
both donor-allospecific CD4+CD25+ Tregs (including FoxP3+CD4+CD25+ Tregs) and 
CD4+CD25- T cells with suppressive properties (the production of immunoregulatory 
cytokines IL-10 and TGF-β) by CTLA4-KDEL-expressing DCs. The reversibility of 
anergy in these induced regulatory populations of T cells, demonstrated with the 
rechallenge assays, is thus consistent with the reports described above of natural or 
adaptive Treg-mediated in vitro suppression being overridden by provision of large 
amounts of IL-2. 
3.14.7. Donor Alloantigen-Specific Regulation by CD4+CD25- T Cells 
 
Experiments undertaken in this study have so far demonstrated (amongst other findings) 
the generation of donor alloantigen-specific Tregs in vivo after intravenous 
administration of EIAV CTLA4-KDEL-transduced DCs. Suppressor assays undertaken 
in sections 3.14.3 and 3.14.5 show in vivo-generated, donor allospecific Tregs to be 
present amongst the CD25+ fraction of the CD4+ T cell population: a dose-dependent, 
donor-specific inhibition of T cell proliferation was observed in an MLR between 
BALB/c DCs and freshly-isolated C3H/He CD4+ T cells in the presence of increasing 
numbers of syngeneic (C3H) CD4+CD25+ T cells purified from mice that were injected 
with BALB/c-derived, CTLA4-KDEL-expressing DCs. However, when ELISAs were 
performed to investigate the production of immunoregulatory cytokines by T cells that 
were rechallenged with donor-derived DCs after primary stimulation in vivo with 
CTLA4-KDEL-expressing DCs (section 3.14.2), there were high levels of TGF-β and 
IL-10 in assays that were depleted for CD4+CD25+ T cells prior to the start of coculture. 
This indicated that CD4+CD25- T cells were a significant source of the 
immunoregulatory cytokines. 
 
The potential role of CD4+CD25- T cells in the induction of donor alloantigen-specific 
T cell anergy by CTLA-KDEL-expressing DCs in vivo, in addition to the role in donor-
allospecific regulation and linked suppression, was therefore investigated with the 
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further use of rechallenge assays. 2.5x106 BALB/c DCs (either untransduced, or 
transduced with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO) were injected 
intravenously into C3H/He mice. After 10 days, CD4+CD25- T cells purified from the 
spleens of injected mice (after CD4+CD25+ T cell depletion ex vivo) were rechallenged 
in vitro (at a 1:10 DC : T cell ratio) with donor BALB/c DCs [Figure 48(a)], third-party 
C57BL/6 DCs [Figure 48(b)], CB6F1 [(BALB/c)x(C57BL/6)F1] DCs expressing both 
donor and third-party MHC [Figure 48(c)] or B6CBF1 [(C57BL/6)x(CBA/Ca)F1] DCs 
expressing only third-party MHC [Figure 48(d)]. CD4+ T cell proliferation was 
assessed by thymidine incorporation on days 3, 5 and 7. Results from the rechallenge 
assays demonstrate that donor alloantigen-specific Tregs generated in vivo after 
intravenous administration of CTLA4-KDEL-expressing DCs are not concentrated 
solely within the CD25+ fraction of CD4+ T cells. After stimulation in vivo with 
CTLA4-KDEL-expressing BALB/c DCs, CD4+CD25- C3H T cells [negatively selected 
from the spleen-derived CD4+ T cell population after depletion of the CD25+ fragment- 
see figure 58(a) for a representative FACS profile of CD4+CD25+ and CD4+CD25- T 
cell populations after magnetic bead separation] demonstrated a considerable, sustained 
reduction in proliferation on days 3 and 5 on rechallenge with donor-derived BALB/c 
DCs, in comparison to CD4+CD25- T cells that were exposed in vivo to untransduced 
and Mock-transduced DCs and subsequently demonstrated a secondary (memory) 
response with highest proliferation on day 3. The memory response seen with 
CD4+CD25- T cells was not unexpected as murine naïve CD4+CD25- T cells that 
upregulate CD25 during a state of activation (and thus different from natural Treg 
populations that consistently express high levels of CD25) then lose expression of 
CD25 by day 7 post-TCR stimulation/activation (Kuniyasu et al., 2000). As the 
CD4+CD25- T cells were purified from the spleens of mice 10 days after intravenous 
DC administration, the secondary/memory response observed on day 3 of the 
rechallenge assay are most likely to be the response of CD25-CD4+ effector memory 
(CD62low) T cells that have developed after previous exposure to the donor alloantigens 
(Akbar et al., 2007). Donor alloantigen-specific tolerance was demonstrated (in the case 
of CD4+CD25- T cells exposed in vivo to CTLA4-KDEL-expressing DCs) as 
rechallenge of these CD25- T cells with third-party C57BL/6-derived DCs resulted in a 
primary C3H/He T cell response with highest proliferation on day 5. 
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Figure 48. Donor Alloantigen-Specific Regulation CD4+CD25- T Cells. 
2.5x106 BALB/c DCs (either untransduced, or transduced with EIAV Mock, EIAV CTLA4-KDEL or EIAV 
IDO) were injected intravenously into C3H/He mice. After 10 days, CD4+CD25- T cells purified from the 
spleens of injected mice (after CD4+CD25+ T cell depletion ex vivo) were rechallenged in vitro (at a 1:10 
DC : T cell ratio) with (a) donor BALB/c DCs, (b) third-party C57BL/6 DCs, (c) CB6F1 
[(BALB/c)x(C57BL/6)F1] DCs expressing both donor and third-party MHC or (d) B6CBF1 
[(C57BL/6)x(CBA/Ca)F1] DCs expressing only third-party MHC. CD4+ T cell proliferation was assessed by 
thymidine incorporation on days 3, 5 and 7. All results shown are the Mean ± SD of triplicate wells. 
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Regulatory activity was detected in CD4+CD25- T cells exposed in vivo to CTLA4-
KDEL-expressing DCs as demonstrated by the induction of donor-specific linked 
suppression. On rechallenge with CB6F1 DCs expressing both donor and ‘linked’ third-
party alloantigens, there was a significant reduction in proliferation of CD4+CD25- T 
cells, whereas rechallenge with B6CBF1 DCs expressing only third-party MHC resulted 
in a primary response with highest proliferation on day 5. Similar to previous 
experiments, CD4+CD25- T cells that were exposed in vivo to IDO-expressing DCs 
displayed a non-specific reduction in proliferation when rechallenged with both donor- 
and third-party-derived DCs. This was also the case when the cells were rechallenged 
with F1 DCs in order to investigate linked suppression. The results therefore 
demonstrate that donor alloantigen-specific Tregs generated in vivo after stimulation 
with CTLA4-KDEL-expressing DCs exist within both CD25+ (as shown by earlier 
suppressor assays) and CD25- fractions of CD4+ T cells. 
 
3.15. Induction of Tolerance Mediated by in vivo-Generated Tregs with 
Indirect Donor Allospecificity using CTLA4-KDEL-, but not IDO-
expressing DCs 
3.15.1. Induction of T Cell Anergy in vivo with Indirect Donor Allospecificity 
 
As the indirect pathway of alloantigen presentation was a primary focus of this 
investigation due to its role in the chronic phase of allograft rejection, it was important 
to investigate (using an indirect pathway murine strain combination) whether indirect 
pathway-specific CD4+ T cells that are exposed in vivo to CTLA4-KDEL- or IDO-
expressing allogeneic DCs as a result of intravenous DC administration, subsequently 
demonstrate anergy with indirect donor allospecificity. The rechallenge assay optimised 
to detect in vivo-generated allogeneic T cell responses with indirect donor 
allospecificity in section 3.10.2 was subsequently applied to investigate anergy 
induction. 2.5x106 CBK (H-2k + Kb) DCs (either untransduced, or transduced with 
EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO) were injected intravenously into 
CBA/Ca mice. After 10 days, CD4+ T cells purified from the spleens of injected mice 
were rechallenged in vitro (at a 1:10 DC : T cell ratio) with donor CBK DCs [Figure 
49(a)] or third-party B10.A (H-2k + Dd) DCs [Figure 49(b)], and CD4+ T cell 
proliferation assessed by thymidine incorporation on days 3, 5 and 7. 
Chapter 3: Results 
Adnan Khan, Department of Immunology, Division of Medicine, Imperial College London 220 
(a) (b)
Rechallenge with
Donor CBK (H-2k+Kb) DCs
1 3 5 7 9
0
10
20
30
40
50
Day
3 H
-
Th
ym
idi
ne
 
In
co
rp
or
at
ion
 
(C
PM
)
(x1
0^
3)
Rechallenge with
Third-Party B10.A (H-2k+Dd) DCs
1 3 5 7 9
0
25
50
75
100
No DC Injection
Untransduced DCs
Mock-Transduced DCs
CTLA4-KDEL DCs
IDO-Transduced DCs
Day
3 H
-
Th
ym
idi
ne
 
In
co
rp
or
at
ion
 
(C
PM
)
(x1
0^
3)
Day 0: CBK DC Culture
Day 6: Transduction with EIAV
10 Days
Day 9: I.V. Injection
of CBA Mice with
2.5x106 CBK DC
populations
Day 19: Spleen-derived CD4+ T cell 
Purification and in vitro Rechallenge with 
Donor CBK and 3rd-Party B10.A DCs.
Harvest on Day 3, 5 and 7.
72 Hours
Fresh Donor or 
3rd-Party DCs
 
 
 
 
Figure 49. Induction of T Cell Anergy in vivo with Indirect Donor Allospecificity. 
2.5x106 CBK (H-2k + Kb) DCs (either untransduced, or transduced with EIAV Mock, EIAV CTLA4-KDEL or 
EIAV IDO) were injected intravenously into CBA/Ca mice. After 10 days, CD4+ T cells purified from the 
spleens of injected mice were rechallenged in vitro (at a 1:10 DC : T cell ratio) with (a) donor CBK DCs or 
(b) third-party B10.A (H-2k + Dd) DCs, and CD4+ T cell proliferation assessed by thymidine incorporation on 
days 3, 5 and 7. All results shown are the Mean ± SD of triplicate wells. 
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The results of the rechallenge assays demonstrate inhibition of CD4+ T cell proliferation 
with indirect donor allospecificity after previous exposure in vivo to CTLA4-KDEL-
transduced DCs relative to DCs that were either untransduced or transduced with EIAV 
Mock: there was a considerable inhibition of CD4+ T cell proliferation on rechallenge 
with donor CBK-derived DCs in vitro whereas rechallenge with third-party B10.A-
derived DCs resulted in a standard, primary CBA/Ca T cell response with highest 
proliferation on day 5. On rechallenge with donor- and third party-derived DCs, CD4+ T 
cells purified from mice that were injected intravenously with IDO-transduced DCs did 
not demonstrate donor allospecificity- thymidine incorporation counts from the two-
stage MLRs show significant inhibition of proliferation in CD4+ T cells after a 
rechallenge in vitro that is not restricted to a rechallenge with donor CBK DCs, but also 
third-party B10.A DCs. It can thus be stated that T cell anergy with indirect donor 
allospecificity was induced in vivo with CTLA4-KDEL-transduced DCs, but not IDO-
transduced DCs. 
3.15.2. Production of TGF-β and IL-10 by CD4+CD25- T Cells in Rechallenge Assays 
After performing the rechallenge assays described in the previous section, a potential 
link between the observed induction in vivo of anergy with indirect donor allospecificity 
(demonstrated with CD4+ T cells purified from CBK mice that were injected 
intravenously with CTLA4-KDEL-expressing DCs), and the production of 
immunoregulatory cytokines TGF-β and IL-10 was investigated. Similar to the indirect 
pathway-specific rechallenge assay protocol used in section 3.15.1, 2.5x106 CBK (H-2k 
+ Kb) DCs (either untransduced, or transduced with EIAV Mock, EIAV CTLA4-KDEL 
or EIAV IDO) were injected intravenously into CBA/Ca mice. After 10 days, whole 
CD4+ T cells and CD4+CD25- T cells (negatively selected after CD4+CD25+ T cell 
depletion ex vivo) purified from the spleens of injected mice were rechallenged in vitro 
(at a 1:10 DC : T cell ratio) with donor CBK DCs. Culture supernatant from the 
rechallenge assays (including CD25+ T cell depleted-rechallenge assays) were harvested 
for detection of the immunoregulatory cytokines TGF-β [Figure 50(a)] and IL-10 
[Figure 50(b)] by ELISA. 
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Figure 50. Production of TGF-β and IL-10 by CD4+CD25- T Cells in Rechallenge Assays. 
2.5x106 CBK (H-2k + Kb) DCs (either untransduced, or transduced with EIAV Mock, EIAV CTLA4-KDEL or 
EIAV IDO) were injected intravenously into CBA/Ca mice. After 10 days, whole CD4+ T cells and 
CD4+CD25- T cells (negatively selected after CD4+CD25+ T cell depletion ex vivo) purified from the 
spleens of injected mice were rechallenged in vitro (at a 1:10 DC : T cell ratio) with donor CBK DCs. 
Culture supernatant from the rechallenge assays (including CD25+ T cell depleted-rechallenge assays) 
were harvested for detection of the immunoregulatory cytokines (a) TGF-β and (b) IL-10 by ELISA. Results 
shown are the Mean ± SD of triplicate wells. 
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Relative to concentrations of TGF-β and IL-10 in the culture supernatant of assays in 
which indirect pathway-specific CD4+ T cells were rechallenged after purification from 
the spleens of mice that were injected with untransduced or Mock-expressing (donor-
derived) DCs, there were significantly higher concentrations of these immunoregulatory 
cytokines in supernatants when the T cells were purified from mice that were injected 
with CTLA4-KDEL-expressing DCs. Furthermore, the production of TGF-β and IL-10 
was not restricted to rechallenge assays in which CD4+CD25+ T cells (with indirect 
donor allospecificity) were present. On the contrary, there were high levels of these 
immunoregulatory cytokines in rechallenge assays that were depleted for CD4+CD25+ T 
cells prior to the start of coculture, indicating that CD4+CD25- T cells produced 
significant levels of the investigated cytokines. In contrast to the above observations, 
TGF-β and IL-10 levels in supernatant taken from assays in which indirect pathway-
specific T cells were rechallenged after previous exposure (in vivo) to IDO-expressing 
DCs were not significantly higher than if they were exposed to untransduced or Mock-
expressing DCs. Therefore, in addition to the demonstration of donor alloantigen-
specific T cell anergy induction in vivo, the use of ELISA on supernatants taken from 
two-stage MLRs clearly demonstrates an induction of TGF-β and IL-10 production in 
indirect pathway-specific CD4+ T cells, including the CD25- compartment, that are 
exposed in vivo to EIAV CTLA4-KDEL-transduced DCs. 
3.15.3. Generation of Tregs in vivo with Indirect Donor Allospecificity 
 
Further to the results of experiments performed in section 3.14.3, which demonstrated 
the in vivo-generation of donor alloantigen-specific Tregs after administration of EIAV 
CTLA4-KDEL-transduced DCs into mice, it was observed that the application of these 
genetically-modified DCs to an indirect pathway strain combination in vivo induced T 
cell anergy with indirect donor allospecificity. It was thus necessary to investigate 
whether the induction of Tregs from T cells rendered anergic in vivo was restricted to 
the direct pathway of alloantigen presentation (as demonstrated by the use of a murine 
BALB/c-C3H multiple mismatch strain combination in section 3.14.3), or applicable to 
the indirect pathway of allopresentation in vivo. This is due to the predominance of the 
latter pathway during the chronic phase of allograft rejection. 
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Suppressor assays were thus optimised to investigate whether indirect pathway-specific 
CD4+ T cells rendered anergic after interaction with CTLA4-KDEL-expressing DCs in 
vivo (as demonstrated in section 3.15.2) are subsequently capable of T cell regulation in 
a primary MLR between donor-derived DCs and freshly-isolated alloreactive CD4+ T 
cells with indirect donor allospecificity. 2.5x106 CBK (H-2k + Kb) DCs (either 
untransduced, or transduced with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO) 
were injected intravenously into C3H/He mice. After 10 days, CD4+CD25+ T cells 
purified from the spleens of injected mice were irradiated and added in increasing 
numbers (0-100000 CD4+CD25+ T Cells) to a primary MLR between freshly-isolated 
CBA/Ca-derived CD4+ T cells and donor CBK DCs [Figure 51(a)] or third-party 
B10.A (H-2k + Dd) DCs [Figure 51(b)] (at a 1:5 DC : T cell ratio). T cell proliferation 
was assessed by thymidine incorporation after 5 days. A dose-dependent inhibition of T 
cell proliferation was observed in the MLR between (donor) CBK DCs and freshly-
isolated CBA/Ca CD4+ T cells in the presence of increasing numbers of syngeneic 
(CBA) CD4+CD25+ T cells purified from mice that were injected intravenously with 
donor CBK-derived, CTLA4-KDEL-expressing DCs. Donor allospecificity was 
demonstrated as CD4+ T cell proliferation was not inhibited in a MLR between third-
party B10.A DCs and freshly-isolated CBA CD4+ T cells in the presence of syngeneic 
CD4+CD25+ T cells purified from mice that were injected 10 days earlier with 
CTLA4-KDEL-expressing CBK DCs. As expected at this point after performing several 
functional assays originating with either the coculture of CD4+ T cells with IDO-
expressing DCs or the intravenous administration of the latter cells, it was observed that 
T cell regulation (donor-specific or otherwise) did not occur in the suppressor assays 
with the addition of CD4+CD25+ T cells purified from mice that were injected with 
IDO-expressing DCs. The results therefore demonstrate the generation of donor 
alloantigen-specific Tregs in vivo after intravenous administration of DCs transduced to 
express CTLA4-KDEL rather than IDO. 
3.15.4. Induction of Linked Suppression Mediated by in vivo-Generated Tregs with 
Indirect Donor Allospecificity 
 
Experiments undertaken thus far in the study have shown that intravenous 
administration of EIAV CTLA4-KDEL-transduced DCs results in the in vivo-generation  
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Figure 51. Generation of Tregs in vivo with Indirect Donor Allospecificity. 
2.5x106 CBK (H-2k + Kb) DCs (either untransduced, or transduced with EIAV Mock, EIAV CTLA4-KDEL or 
EIAV IDO) were injected intravenously into C3H/He mice. After 10 days, CD4+CD25+ T cells purified from 
the spleens of injected mice were irradiated and added in increasing numbers (0-105 CD4+CD25+ T Cells) 
to a primary MLR between freshly-isolated CBA/Ca-derived CD4+ T cells and (a) donor CBK DCs or (b) 
third-party B10.A (H-2k + Dd) DCs (at a 1:5 DC : T cell ratio). T cell proliferation was assessed by thymidine 
incorporation after 5 days. All results shown are the Mean ± SD of triplicate wells. 
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of Tregs with both direct and indirect donor allospecificity. This was demonstrated by 
the use of both multiple-mismatch and indirect pathway strain combinations 
respectively. In addition, in vivo-generated Tregs with direct pathway allospecificity 
also demonstrated the capacity for linked suppression, an encouraging prospect for the 
use of Tregs (generated by CTLA4-KDEL-expressing DCs) in murine transplantation 
studies for the remainder of this investigation and clinical transplantation in general. 
However, before investigating the effect of intravenous administration of CTLA4-
KDEL- and IDO-expressing DCs on allograft rejection, it was necessary to assess 
whether in vivo-generated Tregs with indirect donor allospecificity (as shown in section 
3.15.3) were capable of mediating linked suppression. Although linked suppression was 
demonstrated with in vivo-generated Tregs specific for the direct pathway of alloantigen 
presentation, linked suppression mediated by in vivo-generated Tregs with indirect 
donor allospecificity is of greater importance as the cells would suppress responses by 
effector T cells that exhibit indirect donor allospecificity, and are thus primarily 
responsible for the chronic phase of allograft rejection. In order to answer this question, 
2.5x106 CBK (H-2k + Kb) DCs (either untransduced, or transduced with EIAV Mock, 
EIAV CTLA4-KDEL or EIAV IDO) were injected intravenously into CBA/Ca mice. 
After 10 days, CD4+ T cells purified from the spleens of injected mice were 
rechallenged in vitro (at a 1:10 DC : T cell ratio) with CB6F1 
[(BALB/c)x(C57BL/6)F1] DCs expressing only third-party MHC-peptide [Figure 
52(a)] or B6CBF1 [(C57BL/6)x(CBA/Ca)F1] DCs expressing both donor (Kb presented 
in the context of I-Ak/I-Ek) and third-party MHC-peptide [Figure 52(b)], and CD4+ T 
cell proliferation assessed by thymidine incorporation on days 3, 5 and 7. 
 
Thymidine incorporation counts from the rechallenge assays demonstrate donor-specific 
linked suppression of CD4+ T cell proliferation after previous exposure in vivo to 
CTLA4-KDEL-transduced DCs, in comparison to exposure to untransduced or Mock-
transduced DCs: there was a considerable reduction of CD4+ T cell proliferation on 
rechallenge with B6CBF1 DCs which have the capacity for indirect presentation of Kb 
in the context of I-Ak/I-Ek (donor peptide-MHC) and also express third-party ‘linked’ 
MHC class I and II alloantigens derived from H-2b. This is in contrast to rechallenge 
with CB6F1 DCs expressing only third-party alloantigens derived from H-2b and H-2d,  
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Figure 52. Induction of Linked Suppression Mediated by in vivo-Generated Tregs with Indirect 
Donor Allospecificity. 
2.5x106 CBK (H-2k + Kb) DCs (either untransduced, or transduced with EIAV Mock, EIAV CTLA4-KDEL or 
EIAV IDO) were injected intravenously into CBA/Ca mice. After 10 days, CD4+ T cells purified from the 
spleens of injected mice were rechallenged in vitro (at a 1:10 DC : T cell ratio) with (a) CB6F1 
[(BALB/c)x(C57BL/6)F1] DCs expressing only third-party MHC-peptide or (b) B6CBF1 
[(C57BL/6)x(CBA/Ca)F1] DCs expressing both donor (Kb presented in the context of I-Ak/I-Ek) and third-
party MHC-peptide, and CD4+ T cell proliferation assessed by thymidine incorporation on days 3, 5 and 7. 
CD4+CD25+ T cells purified from the spleens of injected mice were also irradiated and added in increasing 
numbers (0-105 CD4+CD25+ T Cells) to new primary MLRs between freshly-isolated CBA/Ca-derived CD4+ 
T cells and (c) CB6F1 DCs or (d) B6CBF1 DCs (at a 1:5 DC : T cell ratio). T cell proliferation was 
assessed by thymidine incorporation after 5 days. All results shown are the Mean ± SD of triplicate wells. 
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which resulted in a standard, primary CBA/Ca T cell response with highest proliferation 
on day 5. On rechallenge with B6CBF1 and CB6F1 DCs, CD4+ T cells that were 
previously exposed in vivo to IDO-transduced DCs did not demonstrate specific linked 
suppression- thymidine incorporation counts from the two-stage MLRs demonstrate a 
substantial reduction of CD4+ T cell proliferation after a rechallenge with both F1 DCs 
expressing donor and third-party MHC-peptide, and F1 DCs expressing only third-party 
MHC-peptide. 
 
CD4+CD25+ T cells purified from the spleens of injected mice were also irradiated and 
added in increasing numbers (0-100000 CD4+CD25+ T Cells) to new primary MLRs 
between freshly-isolated CBA/Ca-derived CD4+ T cells and CB6F1 DCs [Figure 52(c)] 
or B6CBF1 DCs [Figure 52(d)] (at a 1:5 DC : T cell ratio). T cell proliferation was 
assessed by thymidine incorporation after 5 days. A dose-dependent inhibition of T cell 
proliferation was observed in the MLR between B6CBF1 DCs expressing both donor 
(Kb presented in the context of I-Ak/I-Ek) and ‘linked’ third-party MHC-peptide, and 
freshly-isolated CBA/Ca CD4+ T cells in the presence of increasing numbers of 
syngeneic (CBA) CD4+CD25+ T cells purified from mice that were injected 
intravenously with donor CBK-derived, CTLA4-KDEL-expressing DCs. The in vivo-
generation of Tregs with indirect donor allospecificity and the capacity for donor-
specific linked suppression was demonstrated as CD4+ T cell proliferation was not 
inhibited in a MLR between CB6F1 DCs expressing only third-party MHC-peptide, and 
freshly-isolated CBA CD4+ T cells in the presence of syngeneic CD4+CD25+ T cells 
that were purified from mice injected intravenously with donor CBK-derived, 
CTLA4-KDEL-expressing DCs. Donor-specific linked suppression was not observed in 
the suppressor assays with the addition of CD4+CD25+ T cells purified from mice that 
were injected with CBK-derived, IDO-expressing DCs. 
 
Overall, the results demonstrate the capacity for linked suppression by Tregs with 
indirect donor allospecificity, generated in vivo after the intravenous administration of 
DCs transduced to express CTLA4-KDEL rather than IDO. The results of the 
rechallenge and suppressor assays support the findings of experiments in which 
induction of tolerance to Kb alone resulted in acceptance of a fully mismatched H-2b 
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graft (Wong et al., 1996; Wong et al., 1997). Similarly in this study, in vivo-generated 
Tregs specific for the indirect allopresentation of Kb alone were able to mediate 
suppression to linked third-party alloantigens presented by F1 DCs. It could be 
speculated that Tregs generated in vivo using donor-derived, CTLA4-KDEL-expressing 
DCs would be efficient at inducing long-term transplantation tolerance as a result of the 
capacity for linked suppression, leading to subsequent infectious tolerance. During the 
chronic phase of allorecognition (when the indirect pathway is the predominant pathway 
of alloantigen presentation), Tregs with indirect donor allospecificity would suppress 
effector T cells reactive against unrelated donor alloantigens, so long as the latter 
antigens are presented on the same DC. This would cause Treg-mediated tolerance of 
the donor antigen (presented on the initial tolerogenic/CTLA4-KDEL-expressing DCs) 
to spread to an unrelated antigen, allowing for the infectious nature of transplantation 
tolerance. 
3.15.5. Reversibility of T Cell Anergy (with Indirect Donor Allospecificity) Induced by 
CTLA4-KDEL-expressing DCs 
 
Similar to the earlier rechallenge assays performed to demonstrate the reversibility of 
direct pathway T cell anergy, the CD4+ T cell hyporesponsiveness (with indirect donor 
allospecificity or otherwise) observed in section 3.14.1 with CTLA4-KDEL- and IDO-
expressing DCs was investigated to determine if the CD4+ T cells are rendered anergic 
(and thus in a reversible, anti-proliferative state) or permanently hyporesponsiveness in 
vivo (and thus unresponsive to high-dose IL-2 in vitro). 
 
Assessment of the reversibility of T cell anergy was undertaken by the addition of 
exogenous IL-2 directly to the rechallenge cultures. 2.5x106 CBK (H-2k + Kb) DCs 
(either untransduced, or transduced with EIAV Mock, EIAV CTLA4-KDEL or EIAV 
IDO) were injected intravenously into CBA/Ca mice. After 10 days, CD4+ T cells 
purified from the spleens of injected mice were rechallenged in vitro (at a 1:10 DC : T 
cell ratio) with donor CBK DCs [Figure 53(a)], third-party B10.A (H-2k + Dd) DCs 
[Figure 53(b)], CB6F1 [(BALB/c)x(C57BL/6)F1] DCs expressing only third-party 
MHC-peptide [Figure 53(c)] or B6CBF1 [(C57BL/6)x(CBA/Ca)F1] DCs expressing 
both donor (Kb presented in the context of I-Ak/I-Ek) and third-party MHC-peptide  
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Figure 53. Reversibility of T Cell Anergy (with Indirect Allospecificity) Induced by CTLA4-KDEL-
Expressing DCs. 
2.5x106 CBK (H-2k + Kb) DCs (either untransduced, or transduced with EIAV Mock, EIAV CTLA4-KDEL or 
EIAV IDO) were injected intravenously into CBA/Ca mice. After 10 days, CD4+ T cells purified from the 
spleens of injected mice were rechallenged in vitro (at a 1:10 DC : T cell ratio) with (a) donor CBK DCs, (b) 
third-party B10.A (H-2k + Dd) DCs, (c) CB6F1 [(BALB/c)x(C57BL/6)F1] DCs expressing only third-party 
MHC-peptide or (d) B6CBF1 [(C57BL/6)x(CBA/Ca)F1] DCs expressing both donor (Kb presented in the 
context of I-Ak/I-Ek) and third-party MHC-peptide, in the presence of 100 U/ml exogenous IL-2. CD4+ T cell 
proliferation was assessed by thymidine incorporation on days 3, 5 and 7. All results shown are the Mean 
± SD of triplicate wells. 
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[Figure 53(d)], in the presence of 100 U/ml exogenous IL-2. CD4+ T cell proliferation 
was assessed by thymidine incorporation on days 3, 5 and 7. Addition of exogenous 
IL-2 to rechallenge cultures resulted in reversal of the T cell unresponsiveness (with 
indirect donor allospecificity) that was demonstrated in section 3.15.1 after intravenous 
administration of CTLA4-KDEL-expressing DCs. Similar to results obtained with 
direct-pathway T cells in section 3.14.6, on rechallenge (in vitro) with donor CBK- and 
third-party B10.A-derived DCs in the presence of 100 U/ml IL-2, CBA/Ca CD4+ T cells 
that were previously exposed in vivo to EIAV CTLA4-KDEL-transduced DCs 
demonstrated a primary T cell response with highest proliferation on day 5, in contrast 
to T cells that were exposed to untransduced or EIAV Mock-transduced DCs and 
subsequently demonstrated a secondary (memory) response with highest proliferation of 
day 3. The results confirm that T cells exhibiting a state of unresponsiveness with 
indirect donor allospecificity after exposure to CTLA-KDEL-expressing DCs are 
anergic cells as represented by the restoration of clonal proliferation on rechallenge with 
donor DCs in the presence of exogenous IL-2. Again, this is in contrast to T cells that 
demonstrated non-specific hyporesponsiveness in rechallenge assays after a primary 
challenge in vivo with IDO-expressing DCs. Even in the presence of exogenous IL-2, 
these T cells exhibited a considerable inhibition of proliferation on rechallenge with 
both donor CBK and third-party B10.A DCs. Results from the rechallenge assays 
undertaken here and discussed in section 3.14.6 demonstrate that stimulation of CD4+ T 
cells (whether specific for the direct or indirect pathways) with IDO-expressing DCs 
most likely results in non-specific hyporesponsiveness (with no suppressive properties) 
as the majority of these cells do not proliferate on DC rechallenge in the presence of 
non-specific IL-2 stimulation. 
 
The reversal of donor-allospecific T cell anergy observed on addition of exogenous IL-2 
was also applicable to assays in which CD4+ T cells were rechallenged with F1 DCs 
expressing donor and third-party MHC-peptide to demonstrate the induction of linked 
suppression. After stimulation of CD4+ T cells with CTLA4-KDEL-expressing DCs in 
vivo, results in section 3.15.4 demonstrated a considerable reduction in proliferation of 
CD4+ T cells on rechallenge with B6CBF1 DCs, which have the capacity for indirect 
presentation of Kb in the context of I-Ak/I-Ek (donor peptide-MHC) and also express 
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third-party ‘linked’ MHC class I and II alloantigens derived from H-2b, whereas 
rechallenge with CB6F1 DCs expressing only third-party alloantigens derived from 
H-2b and H-2d resulted in a primary CBA/Ca T cell response with highest proliferation 
on day 5. However, on addition of exogenous IL-2 to these cultures, there was a 
restoration in the proliferation of the CD4+ T cells when rechallenged with B6CBF1 
DCs, with highest proliferation on day 5 that is indicative of a primary response to the 
third-party antigens expressed by the B6CBF1 DCs. Again, this is in contrast to CD4+ T 
cells that demonstrated (in section 3.15.4) non-specific hyporesponsiveness when 
rechallenged in vitro with F1 DCs after a primary challenge in vivo with IDO-
expressing DCs. In the presence of exogenous IL-2, these T cells continued to 
demonstrate non-specific hyporesponsiveness on rechallenge with both CB6F1 and 
B6CBF1 DCs, giving further support to findings that CD4+ T cells that are exposed to 
IDO-expressing DCs then exhibit a non-specific, unreversible state of 
hyporesponsiveness. It is likely that these CD4+ cells would probably be depleted in 
vivo, and that IDO-expressing DCs would induce depletion of alloreactive T cells rather 
than the induction of Treg populations. 
 
Experiments undertaken in sections 3.15.1-3.15.4 have shown the in vivo-generation of 
both CD4+CD25+ Tregs with indirect donor allospecificity and CD4+CD25- T cells with 
suppressive properties (the production of immunoregulatory cytokines IL-10 and 
TGF-β) by CTLA4-KDEL-expressing DCs. The reversibility of anergy in these induced 
Treg populations, demonstrated with the rechallenge assays, is consistent with the 
reports described at length in section 3.14.6 of Treg-mediated in vitro suppression being 
overridden by provision of large amounts of IL-2. 
3.15.6. Regulation by CD4+CD25- T Cells with Indirect Donor Allospecificity 
 
Further to the generation of Tregs with direct pathway allospecificity, functional T cell 
assays undertaken in this study have also demonstrated the generation in vivo of Tregs 
with indirect donor allospecificity after intravenous administration of EIAV CTLA4-
KDEL-transduced CBK DCs into CBA mice. Finding from suppressor assays 
undertaken earlier in the study confirmed the indirect pathway-specific Tregs to be 
present amongst the CD25+ fraction of the CD4+ T cell population. However, ELISAs 
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performed to investigate the production of immunoregulatory cytokines demonstrated 
high levels of TGF-β and IL-10 present in rechallenge assays with CD4+ T cells 
depleted of the CD25+ fraction prior to the start of coculture, indicating that CD4+CD25- 
T cells might contribute to the donor-specific anergy and regulation observed earlier. As 
a result, the potential role of CD4+CD25- T cells in the induction of T cell anergy and 
regulation (with indirect donor allospecificity) by CTLA-KDEL-expressing DCs in 
vivo, was investigated. 2.5x106 CBK (H-2k + Kb) DCs (either untransduced, or 
transduced with EIAV Mock, EIAV CTLA4-KDEL or EIAV IDO) were injected 
intravenously into CBA/Ca mice. After 10 days, CD4+CD25- T cells purified from the 
spleens of injected mice (after CD4+CD25+ T cell depletion ex vivo) were rechallenged 
in vitro (at a 1:10 DC : T cell ratio) with donor CBK DCs [Figure 54(a)], third-party 
B10.A (H-2k + Dd) DCs [Figure 54(b)], CB6F1 [(BALB/c)x(C57BL/6)F1] DCs 
expressing only third-party MHC-peptide [Figure 54(c)] or B6CBF1 
[(C57BL/6)x(CBA/Ca)F1] DCs expressing both donor (Kb presented in the context of 
I-Ak/I-Ek) and third-party MHC-peptide [Figure 54(d)]. CD4+ T cell proliferation was 
assessed by thymidine incorporation on days 3, 5 and 7. 
 
Results from the rechallenge assays demonstrate that Tregs with indirect donor 
allospecificity generated in vivo after intravenous administration of CTLA4-KDEL-
expressing DCs are not concentrated solely within the CD25+ fraction of CD4+ T cells. 
After stimulation in vivo with CTLA4-KDEL-expressing CBK DCs, CD4+CD25- 
CBA/Ca T cells [negatively selected from the spleen-derived CD4+ T cell population 
after depletion of the CD25+ fragment- see figure 58(a) for a representative FACS 
profile of CD4+CD25+ and CD4+CD25- T cell populations after magnetic bead 
separation] demonstrated a considerable, sustained reduction in proliferation on days 3 
and 5 on rechallenge with donor-derived CBK DCs, in comparison to CD4+CD25- T 
cells that were exposed in vivo to untransduced and Mock-transduced DCs and 
subsequently demonstrated a secondary (memory) response with highest proliferation 
on day 3. As discussed earlier in section 3.14.7, this memory response seen with 
CD4+CD25- T cells was not unexpected as murine naïve CD4+CD25- T cells that 
upregulate CD25 during a state of activation have been demonstrated to lose expression 
of CD25 by day 7 post-TCR stimulation/activation (Kuniyasu et al., 2000). Therefore,  
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Figure 54. Regulation by CD4+CD25- T Cells with Indirect Donor Allospecificity. 
2.5x106 CBK (H-2k + Kb) DCs (either untransduced, or transduced with EIAV Mock, EIAV CTLA4-KDEL or 
EIAV IDO) were injected intravenously into CBA/Ca mice. After 10 days, CD4+CD25- T cells purified from 
the spleens of injected mice (after CD4+CD25+ T cell depletion ex vivo) were rechallenged in vitro (at a 
1:10 DC : T cell ratio) with (a) donor CBK DCs, (b) third-party B10.A (H-2k + Dd) DCs, (c) CB6F1 
[(BALB/c)x(C57BL/6)F1] DCs expressing only third-party MHC-peptide or (d) B6CBF1 
[(C57BL/6)x(CBA/Ca)F1] DCs expressing both donor (Kb presented in the context of I-Ak/I-Ek) and third-
party MHC-peptide. CD4+ T cell proliferation was assessed by thymidine incorporation on days 3, 5 and 7. 
All results shown are the Mean ± SD of triplicate wells. 
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the secondary/memory response observed on day 3 of the rechallenge assay (performed 
10 days after DC administration) are most likely to be the response of CD25-CD4+ 
effector memory (CD62low) T cells that have developed after previous exposure to the 
donor alloantigens (Akbar et al., 2007). Tolerance with indirect donor allospecificity 
was demonstrated (in the case of CD4+CD25- T cells exposed in vivo to CTLA4-KDEL-
expressing DCs) as rechallenge of these CD25- T cells with third-party B10.A-derived 
DCs resulted in a primary CBA/Ca T cell response with highest proliferation on day 5. 
 
Regulatory activity with indirect donor allospecificity was detected in CD4+CD25- CBA 
T cells exposed in vivo to CTLA4-KDEL-expressing CBK DCs as demonstrated by the 
induction of donor-specific linked suppression. On rechallenge with B6CBF1 DCs, 
which have the capacity for indirect presentation of Kb in the context of I-Ak/I-Ek 
(donor peptide-MHC) and also express third-party ‘linked’ MHC class I and II 
alloantigens derived from H-2b, there was a significant reduction in proliferation of 
CD4+CD25- T cells over days 3 and 5, whereas rechallenge with CB6F1 DCs 
expressing only third-party MHC-peptide resulted in a primary response with highest 
proliferation on day 5. As demonstrated by the results of all previous functional DC : T 
cell assays, CD4+CD25- CBA T cells that were exposed in vivo to IDO-expressing CBK 
DCs displayed a non-specific reduction in proliferation when rechallenged with both 
donor CBK and third-party B10.A-derived DCs. This was also the case when the cells 
were rechallenged with F1 DCs in order to investigate linked suppression. The results 
therefore demonstrate that Tregs with indirect donor allospecificity, generated in vivo 
after stimulation with CTLA4-KDEL-expressing DCs, exist within both CD25+ and 
CD25- fractions of CD4+ T cells. 
 
3.16. IDO+ DCs Fail to Generate a CTLA4+ Treg-Mediated 
Amplification Cascade 
 
Experimental results from functional T cell assays undertaken during this investigation 
are highly suggestive that the expression of IDO by DCs and the resultant catabolism of 
tryptophan in the microenvironment (culture medium in vitro) is more likely to induce 
non-specific, unreversible hyporesponsiveness in alloreactive T cells than generate 
Tregs [of which there is small evidence (in section 3.12.3) in the suppressor assays 
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performed throughout the study]. The results are thus suggestive, but not conclusive, 
that IDO induces a deletional rather than a regulatory mechanism in alloreactive T cells. 
In addition to the results obtained in this investigation thus far, it has been demonstrated 
in a recent study from this lab that human DCs lacking cell surface expression of 
CD80/86 (due to ER retention by CTLA4-KDEL) do not express IDO (Tan et al., 
2005c). Incubation of these human DCs with alloreactive T cells results in the induction 
of an anergic and subsequent Treg phenotype in vitro, which indicates that IDO is not 
essential for the induction of T cell regulation. It is also known that interaction of 
alloreactive T cells with CTLA4-Ig-treated DCs results in the induction of an anergic 
phenotype in the T cells, which can subsequently regulate/suppress the response of 
other alloreactive T cells (Linsley et al., 1992b; Pearson et al., 1994). However, it is not 
known whether the induction of a regulatory phenotype is solely the result of CD80/86 
costimulation blockade or the expression of IDO by the DCs. There has been continuing 
interest and speculation about the role of IDO in T cell regulation, including whether 
IDO+ DCs can induce expression of the enzyme in neighbouring IDO- DCs via 
induction of Tregs as a mechanism of infectious tolerance [see Figure 9(c)]. It is 
important to verify whether the effect of IDO is to induce apoptosis rather than donor-
specific anergy and regulation, since the advantage of IDO as a therapeutic agent to 
block allograft rejection in the clinic will be increased if T cells became regulatory and 
‘spread’ this effect to T cells (linked suppression) that do not contact IDO+ DCs. 
 
To investigate (specifically) whether the expression of IDO (and the resulting depletion 
of tryptophan in the microenvironment) can promote the induction and/or expansion of 
Tregs, murine DC populations differing in surface CD80/86 costimulation and IDO 
expression were used in cocultures with T cells consisting of specific ratios of induced 
CTLA4+CD4+CD25+FoxP3+ Tregs and CFSE-stained CD4+CD25- T cells. Experiments 
were performed using a temperature-sensitive, immortalised dendritic cell line (tsDC) 
(Volkmann et al., 1996)- described in section 2.5.4- transduced with EIAV to create 
several stable DC lines. The results of the experiments were subsequently duplicated 
using primary BM-derived DCs. The five generated stable cell lines and primary DC 
populations used for experiments were as follows: (1) Wild-type tsDCs, or primary 
untransduced DCs (+costimulation, -IDO); (2) Stable CD80/86- tsDC line expressing 
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CTLA4-KDEL, or primary DCs transduced with EIAV CTLA4-KDEL (-costimulation, 
-IDO); (3) Stable IDO+ tsDC line expressing IDO, or primary DCs transduced with 
EIAV IDO (+costimulation, +IDO); (4) Stable CD80/86-IDO+ tsDC line expressing 
both IDO and CTLA4-KDEL, or primary DCs either incubated with high 
concentrations of CTLA4-Ig or double-transduced with EIAV CTLA4-KDEL and 
EIAV IDO (-costimulation, +IDO); or (5) Stable tsDC line expressing an 
irrelevant/mock (GFP), or primary EIAV GFP-transduced DCs. The five primary DC 
populations and five stable tsDC lines (including the untransduced/wild-type tsDCs) 
numbered above would allow for the dissection of the immunosuppressive role of IDO 
and whether the expression of IDO by DCs (in the presence or absence of CD80/86 
costimulation) could induce Treg populations from CFSE+CD4+CD25- T cells or 
expand populations of pre-induced CTLA4+ Tregs. As demonstrated by the results 
below, these experiments have assessed the possibility of an amplification cycle 
(positive cascade) in which IDO+ DCs induce or expand CTLA4+ Tregs that can then 
further upregulate IDO in IDO- DCs via CD80/86 ligation, providing evidence (or lack 
thereof) of a suggested mechanism for the dominant immunosuppressive role of IDO- 
even when a few IDO-expressing DCs are present (Mellor and Munn, 2004). 
3.16.1. Temperature-Sensitive Dendritic Cell (tsDC) Line: Upregulation of Cell 
Surface Markers after T Cell Coculture and Capacity to Induce/Sustain Allogeneic T 
Cell Proliferation 
 
To investigate whether DC expression of IDO (in the presence and absence of surface 
CD80/86 expression) promotes the induction and/or expansion of a Treg population, 
experiments were first performed using a temperature-sensitive dendritic cell line 
(tsDC), a conditionally immortalised DC line established from the bone marrow of CBA 
(H-2k) mice transgenic for a thermolabile mutant of the SV40 large T antigen under the 
control of the class I Kb promoter (Volkmann et al., 1996). The advantage of this system 
was the conditional immortalisation of cells at the permissive temperatures of 33°C-
37°C- the line divides in the absence of GM-CSF and is efficient at antigen processing 
and presentation. Upon transfer to 39°C, the transgene product (large T antigen) is 
rapidly degraded which arrests growth and results in upregulation of cell surface 
(including costimulatory) markers. Further upregulation of cell surf
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functional maturity occur following contact with T cells and their cognate antigen 
(Volkmann et al., 1996). 
 
To test the immunophenotype and functional capacity of the cell line at different 
temperatures (both permissive and unpermissive for cell growth), the tsDCs were 
cultured at 33°C and transferred to temperatures of 37ºC and 39°C for 48 hours to detect 
changes in the surface expression of DC markers and costimulatory molecules. After 
incubation at the permissive temperature of 33ºC [Figure 55(a) (top row)], there was 
moderate tsDC surface expression of the murine DC marker CD11c and MHC II (I-Ak, 
I-Ek) and minimal expression of the costimulatory molecule CD86, as detected by flow 
cytometry. The surface expression of expression of CD80 was negligible (data not 
shown). On transfer to 37ºC- the upper limit of the permissive temperatures- for 48 
hours [Figure 55(a) (middle row)] there was no change in the surface tsDC expression 
of CD11c although there was moderate upregulation of both MHC II and CD86. 
Unexpectedly however, after transfer to 39ºC for 48 hours, there was no increase in 
tsDC surface expression of CD11c, MHC II or CD86 (data not shown). Additionally, at 
both of the higher temperatures, there was negligible expression of surface CD80. It was 
therefore expected that the low tsDC expression of both CD80 and CD86 would prevent 
usage of the cells in subsequent functional assays to generate allogeneic T cell 
responses. In addition, low surface expression of the marker CD11c contradicted the 
labelling of the cell line as ‘dendritic’ or being derived from DCs. Surface expression of 
DC markers was also analysed on the tsDCs after a 48-hour coculture with allogeneic 
CD4+ T cells. The tsDC line was transferred to 37°C for 48 hours, irradiated and 
cocultured with allogeneic BALB/c-derived CD4+ T cells for 48 hours prior to FACS 
analysis [Figure 55(a) (bottom row)]. The tsDCs showed marked upregulation of the 
markers CD11c (>85%), MHC II, and CD86 (>90%) and were thus used as stimulators 
in subsequent functional T cell assays. The upregulation of these markers was not due to 
the irradiation of tsDCs (data not shown). 
 
In order to investigate the capacity of tsDCs to induce the proliferation of allogeneic 
CD4+ T cells in a MLR, 5x104 tsDCs (H-2k), cultured at either 37ºC or 39ºC for 48 
hours, were subsequently cocultured at 37ºC after irradiation or no irradiation with  
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Figure 55. Temperature-Sensitive Dendritic Cell (tsDC) Line: Upregulation of Cell Surface Markers 
after T Cell Coculture and Capacity to Induce/Sustain Allogeneic T Cell Proliferation. 
(a) The immunophenotype of a temperature-sensitive dendritic cell (tsDC) line was analysed by flow 
cytometry after culture at 33ºC (top row), 37ºC (middle row) and after a 48-hour coculture at 37ºC with 
allogeneic BALB/c-derived CD4+ T cells. FACS histograms are shown for the expression of CD11c (left 
column), MHC II / I-Ak, I-Ek (middle column) and CD86 (right column). (b) 5x104 tsDCs (CBA-derived / H-
2k) cultured at either 37ºC or 39ºC were subsequently cocultured (after irradiation or no irradiation) with 
BALB/c-derived CD4+ T cells at increasing ratios and CD4+ T cell proliferation assessed by thymidine 
incorporation after 5 days. Results shown are the Mean ± SD of triplicate wells. 
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BALB/c-derived CD4+ T cells at the following ratios: 1:0, 1:1, 1:3, 1:5 and 1:7 tsDC : 
CD4+ T cells. CD4+ T cell proliferation was assessed by thymidine incorporation after 5 
days [Figure 55(b)]. Results of the MLR demonstrate the capacity of tsDCs to induce 
and sustain allogeneic T cell proliferation after a 48-hour culture at 37ºC (after 
irradiation or no irradiation). However, the tsDCs could not sustain significant levels of 
allogeneic T cell proliferation after a 48-hour culture at 39ºC (either after irradiation or 
no irradiation). As a result, all subsequent tsDC : CD4+ T cell cocultures carried out in 
this investigation were performed at 37ºC after tsDC irradiation (to prevent growth of 
the cell line at this permissive temperature during coculture with CD4+ T cells). Results 
from the FACS and functional T cell assays demonstrate the upregulation of surface DC 
markers and capacity of tsDCs to induce allogeneic T cell proliferation at 37ºC. 
3.16.2. Generation of Stable tsDC Lines Differing in IDO and CTLA4-KDEL / 
Surface CD80/86 Expression 
 
After confirming the DC-like immunophenotype and functional capacity of the acquired 
tsDC line, it was necessary to generate four stable tsDC lines, each differing in the 
expression of IDO and CD80/86, in order to assess whether expression of IDO by DCs 
can promote the induction and/or expansion of a Treg population. tsDCs were 
transduced with EIAV lentiviruses followed by limited dilution cloning to generate 
stable cell lines. The stable tsDC lines and the lentivirus(es) used to generate them were 
as follows: 1) CD80/86- tsDC line using EIAV CTLA4-KDEL, 2) IDO+ tsDC line using 
EIAV IDO, 3) CD80/86-IDO+ tsDC line using both EIAV IDO and EIAV 
CTLA4-KDEL for the double-transduction, and 4) tsDCs expressing an irrelevant 
(mock) protein using EIAV GFP. Each of the four stable tsDC lines was selected after 
the generation, expansion and screening of 25 (EIAV transduced) tsDC clones. Thus a 
total of 100 tsDC clones were generated by limited dilution and screened prior to 
selection and expansion of four stable cell lines for subsequent use in coculture with 
CD4+ T cells (see section 3.16.3). The four tsDC clones were selected based on 
phenotypic properties associated with the EIAV-based gene transfer, in addition to 
positive function of the expressed protein(s). 
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Phenotypic properties of the four selected stable tsDC lines were compared using 
quantitative / real-time PCR and western blotting. Since tsDC clones positive for the 
relevant proteins (Mock/CTLA4-KDEL/IDO) would be expected to contain the viral 
Woodchuck Hepatitis Post Regulatory Element (WPRE) integrated within genomic 
DNA as a result of EIAV-based gene transfer, the detection of WPRE in the genomic 
DNA of the stable tsDC lines was undertaken using real-time PCR [Figure 56(a)]. In 
comparison to a ‘wild-type’/untransduced tsDC line, tsDC clones transduced with EIAV 
Mock, EIAV CTLA4-KDEL and EIAV IDO (to generate the relevant stable tsDC lines) 
expressed WPRE sequences in the genomic DNA of cells, consistent with EIAV 
transduction. Furthermore, tsDCs doubled-transduced with EIAV IDO and EIAV 
CTLA4-KDEL to generate a CD80/86-IDO+ tsDC line expressed (approximately) 
double the copy number of WPRE sequences in the genomic DNA. In addition to the 
detection of WPRE DNA sequences, the expression of mRNA encoding IDO and 
CTLA4-KDEL was also compared in the four selected stable tsDC lines using real-time 
PCR [Figure 56(b-c)]. As expected, IDO mRNA was detected in tsDCs transduced 
with EIAV IDO alone and in combination with EIAV CTLA4-KDEL to generate the 
CD80/86+IDO+ and CD80/86-IDO+ tsDC lines respectively. CTLA4-KDEL mRNA was 
detected in tsDCs transduced with EIAV CTLA4-KDEL alone and again, in 
combination with EIAV IDO to generate the CD80/86-IDO- and CD80/86-IDO+ tsDC 
lines respectively. Western blotting was used to compare expression of the IDO and 
CTLA4-KDEL protein in the five stable tsDC lines (including the untransduced/wild-
type tsDC line) [Figure 56(d-e)], with the 45 kDa IDO protein detected in IDO tsDCs, 
20 kDa CTLA4-KDEL expression detected in CTLA4-KDEL tsDCs, and both proteins 
detected in the tsDC clones that were double-transduced with both viruses. Lastly, the 
function of the CTLA4-KDEL and IDO proteins in the relevant stable tsDC lines was 
confirmed using both flow cytometry and an l-kynurenine assay. 
 
On FACS analysis of surface CD80/86 expression on the stable tsDC clones, there was 
a complete inhibition in the expression of these costimulatory molecules on the surface 
of tsDC clones that were transduced with EIAV CTLA4-KDEL alone (to generate 
CTLA4-KDEL tsDCs) and in combination with EIAV IDO (to generate IDO/CTLA4-
KDEL tsDCs) [Figure 56(f)]. In contrast, tsDC clones transduced with EIAV IDO and  
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Figure 56. Generation of Stable tsDC Lines Differing in IDO and CTLA4-KDEL / Surface CD80/86 
Expression. 
Four stable tsDC lines, each selected after the generation, expansion and screening of 25 (EIAV 
transduced) tsDC clones, were subsequently used in cocultures with CD4+ T cells. The four tsDC clones 
were selected based on phenotypic properties associated with EIAV-based gene transfer, in addition to 
positive function of the expressed protein(s). Properties of the four expanded stable tsDC lines [tsDCs 
expressing a mock protein (Mock), IDO-expressing tsDCs (IDO), CTLA4-KDEL-expressing tsDCs (CTLA4-
KDEL) and IDO/CTLA4-KDEL-expressing tsDCs (IDO/CTLA4-KDEL)] are shown: quantitative / real-time 
PCR-based detection of (a) WPRE expression in the genomic DNA, (b) IDO mRNA expression and (c) 
CTLA4-KDEL mRNA expression, in addition to detection by western blotting of (d) IDO protein expression 
and (e) CTLA4-KDEL protein expression. (f) Surface CD80 and CD86 expression on the selected tsDC 
clones was assessed by flow cytometry and (g) the functional activity of tsDC IDO expression was 
evaluated by an L-kynurenine assay. Results shown are the Mean ± SD of triplicate wells. (h) Table of 
tsDC populations and associated transgenic protein expression. 
Chapter 3: Results 
Adnan Khan, Department of Immunology, Division of Medicine, Imperial College London 243 
expressing the IDO protein (as detected by western blotting) expressed standard levels 
of CD80/86 on the surface of tsDCs. The functional activity of IDO was evaluated using 
an L-kynurenine assay, [Figure 56(g)] with significant levels of L-kynurenine detected 
in the culture medium of stable tsDC lines in which tsDC clones were transduced with 
EIAV IDO alone (to generate IDO tsDCs) and in combination with EIAV CTLA4-
KDEL (to generate IDO/CTLA4-KDEL tsDCs), in comparison to basal levels of L-
kynurenine detected in the culture medium of tsDCs, Mock tsDCs, and CTLA4-KDEL 
tsDCs. The basal level of L-kynurenine detected in the culture medium of CTLA4-
KDEL tsDCs is further evidence demonstrating that intracellular ligation of CD80/86 by 
CTLA4-KDEL in the endoplasmic reticulum does not result in the upregulation of IDO 
expression. The final stable tsDCs lines generated (and the associated transgenic 
proteins expressed) are shown in [Figure 56(h)]. 
3.16.3. Functional Capacity of Stable tsDC Lines 
 
After confirming the generation of four stable tsDC lines differing in IDO and CD80/86 
expression (as demonstrated in section 3.16.2 using a combination of real-time PCR for 
detection of DNA and mRNA sequences, western blotting for protein expression, FACS 
analysis and L-kynurenine assays), the capacity of each stable tsDC line to induce and 
sustain proliferation of allogeneic CD4+ T cell proliferation in a MLR was determined. 
1x105 wild-type/untransduced tsDCs or each of four generated tsDC clones (Mock-
expressing tsDCs, IDO tsDCs, CTLA4-KDEL tsDCs and IDO/CTLA4-KDEL tsDCs) 
were cocultured with 2x105 BALB/c-derived CD4+ T cells. Responder CD4+ T cell 
proliferation was assessed by thymidine incorporation on days 3, 5 and 7 [Figure 57]. 
As expected from experiments previously undertaken in this investigation with primary, 
EIAV-transduced DCs, thymidine incorporation counts from the MLR demonstrate the 
inability of IDO tsDCs, CTLA4-KDEL tsDCs, and IDO/CTLA4-KDEL tsDCs to 
induce an allogeneic T cell response. The lack of proliferation observed with CD4+ T 
cells after coculture with the generated, stable tsDC lines described above is in contrast 
to counts obtained after coculture of CD4+ T cells with wild-type/untransduced tsDCs 
and Mock tsDCs, which demonstrated highest proliferation on day 5 of the MLR. 
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Figure 57. Functional Capacity of Stable tsDC Lines. 
1x105 wild-type/untransduced  tsDCs or each of four generated tsDC clones (Mock-expressing tsDCs, IDO 
tsDCs, CTLA4-KDEL tsDCs and IDO/CTLA4-KDEL tsDCs) were cocultured with 2x105 BALB/c-derived 
CD4+ T cells. Responder CD4+ T cell proliferation was assessed by thymidine incorporation on days 3, 5 
and 7 to analyse the capacity of the generated stable tsDC lines to induce proliferation in allogeneic T 
cells. Results shown are the Mean ± SD of triplicate wells. 
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3.16.4. In vitro-Generation of CTLA4+CD4+CD25+FoxP3+ Tregs 
 
It was necessary to generate CTLA4+CD4+CD25+FoxP3+ Tregs (CTLA4+ Tregs) in 
order to assess whether the expression of IDO by DCs (including tsDCs as was first 
investigated in this study) could promote the induction of Tregs from CD4+CD25- T 
cells (stained with CFSE) or expand populations of pre-induced CTLA4+ Tregs. T cells 
consisting of specific ratios of in vitro-generated CTLA4+CD4+CD25+FoxP3+ Tregs and 
CFSE-stained CD4+CD25- T cells were cocultured with murine DC populations 
differing in CD80/86 and IDO expression. The experiments investigated the possibility 
of a CTLA4+ Treg-mediated amplification cascade being generated by IDO+ DCs, 
which could provide a mechanism for the dominant immunosuppressive role of IDO 
observed even when a few IDO-expressing DCs are present [see figure 9(c)]. 
 
In order to generate CTLA4+ Tregs in vitro, CD4+CD25+ BALB/c T cells were purified 
from the spleens of BALB/c mice using a combination of negative selection for CD4+ T 
cells and subsequent magnetic bead-selection of CD25+ T cells. The purity of both 
CD25- and CD25+ subsets of CD4+ T cells was confirmed by flow cytometry [Figure 
58(a)] immediately after purification with magnetic beads. Both subsets were then 
stimulated with plate-bound anti-CD3ε antibody in the presence of recombinant murine 
IL-2 for 24 hours (McHugh et al., 2002; Fallarino et al., 2003). After intracellular 
staining, the treated CD4+CD25- and CD4+CD25+ T cell subsets were assessed for 
CTLA4 and FoxP3 expression by flow cytometric analysis [Figure 58(b)]. In 
comparison to (treated) CD25- cells, which expressed negligible levels of total 
(intracellular CTLA4), and moderate expression of intracellular FoxP3, CD25+ T cells 
that were treated identically with plate-bound anti-CD3ε antibody in the presence of 
recombinant murine IL-2 expressed high levels of both total CTLA4 and FoxP3. The 
capacity of these in vitro-generated CTLA4+ Tregs to induce expression of IDO in DCs 
(by ligation of CD80/86 with CTLA4 expressed on the generated Tregs) was assessed 
by western blotting and an L-kynurenine assay. Both (treated) populations of BALB/c-
derived CD4+CD25- and CD4+CD25+ T cell subsets were cocultured with CBA-derived 
DCs for 72 hours. Lysates of DC : T cell cocultures were probed for IDO expression by  
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Figure 58. In vitro-Generation of CTLA4+CD4+CD25+FoxP3+ Tregs. 
(a) CD4+CD25+ BALB/c T cells were purified from the spleens of BALB/c mice using a combination of 
negative selection for CD4+ T cells and subsequent magnetic bead-selection of CD25+ T cells. The purity of 
both CD25- and CD25+ fragments of CD4+ T cells was assessed by flow cytometry for CD4 and CD25 
expression immediately after magnetic bead-selection. (b) Purified CD25- and CD25+ fragments of CD4+ T 
cells were stimulated with plate-bound anti-CD3ε antibody in the presence of recombinant murine IL-2 for 
24 hours. After surface and intracellular staining, the treated CD4+CD25- and CD4+CD25+ T cell subsets 
were assessed for CTLA4 and FoxP3 expression by flow cytometric analysis. Both (treated) populations of 
CD4+CD25- and CD4+CD25+ T cell subsets were cocultured with CBA-derived DCs for 72 hours. (c) 
Lysates of DC : T cell cocultures were probed for IDO expression by western blotting and (d) culture 
medium was harvested for evaluation of IDO function. Results shown are the Mean ± SD of triplicate wells. 
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western blotting [Figure 58(c)] and culture medium was harvested for evaluation of 
IDO function [Figure 58(d)]. As expected from the results of recent studies [from 
which the protocol was derived- (Fallarino et al., 2003)], the CTLA4+ Tregs generated 
in vitro (by treatment of CD4+CD25+ T cells) exhibited a capacity for the induction of 
IDO expression in DCs. This was demonstrated by the detection of the 45 kDa IDO 
protein in lysates of DC : CTLA4+ Treg cocultures, whereas IDO protein expression 
was not detected in lysates of DC : (treated) CD4+CD25- T cell cocultures. Furthermore, 
analysis of culture medium harvested from both cocultures demonstrates the induction 
of functional IDO expression by DCs after incubation with in vitro-generated CTLA4+ 
Tregs, as shown by high levels of L-kynurenine in the culture supernatant. This was in 
contrast to DCs incubated with (treated) CD4+CD25- T cells, which resulted in 
L-kynurenine levels comparable to those after incubation of DCs alone. 
 
The successful generation of CTLA4+ Tregs in vitro therefore allowed for experiments 
to investigate whether expression of IDO by DCs can promote the induction and 
expansion of CTLA4+FoxP3+ Tregs, resulting in a possible CTLA4+FoxP3+ Treg-
mediated amplification cascade generated by IDO+ DCs (in the presence or absence of 
CD80/86 costimulation). 
3.16.5. IDO+CD80/86+ tsDCs Fail to Induce or Expand FoxP3+ T cell Populations; 
IDO+CD80/86- tsDCs Fail to Induce, Expand or Sustain FoxP3+ T cell Populations 
 
After the successful generation of five stable tsDC lines differing in IDO and CD80/86 
expression (section 3.16.2) and the subsequent generation in vitro of CTLA4+ Tregs 
(section 3.16.4) with the capacity for inducing IDO expression in DCs (by ligation of 
CD80/86 with surface CTLA4 expressed on the generated Tregs), it was possible to 
perform an assay investigating whether expression of IDO by DCs (in the absence of 
CD80/86 costimulation) can promote the induction or expansion of CTLA4+FoxP3+ 
Tregs, resulting in a CTLA4+ Treg-mediated amplification cascade generated by the 
IDO+ DCs. As a result, each of five stable (CBA-derived) tsDC lines (Untransduced-, 
Mock-, CTLA4-KDEL-, IDO- and IDO/CTLA4-KDEL tsDCs) was irradiated and 
incubated with BALB/c-derived CD4+ T cells at a 1:1 ratio for 72 hours. The CD4+ T 
cells consisted of ratios of in vitro-generated CTLA4+ Tregs and populations of CFSE-
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labelled CD4+CD25- T cells (CFSE+CD25- T cells). The T cell ratios (x parts CTLA4+ 
Tregs : y parts CFSE+CD25- T cells) were as follows: 0:4, 1:3, 2:2, and 3:1. After 72 
hours of incubation, the tsDC : T cell cocultures were harvested and the T cells analysed 
by flow cytometry for expression of CFSE, intracellular CTLA4 and FoxP3 [Figure 
59(a)]. Contrary to aforementioned speculation that IDO expression by DCs might 
promote the induction and expansion of CTLA4+ Tregs (possibly resulting in a CTLA4+ 
Treg-mediated amplification cascade generated by the IDO+ tsDCs), it was 
demonstrated (albeit using a stable tsDCs line as opposed to primary DCs) that DCs 
expressing IDO in the presence of CD80/86 costimulation do not expand the population 
of Tregs, with intracellular FoxP3 expression being used as the phenotypic marker of 
these cells. Furthermore, it was observed that tsDCs expressing IDO in the absence of 
CD80/86 costimulation fail to sustain live populations of pre-induced CTLA4+ Tregs. 
 
FACS analysis of FoxP3 expression in CD4+ T cells after coculture with a stable 
CD80/86+IDO+ tsDC line at a ratio of 3 parts CTLA4+ Tregs : 1 part CFSE+CD25- T 
cells demonstrates a lack of expansion in the population of CTLA4+ Tregs as assessed 
by expression of the intracellular marker FoxP3, relative to CD4+ T cells incubated with 
an untransduced (CD80/86+IDO-), Mock (CD80/86+IDO-) and CTLA4-KDEL 
(CD80/86-IDO-) tsDC line at the same ratio (3:1) of CTLA4+ Tregs : CFSE+CD25- T 
cells. This observation was strengthened by the demonstration of a lack of CFSE 
expression in FoxP3+ Tregs (regardless of CTLA4 expression) after 72 hours of 
coculture (data not shown). The presence of CFSE+FoxP3+CTLA4+ Tregs after 
coculture of CFSE+CD25- T cells (in the absence or presence of CTLA4+ Tregs) with 
stable CD80/86+IDO+ tsDCs would have indicated the induction/generation of FoxP3+ 
Tregs from CFSE+CD25- T cells. More importantly, FACS analysis of CD4+ T cells 
harvested after a 72-hour coculture with a stable CD80/86-IDO+ tsDC line (as a result of 
IDO and CTLA4-KDEL expression) at a ratio of 3 parts CTLA4+ Tregs : 1 part 
CFSE+CD25- T cells demonstrates that tsDCs expressing IDO in the absence of 
CD80/86 cannot sustain a population of pre-induced CTLA4+ Tregs as demonstrated by 
a total loss of expression of the intracellular marker FoxP3, relative to levels of Foxp3 
expressed by CD4+ T cells after incubation with an untransduced (CD80/86+IDO-),  
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Figure 59 continues on the next page. 
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Figure 59. IDO+CD80/86+ tsDCs Fail to Induce or Expand FoxP3+ T Cell Populations; IDO+CD80/86- 
tsDCs Fail to Induce, Expand or Sustain FoxP3+ T Cell Populations. 
Each of five stable (CBA-derived) tsDC lines (Untransduced-, Mock-, CTLA4-KDEL-, IDO- and 
IDO/CTLA4-KDEL tsDCs) was irradiated and incubated with BALB/c-derived CD4+ T cells at a 1:1 ratio for 
72 hours. The CD4+ T cells consisted of ratios of induced CTLA4+CD4+CD25+FoxP3+ Tregs (CTLA4+ 
Tregs) and treated populations of CD4+CD25- T cells (see figure 58) that were subsequently stained with 
CFSE (CFSE+CD25- T cells). The T cell ratios (x parts CTLA4+ Tregs : y parts CFSE+CD25- T cells) were 
as follows: 0:4, 1:3, 2:2, and 3:1. After 72 hours of incubation, the tsDC : T cell cocultures were harvested 
and the T cells analysed by flow cytometry for expression of CFSE, intracellular CTLA4 and FoxP3. (a) 
FACS histograms of CFSE, total CTLA4, and FoxP3 expression are shown for CD4+ T cells after 
incubation with the stable tsDC lines at a ratio of 3 parts CTLA4+ Tregs : 1 part CFSE+CD25- T cells. (b) 
The bar graph summarises the percentage of CFSE-CD4+ T cells expressing FoxP3, as assessed using 
flow cytometry, after 72-hour coculture with each of five generated stable tsDC lines at all four ratios of 
CTLA4+ Tregs : CFSE+CD25- T cells. (c) The bar graph shows the level of CD4+ T cell death, as assessed 
by the percentage of T cells expressing 7-AAD detected by flow cytometry after coculture with the five 
tsDC lines. Flow cytometry bar graph results shown are the Mean ± SD of three separate experiments. 
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Mock (CD80/86+IDO-), IDO (CD80/86+IDO+) and CTLA4-KDEL (CD80/86-IDO-) 
tsDC line at the same ratio (3:1) of CTLA4+ Tregs : CFSE+CD25- T cells. 
 
The results described above were observed at all four ratios of CTLA4+ Tregs : 
CFSE+CD25- T cells (0:4, 1:3, 2:2, and 3:1), as demonstrated by a bar graph 
summarising the percentage of CFSE-CD4+ T cells expressing FoxP3 on flow 
cytometric analysis 72 hours after coculture with each of five generated stable tsDC 
lines [Figure 59(b)]. The loss of FoxP3 expression observed in CD4+ T cells after a 72-
hour coculture with a stable CD80/86-IDO+ tsDC line, as described above, was 
associated with a considerable level of CD4+ T cell death. This is demonstrated by a bar 
graph showing the level of CD4+ T cell death, as assessed by the percentage of total 
CD4+ T cells (i.e. both CFSE+ and CFSE- populations) expressing 7-AAD on flow 
cytometric analysis after a 72-hour coculture (at a ratio of 3 parts CTLA4+ Tregs : 1 part 
CFSE+CD25- T cells) with the five stable tsDC lines [Figure 59(c)]. A high rate of 
CD4+ T cell death was detected at all ratios of CTLA4+ Tregs : CFSE+CD25- T cells 
after coculture with the stable CD80/86-IDO+ tsDC line (data not shown). Thus, the 
failure of tsDCs expressing IDO in the absence of CD80/86 costimulation to induce, 
expand or sustain FoxP3+ T cell populations was associated with a high rate of cell 
death. 
3.16.6. IDO+CD80/86+ DCs Fail to Induce or Expand FoxP3+ T cell Populations; 
IDO+CD80/86- DCs Fail to Induce, Expand or Sustain FoxP3+ T cell Populations 
 
It was important to verify whether the findings of experiments with stable tsDC lines in 
section 3.16.5 (demonstrating that tsDCs expressing IDO in the presence of CD80/86 
costimulation do not induce or expand populations of Tregs (based on expression of 
FoxP3), and more importantly that tsDCs expressing IDO in the absence of CD80/86 
costimulation fail to induce, expand or sustain populations of pre-induced CTLA4+ 
Tregs) were also observed in primary BM-derived DC populations that were modified 
to differ in the expression of IDO and CD80/86 costimulation. Therefore, similar to the 
coculture of CD4+ T cells [consisting of ratios of in vitro-generated CTLA4+ Tregs and 
CFSE-labelled CD4+CD25- T cells (CFSE+CD25- T cells)] with five stable tsDC lines 
differing in IDO and CD80/86 expression, DC : T cell coculture assays were performed 
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to investigate whether expression of IDO by primary DCs (in the absence of CD80/86 
costimulation) can promote the induction and expansion of FoxP3+CTLA4+ Tregs, 
resulting in a CTLA4+ Treg-mediated amplification cascade generated by the IDO+ 
DCs. 
 
Each of the following seven primary CBA (H-2k) DC populations was incubated with 
BALB/c-derived CD4+ T cells at a 1:1 ratio for 72 hours:  [(i) Untransduced DCs 
(CD80/86+IDO- DCs), (ii) DCs transduced with EIAV Mock (CD80/86+IDO- DCs), (iii) 
DCs transduced with EIAV IDO (CD80/86+IDO+ DCs), (iv) DCs transduced with EIAV 
IDO and subsequently incubated with 50µg/ml CTLA4-Ig for surface CD80/86 
blockade (CD80/86-IDO+ DCs), (v) DCs transduced with EIAV CTLA4-KDEL 
(CD80/86-IDO- DCs), (vi) DCs double-transduced with EIAV IDO and EIAV CTLA4-
KDEL (CD80/86-IDO+ DCs) and (vii) DCs incubated with CTLA4-Ig at a concentration 
(100µg/ml) which resulted, earlier in the investigation, in the expression of IDO and 
blockade of surface CD80/86 (CD80/86-IDO+ DCs)- see figure 28]. Similar to 
experiments conducted with stable tsDC lines, the CD4+ T cells consisted of ratios of 
induced CTLA4+CD4+CD25+FoxP3+ Tregs (CTLA4+ Tregs) and CFSE-labelled 
CD4+CD25- T cells (CFSE+CD25- T cells). The T cell ratios (x parts CTLA4+ Tregs : y 
parts CFSE+CD25- T cells) were as follows: 0:4, 1:3, 2:2, and 3:1. After 72 hours of 
incubation, the primary DC : T cell cocultures were harvested and the T cells analysed 
by flow cytometry for expression of CFSE, intracellular (total) CTLA4 and FoxP3 
[Figure 60A(i)]. 
 
Contrary to speculation that IDO expression by DCs might promote the induction and 
expansion of CTLA4+ Tregs (possibly resulting in a CTLA4+ Treg-mediated 
amplification cascade generated by the IDO+ tsDCs), it was demonstrated that primary 
BM-derived DCs (in addition to stable tsDC lines used in section 3.16.5) expressing 
IDO in the presence of CD80/86 costimulation do not expand populations of Tregs, 
with intracellular FoxP3 expression being used as the phenotypic marker of these cells. 
Furthermore, it was observed that DCs expressing IDO in the absence of CD80/86 
costimulation fail to sustain viable populations of pre-induced CTLA4+ Tregs. FACS 
analysis of FoxP3 expression in CD4+ T cells after coculture with CD80/86+IDO+ DCs  
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Figure 60 continues on the next page. 
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Figure 60. IDO+CD80/86+ DCs Fail to Induce or Expand FoxP3+ T Cell Populations; IDO+CD80/86- 
DCs Fail to Induce, Expand or Sustain FoxP3+ T Cell Populations. 
Each of seven primary CBA (H-2k) DC populations:  [Untransduced DCs (Untransduced), Mock-transduced 
DCs (Mock DCs), IDO-transduced DCs (IDO DCs), IDO-transduced DCs incubated with CTLA4-Ig (IDO 
DCs + CTLA4-Ig), CTLA4-KDEL-transduced DCs (CTLA4-KDEL DCs), IDO/CTLA4-KDEL-double 
transduced DCs (IDO/CTLA4-KDEL DCs) and DCs incubated with high concentration CTLA4-Ig (High 
CTLA4-Ig DCs)] was incubated with BALB/c-derived CD4+ T cells at a 1:1 ratio for 72 hours. The CD4+ T 
cells consisted of ratios of induced CTLA4+CD4+CD25+FoxP3+ Tregs (CTLA4+ Tregs) and CFSE-labelled 
CD4+CD25- T cells (CFSE+CD25- T cells). The T cell ratios (x parts CTLA4+ Tregs : y parts CFSE+CD25- T 
cells) were as follows: 0:4, 1:3, 2:2, and 3:1. After 72 hours of incubation, the primary DC : T cell 
cocultures were harvested and the T cells analysed by flow cytometry for expression of CFSE, intracellular 
CTLA4 and FoxP3. [A(i)] FACS histograms of total CTLA4, FoxP3 and CFSE in addition to a CFSE (FL-1) 
vs. FoxP3 (FL-4) dotplot are shown for CD4+ T cells after incubation with each of the seven DC 
populations at a ratio of 3 parts CTLA4+ Tregs : 1 part CFSE+CD25- T cells. [A(ii)] FACS histograms show 
the percentage of CFSE-CD4+ T cells expressing 7-AAD after incubation of 3 parts CFSE-CTLA4+ Tregs : 
1 part CFSE+CD25- T cells with IDO+CD80/86- DCs (representative of the three IDO+CD80/86- DC 
populations) in comparison to incubation of 2 parts CTLA4+ Tregs : 2 parts CFSE+CD25- T cells with Mock 
DCs. [A(iii)] The bar graph shows the level of CD4+ T cell death, as assessed by the percentage of T cells 
expressing 7-AAD detected by flow cytometry after coculture with the seven DC populations. (B) The bar 
graph summarises the percentage of CFSE-CD4+ T cells expressing FoxP3, as assessed by flow 
cytometry, after 72-hour coculture with each of seven DC populations at all four ratios of CTLA4+ Tregs : 
CFSE+CD25- T cells. Flow cytometry bar graph results shown are the Mean ± SD of three separate 
experiments. 
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(EIAV IDO-transduced DCs) at a ratio of 3 parts CTLA4+ Tregs : 1 part CFSE+CD25- T 
cells demonstrate a lack of expansion in the population of CTLA4+ Tregs as assessed by 
expression of the intracellular marker FoxP3, relative to CD4+ T cells incubated with 
DCs that were untransduced (CD80/86+IDO- DCs), transduced with EIAV Mock 
(CD80/86+IDO- DCs) or transduced with EIAV CTLA4-KDEL (CD80/86-IDO- DCs) at 
the same ratio (3:1) of CTLA4+ Tregs : CFSE+CD25- T cells. This observation was 
strengthened by flow cytometry data respresented by CFSE vs. FoxP3 dotplots obtained 
for CD4+ T cells (after incubation with each of the seven DC populations at a ratio of 3 
parts CTLA4+ Tregs : 1 part CFSE+CD25- T cells), which showed a lack of CFSE 
expression in FoxP3+ Tregs (regardless of CTLA4 expression) after 72 hours of 
coculture. 
 
The presence of CFSE+FoxP3+CTLA4+ Tregs after coculture of CFSE+CD25- T cells 
(in the absence or presence of CTLA4+ Tregs) with stable CD80/86+IDO+ DCs (EIAV 
IDO-transduced DCs) would have indicated the induction/generation of FoxP3+ Tregs 
from CFSE+CD25- T cells in the presence of IDO-expressing DCs. More importantly, 
FACS analysis of CD4+ T cells harvested after a 72-hour coculture with CD80/86-IDO+ 
DCs [as a result of DCs either (i) transduced with EIAV IDO and incubated with 
CTLA4-Ig for blockade of CD80/86 costimulation, (ii) double-transduced with EIAV 
IDO and EIAV CTLA4-KDEL, or (iii) incubated with a high concentration of CTLA4-
Ig proven earlier in the study to induce IDO expression and completely block surface 
CD80/86 expression] at a ratio of 3 parts CTLA4+ Tregs : 1 part CFSE+CD25- T cells 
demonstrates that DCs expressing IDO in the absence of CD80/86 cannot sustain a 
population of pre-induced CTLA4+ Tregs. This was demonstrated by a total loss of 
expression of the intracellular marker FoxP3, relative to levels of Foxp3 expressed by 
CD4+ T cells after incubation with DCs that were untransduced (CD80/86+IDO- DCs), 
transduced with EIAV Mock (CD80/86+IDO- DCs), transduced with EIAV IDO 
(CD80/86+IDO+ DCs) or transduced with EIAV CTLA4-KDEL (CD80/86-IDO-) at the 
same ratio (3:1) of CTLA4+ Tregs : CFSE+CD25- T cells. The results described above 
were observed at all four ratios of CTLA4+ Tregs : CFSE+CD25- T cells (0:4, 1:3, 2:2, 
and 3:1), as demonstrated by a bar graph summarising the percentage of CD4+ T cells 
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expressing FoxP3 on flow cytometric analysis 72 hours after coculture with each of 
seven DC populations [Figure 60B]. 
 
Similar to experiments undertaken with a stable CD80/86-IDO+ tsDC line, the loss of 
FoxP3 expression observed in CD4+ T cells 72 hours after coculture with the three 
populations of primary BALB/c-derived CD80/86-IDO+ DCs (as described above) was 
associated with a considerable level of CD4+ T cell death. This was demonstrated by 
FACS histograms showing a high percentage (~70%) of CFSE-CD4+ T cells expressing 
7-AAD after incubation of 3 parts CTLA4+CFSE-Tregs : 1 part CFSE+CD25- T cells (a 
clear majority of the CFSE-CD4+ T cells) with IDO+CD80/86- DCs (the FACS 
histogram being representative of the three IDO+CD80/86- DC populations) in 
comparison to a negligible level of CD4+ T cell death (7-AAD expression) observed 
after incubation of 2 parts CTLA4+CFSE-Tregs : 2 parts CFSE+CD25- T cells with 
Mock DCs (incubation of 3 parts CTLA4+CFSE-Tregs : 1 part CFSE+CD25- T cells 
with Mock DCs resulted in viable CFSE-CD4+ T cells all retaining FoxP3 expression) 
[Figure 60A(ii)]. The overall level of CD4+ T cell death (as assessed by the expression 
of 7-AAD on flow cytometric analysis) after coculture with the seven DC populations is 
demonstrated by a bar graph [Figure 60A(iii)]. The high rate of cell death observed 
after incubation of CD4+ T cells with the three populations of IDO+CD80/86- DCs was 
detected at all ratios of CTLA4+ Tregs : CFSE+CD25- T cells (data not shown) and 
demonstrates the failure of DCs expressing IDO in the absence of CD80/86 
costimulation to induce, expand or sustain FoxP3+ Treg populations as a result of non-
specific CD4+ T cell death. 
 
The main limitation of the experiments described here and in the previous section is that 
the loss of FoxP3 expression by the in vitro-generated Tregs is equated to a loss of 
suppressive capacity, without demonstrating this functionally. However, a high rate of 
7-AAD expression was demonstrated to be associated with the loss of FoxP3+ T cell 
population. It is known from both experiments undertaken in this study and from 
several studies described in sections 1.6-1.7 and section 3.14.6 that FoxP3- Tregs can be 
generated with the capacity for suppression of alloreactive/effector T cells. For 
example, as demonstrated in section 3.12.4, CTLA4-KDEL-expressing DCs did not 
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generate FoxP3+ Tregs from alloreactive T cells in vitro (consistent with data in this 
section and the last, demonstrating a lack of either expansion of in vitro-generated 
FoxP3+CTLA4+CD4+CD25+ Tregs, or induction of FoxP3+ T cells from 
CFSE+CD4+CD25- T cells, after coculture with either CTLA4-KDEL-expressing tsDCs 
or CTLA4-KDEL-expressing primary DCs) but did however generate FoxP3-
CD4+CD25- Tregs with either direct or indirect donor allospecificity, and the capacity to 
produce the immunoregulatory cytokines IL-10 and TGF-β. On the other hand, both 
FoxP3+ and FoxP3- Tregs were generated in vivo after intravenous administration of 
CTLA4-KDEL-expressing DCs, demonstrating the heterogeneity in Treg generation in 
vitro and in vivo by these modified DCs. 
 
3.17. Murine Orthotopic Corneal Transplantation as a Model for the 
Indirect Pathway of Allograft Rejection 
 
An original aim of the project, the ability of CTLA4-KDEL- and IDO-transduced DCs 
to induce donor-specific tolerance to allografts was investigated using a murine corneal 
transplantation model. Murine corneal transplantation has been developed successfully 
in the laboratory, with graft survival being monitored daily by inspection and the use of 
established scoring systems for graft opacity and neovascularisation (see section 3.17.2 
below). The transparency of the cornea allows for early and continuing monitoring of 
the immunological response. 
3.17.1. High Rate of Corneal Graft Failure in Agouti, but not Albino Mice 
 
After demonstrating the induction of Treg-mediated donor-specific tolerance both in 
vitro and in vivo using CTLA4-KDEL-transduced BALB/c- or CBK-derived DCs 
administered to C3H/He or CBA/Ca mice respectively (the latter strain combination to 
induce tolerance with indirect donor allospecificity), the subsequent aim was to 
investigate the effect of intravenous administration of the EIAV-transduced DC 
populations on corneal allograft rejection using identical BALB/c→C3H/He and 
CBK→CBA strain combinations. Corneal transplants were thus to be performed on 
C3H/He and CBA/Ca mice that had been injected with EIAV-transduced BALB/c and 
CBK DC populations respectively. C3H/He and CBA/Ca mice are both agouti strains, 
unlike the BALB/c mouse which is an albino strain. When corneal transplantation was 
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performed on either of the two agouti strains of mice [Figure 61A(i)], there was a rapid 
loss of donor cornea transparency within 48 hours as observed immediately after eyelid 
suture removal [Figure 61A(ii)]. There was a complete loss of transparency within 7 
days post-transplantation as observed immediately after corneal suture removal [Figure 
61A(iii)]. It has been observed that the high rate of corneal graft failure in agouti mice 
results from glaucoma, itself due to a shallow anterior chamber in these mice with a 
high volume pigmented iris (personal communication / unpublished, Mr Frank Larkin, 
Moorfield’s Eye Hospital, London, UK). Hence, there is a higher rate of corneal graft 
failure in mice with pigmented eyes. The lack of depth in the anterior chamber of agouti 
mice has been noted in a recent study (Puk et al., 2006) in addition to a higher 
intraocular pressure (and hence glaucoma) in agouti strains (John et al., 1997).  
 
Data from studies of human corneal transplantation have demonstrated not only an 
escalation of glaucoma after corneal transplantation (Greenlee and Kwon, 2008), but 
also an increase in corneal endothelial cell loss after corneal transplantation in glaucoma 
eyes (Reinhard et al., 2001). As described in section 1.5, the endothelial cell monolayer 
that forms the posterior surface of the cornea is critical to its functioning. In cases where 
there is trauma to the endothelium (for example in the case of glaucoma), there is 
accelerated loss of cell density. This can result in non-immunological endothelial 
decompensation. The endothelial monolayer functions to pump water out of the stroma 
of the cornea. In the absence of this pump function the cornea swells, the collagen fibres 
are disorientated and the cornea loses transparency (George and Larkin, 2004). 
Glaucoma is one of several conditions that can increase the loss of the endothelial 
monolayer and corneal transparency, mainly as a result of preventing the 
aforementioned efflux of water out of the corneal stroma. It is well known that any 
trauma (including glaucoma) to the lens of the eye will also cause water to enter the 
structure and subsequently dissolve constituent intra-lens proteins resulting in a blurring 
of the lens. The various observations described above, including such non-
immunological factors as synechia (a condition where the iris adheres to the cornea) in 
agouti mice post-transplantation due to the lack of depth in the anterior chamber of each 
eye, indicate possible causes for the graft failure and accelerated loss of donor cornea  
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Figure 61. High Rate of Corneal Graft Failure in Agouti, but not Albino Mice. 
Complete MHC-mismatched corneal transplantation was performed on strains of (A) agouti (representative 
of both C3H/He and CBA strains) and (B) albino (BALB/c strain) mice. Donor grafts were monitored (i) 
immediately after transplantation; (ii) 48 hours post-transplantation immediately after eyelid suture 
removal; and (iii) 7 days post-transplantation immediately after corneal suture removal. 
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transparency detected after corneal transplantation was performed on the agouti strains 
of mice used in this study. 
 
Whereas corneal transplantation in agouti mice resulted in the loss of donor cornea 
transparency and subsequent graft failure, this was not the case for corneal 
transplantation in BALB/c (albino) mice [Figure 61B(i)]. The donor cornea remained 
completely transparent at the time of eyelid suture removal 48 hours after 
transplantation [Figure 61B(ii)], and 7 days after transplantation as observed 
immediately after corneal suture removal [Figure 61B(iii)]. 
3.17.2. Grading Criteria for Corneal Allograft Rejection in Albino Mice 
 
The successful ‘mechanical’ outcome of corneal transplantation in BALB/c mice 
[Figure 62(a)] meant that this strain of albino mice was subsequently used as a 
recipient strain for all corneal transplantation experiments in this study, as opposed to 
the use of either of the agouti strains (which were used to demonstrate the induction 
donor-specific tolerance in vivo). 
 
As explained earlier in the report, corneal transparency is an excellent indicator of 
corneal endothelial function and of graft endothelial injury, along with other factors 
including neovascularisation. The grading of corneal opacity and the onset of graft 
rejection in this study was determined using minor modifications to an established 
protocol (Sonoda and Streilein, 1993). Graft rejection was diagnosed when corneal 
opacity increased to grade 3 (no iris blood vessels visible). The full grading is as 
follows: 0, completely transparent cornea; 1, minimal corneal opacity, iris vessels easily 
visible [Figure 62(b)]; 2, moderate corneal opacity, iris vessels still visible [Figure 
62(c)]; 3, moderate corneal opacity, iris vessels no longer visible, only pupil margin 
visible [Figure 62(d)]; 4, complete corneal opacity, pupil no longer visible [Figure 
62(e)]. For experimental outcomes of any treatment groups to be unbiased, the grading 
of graft transparency was undertaken by examiners masked the treatment of each 
animal. In addition to the high rate of corneal graft failure, a further reason why agouti 
mice were not used as recipients for corneal transplantation experiments is that it would 
have been difficult to apply the detailed grading protocol of corneal opacity proposed by  
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Figure 62. Grading Criteria for Corneal Allograft Rejection in Albino Mice. 
(a) BALB/c mice received a complete MHC-disparate corneal graft. Donor grafts were graded for 
assessment of corneal allograft rejection as follows: 0, completely transparent cornea; (b) 1, minimal 
corneal opacity, iris vessels easily visible; (c) 2, moderate corneal opacity, iris vessels still visible; (d) 3, 
moderate corneal opacity, iris vessels no longer visible, only pupil margin visible; (e) 4, complete corneal 
opacity, pupil no longer visible. 
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Sonoda and Streilein to a pigmented iris as the blood vessels are not visible- any 
assignment of corneal allograft rejection would have had to be judged on corneal 
opacity alone, adding a degree of subjective grading to the criteria. 
3.17.3. CD8+ T Cells do not Contribute to Corneal Allograft Rejection 
 
Although there have been recent reports of MHC class II- (negative) DCs in the cornea, 
the function of these cells remain unclear and rejection of corneal grafts has been 
demonstrated to be predominately through a CD4+ T cell-mediated pathway (He et al., 
1991; Illigens et al., 2002). In order to investigate the contribution of CD8+ T cells to 
corneal allograft rejection, and specifically to corneal allograft rejection in a BALB/c 
mouse, in vivo depletion was carried out by intraperitoneal injection of CD8+ T cell-
depleting antibody prior to transplantation of a C3H/He donor-derived corneal graft into 
a BALB/c recipient. There was no significant difference detected in the median survival 
time (MST) of untreated mice and those mice in which in vivo CD8+ T cell depletion 
was carried out (MST= 11.5 and 12.5 respectively) [Figure 63]. 
 
3.18. Administration of CTLA4-KDEL-Transduced, Donor-Derived 
DCs Causes Moderate Prolongation of Corneal Allograft Survival 
 
Allorecognition in corneal transplantation is primarily through the indirect pathway 
(Sano et al., 1999; Boisgerault et al., 2001; Illigens et al., 2002) because of the paucity 
of resident MHC class II+ DCs in the donor (Gillette et al., 1982). Although there have 
been several reports of MHC class II- (negative) DCs in the cornea, the function of these 
cells remain essentially unclear. Recent evidence has demonstrated cervical lymph 
nodes draining corneal allografts to contain MHC class II+ donor-derived DCs (Hamrah 
et al., 2002; Liu et al., 2002). Speculation resulting from these findings is that MHC 
class II- DCs in the donor cornea migrate to the draining lymph nodes post-
transplantation where there is upregulation of MHC class II expression and potential for 
direct recognition of these DCs by recipient alloreactive CD4+ T cells. What is not 
currently clear is the relative contribution of the direct pathway of alloantigen 
presentation to corneal allograft rejection. 
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Figure 63. CD8+ T Cells do not Contribute to Corneal Allograft Rejection. 
BALB/c mice received either a syngeneic (n=6) or a complete MHC-disparate C3H/He corneal graft. Mice 
that received a C3H/He corneal graft were either treated to deplete peripheral CD8+ T cells (n=4) or left 
untreated (n=4) prior to transplantation. Data for corneal allograft survival was plotted according to the 
Kaplan-Meyer method. 
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The induction of Treg-mediated donor-specific tolerance with direct pathway 
allospecificity was demonstrated in vitro and in vivo in sections 3.12 and 3.14 
respectively using CTLA4-KDEL-transduced DCs and fully MHC-disparate CD4+ T 
cells. Subsequent to these findings, the effect of direct pathway tolerance induction 
using EIAV-transduced DCs on the rejection of corneal allografts was investigated. 
Assessing the effect of tolerance induction to the direct pathway using EIAV-transduced 
DC populations and the subsequent effects on corneal allograft rejection (a process 
thought to be mediated predominantly by the indirect pathway), would give an idea as 
to the relative contribution of this pathway to the rejection of corneal grafts and whether 
inducing tolerance to the direct pathway alone would be sufficient to prevent corneal 
allograft rejection. 
 
Similar to the assays used to assess the induction of tolerance in vitro and in vivo 
described above, corneal transplantation was performed using a fully MHC-disparate 
[C3H/He (H-2k)→BALB/c (H-2d)] strain combination. 2.5x106 donor-derived C3H/He 
DCs (transduced ex vivo) were injected intravenously into BALB/c mice via the tail 
vein followed by corneal transplantation 10 days later. Similar to transduction of 
BALB/c- and CBK-derived DCs used in previous in vitro assays, C3H/He DCs 
transduced with EIAV CTLA4-KDEL were demonstrated to be CD80/86- by flow 
cytometric analysis, whilst C3H/He DCs transduced with EIAV IDO expressed the 
functional enzyme as assessed by L-kynurenine assays (data not shown). 
 
There was a moderate prolongation in the survival of corneal allografts in mice injected 
10 days earlier with CTLA4-KDEL-transduced DCs (MST = 18 days) compared to 
those animals injected with Mock-transduced DCs (MST = 10 days) (P<0.0001) and 
Untransduced DCs (MST = 11 days) (P=0.0002) [Figure 64(a)]. In addition, there was 
minimal prolongation of corneal allograft survival in mice injected with IDO DCs 
(MST = 12 days) compared to mice injected with Mock-transduced DCs (MST = 10 
days) (P=0.0084) and Untransduced DCs (MST = 11 days) (P=0.0244). Furthermore, 
after analysis of post-operative corneal allograft opacity scores over 18 days after 
transplantation [Figure 64(b)], it was observed that there was a significant delay in the 
increase of corneal allograft opacity (and hence a delay in the loss of corneal  
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Figure 64. Administration of CTLA4-KDEL-Transduced, Donor-Derived DCs Causes Moderate 
Prolongation of Corneal Allograft Survival. 
BALB/c mice were either uninjected (n=6) or injected intravenously with 2.5x106 C3H/He DCs. The 
C3H/He DCs were either untransduced (n=5), or transduced 72 hours earlier ex vivo with EIAV Mock 
(n=7), EIAV IDO (n=7) or EIAV CTLA4-KDEL (n=8). 10 days later, the BALB/c mice received a complete 
MHC-disparate C3H/He corneal graft or a syngeneic BALB/c graft. (a) Data for corneal allograft survival 
was plotted according to the Kaplan-Meyer method and differences in graft survival were analysed using a 
log rank test. (b) Corneal graft opacity scores were plotted for all groups and statistical differences 
calculated using the Mann-Whitney U Test: (#, * P<0.008). 
Chapter 3: Results 
Adnan Khan, Department of Immunology, Division of Medicine, Imperial College London 266 
endothelium and infiltration by alloreactive cells) in mice injected with CTLA4-KDEL-
transduced DCs compared to mice injected with Mock-transduced DCs. There was a 
significant difference in the average scores of corneal allograft opacity between these 
groups of mice on day 12 (P<0.008) and day 15 (P<0.008), with CTLA4-KDEL DC-
injected mice not reaching an average corneal opacity of grade 3+ (corneal allograft 
rejection) before day 18 compared Mock DC-injected mice which reached this score at 
observation on day 12. The results thus provide evidence for an initial phase of direct 
allorecognition in corneal allograft rejection as fully-MHC mismatched CTLA4-KDEL-
transduced DCs were used to induce tolerance to this pathway. It could be speculated 
that Tregs induced in vivo by donor-derived, CTLA4-KDEL-expressing DCs (as 
demonstrated in earlier sections) have a non-specific effect on graft survival that is not 
sufficient, in the long-term, to protect from rejection resulting from the indirect pathway 
of alloreactivity. 
 
3.19. Administration of CTLA4-KDEL-Transduced Hybrid/F1 DCs 
Expressing Donor and Recipient MHC Prevents Corneal Allograft 
Rejection 
 
As mentioned in section 1.13, the major aim of this study was to induce donor-specific 
tolerance particularly to the indirect pathway of allorecognition, the predominant 
pathway of recognition during the chronic phase of allograft rejection. As a result of the 
paucity of resident MHC class II+ DCs in the donor cornea, allorecognition in corneal 
transplantation results primarily from the indirect pathway of alloantigen presentation 
and is mediated by CD4+ T cells (Gillette et al., 1982; Sano et al., 1999; Boisgerault et 
al., 2001; Illigens et al., 2002). After using a murine corneal allograft model to assess 
the effect of DC-based tolerance induction with direct pathway allospecificity on graft 
rejection, the same transplant model was used to assess the effect of tolerance induction 
to the indirect pathway on graft rejection. 
 
Although the CBK→CBA strain combination was used to demonstrate the in vitro- and 
in vivo-induction of donor-specific tolerance with indirect allospecificity in sections 
3.13 and 3.15 respectively, the use of this strain combination to investigate the effect on 
corneal allograft rejection was not possible due to non-immunological corneal graft 
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failure associated with the shallow anterior chamber in the eyes of agouti mice as 
described in section 3.17.1. Corneal transplantation in CBA/Ca or C3H/He would have 
had a high risk of corneal graft failure. An alternative strain combination was therefore 
used to investigate the effect of DC-based tolerance induction to the indirect pathway 
using CTLA4-KDEL and IDO.  
 
Several studies have demonstrated that administration of ‘tolerogenic’ hybrid/F1 DCs 
expressing both donor and recipient MHC are effective at inducing donor-specific 
tolerance with indirect allospecificity (Morelli and Thomson, 2007). For example, 
dexamethasone-treated immature DCs have been shown to induce T cell anergy in vitro, 
and administration of dexamethasone-treated F1 DCs- expressing self and allogeneic 
MHC molecules- has been shown to be effective at inducing tolerance to rat kidney 
allografts by inducing indirect pathway Tregs (Mirenda et al., 2004). 
 
The strategy of using hybrid/F1 DCs to induce tolerance with indirect allospecificity 
was used as a replacement to the CBK→CBA indirect pathway strain combination. 
Whereas a C3H/He (H-2k)→BALB/c (H-2d) corneal transplantation strain combination 
(a complete MHC mismatch) was used for experiments in section 3.18 to address the 
direct pathway,  a CBA/Ca (H-2k)→BALB/c (H-2d) corneal transplantation strain 
combination was used in conjunction with [(CBA/Ca)x(BALB/c)F1] DCs to address the 
indirect pathway. This was because of the availability of a CBACF1 
[(CBA/Ca)x(BALB/c)F1] mouse strain from which BM-derived F1 DCs could be 
derived. At the time of the study, a [(C3H/He)x(BALB/c)F1] was not available. 
C3H/He and CBA/Ca mice are of the same haplotype (H-2k) and C3H→CBA or 
CBA→C3H skin transplants were shown to be accepted in early studies- the only 
mismatches between the two strains being restricted to non-H2 minor antigens 
(Gowland, 1965; Argyris, 1968). C3H→BALB/c and CBA→BALB/c corneal 
transplants both have the same rejection kinetics with a median survival time of 11 days 
(this is described both above and below in the direct and indirect pathway experiments). 
Thus, C3H/He DC injection into BALB/c mice prior to C3H→BALB/c corneal 
transplants would test the direct pathway as injected DCs would express donor peptide 
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only in the context of donor MHC whereas corneal transplants are rejected via the 
indirect pathway. 
 
The administration of CBACF1 DCs followed by a CBA→BALB/c corneal transplant 
would test the indirect pathway as injected F1 DCs would express donor peptide in the 
context of recipient MHC. The direct pathway would also be tested as these DCs would 
also express donor peptide in the context of donor MHC. Similar to the transduction of 
BALB/c- and CBK-derived DCs used in previous in vitro assays, CBACF1 DCs 
transduced with EIAV CTLA4-KDEL were demonstrated to be CD80/86- by flow 
cytometric analysis, whilst CBACF1 DCs transduced with EIAV IDO expressed the 
functional enzyme as assessed by L-kynurenine assays (data not shown). 
 
There was considerable prolongation of corneal allograft survival (at least 75 days) in 
100% of mice, and indefinite survival (>100 days) of corneal allografts in 80% of mice 
injected 10 days earlier with CTLA4-KDEL-transduced F1 DCs compared to Mock-
transduced F1 DCs (MST = 9 days) and Untransduced F1 DCs (MST = 11 days) 
[Figure 65(a)]. In comparison, there was only a moderate prolongation of corneal 
allograft survival in mice injected with IDO-transduced F1 DCs (MST = 18 days) 
compared to Mock F1 DCs (MST = 9 days) (P=0.0016) and Untransduced F1 DCs 
(MST = 11 days) (P=0.0031). 
 
Analysis of post-operative corneal allograft opacity scores over 100 days after 
transplantation [Figure 65(b)] reveals complete transparency of corneal allografts in 
mice injected with CTLA4-KDEL F1 DCs over the first 60 days and a considerably 
delayed subsequent increase in corneal allograft opacity (and thus a delay in the 
infiltration of the cornea by alloreactive cells and the subsequent loss of corneal 
endothelium) compared to mice injected with Mock-transduced F1 DCs. There was a 
significant difference in the average scores of corneal allograft opacity between these 
groups of mice on week 3 (P<0.008) through to week 14 (P<0.008), with CTLA4-
KDEL F1 DC-injected mice not reaching an average corneal opacity of grade 2 at day 
100 (and thus reaching only grade 1 with minimal corneal opacity) compared to Mock 
F1 DC-injected mice which reached grade 2 by day 7 and grade 3 within the next week. 
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Figure 65. Administration of CTLA4-KDEL-Transduced DCs Expressing Donor and Recipient MHC 
Prevents Corneal Allograft Rejection. 
BALB/c mice were either uninjected (n=4) or injected intravenously with 2.5x106 CBACF1 
[(CBA)X(BALB/c)]F1 DCs. The CBACF1 DCs were either untransduced (n=5), or transduced 72 hours 
earlier ex vivo with EIAV Mock (n=5), EIAV IDO (n=5) or EIAV CTLA4-KDEL (n=5). 10 days later, the 
BALB/c mice received a complete MHC-disparate CBA/Ca corneal graft or a syngeneic BALB/c graft. (a) 
Data for corneal allograft survival was plotted according to the Kaplan-Meyer method and differences in 
graft survival were analysed using a log rank test. (b) Corneal graft opacity scores were plotted for all 
groups and statistical differences calculated using the Mann-Whitney U Test: (#, •, * P<0.008). 
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This result is consistent with rejection of corneal allografts being predominantly through 
the indirect pathway of allorecognition (George and Larkin, 2004), as the F1 DCs 
present donor alloantigen in the context of recipient MHC. The indefinite survival of 
corneal allografts in mice injected with CTLA4-KDEL F1 DCs is consistent with a 
donor-specific tolerance induction mechanism mediated by the induction of Tregs 
whereas only a moderate prolongation of corneal allograft survival in mice injected with 
IDO F1 DCs is consistent with a deletional mechanism resulting from the apoptosis of 
alloreactive T cells after localised tryptophan depletion. 
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Chapter 4: DISCUSSION 
 
4.1. Intracellular Retention of CD80/86 by Dendritic Cells, unlike 
Tryptophan Catabolism, as a Mechanism to Induce Regulatory T Cell-
Mediated, Donor-Specific Transplantation Tolerance 
 
Data generated both in vitro and in vivo during the course of this study has 
demonstrated the potential of DCs expressing the intracellular fusion protein 
CTLA4-KDEL in the induction of Treg-mediated, donor-allospecific transplantation 
tolerance. In a clinical setting, this strategy would be patient-specific and crucially, 
Tregs generated in vivo through contact with recipient CTLA4-KDEL-expressing DCs 
presenting donor peptide, would regulate the indirect pathway of allorecognition, the 
predominant pathway of recognition during chronic allograft rejection. Using a murine 
corneal allograft model, indefinite survival of allografts was observed after a single 
intravenous injection of CTLA4-KDEL-expressing (donor x recipient) F1 DCs without 
the use of any other treatment (i.e. transient pharmacological immunosuppression, 
monoclonal antibodies for the blockade of costimulation pathways such as CD40-
CD154, CTLA4-Ig, etc.) 
 
In this study, two potential strategies of tolerance induction were investigated: the 
intracellular retention of CD80/86 in DCs by CTLA4-KDEL, and the DC expression of 
IDO after lentiviral gene transfer. It was demonstrated that CTLA4-KDEL- or IDO-
transduced DCs are unable to induce and/or sustain allogeneic T cell proliferation. After 
developing two-stage murine DC : T cell coculture assays, it was observed that 
CTLA4-KDEL-, but not IDO-transduced DCs, can induce donor-specific T cell anergy 
both in vitro and in vivo. Tolerance to both the direct and indirect pathways of 
alloantigen presentation was demonstrated using CTLA4-KDEL-expressing DCs, and 
linked suppression was mediated by the generation of donor-specific Tregs. Crucially, 
both the expansion of FoxP3+ Tregs was detected in vivo in addition to the in vitro- and 
in vivo-induction of IL-10-secreting CD4+CD25- cells and TGFβ-secreting CD4+CD25- 
cells, as detected by flow cytometry, ELISA assays on both CD4+CD25+ and 
CD4+CD25- T cell subsets, T cell rechallenge assays and suppressor assays. Tolerance 
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to the direct pathway was demonstrated in vitro and in vivo using a multiple mismatch 
strain combination (BALB/c→C3H), and to the indirect pathway using a CBK→CBA 
model in which CBK DCs express a transgenic Kb (MHC class I) and CBA-derived 
CD4+ T cell-directed MLRs are generated in response to the Kb peptide presented in the 
context of recipient MHC (H-2k). The reversibility of the donor-specific 
unresponsiveness in T cells induced after coculture with EIAV CTLA4-KDEL-
transduced DCs was demonstrated by the addition of exogenous IL-2 to rechallenge 
cultures, confirming donor-specific anergy in these cells. EIAV IDO-transduced DCs 
were unable to generate Tregs. Results from the rechallenge assays demonstrated that 
exposure of CD4+ T cells (whether specific for the direct or indirect pathways) to IDO-
expressing DCs either in vitro or in vivo, most likely results in non-specific 
hyporesponsiveness (with no regulatory/suppressive properties as shown from 
suppressor assays) as the majority of these cells do not proliferate on rechallenge with 
DCs in the presence of non-specific IL-2 stimulation. 
 
Treatment of DCs with the glucocorticoid dexamethosone resulted in the inhibition of 
allogeneic CD4+ T cell proliferation, but only in the absence of LPS stimulation. If DCs 
were treated with dexamethasone, followed by LPS, there was only a moderate 
inhibition in the proliferation of allogeneic CD4+ T cells. Furthermore, CD4+ T cells 
rechallenged with donor- and third-party-derived DCs after previous exposure to 
dexamethasone-treated DCs either in vitro or in vivo did not exhibit donor-specific 
hyporesponsiveness. The considerable proliferation exhibited by allogeneic CD4+ T 
cells after coculture with Dexamethasone-treated DCs that were subsequently 
stimulated with LPS supports claims (and the hypothesis of this study) that particular 
stimuli may be capable of maturing dexamethasone-treated DCs. The potential exists 
wherein pharmacologically-treated (e.g. dexamethasone-treated) immature DCs 
administered for tolerogenic therapy could be activated in vivo as a result of local 
inflammation. 
 
Results generated from murine corneal transplantation experiments were consistent with 
rejection of corneal allografts being predominantly through the indirect pathway of 
allorecognition, as the CTLA4-KDEL-expressing F1 DCs presented donor alloantigen 
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in the context of recipient MHC. The indefinite survival of corneal allografts in mice 
injected with CTLA4-KDEL F1 DCs was consistent with a donor-specific tolerance 
induction mechanism mediated by the induction of Tregs with direct and indirect 
allospecificity, whereas only a moderate prolongation of corneal allograft survival was 
observed in mice injected with IDO F1 DCs, consistent with a deletional mechanism as 
a result of the induction of a state of unreversible, non-specific unresponsiveness in 
alloreactive T cells after localised tryptophan depletion. Although there have been 
several studies to date demonstrating prolongation of allograft survival after treatment 
of the graft for upregulation of IDO expression (Mellor and Munn, 2004; Beutelspacher 
et al., 2006), the results from this study demonstrate that donor-specific anergy and 
regulation cannot be induced. 
 
It is noteworthy that the C3H/He (H-2k) → BALB/c (H-2d) donor-recipient strain 
combination used in the direct pathway corneal transplantation experiment is a high-
responder allogeneic combination, with median corneal graft survival in unmodified 
(uninjected) graft recipients of 11.5 days. In contrast, reported survival times in BALB/c 
recipients of C57BL/6 (H-2b) and C57BL/10 (H-2b) donor corneas were 5 weeks 
(Yamagami et al., 2002) and 38 days (Vitova et al., 2004), respectively. Irrespective of 
the immunogenetic basis of the variation in survival in combinations with different 
histocompatibility mismatches, experimentation in a high-responder combination is a 
useful strategy for evaluating immunomodulation with great therapeutic potential 
(Watson et al., 2006). In the case of CD4+ T cells, the indirect pathway of 
allorecognition is of importance in both corneal rejection (due to the paucity of APCs in 
the cornea), and in the chronic phase of rejection of other (vascularised) organs. 
However, the direct pathway dominates the acute phase of rejection of most organs.  
 
Although experiments undertaken with the CBK→CBA combination focus on indirect 
recognition by CD4+ T cells, the murine data obtained in this study both in vitro and in 
vivo in sections 3.12 and 3.13 indicates that the CTLA4-KDEL strategy will be effective 
at tolerance to the direct pathway. Indeed, data from the multiple-mismatch 
(C3H→BALB/c) corneal transplant model even suggests a potential role for the direct 
pathway in corneal allograft rejection, a rejection process that is dominated via the 
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indirect pathway of allorecognition. The results obtained in this study from the 
intravenous administration of donor-derived CTLA4-KDEL-expressing DCs and the 
resultant (moderate) prolongation in corneal allograft survival supports recent studies 
demonstrating the presence of DCs in the donor cornea (Liu et al., 2002). It can also be 
speculated from the moderate prolongation in corneal allograft survival that non-
specific immunosuppression by Tregs was induced in vivo by the donor-derived, 
CTLA4-KDEL-expressing DCs but was ultimately not sufficient to protect from 
rejection resulting predominantly from the indirect pathway of alloreactivity. 
 
Most protocols that use donor-derived DCs require preparation of the DCs several days 
before transplantation, which is not applicable to organ transplantation from deceased 
donors (although it is applicable to the now common live-donor renal and liver 
transplantation). Once injected, donor-derived DCs may be eliminated by host NK cells, 
as has been demonstrated recently in mice (Yu et al., 2006). Therefore, from practical 
and therapeutic perspectives, the administration of recipient-derived (autologous) 
tolerogenic DCs loaded with donor alloantigen appears to be more advantageous, as 
these DCs can be generated in vitro at any time, and have an inherent potential to 
regulate the indirect pathway and ameliorate chronic rejection. 
 
Given the strength of the direct pathway after transplantation of vascularised organs, the 
most plausible strategy for inducing tolerance in the clinical setting will be a dual 
approach in which the frequency of direct pathway alloreactive T cells is reduced by 
deletion and/or anergy (for example using antibodies or soluble proteins such as 
CTLA4-Ig), and that tolerance of the residual direct and the indirect pathway then 
induced by a regulatory mechanism (Lechler et al., 2003). It is interesting to note that 
recent data suggests that CD4+CD25+ Tregs are not responsible for controlling the direct 
pathway of allorecognition in renal transplant patients, but can prevent indirect pathway 
alloreactivity (Game et al., 2003; Salama et al., 2003). 
 
At the start of preliminary experiments investigating the effect of EIAV-transduced DCs 
on alloreactive T cells in vivo, the administration of a single dose of CTLA4-Ig was 
considered in order to inhibit potential sensitisation due to any representation of the 
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donor-derived DCs by recipient DCs, for example as a result of apoptosis of the 
administered DCs (Mirenda et al., 2004). In previous reports, the administration of a 
single dose of CTLA4-Ig was necessary when dexamethasone-treated DCs were 
injected intravenously, albeit into rats, to induce tolerance with indirect donor 
allospecificity (Mirenda et al., 2004). As demonstrated by the results of rechallenge and 
suppressor assays showing the in vivo-generation of donor-allospecific Tregs, in 
addition to the indefinite survival of corneal allografts after a single intravenous 
injection of CTLA4-KDEL-expressing DCs, CTLA4-Ig treatment for the temporary 
blockade of the CD28-CD80/86 pathway was not necessary. Similarly, there was no 
requirement for transient pharmacological immunosuppression or the use of monoclonal 
antibodies to block other costimulation pathways. 
 
It has been demonstrated that, when administered after transplantation, the 
immunosuppressive agent rapamycin can significantly reduce the number of effector 
alloreactive T cells by deletion, leaving a small pool of residual alloreactive T cells that 
could be regulated by Tregs (Wells et al., 1999). Furthermore, recent data has shown 
that rapamycin can selectively expand Tregs in vitro and in vivo (Tian et al., 2004; 
Battaglia et al., 2005). Therefore, the combination of short-term immunosuppression by 
rapamycin during the acute phase of rejection post-transplantaion and the administration 
of CTLA-KDEL-transduced recipient DCs pulsed with donor-derived peptide prior to 
the induction of the chronic phase of allograft rejection (when the indirect pathway of 
alloantigen presentation establishes dominance) could be a clinically applicable strategy 
to achieve donor-specific transplantation tolerance (Lechler et al., 2003). 
 
CD80/86 expression is not only involved in the activation of T cells, but also in their 
regulation, not only through interaction with CTLA4 but also by influencing CD4+ 
Tregs. Thus CD80/86-/- animals have a reduced number of CD4+CD25+ regulatory cells, 
and low levels of constitutive CD80/86 expression have been shown to be necessary for 
the maintenance of regulatory cells (Lohr et al., 2003). In addition lack of CD80/86-
CD28 interactions can exacerbate autoimmunity (Salomon et al., 2000). However, the in 
vivo data presented in sections 3.14 and 3.15 indicates that intravenous administration 
of CTLA4-KDEL-expressing DCs (and hence the inhibition of CD80/86-CD28 
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signalling) is capable of inducing donor-specific tolerance after the induction in vivo of 
FoxP3+ Tregs, IL-10-secreting CD4+CD25- cells and TGFβ-secreting CD4+CD25- cells. 
It is known that CD80/86 expession is not required for induction of anergy- for example 
anti-CD3 antibody will induce anergy in vitro (Chai and Lechler, 1997), and cells 
rendered anergic by anti-CD3 treatment can regulate immune responses in vivo (Chai et 
al., 1999). It may be that in such settings CD80/86 expression is provided in trans, 
possibly by CD80/86 expressed on T cells (Chai et al., 1998), or (in vivo) by resident 
DCs. It may also be that the kinetics of regulatory cell survival is influenced by 
CD80/86 interactions. 
 
A recent study using a several classes of viral vectors to transduce immature human 
DCs detected the upregulation of MHC class II and costimulatory molecule expression, 
as well as the production of TH1 / proinflammatory cytokines. Lentiviral transduction of 
mature DCs was also shown to result in a reduced ability of the cells to stimulate 
allogeneic T cells in a MLR due to the upregulation of IDO expression (Tan et al., 
2005b). The upregulation of IDO after transduction of murine BM-derived DCs with 
EIAV mock was not detected in this study. However, if IDO was detected, expression 
of this enzyme would not have compromised the use of lentiviral vectors in the 
modification of DCs for the induction of tolerance (as opposed to the induction of 
immunity). As the aim of the study was to prevent the expression of CD80/86 on the 
DC surface subsequent to lentiviral transfer of the murine CTLA4-KDEL gene, the 
upregulation of MHC II and a mild increase in IDO expression would not have 
counteracted the functional effects of a DC that is a CD80/86 ‘phenotypic knockout’. 
Contrary to any compromise of anergy induction, the upregulation of MHC class II 
resulting from viral transduction would more likely have led to enhanced antigen 
presentation in the absence of CD28-CD80/86 costimulation. 
 
The research conducted in this study also offers promising results for the use gene 
transfer to modify DC function. As outlined in section 1.12, these results have been 
made possible by the vast improvements in the development of viral vectors that allow 
relatively efficient gene transfer without significant alteration of cellular function. 
While recent cases of leukaemia have blunted the enthusiasm of many for viral gene 
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therapy, the development of non-integrating viral vectors (Yanez-Munoz et al., 2006) 
and vectors with minimal risk of oncogenesis or insertional mutagenesis offers great 
potential for the use of these vectors in cell-based tolerogenic therapy. However, the 
oncogenic potential of WPRE (expressed in several lentiviral vectors) has been noted. 
This is the result of the lentiviral constructs encoding a truncated form of the 
woodchuck hepatitis virus (WHV) X protein, implicated in insertional mutagenesis and 
hepatic cancers (Kingsman et al., 2005). In response, there have been several recent 
improvements to the safety of lentiviral vectors such as the development of constructs 
encoding WPRE that lack the truncated form of the WHV X protein (Schambach et al., 
2006). 
 
A practical problem associated with the introduction of lentivirus-transduced 
tolerogenic DCs in the clinic is the generation of concentrated viral stocks that would be 
needed for therapy. MOIs of 300 were used in this study, which, if translated to a 
clinical setting, would be very difficult to achieve in a short period of time. In personal 
communition with A J Thrasher, Professor of Molecular Immunology at the Institute of 
Child Health, UCL, in addition to isolated cases of leukaemia, the lack of concentrated 
viral stocks was a major factor contributing to the temporary suspension of bone 
marrow transplants undertaken to cure X-linked SCID. Murine primary cells have been 
demonstrated to be poorly permissive to HIV-1 vector infection. Retroviral infectivity is 
influenced by dominant inhibitors such as TRIM5α. Sensitivity to TRIM5α is altered by 
interactions between cyclophilin A and the HIV-1 capsid. It was demonstrated in a 
recent study that competitive inhibitors of cyclophilins, cyclosporine or the related 
Debio-025, stimulate HIV-1 vector transduction of primary murine cells, including bone 
marrow and macrophages, upto 20-fold. It is thus possible that HIV-1 infection of 
murine cells is inhibited by dominant factors related to immunophilins (Noser et al., 
2006). However, the use of cyclosporine could cause several problems in a T-cell 
mediated tolerance induction program, and thus, in this study a higher MOI was used to 
saturate dominant inhibitors such as TRIM5α. Although primary cells were not used, a 
study demonstrated that murine cells lines require higher MOIs to achieve equivalent 
transduction efficiencies as cell lines derived from other species (Ikeda et al., 2002). 
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A difficulty that exists with cell-based tolerogenic therapy in the clinic is the 
identification of a patient group in whom it would be ethical to test new strategies. The 
success of immunosuppressive therapy in preventing acute rejection means that it would 
probably be unethical in most patients to withdraw them from this treatment, yet in most 
models immunosuppression interferes with tolerance induction. However, only recently 
has it been demonstrated that whereas certain immunosuppressive drugs (e.g. 
cyclosporine) would interfere with cell-based tolerogenic therapy, other drugs such as 
rapamycin would actively support it as demonstrated by the selective expansion of 
Tregs and deletion of alloreactive T cells (Zheng et al., 2003; Tian et al., 2004; Battaglia 
et al., 2005). One exception to this is corneal transplantation, in which there are a group 
of high-risk patients (paediatric recipients, those with previous failed grafts, those with 
ongoing infection or inflammation in the cornea) who are at very high risk of rejection 
(typically 50% loss within 6-12 months). These patients may offer a group in which 
novel tolerogenic strategies, including the use of CTLA4-KDEL-expressing DCs (as 
demonstrated by the result of the murine corneal transplantation experiments), could be 
assessed. 
 
4.2. The Complex Role of Tryptophan Catabolism in the Generation 
and Maintenance of Regulatory T Cell Populations 
 
As described in section 1.9, there has been wide speculation into the role of IDO in T 
cell regulation, and whether IDO+ DCs can induce expression of the enzyme in 
neighbouring IDO- DCs via induction of Tregs as a mechanism of infectious tolerance 
(Mellor and Munn, 2004). This would provide a possible mechanism for the dominant 
immunosuppressive role of IDO- even when a few IDO-expressing DCs are present 
within a population of APCs. To investigate whether expression of IDO (and the 
resulting tryptophan depletion in the microenvironment) could promote the induction 
and/or expansion of a Treg population (possibly by enhancing the effects of 
costimulation blockade), murine DC populations (and stable tsDC lines) differing in 
surface CD80/86 costimulation and IDO expression were used in cocultures with T cells 
consisting of specific ratios of induced CTLA4+CD4+CD25+FoxP3+ Tregs and CFSE-
stained CD4+CD25- T cells. It was demonstrated that IDO+CD80/86+ -DCs  and -tsDCs 
fail to induce and/or expand FoxP3+CTLA4+ Treg populations. Additionally, it was 
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observed that IDO+CD80/86- -DCs and –tsDCs fail to sustain pre-induced populations 
of FoxP3+CTLA4+ Tregs. The failure of tsDCs expressing IDO in the absence of 
CD80/86 costimulation to induce, expand or sustain FoxP3+ Treg populations was 
associated with a high rate of cell death, as determined by 7-AAD expression. Similarly, 
a high rate of cell death was observed after incubation of CD4+ T cells with three 
separate populations of IDO+CD80/86- DCs- this was detected at all ratios of CTLA4+ 
Tregs : CFSE+CD25- T cells and clearly demonstrates the lack of a Treg-mediated 
infectious tolerance mechanism utilised by DCs expressing IDO in the presence or 
absence of CD80/86 costimulation. 
 
The results of the study therefore demonstrate that despite CTLA4+ Tregs having the 
capacity to induce the expression of IDO by DCs (as detected by western blotting and 
real-time PCR analysis for mRNA detection- see section 3.16.4), expression of this 
enzyme by the same cells cannot in turn generate populations of Tregs (more so in the 
absence of CD80/86 expression, which leads to Treg death), i.e. an IDO+ DC cannot 
induce Tregs merely through microenvironmental tryptophan depletion. It is more likely 
that IDO+ DCs induce apoptosis and/or accentuate the dampening of T cell activation 
(Mellor and Munn, 1999). Results of experiments also demonstrate that CTLA4+ Tregs 
remain viable and express the intracellular marker FoxP3 after incubation with DCs 
lacking suface expression of CD80/86, so long as this is in the absence of IDO 
expression. Furthermore, it was observed that IDO+ DCs do not have the capacity to 
induce FoxP3+Tregs from CD4+CD25- T cells- this is expected as, in a physiological 
environment, this might lead to ‘uncontrolled’ tryptophan depletion as these cells would 
then induce DC expression of IDO via ligation of surface CD80/86. It seems from the 
experiments undertaken here that the Treg is the initiator of immunoregulation when 
IDO expression is the suppressor mechanism. The results obtained through the 
experiments undertaken in section 3.16 support the lack of donor-specific anergy and 
regulation observed after EIAV IDO-transduced DCs were used in in vitro and in vivo 
MLRs and suppressor assays. As explained earlier, the main limitation of the 
experiments in section 3.16 is that the loss of FoxP3 expression by the in vitro-
generated Tregs is equated to a loss of suppressive capacity, without demonstrating this 
functionally, although a high rate of 7-AAD expression was demonstrated to be 
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associated with the loss of FoxP3+ T cell population. This demonstrates that the 
considerable reduction in FoxP3-expressing T cells was due to cell death induced by 
IDO-expressing DCs.  
 
Data obtained during this study regarding the depletion of pre-induced populations of 
CTLA4+FoxP3+ Tregs by DCs expressing IDO in the absence of surface CD80/86 
expression can be supported by a recent in vivo study demonstrating that in vivo-
administration of CTLA4-Ig into mice selectively depletes the CTLA4+CD4+FoxP3+ 
Treg subset (Tang et al., 2008). Costimulation blockade with CTLA4-Ig and LEA29Y, 
a variant of CTLA4-Ig, is currently effective at preventing acute rejection and 
prolonging graft survival by inhibiting the CD28-CD80/CD86 costimulatory pathway 
(Baliga et al., 1994; Levisetti et al., 1997). CD28 costimulation has been implicated in 
the generation and survival of Tregs (Tang et al., 2003). After administering CTLA4-Ig 
(250µg/dose) intraperitoneally into mice, the authors of the study purified CD4+ T cells 
from the spleens after 3 days and analysed the expression of CD25, CTLA4 and FoxP3. 
The short-term CTLA4-Ig treatment substantially decreased the frequency of 
CD4+FoxP3+ subset and most notably the CTLA4+FoxP3+ subset, with the authors 
subsequently suggesting that the maintenance and/or peripheral generation of Tregs is 
dependent on CD28-mediated costimulation. The findings by the authors of this study, 
together with the in vitro results in this study have important implications regarding the 
constitution of Treg subsets and their balance within non-regulatory populations in 
patients receiving CTLA4-Ig and LEA29Y. An alternative explanation for the 
observations reported by Tang and colleagues is that rather than the maintenance and/or 
peripheral generation of Tregs being dependent on CD28-mediated signalling, IDO 
expression by the APCs in the absence of CD80/86-CD28 signalling (both factors 
resulting from the high concentration of CTLA4-Ig injected into mice) is the 
determining factor resulting in the selective depletion of CTLA4+ Tregs. This can be 
further supported by results obtained in this study demonstrating the viability of 
CTLA4+FoxP3+ Tregs after coculture with IDO-CD80/86- DCs (resulting from CTLA4-
KDEL expression, but not IDO expression). 
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One explanation regarding the lack of donor-specific Treg induction by IDO-expressing 
DCs (and depletion of Tregs in the case of IDO+CD80/86- DCs) throughout this study 
(including for the murine corneal transplantation experiments) is that Tregs are 
generated at tryptophan concentrations within a narrow range, higher than the 
concentrations that were used throughout this study. The expression of IDO by DCs 
subsequent to transduction with EIAV IDO (at the standard MOI of 300), resulted in a 
concentration of approximately 60 µM L-kynurenine 72 hours after DC transduction- 
see section 3.6. This concentration might have been relatively higher than the 
concentration of L-kynurenine produced by IDO+ DC populations used in studies that 
have reported the generation of FoxP3+ Tregs after incubation of T cells with either 
IDO+ DCs or tryptophan catabolites (Fallarino et al., 2006a; Fallarino et al., 2006b; Hill 
et al., 2007). It is also possible that IDO-expressing DCs induce populations of non-
specific Tregs, which might result in non-specific T cell hyporesponsiveness, similar to 
that observed in rechallenge assays with CD4+ T cells exposed previously to IDO-
expressing DCs either in vitro or in vivo.  
 
Another explanation is that IDO has a role in the induction of Tregs in vivo in the 
periphery, as opposed to having a role in the induction or expansion of in vitro-
generated, FoxP3+ Tregs. However, this is unlikely as a high rate of T cell death was 
observed in experiments undertaken in section 3.16, and expression of IDO by DCs 
would not be expected to deplete naturally-occuring FoxP3+ Treg populations in a 
physiological environment. 
 
The data generated from the experiments described above, however, certainly does not 
exclude the possibility of tryptophan catabolism having a major role in the induction of 
Tregs. This is because bone marrow-derived DCs were used throughout the 
investigation as opposed to spleen-derived DCs (including plasmacytoid DCs), the 
major population of murine DCs used in elaborate studies from the laboratories of Paolo 
Puccetti and Andrew Mellor reporting the generation of Tregs by IDO-expressing DCs 
(see below). 
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The term ‘reverse signalling’ is used conventionally to indicate a two-way 
communication between cells or cell types, whereby information is actually flowing in 
both directions, but one direction (‘forward’) is of greater or longer-standing 
importance. Reverse signalling applies to the triad of coreceptors consisting of CTLA4, 
CD28 and CD80/86, and this enables bidirectional conditioning of T cells and DCs 
(Grohmann et al., 2002; Mellor et al., 2003; Orabona et al., 2004). Thus, mouse and 
human DCs respond to CTLA4 engagment of their surface CD80/86 molecules with the 
activation of the immunoregulatory role of tryptophan catabolism that is initiated by 
IDO and controlled by interferons (Taylor and Feng, 1991), through the involvement of 
the poorly characterised transcription factors of the nuclear factor-κB (NF-κB) family 
(Du et al., 2000) and often associated with the expression of IL-10 (Munn et al., 2002; 
Romani and Puccetti, 2006). 
 
Reverse signalling in DCs leading to expression of IDO following T cell contact has 
already been explained earlier as one of the contact-dependent effector mechanisms of 
naturally-occurring Tregs that express surface CTLA4 (Finger and Bluestone, 2002; 
Fallarino et al., 2003; Mellor and Munn, 2004), thereby reconciling a long-established 
role of IDO in mammalian pregnancy (Munn et al., 1998) with the speculative role of 
IDO in Treg function (Aluvihare et al., 2004). It has been suggested by Puccetti and 
Grohmann, however, that there is increasing recognition of a broader and truly 
immunoregulatory role for IDO in physiology, far beyond its function in pregnancy or 
as a grossly immunosuppressive mechanism (Mellor and Munn, 1999). The role of IDO 
has shifted in importance from that of a metabolic regulator of tryptophan availability in 
local tissue microenvironments, to one that is central to immune homeostasis and the 
plasticity of the immune system, with implications for many aspects of 
immunopathogenesis (Mellor and Munn, 2004; Puccetti and Grohmann, 2007). 
 
Recent molecular dissection of NF-κB activation has demonstrated that NF-κB can be 
induced by the ‘canonical’ (classical) and ‘non-canonical’ (alternative) signalling 
pathways, leading to distinct patterns in the individual NF-κB subunits that are activated 
and the downstream genetic responses that are induced. The canonical pathway involves 
activation of the inhibitor of NF-κB (IκB) kinase-β (IKKβ) and the non-canonical 
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pathway involves activation of IKKα (Bonizzi and Karin, 2004). IKKβ mediates NF-κB 
activation in response to pro-inflammatory stimuli and is indispensable in the canonical 
pathway, whereas IKKα is pivotal in the non-canonical activation that leads to 
resolution of the early inflammatory process and to the onset of tolerance to self 
(Kinoshita et al., 2006) or adaptive immunity to foreign antigens (Bonizzi and Karin, 
2004; Lawrence et al., 2005). The cross-regulation between canonical and non-
canonical signalling pathways is crucial in promoting an optimally protective response 
that is balanced between inflammation and tolerance (Lawrence et al., 2005). It has 
recently been demonstrated that non-canonical NF-κB activation is necessary for the 
induction of IDO expression in response to reverse signalling (Grohmann et al., 2007). 
 
Through their ability to produce type I interferons, pDCs drive protective antiviral 
inflammation and promote the function of bystander myeloid DCs, B cells, T cells and 
NK cells (Bonizzi et al., 2004). However, a protective function of type I or type II 
interferons has been demonstrated in several experimental models of autoimmunity and 
allergy (Wood and Sawitzki, 2006). The protective functions of pDCs, and of the 
associated type I interferon response, appear to be an intrinsic ability of the immune 
system to co-activate cytostatic mechanisms, induce the death of pathogenic T cells and 
polarise T cells towards a Treg phenotype (Gilliet and Liu, 2002; Moseman et al., 
2004). It has been suggested that tryptophan catabolism may, in principle, fulfil all the 
requirements to mediate these functions, including the generation of IL-10-producing 
TR1 cells (Fallarino et al., 2006b). There is increasing evidence linking type I 
interferons with resistance to specific forms of immunopathogenesis, including those 
associated with infection (Romani and Puccetti, 2006), by way of a potential link 
between pDCs and Tregs (Tang and Bluestone, 2006), and IDO has been implicated in 
this regard, being a participant in the maintenance of the tenuous balance between the 
opposing actions of the interferons in immune protection and pathology. 
 
Interestingly, signalling through TLR4, the receptor for bacterial LPS, neither activates 
non-canonical NF-κB signalling (Hayden and Ghosh, 2004) nor induces IDO expression 
(Braun et al., 2005; Orabona et al., 2006). In contrast, signalling through TLR9 activates 
IKKα and the induction of IDO expression (Hayashi et al., 2004; Mellor et al., 2005; 
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Wingender et al., 2006). In addition, IKKα is required for the development of self-
tolerance (Lomada et al., 2007), and NIK (an intergral component of the non-canonical 
pathway) may be necessary for the generation of autoimmune-preventative Tregs (Lu et 
al., 2005). Evidence thus suggests that TLRs, NF-κB and IDO are intimately linked in 
the prevention of immunopathogenesis that involves Treg function. IDO has been 
demonstrated to play a role in the peripheral generation of Tregs under physiological 
(Fallarino et al., 2006b) or pathological conditions (Curti et al., 2007). A mechanism 
has recently been identified that intrinsically links maturing pDCs to the generation of 
IL-10-producing TR1 cells, through TLR-dependent (described above) and TLR-
independent pathways, and that may provide a means to prevent excessive inflammation 
during infection (Ito et al., 2007). The TLR-independent mechanism appears to be 
mediated by CD40 signalling, and CD40 signalling activates NF-κB to induce IDO 
expression under environmental conditions that favour the non-canonical pathway (Hwu 
et al., 2000; Grohmann et al., 2003a; Vacca et al., 2005; Tas et al., 2007). It has been 
discovered recently that reverse signalling through GITR ligand (GITRL) also activates 
non-canonical NF-κB signalling and IDO expression in pDCs (Grohmann et al., 2007). 
Recent data thus indicate that several ligands acting on pDCs- including TLR9 ligands 
(Fallarino and Puccetti, 2006; Hoshino et al., 2006; Romani et al., 2006), CTLA4 
(Grohmann et al., 2002; Mellor et al., 2003), CD40L (Moseman et al., 2004; Ito et al., 
2007; Tas et al., 2007) and GITR (Grohmann et al., 2007), all contribute to IDO-
mediated Treg generation through pathways that converge on non-canonical NF-κB 
signalling. It has also been suggested that Treg cells use reverse signalling and 
consequent IDO production by pDCs to expand their own population in the periphery 
(Belladonna et al., 2006; Fallarino et al., 2006b; Grohmann et al., 2007). Thus, a model 
of Treg generation by IDO+ pDCs has been suggested in which the combined actions of 
CTLA4+GITR+ Tregs on the one hand, and NF-κB signalling in the pDCs on the other 
hand, are crucial in maintaining a regulatory environment (Puccetti and Grohmann, 
2007). 
 
It is widely believed that the anti-inflammatory properties of glucocorticoids, as well as 
non-steroidal anti-inflammatory drugs, are in part related to their inhibition of NF-κB 
(De Bosscher et al., 2003). It was demonstrated recently using naïve mice, that 
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glucocorticoid treatment in vivo increased the amount of GITR expressed by CD4+ T 
cells and of GITRL expressed by pDCs (Grohmann et al., 2007). Glucocorticoid 
treatment also conferred immunoregulatory properties on pDCs that were dependent on 
GITR expression by the host and required functional IDO in vivo. It was suggested by 
the authors that through the synergistic effects on T cell expression of GITR and pDC 
expression of GITRL, glucocorticoid acts on the GITR-GITRL co-receptor system to 
induce IDO expression via non-canonical NF-κB signalling. This would support the 
view that glucocorticoids, pDCs expression of GITRL and Treg activity are linked by a 
positive feedback loop, whereby CTLA4+GITR+ Tregs would expand their own 
population by inducing production of IDO by pDCs. Furthermore, the data would 
suggest that glucocorticoids function by reverse signalling through GITRL to activate 
the non-canonical NF-κB pathway (Grohmann et al., 2007). A model can be introduced 
that effectively incorporates non-canonical NF-κB signalling in tolerance mechanisms 
for IDO and glucocorticoids in a Treg-dominated scenario. Ligands and modulators of 
TLR9 signalling, soluble forms of costimulation antagonists (Finger and Bluestone, 
2002; Santucci et al., 2007), and inhibitors of canonical NF-κB signalling (De Bosscher 
et al., 2003; Karagiannidis et al., 2004) may follow tolerogenic pathways that converge 
on Treg generation. 
 
As demonstrated by the results of experiments in this study, and the studies described 
above, key questions still remain unanswered. These relate mainly to the nature of the 
adverse effect of soluble CTLA4 on Treg survival after short-term administration of the 
recombinant protein (Tang et al., 2003); how the integrated stress response (Munn et al., 
2005; Fallarino et al., 2006b) and various tryptophan catabolites (Platten et al., 2005; 
Belladonna et al., 2006) contribute to IDO-dependent regulatory responses in vivo. IDO 
seems to have a complex role in the induction of Tregs that involves greater input from 
plasmacytoid DCs, the type I interferons, and T cell expression of CTLA4 and GITR. 
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ARIODANTE:    ARIODANTE: 
 
‘Dopo notte, atra e funesta,   ‘After night, dark and melancholy 
Splende in ciel più vago il sole,  the sun wanders brilliant in the Heavens 
E di gioia empie la terra.   and with joy fills the earth. 
 
Mentre in orrida tempesta   Whereas in the fearful tempest 
Il mio legno è quasi assorto,   my barque was almost engulfed, 
Giunge in porto,    now it has entered harbour 
E ’l lido afferra.’    and reached the shore.’ 
 
 
 
From: 
 
Ariodante, Dramma per musica (HWV 33) in three acts  
by George Frideric Handel (1685-1759). 
(Libretto anonymously adapted from Ginevra, principessa di Scozia (Pratolino, 1708) 
by Antonio Salvi, 
based on Orlando Furioso (Canti 4-6) by Ludvico Ariosto). 
